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Abstract 
Introduction 
Outcomes in colorectal cancer (CRC) might be improved by identification of novel drug 
targets. Nrf2 is a transcription factor that regulates cellular stress response and irinotecan-
metabolising pathways; it is inhibited by the naturally occurring quassinoid brusatol. This 
thesis assessed the expression of Nrf2 in CRC and explored the effect of Nrf2 modulation 
alone and in combination with irinotecan in vitro and in an orthotopic syngeneic mouse 
model, developed as part of this thesis. 
 
Methods 
Tissue microarrays (TMA) were constructed from normal colon, primary CRC tumours and 
liver metastases from the same patient and stained for Nrf2. Cell viability and irinotecan 
cytotoxicity were assessed in murine (CT26) and human (HCT116) CRC cell lines following 
siRNA or pharmacological modulation of Nrf2. In vitro findings were validated in the murine 
model, utilising bioluminescent imaging to quantify disease burden following caecal 
implantation of luminescent CT26 cells. iTRAQ proteomic pathway analysis was 
subsequently undertaken on liver tissue from mice exposed to brusatol over a two-week 
period in attempt to determine the specificity of brusatol as an Nrf2 inhibitor and its safety 
profile. 
 
Results 
An orthotopic syngeneic murine model of CRC was developed using the CT26 cell line 
transfected with the luciferase gene and cloned by serial dilution. This model allowed the 
monitoring of disease burden in mice through the measurement of luminescent signal 
longitudinally over the study period. Disease development in mice was a reasonable 
recapitulation of the disease process in humans; tumours developed in the correct 
microenvironment in the presence of an intact immune system with up to 20% of mice 
developing liver metastases. 
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Nrf2 expression was significantly higher in primary CRC and metastatic tissue than in 
normal colon (p<0.01), with a positive correlation between Nrf2 expression in matched 
primary and metastatic samples included in the TMA. In vitro viability was decreased in 
human and mouse CRC cell-lines by Nrf2 siRNA, confirming a role for Nrf2 in cell survival.  
The Nrf2 inhibitor, brusatol, also resulted in a loss of cell viability, in concordance with the 
effect of Nrf2 siRNA. Furthermore, inhibition of Nrf2 by siRNA or brusatol significantly 
enhanced the cytotoxicity of irinotecan in vitro, with drug synergy noted for combinations 
of brusatol with irinotecan in both cell lines. 
Brusatol effectively abrogated tumour growth in orthotopically-allografted mice, resulting 
in an average 8-fold reduction in luminescence at the study end-point (p=0.02). There was 
a trend toward enhanced cytotoxicity of irinotecan when combined with brusatol in the 
mouse model.  
Nrf2 inhibition was confirmed in the livers of mice receiving brusatol treatment by western 
immunoblotting prior to iTRAQ analysis. Many of the pathways significantly altered in the 
analysis of murine livers following prolonged brusatol therapy could be linked to Nrf2, 
implying that brusatol may exert much of its effect through Nrf2.  
 
Conclusions 
Nrf2 offers a promising drug target in the treatment of CRC. Brusatol provides the potential 
for translation to clinical trials, although further work is required to determine the 
mechanism by which brusatol achieves inhibition on Nrf2 and how specific this effect is. 
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1.1 Epidemiology of Colorectal Cancer 
According to the 2011 data set published by Cancer Research United Kingdom (UK), 
colorectal cancer (CRC) is the fourth most common carcinoma and the second leading 
cause of cancer related death in the UK. CRC makes up 12.4% of the total cancer burden in 
the UK and the incidence continues to increase, rising by 6% over the last ten years. There 
were approximately 41 600 new cases of CRC diagnosed in the UK in 2011 with a slight 
preponderance for the disease in men.  The lifetime risk of CRC is 5% in the general 
population and increases with age; 95% of cases occur in those over the age of 50. 
(http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/) 
Duke's Stage TNM Stage Frequency 5-year survival 
A T1-2, N0,M0 8.70% 80-95% 
B T3, N0, M0 24.20% 72-75% 
  T4, N0, M0   65-66% 
C1 T1-2, N1, M0 23.60% 55-60% 
 
T3-4, N1, M0 
 
35-42% 
 C2 Any T, N2, M0   25-27% 
D M1 9.20% 0-7% 
Unknown   34.30% 35.40% 
Table 1.1 - Percentage of cases and 5 year survival by Dukes' and TMN (Tumour, Node and 
Metastases) stage at diagnosis for colorectal cancer patients [1, 2]. 
The best predictor of prognosis remains radiological and histopathological staging (Table 
1.1), and whilst survival across all stages of CRC continues to improve, with 57% of patients 
alive at five years, outcomes for those presenting with metastatic disease remain poor (7% 
five-year survival). Metastatic disease may be confined to the lymphatic nodal tissue which 
follows the arterial blood supply of the tumour or to the liver through haematological 
spread via the portal venous system. Approximately 25% of CRC patients present with 
metastases while an additional 25–35% will develop them during the course of their 
disease. Metastatic disease is confined to the liver alone in 20-30% of patients at 
presentation and 50% of recurrent disease following resection occurs in the liver [3]. 
Spread may also be transcoelomic to the omentum or peritoneal cavity and metastatic to 
the lungs. 
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Figure 1.1 – Local staging of colorectal cancer by T (local tumour stage) stage with common sites of 
metastases 
Surgical resection remains the cornerstone of curative treatment but is not always possible 
or advantageous in those with advanced disease, whose only therapeutic options are 
chemo- or radiotherapy. Others will benefit from adjuvant or neoadjuvant chemo- or 
radiotherapy in conjunction with oncological resection. Advances in chemotherapy have 
increased survival, reduced recurrence rates and prolonged life in advanced disease but 
more can be accomplished through the utilisation of improved or novel therapies. 
Achieving this will require a greater understanding of the pathogenesis of CRC and the 
pharmacology of chemotherapeutic and biological treatment agents on an individual 
patient basis. The ultimate aim is the personalisation of treatment for all CRC patients 
based on the genetic and biological characteristics of their tumour, and the enhancement 
of chemotherapy through the manipulation of novel targets to improve tumour response, 
whilst minimising side effect profiles.  
1.2 Aetiology of Colorectal Cancer 
The aetiological factors and patho-genetic mechanisms underlying CRC development are 
complex and heterogeneous. Contributory agents and mechanisms in CRC include lifestyle 
factors in addition to inherited and genetic mutations. Many factors have been examined 
for their influence on the development of sporadic CRC and, although knowledge of 
molecular genetics has increased in recent years, the stimuli that lead to malignant change 
remain obscure.  
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1.2.1 Diet 
Numerous dietary factors have been linked with the development of or protection against 
CRC. There is good evidence that eating red and processed meat increases CRC risk as 
assessed in four separate meta-analyses. These reported a 17-30% increase in the risk of 
CRC with ingestion 100-120g of red meat per day and a 9-50% increase on consuming 25-
50g of processed meat per day [4-7]. High quality level 4 evidence suggests that a diet high 
in fibre reduces the risk of developing CRC. Meta-analysis of 25 prospective studies 
involving over 2 million participants revealed that CRC risk was reduced by 10% for every 
10g of total dietary fibre ingested per day [8]. Evidence consistently reports that garlic and 
milk have a protective effect against CRC, while limited inconsistent evidence suggests 
vegetable and fruit consumption may offer some risk reduction, although this may be due 
to the fibre content [9-11]. It is possible that eating cheese [10] and sugary foods [12, 13] 
may increase risk, but evidence is inconsistent and no definite conclusions can be drawn. 
Other possible dietary influences on CRC pathogenesis include calcium, vitamin D [14, 15], 
folate [16-19], vitamin B6 [20] and vitamin B12 [21, 22] but published data reveal 
conflicting outcomes between studies. 
1.3.2 Alcohol 
Evidence consistently demonstrates that alcohol intake increases CRC risk, even at 
relatively moderate levels of consumption. In 2011 a systematic review reported relative 
risks (RR) were 1.21 for moderate (2-3 drinks/day) and 1.52 for heavy (≥4 drinks/day) 
alcohol drinkers when compared with light drinkers (≤1 drink/day). Dose-response analysis 
revealed a 7% increase in risk for every 10g per day of alcohol consumed [23]. The 
association between an increased risk of CRC and alcohol have been confirmed by two 
other meta-analyses conducted in 2007 [24] and 2011 [25].  
1.3.3 Smoking 
Three meta-analyses explored the effect of having been a smoker on bowel cancer risk, 
finding smokers were significantly more likely to develop CRC than those who have never 
smoked [26-28]. Laing et al. included 36 studies, involving over 3 million participants, in 
their 2009 review. Separate analyses were performed for smoking status, daily cigarette 
consumption, duration, pack-years and age of initiation. Compared with those who had 
never smoked, current smokers had a 17% higher chance of developing CRC while in 
former smokers the RR for CRC incidence was 1.25 [26]. 
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1.3.4 Obesity 
Studies consistently report an association between CRC risk and increasing Body Mass 
Index (BMI). Meta-analysis of 56 case-control and cohort studies involving 93 812 
individuals with CRC examined this relationship. Compared with those whose BMI was less 
than 23.0 kg/m2, the increased risk of colorectal cancer was 14% for individuals with a BMI 
of 23.0 to 24.9 kg/m2, 19% for a BMI of 25.0 to 27.4 kg/m2, 24% for a BMI of 27.5 to 29.9 
kg/m2 and 41% for a BMI of 30.0 kg/m2 or more. The association was stronger for men than 
women and for the colon than the rectum [29]. In a separate meta-analysis of prospective 
studies colon cancer risk increased by 33% and 16% for men and women respectively per 
10-cm increment in waist circumference [30]. 
1.3.5 Physical activity 
Three meta-analyses report that physically active individuals have a lower risk of colon 
cancer. The association between physical activity levels and rectal cancer risk is less well 
defined with one of these studies reporting a non-significant 6% reduction in risk [31], the 
second no reduction in risk [32] and the third only focusing on colon cancer [33]. These 
studies report that the most active men and women can reduce their risk of colon cancer 
by up to 28% and 32% respectively in comparison to the least active. These analyses suffer 
from a lack of consistency in defining activity levels in individuals between studies. 
Examined outcomes varied significantly with some studies focusing on the duration of 
activity with no assessment of intensity. 
1.3.6 Medication 
Aspirin taken for several years at doses of at least 75 mg daily reduced long-term incidence 
and mortality due to colorectal cancer in a review of four randomised control trials. These 
trials were conducted to assess the benefit of aspirin in reducing thromboembolic events 
but it was noted that allocation to daily aspirin reduced the 20-year risk of colon cancer 
significantly (incidence hazard ratio 0·76, p=0.02). This effect was more pronounced for 
proximal than distal tumours and there was no significant reduction in the risk of rectal 
cancer. There was no increase in benefit as the dose of aspirin was increased from 75 mg 
daily [34]. Aspirin may be considered in patients deemed to be a high risk of colon cancer 
based on family history or previous polyp disease. 
  
33 
Preclinical studies have suggested that statins may protect against CRC by inducing 
apoptosis, an upregulation of pro-apoptotic proteins and inhibiting tumour angiogenesis. 
No definitive conclusions can be drawn from meta-analysis of clinical data. These report a 
modest trend towards reduced CRC risk (RR 0.94, p=0.23) with statin therapy [35]. Current 
evidence is too inconsistent to recommend the routine use of statins in preventing CRC. 
Two meta-analyses from the late 1990s reported a reduction in the incidence of CRC in 
women who had or were taking hormone replacement therapy (HRT). The more recent of 
these examined 18 epidemiologic studies of postmenopausal hormone therapy and 
colorectal cancer. They found a 20% reduction (RR = 0.80) in colon cancer risk and a 19% 
decrease (RR = 0.81) in the risk of rectal cancer for postmenopausal women who had ever 
taken hormone therapy [36]. More recent studies report mixed findings. Oestrogen-only 
HRT was found to have no effect on bowel cancer risk in a randomised trial [37], but a 
significant risk-reducing effect in a large nested case-control study [38]. Combined HRT did 
not affect CRC risk in the two large cohort studies [39, 40] and did not reduce colon cancer 
risk significantly in a randomised trial of women with pre-existing cardiovascular disease 
[41]. This contrasts findings from a randomised control trial demonstrating a significant 
44% decrease in the risk of CRC with hormonal therapy versus placebo [42]. The evidence is 
not consistently in favour of supplementation with HRT to reduce CRC risk, especially given 
the well-publicised side-effects associated with hormonal therapy. 
1.3.7 Inflammatory bowel disease  
Inflammatory bowel disease (IBD) is associated with an increased risk of developing CRC. A 
2001 meta-analysis reported cumulative probabilities of 2% by 10 years, 8% by 20 years, 
and 18% by 30 years in patients with ulcerative colitis [43]. More recent data publish a 
cumulative risk of CRC in patients with ulcerative or Crohn’s colitis of 1%, 2%, and 5% after 
10, 20, and >20 years of disease duration, respectively [44]. This decreased risk may reflect 
improving treatments of IBD reducing the incidence of CRC, in combination with improved 
surveillance identifying those at high risk of malignancy due to polyps or dysplasia and 
selection to resection. 
The sheer number of causative factors associated with CRC is indicative of the complex 
genetic alterations associated with its development. Knowledge of these continues to 
improve through gene sequencing and bioinformatics, leading to a better understanding of 
potential therapeutic targets.   
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1.3 Genetics of Colorectal Cancer  
The development of a colorectal malignancy was believed to follow a series of genetic 
mutations in oncogenes and tumour suppressor genes from benign polyp to invasive 
cancer (figure 1.2) [45]. The genes responsible for the various stages were identified as 
Adenomatous Polyposis Coli (APC), KRAS and TP53 and the process labelled the adenoma-
carcinoma sequence. Since this model was proposed, understanding of the molecular 
pathogenesis of CRC has advanced considerably. Sequencing of CRC genomes has revealed 
numerous mutations in the average colon cancer, determining which of these mutations 
have a pathogenic role is challenging. Analysis of approximately 13,000 genes revealed 
mutations in the coding sequences of approximately 67 of these [46], while recent genome 
sequencing highlighted twenty-four genes that were commonly mutated in CRC. As 
expected, mutations commonly occurred in APC, TP53, SMAD4, PIK3CA and KRAS but there 
were also frequent mutations in ARID1A, SOX9 and FAM123B [47].  
It is now appreciated that there are multiple molecular pathways associated with the 
development of CRC and it is possible separate CRC into three phenotypical groups based 
on their genetic profile; tumours with microsatellite instability (MSI), those that are 
microsatellite stable but have chromosomal instability (CIN) and those with CpG island 
methylator phenotype (CIMP).  
 
 
Figure 1.2 – The adenoma-carcinoma sequence; from normal colonic epithelium through adenoma 
to carcinoma. The increasing loss of cellular differentiation and capacity to metastasise 
correspond to the accumulation of genetic mutations as originally described by Vogelstein. 
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1.3.1 Microsatellite instability 
MSI is identified by the presence of frequent insertion and deletion mutations in short 
tandem repeats of nucleotide sequences that are 1-6 base pairs long and known as 
microsatellites. These make up 3% of Deoxyribonucleic acid (DNA) and are found 
throughout the genome. Microsatellites are prone to errors in replication that, if missed by 
DNA polymerase, are corrected by the mismatch repair (MMR) system in normal cellular 
function. As microsatellite sequences are present in the coding regions of genes that 
regulate cell growth and apoptosis, defective MMR can result in frameshift mutations that 
create an environment promoting cell survival and carcinogenesis. Inactivation of the MMR 
system may be due to epigenetic mechanisms or mutations that alter the function of the 
MMR genes, for example MLH1, MSH2, MSH6 and PMS2 [48]. 
 In 1998 the National Cancer Institute recommended the testing of five microsatellite 
biomarkers by polymerase chain reaction (PCR) and immunohistochemistry (IHC) for 
determination of MSI status; these markers include BAT-25, BAT-26, D2S123, D5S346 and 
D17S250 [49]. Two or more positive markers demonstrate instability and define the 
tumour as microsatellite high (MSI-H). Although this is often adequate for determining MSI-
H tumours it may not select between microsatellite low (MSI-L) and microsatellite stable 
(MSS) tumours.  A large number of markers may be required to make this distinction with 
MSI-H tumours defined as having instability in ≥30% of the markers tested; MSI-L defined 
as the presences of instability in 10%–29% of markers, and MSS defined as no unstable 
markers [48]. 
MSI tumours account for approximately 15%−20% of sporadic CRCs and have specific 
clinical and histopathological features [50, 51]. These tumours tend to be proximal to the 
splenic flexure, have a high histological grade, a mucinous histology with prominent 
numbers of tumour-infiltrating lymphocytes and display a Crohn’s like inflammatory 
response. They are associated with an improved prognosis despite studies suggesting a lack 
of efficacy with 5-fluorouracil (5-FU) based chemotherapy [52]. 
1.3.2 Chromosomal instability 
CIN refers to accelerated rates of gain or loss of whole or large portions of chromosomes 
and fits more with the traditional view of the adenoma-carcinoma sequence [45].  The 
genomic changes associated with the CIN pathway include activation of KRAS, inactivation 
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of APC, loss of TP53 and loss of heterozygosity at chromosome 18q, which contains the 
tumour suppressor genes SMAD2, SMAD4 and deleted in colon cancer (DCC). These 
mutations were believed to occur in a stepwise fashion as the tumour progressed from 
adenoma to carcinoma. This model continues to be refined as evidence emerges on the 
complexity and number of mutations associated with the development of CRC. However, it 
did establish the key principle that multiple genetic hits were required for the progression 
to CRC.  Genome-wide sequencing has demonstrated up to 80 mutated genes per CRC but 
a smaller group of mutations (less than 15) were considered to be drivers of 
tumourigenesis [53]. The consequence of CIN is aneuploidy, genomic amplifications and 
loss of heterozygosity leading to the activation of pathways initiating the development and 
progression of CRC. (Table 1.2) 
CIN is observed in 65%–70% of sporadic colorectal cancers with tumours occurring 
predominantly in the descending colon and rectum. It is accepted that most MSS tumours 
follow the CIN mechanism of tumourigenesis, but the MSI and CIN phenotypes are not 
mutually exclusive with up to 25% of MSI colorectal cancers exhibiting chromosomal 
abnormalities [54]. Data indicate that the CIN phenotype is associated with less favourable 
outcomes in patients in comparison to those with tumours that exhibit MSI [53, 55]. 
 
Gene Chromosomal 
location 
Prevalence of 
mutations 
Function of gene product 
Oncogenes 
KRAS 12p12 ~ 30–50% Cell proliferation, survival, and transformation 
CTNNB1 3p22 ~ 4–15% (~ 50%*) Regulation of Wnt pathway target genes that 
promote tumour growth and invasion 
PIK3CA 3q26 ~20% Cell proliferation and survival 
Tumour suppressor genes 
APC 5q21 ~ 30–70% Inhibition of Wingless/Wnt signalling; cytoskeletal 
regulation 
TP53 17p13 ~ 40–50% Cell cycle arrest, apoptosis induction 
SMAD4, 
SMAD2 
18q21 ~ 10–20% Intracellular mediators of the TGF-β pathway 
DCC 18q21 ~ 6% Cell surface receptor for netrin-1 
Table 1.2 - Overall Prevalence of common genetic mutations in CIN-positive CRCs as adapted from 
Pino and Chung, 2014 [53]. *Identified in 50% of tumours without APC mutations. 
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1.3.3 CpG island methylator phenotype 
CIMP is a subset of CRCs that occur through an epigenetic instability pathway characterised 
by hypermethylation of promoter CpG island sites [56]. Methylation refers to the 
enzymatic addition of a methyl group to cytosine by DNA methyltransferases. CpG 
(cytosine preceding guanine) islands are regions within the genome where the percentage 
of the CpG dinucleotides is higher than expected. CpG islands overlap the promoter region 
of 60–70% of genes and tend to be protected from methylation. However, they can 
become abnormally methylated in cancer resulting in epigenetic silencing of several 
tumour suppressor genes. The mechanisms involved in aberrant methylation are unclear 
but could include overexpression, hyper-activation or misdirection of enzymes, such as 
DNMT1, DNTM3a, and DNMT3b, that mediate DNA methylation or impairment of the 
control elements that normally prevent DNA methylation [56]. Hundreds to thousands of 
genes can be aberrantly methylated in the average CRC and only subsets of these are likely 
to be important in its pathogenesis. (Table 1.3) 
Meta-analysis of 19 studies suggested CIMP tumours to be independently associated with a 
worse overall survival but highlighted the inconsistent definitions of CIMP positivity 
employed. However, unlike the MSI phenotype tumours, CIMP tumours do not seem to be 
associated with a poor response to 5-FU based adjuvant therapy [57, 58]. 
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Gene Protein Effect of loss of function 
APC Adenomatous polyposis coli Increased Wnt/β-catenin signalling 
MLH1 MutL homolog 1 Microsatellite instability 
MGMT O-6-methylguanine-DNA 
methyltransferase 
Increased G>A mutation frequency 
RASSF1A Ras association domain family 1 
(isoform A) 
Increased RAS/RAF/MAP kinase 
signalling, death-receptor-dependent 
apoptosis SLC5A8 Sodium solute symporter family 5 
member 8 
Not known 
RUNX3 Runt-related transcription factor 3 Decreased TGF-β/BMP signalling 
MINT1* Methylated in tumour locus 1 Not applicable 
MINT31* Methylated in tumour locus 31 Not applicable 
SFRP1 Secreted frizzled-related protein 1 Increased Wnt/β-catenin signalling 
SFRP2 Secreted frizzled-related protein 2 Increased Wnt/β-catenin signalling 
CDH1 E-cadherin Loss of cell adhesion, possible 
increased Wnt/β-catenin signalling 
CDH13 Cadherin 13 Increased PI3K/Akt/mTOR signalling, 
MAPK signalling 
CRABP1 Retinol-binding protein 1 Not known 
CDKN2A/p16 Cyclin-dependent kinase inhibitor 2A Increased cell proliferation 
HLTF Helicase-like transcription factor Impaired DNA repair 
CDKN2A 
(P14,ARF) 
p14(ARF) Decreased p53 stabilization and 
activation 
ESR1 Oestrogen receptor 1 Loss of oestrogen receptor signalling 
TIMP3 Tissue inhibitor of metalloproteinase 
3 
Increased EGFR signalling, TNF 
signalling 
CXCL12 Chemokine (CXC motif) ligand 12 Increased tumour cell metastases 
ID4 Inhibitor of DNA binding 4 Not known 
IRF8 Interferon regulatory factor 8 Interferon signalling 
THBS1/TSP1 Thrombospondin 1 Decreased TGF-β1 signalling 
DAPK Death associated protein kinase Interferon gamma signalling, TNF 
alpha signalling, Fas/APO1 signalling 
VIM Vimentin No known biological effect 
SEPTIN 9 Septin 9 Impaired cytokinesis and loss of cell 
cycle control 
Table 1.3 – Genes commonly hypermethylated and silenced in CRC as adapted from Lal and Grady, 
2011 [56]. * MINTs are 'methylated in tumour' loci and not specific genes. 
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1.3.4 Adenomatous polyposis coli (APC) 
Many of the gene mutations now known to be associated with the development of CRC 
were originally identified and described in the adenoma-carcinoma sequence as described 
by Volgestein [45].  The APC tumour suppressor gene encodes for a protein known to 
regulate cell-adhesion, migration, apoptosis and proliferation; halting the progression from 
G1 to S phase of the cell cycle. The defect is present in 30-70% of CRCs and is widely 
believed to be an early step in sporadic carcinogenesis due to its reported presence across 
the adenoma-carcinoma sequence [59]. The majority (95%) of APC mutations are either 
frameshift or nonsense leading to the synthesis of a truncated protein [60]. The 
downstream effect of APC mutations is disruption of the WNT pathway. APC targets β-
catenin for proteasomal degradation and therefore mutation results in the nuclear 
accumulation of β-catenin, increased WNT activity and cellular proliferation. The end 
product of this over-proliferation is the overgrowth of colonic epithelial cells, resulting in 
the formation of polyps. Malignant transformation of a polyp may then occur as further 
genetic mutations accumulate [61]. 
1.3.5 KRAS/BRAF 
The RAS family (KRAS, HRAS and NRAS) are membrane bound guanine nucleotide binding 
proteins that predominantly act as molecular switches. KRAS is a proto-oncogene which, 
after activation by the endothelial growth factor (EGFR) receptor, triggers downstream 
signalling through the PI3K/AKT/MTOR and RAF/MEK/ERK pathways resulting in cellular 
proliferation and growth factor induced differentiation [62, 63]. KRAS is mutated in 30%-
50% of CRCs with single nucleotide point mutations occurring in codons 12 and 13 of exon 
2 and to a lesser extent in codon 61 of exon 3. These lock KRAS in the guanine-triphosphate 
bound activated form, leading to constitutive activation of RAS downstream signalling [53].  
The RAF family (ARAF, BRAF and RAF1) were the first downstream effectors of RAS to be 
identified. BRAF exhibits a high propensity to MEK/ERK activation, explaining why only 
BRAF mutations have been associated with malignancy and not ARAF or RAF1. BRAF 
mutations have been reported in 10% of CRCs and are associated with a significantly higher 
proportion of MSI tumours [64, 65]. 
  
40 
1.3.6 TP53 (p53)  
TP53 is a tumour suppressor gene located on the short arm of chromosome 17. It induces 
arrest of the cell-cycle in the G1 phase and facilitates DNA repair prior to a cell committing 
to DNA replication; if DNA repair is unsuccessful p53 induces apoptosis [66]. Referred to as 
the ‘guardian of the genome’ p53 is implicated in a number of malignancies. TP53 
mutations occur as a late event in the transition from adenoma to carcinoma in CRC; they 
are present in 4% to 26% of adenomas and in 50 to 75% of CRCs [67, 68]. Most of TP53 
mutations are missense mutations occurring most frequently in codons 175, 248 and 273, 
leading to the synthesis of an inactive protein [69]. 
1.3.7 18Q loss of heterozygosity 
Loss of heterozygosity (LOH) is defined as loss of one of the two alleles or copies of a gene 
and is frequently noted in chromosome 18Q in advanced CRC. The DCC gene is located on 
the long arm of chromosome 18 and was initially proposed to be a colorectal cancer 
tumour suppressor gene. This was debated when its product was found to be a cell surface 
receptor for the neuronal protein netrin-1, involved in axon guidance in the developing 
nervous system [70]. However, DCC also has a role in intracellular signalling, blocking cell 
growth in the absence of netrin-1 and mutations may promote cell survival and tumour 
development [71]. In normal conditions netrin-1 is produced deep in the crypts of the 
colorectal mucosa and as epithelial cells differentiate and migrate to the surface netrin-1 
concentrations fall. This results in reduced activation of the DCC surface receptor and 
reduced cell survival and growth. However, mutation of the DCC gene results in failure of 
netrin-1 to bind to the transmembrane protein, causing abnormal cell survival [48]. 
Approximately 70 % of CRC show allelic losses in DCC with studies suggesting that loss of 
DCC expression occurs more frequently in the later clinical stages and higher pathological 
grades of CRC [72, 73]. 
The tumour suppressor gene SMAD4 is also located on chromosome 18Q and is an 
intracellular mediator of the transforming growth factor pathway; involved in the 
regulation of cell growth, differentiation and apoptosis. SMAD4 mutations have been found 
in 10% of CRCs with the frequency of mutation increasing with stage [74]. 
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1.4 Familial Colorectal Cancer Syndromes 
Although the majority of CRC are believed to be sporadic, estimates indicate that familial 
CRC, defined by the presence of two or more first-degree relatives affected with CRC, may 
account for 20% of cases [75]. CRC can be directly attributed to one of the well-
characterised familial syndromes in 5-10% of cases, these include: Lynch syndrome (LS), 
familial adenomatous polyposis (FAP), attenuated familial adenomatous polyposis (AFAP), 
MUTYH-associated polyposis (MAP), Peutz–Jeghers syndrome (PJS), juvenile polyposis 
syndrome (JPS), Cowden syndrome (CS) and serrated (hyperplastic) polyposis syndrome 
(SPS) [76]. Each syndrome is associated with a specific phenotype that often include extra-
colonic manifestations [77]. (Table 1.4) 
1.4.1 Lynch Syndrome (LS) 
LS is the most common of the inherited CRC syndromes, accounting for up to 3% of all 
colorectal cancers [78]. It is an autosomal-dominant condition defined by the presence of a 
germline mutations in MMR genes resulting in MSI-high tumours that tend to occur in the 
right side of the colon with the histological findings matching those discussed in section 
1.3.1. Patients with LS typically develop colorectal and endometrial cancers in their 40s and 
are also at increased risk of developing adenocarcinomas of the stomach, small intestine, 
upper urinary tract, ovary, pancreatobiliary tract, brain and skin. Tumours are often 
synchronous or metachronous and 70% of patients with LS will develop CRC by the age of 
70 [79]. 
The revised Bethesda guidance are helpful in determining when a patient is at increased 
risk of LS and state patients should have their tumour assessed for MSI if they fulfil any of 
the following conditions:  
1. diagnosed with CRC under 50 years of age  
2. present with synchronous or metachronous CRC or other LS-related tumours, 
regardless of age  
3. diagnosed with a MSI-high CRC under 60 years of age  
4. have one or more first-degree relatives with an LS-related cancer, with one of the 
cancers being diagnosed under 50 years of age  
5. have two or more first- or second-degree relatives with LS-related cancer, 
regardless of age [76] 
  
42 
In 2015 the American College of Gastroenterology released comprehensive guidance 
stating that individuals at risk for or affected with LS should be screened for CRC by 
colonoscopy at least every two years, beginning between the ages of 20 and 25. These also 
state that colectomy with ileo-rectal anastomosis is the preferred treatment for LS patients 
diagnosed with a colon cancer or colonic neoplasia not controllable by endoscopy. 
Segmental colectomy is an option in patients unsuitable for total colectomy if regular 
postoperative surveillance is conducted [76]. 
1.4.2 Familial Adenomatous Polyposis (FAP) 
FAP was the first hereditary CRC syndrome to be fully characterised. FAP is due to a 
germline mutation in the APC gene located on the long arm of chromosome 5 (5q21-22) 
and is inherited in an autosomal dominant fashion with a high penetrance. FAP is the 
defined by the presence of ≥100 synchronous colorectal adenomas. It carries a 100% 
lifetime risk of CRC, with most malignancies occurring before the age of 40 [80]. However, 
some germline mutations, particularly those at either the 5′ or 3′ ends of the gene, lead to 
a milder phenotype known as AFAP, defined by the presence of 10-100 adenomas that 
tend to be confined to the right-colon [77].  
Individuals who have a personal history of more than 10 colorectal adenomas, a family 
history of one of the adenomatous polyposis syndromes or a history of adenomas and FAP-
type extra-colonic manifestations (duodenal or ampullary adenomas, desmoid tumors, 
papillary thyroid cancer, congenital hypertrophy of the retinal pigment epithelium, 
epidermal cysts and osteomas) should undergo assessment for the adenomatous polyposis 
syndromes. Those found to be at risk for or affected should be screened annually for CRC 
by colonoscopy, beginning at puberty. The absolute indications for immediate colorectal 
surgery in FAP and AFAP include the presence of malignancy or significant symptoms. 
Relative indications for surgery include the presence of multiple adenomas greater than 
6mm in size, a significant increase in adenoma number, the presence of an adenoma with 
high-grade dysplasia and/or inability to adequately survey the colon because of multiple 
polyps.  
Pan-proctocolectomy with ileo-anal pouch formation or an end-ileostomy is often 
preferred for patients with FAP. Subtotal colectomy may be more appropriate in AFAP as 
polyp numbers are fewer and have a predilection to the right-colon. Postsurgical 
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surveillance should include yearly endoscopy of rectum or ileal pouch and examination of 
an ileostomy every two years [76]. 
1.4.3 MUTYH-associated polyposis (MAP) 
First described in 2002, MAP is a recessively inherited syndrome due to bi-allelic MUTYH 
mutations. MUTYH is a base excision repair gene involved in DNA oxidative damage. Failure 
of base excision repair results in CG–AT transversions in multiple genes, including APC and 
KRAS [81]. Although MAP was believed to mimic AFAP, it is now known that MAP patients 
frequently develop serrated type polyps (hyperplastic polyps and sessile serrated lesions) in 
addition to classical adenomas [77]. MAP is most commonly found in patients presenting 
with 20 to 99 adenomas but patients may present with over a 1000 colonic polyps. 
Guidelines recommend the same screening, management and surveillance regimens as FAP 
or AFAP. Colectomy and ileo-rectal anastomosis is possible in those with relative rectal 
sparing [76]. 
1.4.4 Peutz–Jeghers syndrome (PJS) 
PJS is an autosomal-dominantly inherited syndrome that includes histologically distinctive 
hamartomatous polyps of the gastrointestinal tract and characteristic mucocutaneous 
pigmentation. Most (94%) cases are associated with a germline mutation in the 
serine/threonine kinase 11 (STK11) gene on chromosome 19p [82]. Affected individuals 
have an increased risk of the colorectal, pancreatic, gastric, small intestine, oesophageal, 
breast, ovarian, endometrial and lung carcinomas [77].  
The lifetime risk for CRC in PJS is estimated at 39% and any individual with perioral or 
buccal pigmentation and/or two or more histologically characteristic gastrointestinal 
hamartomatous polyps or a family history of PJS should be tested for STK11 mutations. In 
affected individuals colonoscopic surveillance should begin at eight years old and, if polyps 
are present, repeated every three years. If no polyps are found, colonoscopy should be 
repeated at 18 years of age and then every three years or earlier if symptoms occur. 
Treatment involves endoscopic excision of polyps with colectomy sometimes necessary to 
control colonic especially if neoplastic change is identified [76]. 
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1.4.5 Juvenile Polyposis Syndrome (JPS) 
JPS occurs as a result of mutations of the SMAD4 or BMPR1A genes and is inherited in an 
autosomal dominant fashion, although 25% of newly diagnosed cases represent a new 
mutation without a family history [76].  JPS is a pure intestinal polyposis syndrome without 
the extra-intestinal manifestations seen in many of the others. Patients develop 
characteristic polyps throughout the gastrointestinal (GI) tract, typically by the age of 20 
years, with a reported cumulative lifetime risk for developing colorectal adenocarcinoma of 
40–70%. The World Health Organization stated an individual with any of the following 
should be tested for JPS: 
1. more than five juvenile polyps in the colon or rectum 
2. juvenile polyps throughout the gastrointestinal tract 
3. any number of juvenile polyps in a person with a family history of juvenile 
polyposis  
Screening with colonoscopy should begin at 12 years old and continual annually if polyps 
are found and every three years in the absence of polyps. Indications for surgery are the 
same as the other polyposis syndromes [83].  
1.4.6 Cowden’s syndrome (CS) 
CS is the most common variant of the PTEN-hamartoma tumour syndromes which are 
caused by germline mutations in the tumour suppressor phosphatase and tensin (PTEN) 
homologue, situated on chromosome 10q23. CS is inherited in an autosomal dominant 
fashion, although up to 30% of patients may have de-novo mutations [84]. Patients can 
develop hamartomas in multiple organ systems, with an increased risk of malignancy of the 
breast, thyroid, endometrium and kidney. Nearly 95% of patients develop a polyposis, 
which can include hyperplastic-, adenomatous-, hamartomatous-, ganglioneuromatous- 
and inflammatory-type polyps. Colonic involvement is typical resulting in an increased risk 
of CRC with prevalence of approximately 14% and a mean age of 47 at diagnosis [77]. 
Individuals with multiple gastrointestinal hamartomas or ganglioneuromas should be 
evaluated for CS by testing for mutations in PTEN. Screening with colonoscopy should 
continue annually from diagnosis [76]. 
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1.4.7 Serrated (hyperplastic) Polyposis Syndrome (SPS) 
The exact mode of inheritance of SPS remains unclear but 40 to 60% of affected individuals 
report a family history of CRC in first or second-degree relatives. Individuals develop 
serrated polyps which can include a mixture of hyperplastic polyps, sessile serrated lesions 
and traditional serrated adenomas [77]. The lifetime risk of colorectal in SPS has been 
estimated to be greater than 50% [85]. Diagnosis is made clinically and is based on the 
World Health Organization diagnostic criteria which includes any one of the following: 
1. at least five serrated polyps proximal to the sigmoid colon with two or more of 
them >10 mm in diameter 
2. any number of serrated polyps proximal to the sigmoid colon in an individual who 
has a first-degree relative with SPS  
3. >20 serrated polyps of any size, but distributed throughout the colon 
It is recommended that patients with SPS should undergo colonoscopies every one to three 
years with attempted removal of all polyps >5 mm diameter. Surgery is indicated when the 
growth of polyps cannot be controlled by colonoscopy or malignant change is identified 
[76]. 
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Syndrome Gene(s) involved Inheritance Mean age CRC Polyp type(s) Polyp number Extra-intestinal features 
FAP APC 5q21 Autosomal dominant 39 years Conventional adenomas >100–1000s CHRPEs 
      
Fundic gland polyps 
      
Desmoids 
      
Thyroid carcinoma 
      
Hepatoblastoma 
      
Osteomas, cysts and fibromas 
       Attenuated FAP APC 5q21 Autosomal dominant 55 years Conventional adenomas <100 (as FAP) 
       Lynch syndrome MLH1 3p21.3 Autosomal dominant 45 years Conventional adenomas 0–10 Endometrial adenocarcinoma 
 
PMS2 7p22.1 
    
TCC of upper urogenital tract 
 
MSH2 2p21 
    
Ovarian carcinoma 
 
MSH6 2p16.3 
    
Pancreatobiliary carcinoma 
      
Brain tumours 
      
Skin tumours 
       
MYH-associated polyposis MUTYH 1p34.3 Autosomal recessive 48 years Conventional adenomas. 
Typically, <100 
(may be 1000s) 
Some FAP-type extra-intestinal 
features but at low incidence 
    
Serrated polyps 
  
       Peutz-Jegher's syndrome STK11 19p13.3 Autosomal dominant 46 years Hamartomas (PJ polyps) 1–10s Carcinomas in multiple organs 
       Juvenile polyposis SMAD4 18q21.1 Autosomal dominant 34 years Hamartomas (juvenile polyps) 5–200 No 
 
BMPR1A 10q23 
     
       Cowden Syndrome PTEN 10q23 Autosomal dominant 47 years Conventional adenomas 0–50 Breast carcinoma 
    
Hyperplastic polyps Hamartomas 
  
    
Ganglioneuromas 
  
    
Inflammatory polyps 
  
       
Serrated polyposis Unknown Unknown Uncertain 
Serrated polyps (Conventional 
adenomas) 
2–200 No 
1. CHRPE: Congenital hypertrophy of the retinal pigment epithelium 2. TCC: transitional cell carcinoma 
 
Table 1.4 – Summary of the familial CRC syndromes with their associated extra-colonic manifestations. Adapted from Novelli, 2015 [77]. 
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1.5 Clinical Presentation, Diagnosis and Staging of Colorectal Cancer 
CRC is a potentially preventable disease with tumours often arising from malignant change 
in an adenomatous polyp [86]. It is hoped that CRC screening programs, with endoscopic 
control of polyp disease, will reduce the incidence of CRC in the future [87]. However, the 
majority of patients still present with symptoms which may include a change in bowel 
habit, iron deficiency anaemia, weight loss, abdominal pain, rectal bleeding, tenesmus or 
the presence of an abdominal or rectal mass. Patients may also present acutely with bowel 
obstruction, perforation or haemorrhage, requiring emergency management. Staging is an 
assessment of local and metastatic CRC burden completed by endoscopic and radiological 
investigation and used to guide evidence based treatment. A number of systems have been 
used for staging of disease in CRC and will be discussed below. Most utilise a description of 
tumour invasion (T stage), lymph node positivity (N stage) and the presence of metastatic 
disease (M stage) to guide treatment and estimate prognosis.   
1.5.1 Screening 
Population based screening for CRC, labelled the Bowel Cancer Screening Program (BCSP), 
commenced in the UK in June 2006. This involves all individuals between 60 and 74 years 
old being offered testing for Faecal Occult Blood (FOB) every two years. Those with a 
positive test are then considered for colonoscopy. Meta-analyses of published randomised 
control trial data demonstrates that FOB testing strategies appear to be effective in 
reducing the CRC mortality but not in reducing CRC incidence [88, 89]. Two forms of the 
FOB test are available for use in clinical practice, the guaiac-based FOB test (gFOBT) and 
Faecal Immunochemical Test (FIT). Evidence from randomised trials suggest that FIT has a 
significantly higher sensitivity but non-significantly lower specificity for CRC that gFOBT and 
therefore may be considered a superior method [87].  
From 2013 to 2014 trials of an alternate screening protocol were conducted at six centres 
in the UK. This utilised visualisation of the left colon with a one off flexible-sigmoidoscopy 
(FS) at the age of 55 years old; preliminary published data report uptake rates of only 43% 
[90]. Results from a meta-analysis of five randomised control trials demonstrate that an FS-
based strategy is effective in reducing the CRC mortality (by 28%) and incidence (by 18%) in 
a population with an average risk of CRC [91]. 
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1.5.2 Clinical Assessment 
Clinical assessment of patients with a suspected CRC should include a history and 
examination focusing on disease specific symptoms (described in 1.5), the coexisting 
comorbidity and the signs of malignant disease such as a palpable mass on abdominal or 
per rectal examination. Subsequent investigations or treatment should take into account 
the nature of the disease itself, such as the presence of metastatic disease, in addition to 
the general comorbidities of the patient.  
1.5.3 Endoscopic Assessment 
Flexible-sigmoidoscopy refers to endoscopic assessment of the colon from the rectum to 
the splenic flexure. Colonoscopy involves examination of the entire colon up to and 
sometimes including the terminal ileum. Colonoscopy is the recognised gold standard 
investigation for the identification of colonic polyps or malignancies. It allows direct 
visualisation of the entire colon colonic mucosa, biopsy of suspected malignant lesions for 
histological diagnosis and the removal of polyps for the prevention of progression to 
invasive tumours. The marking of colonic tumours with tattoo ink at colonoscopy has 
become invaluable in the modern era of laparoscopic surgery where tumour localisation 
can be challenging. Examination of the entire colon is especially important given the 
relatively high incidence of synchronous CRC (5%) or colonic polyps (28%) which may alter 
management decisions [92]. Complications from colonoscopy are rare and were reported 
at 0.5% in the Nottingham FOB test trial, including post-polypectomy bleeding, perforation 
and snare entrapment [93]. Missed lesions are reported in the literature with a recent 
review of tandem colonoscopy reporting a miss rate of 2.1% for adenomas larger then 1cm. 
However, the miss rate for a small polyp of less than 5mm was very high at 26% [94]. 
1.5.4 Radiological Assessment 
Radiological staging in CRC is essential prior to selection to treatment in the non-
emergency setting; allowing assessment of the feasibility of surgical resection and guiding 
patient selection to specific neoadjuvant therapies, for example long course chemo-
radiotherapy in rectal cancer. Radiological imaging in the form of Computerised 
Tomography Colonography (CTC) or, less frequently, Barium Enema (BaE) may also be used 
for diagnostic purposes in patients in which complete colonoscopy is not possible due to 
comorbidity, colonic anatomy or the presence of an impassable stenosing tumour.  
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Computerised Tomography (CT) scanning is the most widely utilised imaging modality for 
the local staging of CRC and the detection of distant metastases. It accurately distinguishes 
between tumours confined to the bowel wall and those invading beyond it. Nodal staging 
of CRC by CT is unreliable as it relies on lymph node size as a criterion for positivity [95, 96]. 
The sensitivity (74%-78%) and specificity (93-97%) of CT for the detection of liver 
metastases is good [97]. CTC allows the use of CT scanning as a diagnostic tool in CRC. Gas 
insufflation of the colon provides contrast between the colonic mucosa and lumen which, 
in combination with CT imaging, allows detection of even small colonic polyps. This can be 
used for diagnostic purposes with meta-analyses reporting a sensitivity of 100% for the 
detection of CRC and 87.9% for adenomas less than 10mm [98]. 
Positron Emission Topography (PET) can be combined with CT (PET-CT) and uses the 
increased glucose metabolism in tumour cells to uptake 18-fluorodeoxyglucose and aid the 
detection of small malignant deposits. A meta-analysis reported that PET had a slightly 
lower sensitivity than CT on patient based assessment (93 % and 98 % respectively) and 
lesion based assessment (66 % and 79 % respectively) but appeared to be more specific 
than CT (86 % and 67 % respectively). PET findings were shown to alter the management in 
24 % of patients [99].   
Magnetic Resonance Imaging (MRI) supplements CT staging in two specific situations. 
Firstly, in the local staging rectal cancer high resolution MRI can provide information 
previously only available on histological assessment of the resection specimen. Details on 
local tumour stage, lymph node status and extramural vascular invasion can all be observed 
with varying degrees of accuracy on T2-weighted images [100]. The MERCURY study group 
reported that tumour visualised within 1mm of the mesorectal fascia on MRI to be a 
sensitive predictor of circumferential resection margin (CRM) positivity at surgery [101]. 
Pre-operative knowledge of these details can allow the selection of patients to neoadjuvant 
chemoradiotherapy, potentially preventing positive resection margins and reducing 
recurrence. Secondly, MRI with gadolinium contrast can be employed for the 
characterisation of indeterminate liver lesions found on CT with improved sensitivity and 
specificity [102]. 
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1.5.5 Histopathological Assessment 
As endoscopic examination of the colon allows the acquisition of tissue from the primary 
tumour, histopathological assessment is possible prior to surgical resection. Tissue for 
analysis is formalin-fixed, paraffin-embedded (FFPE), sliced for examination and stained 
with haematoxylin and eosin (H&E). The histological diagnosis of colorectal cancer is based 
on invasion through the muscularis mucosae into the submucosa. Further classification into 
a number of histopathological subtypes is also possible and include; adenocarcinoma, 
mucinous adenocarcinoma, signet-ring cell carcinoma and medullary carcinoma. Pre-
operative histopathological examination of metastatic disease, particularly of the liver, 
remains a controversial issue due to the risks of tumour seeding and the poor outcomes 
reported in the literature following biopsy and should be avoided [103]. (Table 1.5) 
Grading of tumour tissue allows an interpretation of the degree of de-differentation from 
the morphology of the original tissue assigned on a scale of G1-G3. Assignment of tumour 
grade considers nuclear features such as pleomorphism, cellular architecture and mitotic 
count. G1-2 tumours and G3 tumours are often grouped together for simplicity as low and 
high grade respectively. Grading of a colorectal cancer may offer some prognostic 
information to guide management, although this has not been formally incorporated into 
specific grading systems [104]. 
Histopathological assessment of the post-resection specimen provides further information 
on the morphology of primary tumour and on the presence of lymph node disease; 
allowing staging of disease burden and allocation to treatment as discussed below. 
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Authors Year Design 
Number 
of 
Patients 
Findings 
Al-Leswas et al. 2008 Case report 2 2 cases of implantation 
Jones et al. 2005 Retrospective review 17 19% seeding rate; 
poorer long term 
survival after biopsy 
Rodgers et al. 2003 Retrospective review 7 16% risk of seeding 
irrespective of route of 
biopsy 
Metcalfe et al. 2004 Case report 1 Biopsy added nothing to 
diagnostic pathway 
Ohlsson et al. 2002 Case series 5 10% seeding rate 
Scheele & Altendorf-
Hofmann 
1990 Case report 2 Seeding following 
biopsy of resectable 
lesion 
Ferrucci et al. 1979 Case report 1 First documented case 
of tract seeding 
Table 1.5 - Summary of the evidence highlighting the complications of percutaneous needle biopsy 
of colorectal liver metastases. Adapted from Cresswell, Welsh and Rees, 2009 [103]. 
1.5.6 Staging Systems  
The first staging system for CRC was described by Dr Cuthbert Dukes and initially only 
applied to rectal cancers. Tumours were classified from Dukes’ stage A to C with stage A 
cancers confined to the bowel wall, stage B through the bowel wall and stage C used to 
describe lymph node involvement [105]. This was system was later correlated with 
prognosis  and stage C subdivided into stages C1 and C2 (apical node involvement) [106]. In 
1967 stage D was added, representing the presence of metastatic disease [107]. (Table 1.1) 
As a result of the increasing understanding of cancer biology and the advances in 
radiological techniques, allowing more accurate pre-operative characterisation of CRC, 
updated staging systems have been developed. The Union for International Cancer 
Control/American Joint Committee for Cancer (UICC/AJCC) TNM classification is now 
regarded as the standard of care [108]. Three variables are used to describe cancer stage, 
including: the degree of invasion of the primary tumour as described by a T stage; the 
presence and extent of local lymph node invasion referred to as N stage; and M stage 
describing the presence or absence of metastatic disease. (Table 1.6) 
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Tumour (T) Stage Nodal (N) Stage Metastatic (M) Stage 
TX Primary tumour 
cannot be assessed 
NX Regional lymph nodes 
cannot be assessed 
M0 No distant metastasis 
T0 No evidence of 
primary tumour 
N0 No regional lymph node 
metastasis 
M1 Distant metastasis 
Tis Carcinoma in situ: 
intraepithelial or 
invasion of lamina 
propria 
N1 Metastasis in 1-3 regional 
lymph nodes 
M1a Metastasis confined to 
one organ or site 
T1 Tumour invades 
submucosa 
N1a Metastasis in 1 regional 
lymph node 
M1b Metastases in more 
than one organ/site or 
the peritoneum 
T2 Tumour invades 
muscularis propria 
N1b Metastasis in 2-3 regional 
lymph nodes 
    
T3a Tumour extends <1 
mm beyond 
muscularis propria 
N1c Tumour deposit(s) in the 
subserosa, mesentery, or 
non-peritonealised 
pericolic or perirectal 
tissues without regional 
nodal metastasis     
T3b Tumour extends 1-5 
mm beyond 
muscularis propria 
N2 Metastasis in 4 or more 
regional lymph nodes 
    
T3c Tumour extends 5-15 
mm beyond 
muscularis propria 
N2a Metastasis in 4-6 regional 
lymph nodes 
    
T3d Tumour extends 15 
mm beyond 
muscularis propria 
N2b Metastasis in 7 or more 
regional lymph nodes 
    
T4a Tumour penetrates 
to the surface of the 
visceral peritoneum 
  
    
T4b Tumour directly 
invades or is 
adherent to other 
organs or structures 
  
    
Table 1.6 - UICC/AJCC TNM staging of colorectal cancer; 7th edition (2010). Adapted from 
https://cancerstaging.org/references-tools/quickreferences/Pages/default.aspx 
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The UICC/AJCC staging system was simplified by grouping into disease stages to allow 
easier selection to treatment. This divides the CRC staging into four major groups (I to IV) 
with further subdivision to A or B, including: 
 Stage 0: Tis, N0, M0 
 Stage I: T1, N0, M0; T2, N0, M0 
 Stage IIA: T3, N0, M0 
 Stage IIB: T4a, N0, M0 
 Stage IIC: T4b, N0, M0 
 Stage IIIA: T1-T2, N1/N1c, M0; T1, N2a, M0 
 Stage IIIB: T3-T4a, N1/N1c, M0; T2-T3, N2a, M0; T1-T2, N2b, M0 
 Stage IIIC: T4a, N2a, M0; T3-T4a, N2b, M0; T4b, N1-N2, M0 
 Stage IVA: Any T, any N, M1a 
 Stage IVB: Any T, any N, M1b. 
Due to the unreliability of radiological assessment for predicting nodal disease in the 
resection specimen accurate TNM staging is often only available on post-operative 
histopathological inspection. For this reason, a number of prefixes to the TNM system have 
been created to describe the origin of the information used for staging. These include: 
 c - for clinical classification  
 p - for histopathological staging of a surgical specimen 
 y - indicating the stage is assessed after chemotherapy and/or radiotherapy 
  r - for recurrent tumours after a substantial disease-free period  
 A - determined at post mortem  
Histopathological assessment of the post-resection specimen can provide further 
prognostic information beyond nodal staging, which may be beneficial in predicting 
outcome. The presence of tumour budding and poorly differentiated clusters of cancer 
cells or invasion into lymphatic vessels, blood vessels and perineural tissue has been shown 
to influence prognosis. However, these variables have not been incorporated in to a formal 
staging system, perhaps due to the significant observer error reported in the literature 
[109]. The Jass classification is currently the best utilised staging system that takes into 
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account some of the genetic abnormalities discussed previously, in addition to the macro- 
and microscopic characteristics of the tumour. It is used for the molecular classification of 
CRC [110]. 
Accurate staging of patients is essential as it allows prognostication and allocation to 
treatment. Currently patients with nodal disease are recommended to receive adjuvant 
chemotherapy. Further studies are needed to clarify whether a select group of node 
negative patients would benefit from adjuvant therapy based on histopathological 
assessment of the primary tumour. 
Feature Group 1 Group 2 Group 3 Group 4 Group 5 
MSI status H S/L S/L S H 
Methylation +++ +++ ++ +/– +/– 
Ploidy Dip > An Dip > An An > Dip An > Dip Dip > An 
APC +/– +/– + +++ ++ 
KRAS – + +++ ++ ++ 
BRAF +++ ++ – – – 
TP53 – + ++ +++ + 
Location R > L R > L L > R L > R R > L 
Gender F > M F > M M > F M > F M > F 
Precursor SP SP SP/AD AD AD 
Serration +++ +++ + +/– +/– 
Mucinous +++ +++ + + ++ 
Dirty necrosis + + ? +++ + 
Poor differentiation  +++ +++ + + ++ 
Circumscribed +++ + ? ++ ++ 
Tumour budding +/– + ? +++ + 
Lymphocytes +++ + ? + +++ 
MSI, microsatellite instability; H, high; S, stable; L, low; Dip, diploid; An, aneuploid; 
Serration, serrated morphology; SP, serrated polyp; AD, adenoma; Circumscribed, 
circumscribed invasive margin. 
Table 1.7 – Jass classification system for CRC as adapted from Jass, 2007 [110]. 
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1.6 Surgical management of colorectal cancer  
The surgical resection of the primary tumour, with the draining lymph nodes or metastatic 
disease where possible, remains the mainstay of treatment in CRC. The exact oncosurgical 
strategy employed can vary considerably with local T stage, the location of the primary 
tumour or the presence and location metastases, as can the timing of resection in relation 
to other treatment modalities.  
1.6.1. Local resection of the primary tumour 
Local excision is possible for adenomas or early CRC, such as those confined to the 
submucosa. This can be undertaken at colonoscopy for colonic tumours or using a variety 
of transanal techniques for rectal lesions. Endoscopic Mucosal Resection (EMR) and 
Endoscopic Submucosal Dissection (ESD) have allowed the local resection of larger colonic 
polyps, with ESD resulting in a deeper margin of resection into the layers of the colonic wall 
and excision of larger lesions. Local recurrence rates for EMR and ESR are 13% and 1% 
respectively, with no statistical differences in complication rates reported on meta-analysis. 
However, ESD is a more difficult technique and procedures take longer to complete [111]. 
Transanal excision (TE), Transanal Endoscopic Microsurgery (TEMS) and Transanal 
Minimally Invasive Surgery (TAMIS) are all utilised for the local excision of larger rectal 
lesions specifically. TEMS has been compared with radical resection for T1 and T2 rectal 
tumours, with an increased risk of local recurrence reported with TEMS (11% versus 3%); 
distant recurrence rates were equivocal [112]. However, local resection is associated with 
fewer postoperative complications and lower mortality in T1 lesions specifically [113]. 
TAMIS is a relatively recent development with published data consisting mostly of small 
case-series [114].  
A concern with local resection of colorectal cancer is incomplete histopathological staging. 
Excision and examination of the draining lymph nodes is not undertaken and nodal staging 
is reliant on radiology. This may result in under-treatment, as lymph node positive patients 
may be incorrectly excluded from the benefit of adjuvant chemotherapy. Local excision for 
CRC is therefore only advisable in early low-risk tumours or in patients unfit for formal 
resection. Identifying those patients considered to have low risk lesions is challenging with 
positive nodes reported in at least 6% of T1 tumours [115, 116]. 
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1.6.2 Radical resection of the primary tumour  
Radical resection of CRC refers to the removal of the section of bowel containing the 
primary tumour with its draining lymph nodes, which follow the vascular supply to that 
segment. The arterial supply is divided at the highest point possible, while preserving the 
bloody supply to non-resected segments. For tumours in the right colon a right hemi-
colectomy is performed with division of the ileo-colic artery close to its origin from the 
superior mesenteric artery, which supplies much of the small bowel. For tumours in the left 
colon and rectum the inferior mesenteric artery is ligated as it branches from the 
abdominal aorta. If the patient is deemed to be at a lower risk for a leak, then an 
anastomosis is created to restore intestinal continuity and avoid the formation of a stoma. 
The anastomotic leak rate was 8.7% in patients undergoing colonic resection for malignant 
disease in a large multicentre prospective study. An increased risk of leak was noted with 
obesity, male sex, poor nutrition, anticoagulation treatment, emergency surgery and 
intraoperative complications [117].  
The proximal division of vessels maximises the mesenteric resection and therefore lymph 
node yield, allowing more accurate histopathological staging and prognostication. The 
National Cancer Institute and the National Quality Forum recommend that at least 12 
lymph nodes are examined for adequate staging [118]. 
Anterior resection with total mesorectal excision (TME) has become the standard surgical 
technique for the radical resection of rectal cancers in which clear distal margins can be 
achieved. First described in 1988, TME involves removal of the rectum with its supporting 
mesentery from the pelvis, allowing wider resection margins. The anal canal is not removed 
and intestinal continuity can be restored with the option to perform a de-functioning loop-
ileostomy. TME dissection reduced local recurrence rates from 30% to 3-6% [119, 120]. 
Involvement of the circumferential resection margin is now believed to be a predictor of 
local recurrence, distant metastasis and survival [121].  
The widespread adoption of this technique has reduced the number of abdomino-perineal 
excisions of the rectum (APER) performed. This entails removal of the rectum and anal 
canal in its entirety with formation of a permanent colostomy. Combinations of 
neoadjuvant chemoradiation, total mesorectal excision, intersphincteric proctectomy and 
colonic-J pouch to anal anastomosis means that sphincter preservation can be achieved in 
most patients, reducing the rate of APER [122]. 
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Resections for CRC may be performed using an open, laparoscopic or robotic approach. 
International multi-centre studies have attempted to confirm the oncological equivalence 
of laparoscopic colorectal cancer surgery to open. Early results from the Colon Cancer 
Laparoscopic or Open Resection (CoLOR) trial reported equivalent short-term outcomes, 
including complication rate, mortality, positive resection margins and blood loss during 
surgery between groups [123]. While the Conventional versus Laparoscopic-Assisted 
Surgery in Colorectal Cancer (CLASSIC) trial concluded that, for colonic resections, 
laparoscopic techniques are oncologically equivalent but reported a non-significant 
increased rate of circumferential margin positivity for laparoscopic anterior resections. This 
could translate to a higher rate of local recurrence in the longer-term, despite a higher rate 
of TME in the laparoscopic-assisted group [124]. Longer-term analysis of data from the 
CoLOR trial found no difference in overall and disease free survival, but could not rule out a 
difference in disease-free survival at three years in favour of open colectomy. However, 
this difference was felt to be small enough to justify the use of laparoscopic surgery in daily 
practice [125]. Studies agree that laparoscopic surgery reduces wound infection rates, 
allows earlier recovery of bowel function, reduces narcotic use, decreases overall morbidity 
and results in a shorter hospital stay, at the cost of modest increase in operative times. 
Robotic surgery for rectal cancer remains in its relative infancy. Published data consists of 
short-term outcome reporting of small single centre experience. Meta-analysis of four 
randomised control trials comparing robotic to laparoscopic resection for rectal cancer 
reported no differences in complication rates, length of hospital stay, proximal margin, 
distal margin or harvested lymph node yield between techniques [126], but a lower 
conversion rate to open surgery has been reported for robotic rectal resection [127]. 
Results of an international, multicentre, prospective, randomised, controlled, unblinded, 
parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative 
treatment of rectal cancer (ROLARR) are awaited [128]. 
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1.6.3 Resection of metastatic disease 
Increasing numbers of patients are now offered potentially curative surgery for CRC 
metastases, particularly those confined to the liver. A more aggressive approach to 
neoadjuvant chemotherapy, combined with improved surgical techniques, brings more 
patients to resection. Variable survival rates are reported in those patients who undergo 
resection of liver metastases, ranging from 16% to 74% at five years [129]. 
Traditionally there was a conservative approach to the management of metastatic disease 
in the liver. Patients with 1-3 unilobar metastases which were resectable with a generous 
margin were considered for surgical management. Presenting with stage IV disease, a 
rectal primary,  multiple diffuse metastases, metastases larger than 5cm, a disease free 
interval of less than one year from the diagnosis of the primary and high serum 
carcinoembryonic antigen (CEA) were considered relative contraindications to curative 
surgical resection due to a poor prognosis [130]. 
The approach to the surgical resection of liver metastases is now more a consideration of 
both technical and oncological feasibility. Resection is considered when it is possible to 
remove all macroscopic disease with negative margins (refered to as an R0 resection), 
preserve blood supply and leave sufficient future remnant liver to ensure adequate hepatic 
function. The volume of liver remnant required to ensure adequate hepatic function 
depends on the quality of the remaining liver parenchyma; those with cirrhosis, steatosis or 
drug induced liver injury (DILI) require a larger liver remnant to maintain function [131]. 
National Institute for Health and Care Excellence (NICE) guidance (CG131) now 
recommends that surgery for metastatic disease in the liver be considered in those patients 
fit enough and in whom complete resection can be obtained leaving adequate a hepatic 
remnant. 
Radiofrequency ablation, microwave ablation and laser induced thermotherapy, performed 
at open surgery or percutaneously, offer less invasive alternatives to the surgical resection 
of liver metastases. Given the varying local progression rates reported with these 
techniques their role in the curative management of patients is unclear [132]. They are 
often reserved for unfit patients with low volume disease, as an adjunct to formal resection 
or in the non-curative setting. 
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Guidance on the surgical management of extra-hepatic metastases from CRC is less clear. 
Pulmonary metastasectomy in a select group of patients with lung limited metastases 
resulted in five year survival rates greater than 50% [133]. Results of the Pulmonary 
Metastasectomy in Colorectal Cancer (PulMICC) trial, a feasibility study randomising to 
surgical resection or active monitoring, will hopefully add clarity to the role of surgery for 
metastatic colorectal cancer in the thorax when results are published [134]. 
The best surgical approach for patients presenting with a resectable primary tumour and 
synchronous metastatic disease requires clarification due to a lack of high-level prospective 
data. Options include a classical approach (primary first and then liver), reverse approach 
(liver first and then primary) or to synchronously (simultaneously) resect disease at both 
sites within a single procedure. All of these approaches would need to be integrated with 
neoadjuvant or adjuvant chemotherapy and possibly radiotherapy in some cases of rectal 
cancer specifically. A systematic review of the surgical management of synchronous 
metastatic disease identified 18 papers in which 21 comparisons had been performed 
between two or more of these strategies; concluding that no strategy is inferior to the 
others [135]. A more recent review noted no difference in survival between the three 
surgical approaches [136]. Based on the evidence to date, patients with synchronous 
metastatic disease should be managed on an individual basis by a specialist 
multidisciplinary team. 
1.7 Radiotherapy in the treatment of rectal cancer 
Radiotherapy is a recognised treatment utilised in the management of patients with rectal 
cancer to shrink locally advanced tumours and facilitate complete surgical resection, or to 
reduce the risk of local recurrence. The potential complications of radiotherapy, such as 
increased bowel frequency, incontinence and delayed wound healing, should always be 
balanced against the potential benefits. 
1.7.1 Effect of radiation 
Radiotherapy works through the direct and indirect ionisation of atoms. Direct effects 
occur when radiation causes ionisation of atoms in DNA, resulting in double strand breaks 
or adducts, essential to the survival and reproduction of the cell. The indirect action is the 
result of the ionisation of water leading to the formation of free radicals. Oxygen is 
required for free radical formation and therefore radiotherapy is less effective in relatively 
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hypoxic cells, such as those found in central areas of large solid tumours [137]. The effect 
of radiotherapy is more marked in malignant cells due to their rapid replication rate, with 
progeny requiring the correct DNA to survive or replicate. The relative mobility of the colon 
and small bowel within the abdomen, combined with the risk of radiation enteritis due to 
the rapidly dividing small bowel epithelial cells, limits the use of radiotherapy to the 
treatment of rectal cancer. The fixed position of the rectum in the pelvis allows more 
accurate tumour targeting and reduces the risk of small bowel irradiation. 
1.7.2 Resistance to radiotherapy 
The ability of cancer cells to repair DNA damage is at least partially responsible for the 
variation in response seen in tumours. Base excision repair (BER) mechanisms remove 
damaged bases that could otherwise cause mutations by mispairing or lead to breaks in 
DNA during replication. AP endonuclease 1, DNA polymerase β and DNA ligase III with its 
cofactor XRCC1 are all believed to be key proteins involved in BER and have been 
investigated as both biomarkers and therapeutic targets for radiotherapy treatment [138]. 
The tumour microenvironment may also influence radiotherapy response. Vascular, 
stromal and immunological changes following radiotherapy treatment may all alter tumour 
regression. There are numerous potential targets within the tumour microenvironment 
which could be manipulated for radio-sensitisation. These are categorised as hypoxia, 
fibrosis, cancer-associated fibroblast and immune related, dependent on their area of 
action [139]. (Table 1.8) 
All these factors mean a number of patients treated with radiotherapy will receive little or 
no benefit but are still exposed to the potential risks and complications. Up to 40% of 
patients have been shown to experience no tumour regression following radiotherapy 
[140]. Predicting and modifying this response is essential to improving outcomes and 
reducing overtreatment.  
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Resistance 
mechanism 
Drugs Targets Mode of action 
Immune 
response 
Ipilimumab CTLA4 T cell activation 
Nivolumab and 
pembrolizumab 
PD1 T cell exhaustion 
Imiquimod TLR7 DC activation 
Oncolytic viruses Tumour cells Activate immune response 
Future inhibitors IL-6 and IL-10 T cell activation 
PDL1, TIM3 and LAG3 Prevent T cell exhaustion 
Future agonists GM-CSF, CXCL16, OX40, CD40L, 
CD80 and CD137 
T cell recruitment and activation 
CCL3, CCL5, IL-2, IL-4, IL-12 and 
IRX-2 
Activate immune response 
Hypoxia Nitroimidazole derivatives 
(that is, nimorazole) 
Hypoxic cells Reduce tumour hypoxia 
Bioreactive albumin–MnO2 
nanoparticles 
Hypoxic cells Reduce tumour hypoxia 
Acriflavine and YC-1 HIF1α Reduce hypoxia response pathway 
activity 
Aflibercept All VEGF molecules and PlGF Vessel normalization 
AMG386 ANG1 and ANG2 Inhibit pBMDC recruitment 
Endostar VEGF, TGFβ, HIF1α and bFGF Inhibit angiogenesis 
AMD3100 CXCL12 and CXCR4 Inhibit BMDC recruitment and 
vasculogenesis 
Integrin inhibitors (cilengitide, 
vitaxin and volociximab) 
Integrins αvβ3, αvβ5 and α5β1 Inhibit angiogenesis 
Future inhibitors Integrins α6β1 and α6β4 Reduce endothelial cell survival 
and inhibit angiogenesis 
PlGF and ANG2 Vessel normalization and 
overcome resistance to anti-VEGF 
therapies 
Fibrotic 
processes 
BIBF1000 and BIBF1120 PDGF, VEGF and bFGF 
receptors 
Reduce GF signalling and TME 
remodelling; fibrosis 
Imatinib, nilotinib and 
dasatinib 
TGFβ and PDGF GF signalling; collagen synthesis 
Vismodegib, saridegib and 
sonidegib 
SMO Reduce HH signalling; fibrosis 
Suramin PDGF, EGF, TGFβ, FGF2 and IGF 
receptors and heparanase 
enzymes 
Reduce GF signalling and TME 
remodelling; fibrosis 
ST0001, PG545 and M402 Heparanase Inhibit TME remodelling 
SD-208 TGFβR1 Inhibit TGFβ signalling 
Simtuzumab LOXL2 Reduce TME remodelling; liver 
fibrosis 
81C6 and F16SIP TNC Reduce CAF-mediated TME 
remodelling 
Future inhibitors HGF, CTGF, MMP2, MMP3, and 
integrins α11β1, αvβ6 and 
α3β1 
TME activation and remodelling; 
radiation-mediated fibrosis 
ANG, angiopoetin; bFGF, basic fibroblast growth factor; BMDC, bone marrow-derived cell; CAF, cancer-associated fibroblast; CTGF, connective tissue growth factor; 
CTLA4, cytotoxic T lymphocyte antigen 4; CXCL, chemokine (C-X-C motif) ligand; CXCR4, C-X-C chemokine receptor 4; DC, dendritic cell; EGF, epidermal growth factor; 
FGF2, fibroblast growth factor 2; GF, growth factor; GM-CSF, granulocyte–macrophage colony-stimulating factor; HGF, hepatocyte growth factor; HH, Hedgehog; HIF1α, 
hypoxia-inducible factor 1α; IGF, insulin-like growth factor; IL, interleukin; IRX2, iroquois homeobox 2; LAG3, lymphocyte activation gene 3; LOXL2, lysyl oxidase-like 2; 
MMP, matrix metalloproteinase; pBMDC, perivascular bone marrow-derived cell; PD1, programmed cell death protein 1; PDL1, programmed cell death protein ligand 1; 
PDGF, platelet-derived growth factor; PlGF, placental growth factor; SMO, Smoothened; TGFβ, transforming growth factor-β; TGFβR1, transforming growth factor-β 
receptor 1; TIM3, T cell immunoglobulin mucin 3; TLR7, Toll-like receptor 7; TME, tumour microenvironment; TNC, tenascin C; VEGF, vascular endothelial growth factor.  
Table 1.8 - Tumour microenvironment therapeutic biomarkers for radio-sensitisation. Adapted 
from Barker, 2015 [139]. 
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1.7.3 Short-course pre-operative radiotherapy (SCPRT) 
Short-course pre-operative radiotherapy (SCPRT) is given to patients to reduce the risk of 
post-surgical local recurrence. SCPRT is an irradiation regimen designed to not delay 
definitive surgical treatment; a typical regimen is 25Gy in five equal fractions delivered over 
five days. This approach was supported by a number of randomised trials, the most 
significant of which was the Swedish Rectal Cancer Trial which demonstrated improved 
survival and reduced local recurrence rates with compared with surgery alone, with median 
follow up of 13 years in the more recently published data [141, 142]. Some caution should 
be exercised in interpreting these data, with many of the patients operated on before the 
widespread introduction of TME.  
More recent trials do confirm similar benefits. The Dutch Colorectal Cancer Study Group 
trial compared SCPRT and TME surgery with TME surgery alone. Overall survival at two 
years was comparable between groups but the rate of local recurrence was 2.4% in those 
receiving SCPRT-TME and 8.2% in the group receiving TME alone [143]. Similarly the 
Medical Research Council CR07 trial compared SCPRT with selective post-operative 
chemoradiotherapy for patients with CRM involvement. Eighty centres randomised 1350 
patients to treatments with a 61% reduction in local recurrence and 6% increase in disease 
free survival at three years in those patients undergoing SCPRT [144]. 
1.7.4 Long-course neoadjuvant chemoradiotherapy (LCCRT) 
Long-course radiotherapy involves the delivery of 45-50Gy over 5-6 weeks at 1.8 or 2.0Gy 
per fraction, generally followed by surgery 4-8 weeks later. As with SCPRT, there is good 
evidence for improved local control but no evidence of an increase in survival benefit. 
Controversy exists as to whether there is any additional benefit to LCCRT when compared 
with SCPRT; the Trans-Tasman Radiation Oncology Group trial 01.04 concluded there were 
no statistically significantly differences between the two treatments in 326 randomised 
patients with T3 lesions [145]. Long-term results of the Stockholm III Trial of radiotherapy 
regimens for rectal cancer are awaited. This three-armed trial randomises patients with 
primary operable rectal cancers to either SCPRT with immediate surgery, SCPRT with 
surgery delayed 4-8 weeks or long-course RT with surgery delayed 4-8 weeks. Interim 
results have only compared SCPRT to SCPRT with delayed surgery, suggesting an improved 
tumour regression in delayed surgery [146]. 
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 A potential benefit of LCCRT is the ability to combine it with neoadjuvant chemotherapy. 
Trials (FFCD 9203 and EORTC Radiotherapy Group 22921) compared preoperative 
chemoradiotherapy to radiotherapy alone for the management of T3-T4 rectal cancer 
concluding that, despite a moderate increase in acute toxicity and no impact on overall 
survival, the addition of chemotherapy significantly improves local control [147, 148]. Only 
one trial has compared SCPRT and LCCRT in patients with operative disease; longer courses 
of radiotherapy were associated with greater tumour down-staging and CRM-negative 
resections but resulted in higher rates of radiation toxicity and no improvement in local 
recurrence or survival [149]. More recently the German CAO/ARO/AIO-04 study concluded 
that the addition of oxaliplatin to fluorouracil-based neoadjuvant chemoradiotherapy alone 
significantly improved the disease-free, but not overall,  survival of patients with clinically 
staged T3-4 or N1-2 rectal cancer [150]. The potential benefits of LCCRT to local disease 
control must always be balanced with the risk of side effects. 
The timing of LCCRT relative to surgical excision has been subject to debate. However, the 
recent CAO/ARO/AI0 94 trial, comparing pre-and post-operative chemoradiotherapy in the 
context of standardised TME surgery and adjuvant chemotherapy, reported lower 
recurrence rates when the radiotherapy is delivered pre-operatively (7.1% vs. 10% at 10 
year follow up) [151].  
1.7.5 Selection of patients to radiotherapy 
With the universal acceptance of TME surgery for rectal cancer the routine use of 
radiotherapy has become more controversial. However, for patients with a threatened 
CRM or at high risk of local recurrence, radiotherapy may be indicated.  
More accurate prediction of CRM involvement, defined as a tumour encroaching upon the 
mesorectal fascia and therefore likely to result in a positive CRM given a satisfactorily 
performed TME resection, has become possible with the routine use of MRI staging in 
rectal cancer. The MERCURY study group reported the best cut-off distance for predicting 
CRM involvement post-resection using pre-operative MRI was 1mm; five year follow-up 
highlighted a fall in disease free and overall survival  in patients whose tumour was closer 
than this to the CRM on MRI [152]. It has also been suggested that MRI prognostication can 
be used to define tumours likely to have a poor prognosis which should receive 
radiotherapy prior to resection, despite a low risk of CRM involvement [153]; poor 
prognosis tumours were defined by the criteria displayed in table 1.9.  
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MRI feature Good Prognosis Poor Prognosis 
CRM >1mm clear <1mm involved 
Low rectal <5cm Intersphincteric plane clear Intersphincteric plane involved 
T stage T1, T2 or T3a-b T3c-d or T4 
Extra-mural venous invasion Absent Present 
N stage Any Any 
Table 1.9 - Good and poor prognosis rectal cancers as defined by MRI pre-operative local staging. 
Adapted from Taylor, 2011 [153]. 
Attempts to select between SCPRT or LCCRT in patients with rectal cancer lead to the 
publication of NICE guidance in 2011 (CG131). These divide rectal cancers into low, 
moderate or high risk groups; low risk tumours proceed straight to surgery, moderate risk 
tumours with no CRM involvement receive SCPRT and high risk tumours are treated with 
LCCRT. Criteria for defining risk groups are displayed in table 1.10. 
 
Risk of local recurrence Characteristics of rectal tumours predicted by MRI 
High A threatened (<1 mm) or breached resection margin or 
  
Low tumours encroaching onto the intersphincteric plane or with 
levator involvement 
Moderate Any cT3b or greater, in which the potential surgical margin is not 
threatened or 
  
Any suspicious lymph node not threatening the surgical resection 
margin or 
 
The presence of extramural vascular invasion 
Low cT1 or cT2 or cT3a and 
  No lymph node involvement 
Table 1.10 - Risk of local recurrence for rectal tumours as predicted by MRI according to NICE 
guidance CG131. Low risk tumours are recommended to proceed straight to surgery, moderate to 
SCPRT if no CRM involvement and high risk to LCCRT. Adapted from NICE guidance CG131. 
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1.7.6 Other uses for radiotherapy in rectal cancer 
Discussion so far has focused on the use of radiotherapy to reduce the risk of local 
recurrence in rectal cancer in combination with surgical resection but it may have a role in 
other scenarios. 
The Papillon system has been used for the delivery of direct contact local radiotherapy to 
rectal cancer, often in patients not suitable for TME resection or in conjunction with a local 
resection technique such as TEMS. A case series of 220 patients with T1-T3 tumours less 
than 3cm in diameter was reported from the Clatterbridge Centre of Oncology. A local 
control rate of 93% was reported, with no significant morbidity, accepting that their 
population was highly selective and that close follow-up and plans for salvage surgery are 
advised [154]. 
Radiotherapy may also help to alleviate symptoms, such as pain or bleeding, in the 
palliative setting when disease is unresectable or has reoccurred post-resection. A total 
radiotherapy dose of 20-60Gy was shown to relieve pain and bleeding in 75% of patients 
for a median duration of 6-9 months [155]. 
1.8 Chemotherapeutics used in colorectal cancer 
The use of chemotherapy for advanced and metastatic CRC (mCRC) began in the late 1950s 
with the development of 5-FU. The use of alternative agents has dramatically altered the 
approach to the management of these patients. Combination regimens have become 
standard practice since their introduction in the early 2000’s and include; 5-FU, oxaliplatin 
and leucovorin (FOLFOX); 5-FU, irinotecan and leucovorin (FOLFIRI); and 5-FU, oxaliplatin, 
irinotecan and leucovorin (FOLFIRINOX) [156]. The increasing understanding of tumour 
biology had led to the development of additional biological agents, such as cetuximab, 
panitumumab and bevacizumab, which can be combined with the standard chemotherapy 
regimens. 
 
 
  
66 
1.8.1 5-Fluorouracil (5-FU) 
The fluotopyrimidine anti-metabolite 5-FU remains the primary chemotherapeutic agent 
used in the treatment of CRC. Analogous to uracil, it substitutes hydrogen with a fluorine 
atom at the C5 position and acts as a specific uracil antagonist. Misincorporation of 5-FU 
into RNA and DNA arrests RNA synthesis and inhibition of the nucleotide synthetic enzyme 
thymidylate synthase (TS) results in the arrest of cell division and tumour growth.   
After entering the cell via a facilitated transport mechanism, 5-FU is converted to three 
main active metabolites: fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine 
triphosphate (FdUTP) and fluorouridine triphoshate (FUTP). The predominant mechanism 
of 5-FU activation is conversion to fluorouridine monophosphate (FUMP) by orotate 
phosphoribosyltransferase (OPRT), with phosphoribosyl pyrophosphate (PRPP) as the 
cofactor, or via fluorouridine (FUR) through the sequential action of uridine phosphorylase 
(UP) and uridine kinase (UK). FUMP is subsequently phosphorylated to fluorouridine 
diphosphate (FUDP) which can then be further phosphorylated to FUTP, or further 
converted to fluorodeoxyuridine diphosphate (FdUDP) by ribonucleotide reductase (rr). 
FdUDP is then phosphorylated or dephosphorylated to FdUTP and FdUMP respectively. 
Alternatively, 5-FU can undergo thymidine phosphorylase catalysed conversion to 
fluorodeoxyuridine (FUDR) which is phosphorylated by thymidine kinase (TK) to FdUMP. 
The rate-limiting step in 5-FU catabolism is the enzyme dihydropryrimidine dehydrogenase 
(DPD) that converts 5-FU to dihydrofluorouracil (DHFU); it is believed that up to 80% of 
administered 5-FU is broken down by DPD in the liver (figure 1.3) [157].  
Frequently occurring side effects of 5-FU therapy include nausea, vomiting, diarrhoea, 
mucositis, headache, myelosuppression and alopecia.  
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Figure 1.3 – The activation and metabolism of 5-FU. Adapted from Longley, 2003 [157]. 
1.8.2 Leucovorin 
High intracellular levels of the reduced folate CH2 THF are necessary for optimal binding of 
FdUMP to TS. As a result, 5-FU is given in combination with leucovorin (LV, 5'-
formyltetrahydrofolate) to expand the intracellular concentration of CH2 THF and 
potentiate the effects of 5-FU. Leucovorin is transported into cells via the reduced folate 
transporter, anabolised and polyglutamated. This not only increases intra-cellular retention 
but further help stabilise the complex formed with FdUMP and TS [158].  
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1.8.3 Oxaliplatin 
Oxaliplatin is a third-generation platinum compound with a 1,2-diaminocyclohexane 
(DACH) ring. It undergoes intra-cellular transformation into a number of active metabolites 
all of which contain the DACH ring. The primary target of all platinum complexes is DNA, 
particularly guanine, resulting in DNA inter- and intra-stand cross link adducts which 
prevent replication and transcription [159]. The main side effect of oxaliplatin is 
polyneuropathy, but patients may also experience nausea, vomiting, diarrhoea, mucositis, 
headache and myelosuppression [160]. Hepatic sinusoidal obstruction syndrome has also 
been reported following the administration of oxaliplatin based regimens. Evidence of this 
process was reported in the livers of 51% patients receiving oxaliplatin on histological 
assessment [161].  
1.8.4 Irinotecan 
Irinotecan (7-ethyl-10[4-(1-piperidino)-1-] carbonyloxycamptothecin (CPT-11, Camptostar) 
is a camptothecin analogue derived from Camptotheca acuminate [162]. It is a pro-drug 
metabolically activated to 7-ethyl-10-hydroxycamptothecin (SN-38) by cleavage of a 
dipiperidino side chain [163]. Although more cytotoxic than irinotecan (100-1000-fold), SN-
38 is poorly soluble and highly cytotoxic, meaning it cannot be administered systemically 
[164]. The primary therapeutic target of SN-38 is Topoisomerase 1 (Topo1), which is 
responsible for the relaxation of supercoiled DNA by the cutting of one DNA strand. It then 
allows the intact strand to pass through the DNA-Topoisomerase cleavage complex and re-
joins the cleaved DNA strand without damage [165]. The persistence of single-stranded 
DNA breaks can lead to double-stranded breaks due to the interaction at advancing 
replication forks and cell division subsequently stalls in S phase [166]. If these DNA breaks 
remain unrepaired then apoptotic cell death results [167]. 
Irinotecan administration can result in severe neutropenia and diarrhoea. The incidence of 
early-stage diarrhoea is as high at 80% and is dose dependent. Late-stage diarrhoea, 
occurring over 24 hours after administration, occurs in 60–87% of patients [168]. Although 
early-stage diarrhoea is often treatable with atropine, late-stage diarrhoea is more difficult 
to manage and can result in severe colitis. Hepato-toxicity is also reported, with 12-15% 
developing steatohepatitis [169]. 
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A number of intracellular proteins play a role in the activation, transport, metabolism and 
excretion of irinotecan including the carboxylesterases (CES), CYP3A, UDP-
glucuronosyltransferases (UGT), adenosine-triphosphate binding cassette (ABC) 
transporters and β-glucuronidase. Variations in these proteins are thought to contribute to 
inter-patient differences in the side effects, pharmacokinetic profile and response rates 
seen with irinotecan therapy; there is a growing interest in using these as potential 
predictors of response and toxicity (figure 1.4).  
 
 
Figure 1.4 – Diagram displaying the metabolism of irinotecan. The key pathways and enzymes are 
highlighted (key pathway = red arrow and key enzyme = yellow bubble). 
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1.8.4.1 Carboxylesterase mediated hydrolysis 
The CES are phase 1 drug metabolism enzymes located in the endoplasmic reticulum and 
responsible for the hydrolysis of irinotecan to the active metabolite SN-38. The most 
abundant and well-studied human enzymes are CES1 and CES2. CES2 has been 
demonstrated to be a better converter of irinotecan to SN-38 with a 64-fold higher catalytic 
efficiency [170]. Relative CES expression across tissue types has also been explored in an 
attempt to establish the primary site of irinotecan activation. CES2 expression was found to 
be greater than CES1 in normal colon and in CRC, while in normal liver CES1 was six times 
more abundant than CES2. Despite the lower expression of CES2 than CES1 in hepatic 
parenchyma, CES2 is still two to three times more abundant than in CRC tissue and, as a 
result, the liver may be responsible for up to 50% of the conversion of irinotecan to SN-38 
[171, 172]. The anti-tumourigenic effects of irinotecan are most likely to be the result of 
both local production of SN-38 in tumour tissue and SN-38 produced in the liver and 
transported to the tumour site either through the bloodstream or directly after excretion in 
bile. 
In primary and metastatic tumour tissue there was a good correlation between CES2 
expression and irinotecan activity; large variations in CES expression were noted between 
patient samples [168]. A study investigating the hepatic metabolism of irinotecan as a 
potential predictor of tumour response to irinotecan-eluting beads found response to 
treatment positively correlated with CES2 expression in human liver tissue [173]. 
Additionally, CES2 mRNA expression in peripheral blood mononuclear cells was 
demonstrated to predict irinotecan to SN38 activation [174]. These findings suggest that 
induction of CES expression could improve the conversion of irinotecan to SN-38 and 
therefore the efficacy of therapy. This theory was been explored in CRC cell lines and 
xenograft studies, demonstrating improved sensitivity to irinotecan with overexpression of 
CES2 using a recombinant adenoviral vector [175]. 
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1.8.4.2 Cytochrome P450 3A (CYP3A) metabolism 
Irinotecan can also be metabolised directly to the pharmacologically inactive compounds 
APC and NPC by the Cytochrome P450 3A subfamily members CYP3A4 and CYP3A5 [176]. 
APC is the more abundant of these metabolites and is formed by oxidation of the terminal 
piperidine ring, while NPC results from cleavage of the distal piperidine ring [177, 178]. 
CYP3A expression is highest in human hepatic parenchyma, but with a 30-fold difference in 
protein and mRNA expression reported between individuals, suggesting most direct 
inactivation of irinotecan occurs in the liver [179]. CYP3A4 expression, which is believed to 
produce the majority of the inactive metabolites, is lower in colorectal tumour tissue than 
in normal colon, perhaps implying that reduced direct deactivation of irinotecan may make 
CRC tissue more chemo-susceptible [180]. Within the setting of a randomised control trial, 
modifying the dose of irinotecan based on CYP3A function; calculated by an algorithm 
based on the patient’s midazolam clearance, gamma-glutamyl-transferase level and height; 
resulted in an improved predictability of the pharmacokinetic and toxicity profile of the 
drug, lowering the incidence of severe neutropenia [181]. 
1.8.4.3 UDP-glucuronosyltransferase 
UDP-glucuronosyltransferase (UGTs) are a group of enzymes, bound to the endoplasmic 
reticulum, involved in the phase II metabolism of irinotecan. UGTs are responsible for the 
glucuronidation of SN-38 to the inactive metabolite SN-38G, allowing its conjugation and 
excretion. The liver is the predominant site of glucuronidation, but considerable variation 
exists (52-fold) in the conversion of SN-38 to SN-38G by microsomes isolated from human 
liver homogenate [177, 182]. 
Several studies have investigated the effects of polymorphisms in UGT’s on SN-38 
glucuronidation, the most extensively investigated of which are the isoforms of UGT1A1. 
UGT1A1 is involved in the conjugation of bilirubin and therefore plays a key role in drug 
excretion; mutations in UGT1A1 are implicated in Gilbert’s syndrome, characterised by an 
inability to conjugate bile and intermittent hyperbilirubinaemia. The UGT1A1*28 
polymorphism results in reduced enzyme production and therefore SN-38 glucuronidation 
due mutations in the promoter region [183]. The effect of the UGT1A1*28 polymorphism 
on irinotecan toxicity in CRC has been the subject of a number of studies (Table 1.11), the 
results of which have been assessed by meta-analysis. This study concluded that 
homozygosity (Odds ratio = 4.79, p<0.00001) and heterozygosity (Odds ratio = 1.68, 
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p<0.0001) of UGT1A1*28 was associated with an increased risk of neutropenia, regardless 
of the dose of irinotecan. The incidence of severe diarrhoea was only significantly higher in 
the homozygote group (Odds ratio = 1.78, p = 0.009) at medium and higher doses of 
irinotecan [184]. As a result of these data UGT1A1*28 genotyping should be considered 
prior to commencing irinotecan based therapies to allow dose modification.  It could be 
hypothesised that impaired glucuronidation of SN-38 could lead to accumulation of the 
active metabolite and increased irinotecan efficacy, but this theory was not supported in 
the conclusions of a high quality meta-analysis [185]. 
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Study  Country, race 
Phase of 
clinical 
trial 
No. of 
patients 
(male%) 
Age (a) 
Population 
source 
Mutation 
detection 
methods 
Regimen 
IRI dose 
(mg m
−2
)/schedule 
Grade 
criteria 
Neutropenia 
grade 3–4 (%) 
Diarrhoea 
grade 3–4 (%) 
Study 
design 
Lamas et al. Spain, U U 100 (63.4) 67 U SPR FOLFIRI 180/biweekly N3 18 (18.0) 12 (12.0) R 
Shulman et al. Israel, C I 214 (46.3) 63 M SPR 
TEGAFIRI, 
XELIRI, 
FOLFIRI, IFL 
U U 48 (22.4) 19 (8.9) R 
Martinez et al. Spain, C III 149 (U) U M Sequencing FOLFIRI, FUIRI 
80/weekly or 
180/biweekly 
U 31 (20.8) 45 (30.2) R 
McLeod et al. USA/UK/Canada, mainly C III 212 (U) 61 M PYRS IFL, IROX 
100–125/weekly or 
200/every 3 weeks 
N2 
Only grade 4: 28 
(13.2) 
60 (28.3) P 
Glimelius et al. 
Sweden/UK/Norway, 
mainly C 
III 136 (U) 62 M SPR 
FLIRI, Lv5FU-
IRI 
180/biweekly N2 18 (13.2) 10 (7.4) R 
Braun et al. UK, U III 326 (U) 64 M SPR IrFu, IRI 
300–350/every 3 
weeks, 180/biweekly 
C2 35 (10.7) 18 (5.5) P 
Parodi et al. USA, U III 110 (52.2) 60 M SPR 
FOLFIRI, mIFL, 
CapeIRI 
125 or 180/ biweekly, 
250/every 3 weeks 
U 42 (38.2) / P 
Ferraldeschi et 
al. 
UK, mainly C U 92 (69.0) 63 S SPR 
FOLFIRI/ IRI—
VEGF 
inhibitor, 
CapeIRI, UFT- 
Lv- IRI- OX 
180/biweekly N2 16 (17.4) 6 (6.5) P 
Toffoli et al. Italy, C I 250 (64.8) 61 M PYRS 
FOLFIRI, 
mFOLFIRI 
180/biweekly N2 35 (14.0) 21 (8.4) P 
Kweekel et al. Netherlands, C III 218 (62.8) 61 M PYRS CapeIRI, IRI 
250 or 350/every 3 
weeks 
N2 / 48 (22.0) R 
Ruzzo et al. Italy, C U 146 (55.6) 61 M SPR FOLFIRI 180/biweekly N2 34 (23.0) / P 
Côté et al. France, C III 89 (U) U M SPR FOLFIRI 180/biweekly N2 19 (21.3) / P 
Massacesi et al. Italy, C II 56 (52.7) 64 M Sequencing IRI- raltitrexed 80/weekly N2 4 (7.1) 10 (17.9) P 
Carlini et al. USA, mainly C II 62 (55.0) 61 M SPR CapeIRI 100 or 125/weekly N2 2 (3.3) 20 (32.3) P 
Rouits et al. France, C U 73 (61.1) 62 S PYRS 
FOLFIRI, 
mFOLFIRI 
85/weekly or 
180/biweekly 
N2 22 (30.1) 13 (17.8) R 
Marcuello et al. Spain, C U 95 (63.3) 68 U SPR 
IRI-Tomudex, 
IRI-5FU-LV, 
IRI-5FU, IRI 
80/weekly or 
180/biweekly or 
350/every 3 weeks 
C2 / 29 (30.5) P 
Abbreviations: C, Caucasian; CAPe, capecitabine; C2/3, CTCAEv2/3, Common Terminology Criteria for Adverse Events version 2/3; IRI, irinotecan; LV, leucovorin; M, multicentre; N2/3, NCI-CTC v2/3, National Cancer Institute-Common Cytotoxicity Criteria version 2/3; OX(A), oxaliplatin; P, 
analysis was planned prospectively; PYRS, pyrosequencing; R, analysis was planned retrospectively; S, single centre; SPR, sizing of PCR products; Sequencing, other DNA sequencing methods; TEGAF, UFT/LV; U, unknown; 5FU, 5-fluorouracil; UFT, uracil/tegafur; VEGF, vascular endothelial 
growth factor; XEL, xeloda. a = median or mean age. 
Table 1.11 - Studies assessing the effect of UGT1A1*28 polymorphism on irinotecan toxicity. Adapted from Liu, 2014 [184]. 
  
74 
1.8.4.3 Adenosine-triphosphate binding cassette (ABC) transporters 
ABC transporters are adenosine-triphosphate (ATP) dependent transmembrane proteins 
responsible for the movement of a number of molecules across cell membranes. 
Irinotecan, SN-38, and their metabolites are all excreted by ABC transporters via a 
hepatobiliary pathway into the faeces and urine [186]. ABC transporters are classified into 
7 groups (ABCA to ABCG) based on the topology of their transmembrane domains [187]. 
ABCB1 (P-glycoprotein), ABCC2 (canalicular multi-specific organic anion transporter), and 
ABCG2 (breast cancer resistance protein) are the most studied of these and believed to be 
the most influential in the excretion of irinotecan and its metabolites [164, 188].   
Published data suggest a role for the ABC transporters in predicting irinotecan toxicity. In a 
study of 167 patients with metastatic CRC ABCC5 and ABCG1 polymorphisms were a 
predictor of severe diarrhoea following irinotecan therapy. ABCC1, ABCC2, ABCC5, and 
ABCG2 were shown to predict neutropenia in the same study [189]. There are conflicting 
data on the effect variations in these proteins have on the efficacy of irinotecan. Two 
variants of the ABCG2 gene were found to predict response to FOLFIRI treatment in 71 
patients with metastatic CRC [190].  
However, tissue microarray assessment of ABCB1 and ABCG2 protein expression in the 
primary tumours of 566 patients with metastatic CRC, recruited in the CAIRO study, found 
no correlation between expression and irinotecan response [191]. 
1.8.4.4 β-glucoronidase 
β-glucoronidase allows the reactivation of SN-38G by cleavage of the glucuronide group 
and, although also present at the colonic epithelium due to its release from bacteria, it 
accumulates in the tumour microenvironment due to lysosomal excretion from 
inflammatory cells and necrotic tumour tissue [192]. Plasmid transduction of CRC cells 
resulting in membrane tethering and overexpression of β-glucoronidase was found to 
increase cytotoxicity to SN-38G by up to 80-fold. These finding were confirmed in vivo 
where an enhanced response to irinotecan was confirmed in mice flank grafted with β-
glucoronidase overexpressing CRC cell lines [193]. 
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1.8.4.5 Enterohepatic reactivation 
Faecal excretion accounts for 64% of the elimination of irinotecan and its metabolites. 
Most of this is this result of biliary excretion into the lumen of the gastrointestinal tract 
[186]. Due to the conversion of SN-38G to SN-38 by β-glucoronidase produced by bacteria 
present in the bowel lumen; including Escherichia coli, Bacteroides species, and Clostridium 
perfringens; the amount of SN-38 in faeces is higher than seen in bile [194].  Although SN-
38 and SN-38G may be reabsorbed to some extent by the intestinal epithelium and re-
enter the portal circulation, the accumulation of active SN-38 in the intestinal lumen is 
believed to contribute to irinotecan induced diarrhoea through direct mucosal damage and 
the resulting inflammation [195, 196].  
1.8.5 Biological agents 
Biological small molecule inhibitors are increasingly incorporated in treatment regimens 
used in the treatment of CRC. They can be categorised by their target protein and currently 
include:  extracellular EGFR receptor inhibitors (e.g. cetuximab and panitumumab); tyrosine 
kinase inhibitors (e.g. gefitinib, elotinib and lapatanib); and vascular endothelial growth 
factor (VEGF) inhibitors (e.g. bevacizumab, ramucirumab, regorafenib and aflibercept). 
Cetuximab is a chimeric mouse/human monoclonal antibody and panitumumab a human 
monoclonal antibody. Both target the extracellular side of the membrane bound EGFR 
receptor directly by preventing the binding of epidermal growth factor and transforming 
growth factor α to the receptor. This inhibits activation of the PI3K/AKT/MTOR and 
RAS/RAF/MEK/ERK pathways (see section 1.3.5) and subsequently a number of cell-cell 
adhesion, DNA synthesis and cellular proliferation pathways associated with carcinogenesis 
[197]. In an example of individualised treatment, their use is restricted to tumours 
expressing EGFR that are KRAS wildtype. A mutated KRAS will continue to trigger 
downstream signalling even after EGFR inhibition rendering these drugs ineffective in this 
scenario [198].  
Gefitinib and elotinib act of the cytoplasmic side of the receptor by reducing tyrosine 
kinase activity. This prevents the autophosphorylation and activation of the EGFR receptor 
required for downstream signalling and pathway activation. None of the drugs in this 
category are used routinely in the current treatment of CRC [199, 200]. 
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Over-activation of VEGF is a feature of a number of malignancies. VEGF activation 
promotes angiogenesis, essential to the survival of cancer cells requiring the delivery of 
oxygen and glucose to meet their high metabolic demand [201]. Bevacizumab is a human 
monoclonal antibody which inhibits angiogenesis by binding directly to VEGF, forming a 
complex which is unable to bind to any other receptors. It is the only anti-angiogenic drug 
approved for first line use in metastatic CRC. 
Other small molecule inhibitors are under investigation, with a number now undergoing 
testing in clinical trials.  
1.9 The treatment of colorectal cancer with chemotherapy 
The use of chemotherapy regimens based around 5-FU in combination with other 
chemotherapeutics is now routinely employed in the treatment of qualifying patients with 
CRC. In the adjuvant setting chemotherapy significantly improves absolute survival 
compared with surgery alone (hazard ratio 0.62 versus 0.76) [202]. As a result of the clear 
benefits to overall survival, NICE guidance (CG131) recommends the use of 
chemotherapeutics in all high-risk Stage II and all Stage III tumours following resection. The 
use of chemotherapy in Stage IV disease is less well defined but the combination of hepatic 
resection with chemotherapy was shown to improve outcomes in a retrospective review of 
2470 patients [203]. 
1.9.1 Chemotherapy in advanced colorectal cancer 
Advanced disease in this setting refers to patients with high-risk Stage II or Stage III disease 
who are currently recommended to receive chemotherapy following surgical resection of 
the primary tumour. A number of trials have sort to clarify the most effective regimen, with 
FOLFOX favoured as the first line therapy in the UK and FOLFIRI in the United States of 
America (USA). 
The first trial to combine 5-FU with leucovorin, the NSABP (National Surgical Adjuvant 
Breast and Bowel Project) C-03 study, reported a significant 11% increase in disease free 
survival compared with  treatment with 5-FU combined with the alkylating nitrosourea 
lomustine and the alkaloid vincristine [204]. Following this IMPACT (International 
Multicenter Pooled Analysis of Colorectal Cancer Trials) pooled data from 3 randomised 
trials investigating high-dose 5-FU/leucovorin compared with no adjuvant therapy. 
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Adjuvant therapy significantly increased three-year disease free and overall survival by 9% 
and 5% respectively [205]. The intergroup-0089 study then evaluated four of the mostly 
commonly used combination regimens, including; the Mayo Clinic regimen (20 mg/m2 
intravenous (IV) bolus of leucovorin and 425 mg/m2 IV bolus of 5-FU daily for 5 consecutive 
days repeated every 4 to 5 weeks), and the Roswell Park regimen (500 mg/m2 IV bolus of 
leucovorin and 500 mg/m2 IV bolus of 5-FU weekly for 6 weeks). This study reported no 
difference in overall or disease free survival between treatment arms [206]. Finally the 
GERCOR C96.1 study compared the Mayo regimen with the de Gramont regimen (twice-
monthly IV 5-FU/leucovorin) with no statistically significant differences in disease free or 
overall survival observed between arms. However, the de Gramont regimen was associated 
with significantly fewer side effects than the Mayo regimen [207]. 
More recently a number of trials have combined 5-FU with other chemotherapy agents. 
The MOSAIC trial of 2246 patients compared 5-FU/ leucovorin with 5-FU/ leucovorin 
Acid/Oxaliplatin, reporting an increase in 3-year disease free survival of 5%. A subgroup 
analysis within this study also reported an improvement (5%) in overall survival for stage III 
but not stage II patients [208]. The NSABP C-07 trial similarly reported an increase in 3-year 
disease free survival rates of 5% with the addition of oxalipatin [209]. Both trials noted 
significant neurosensory toxicity associated with the use of oxaliplatin but despite this the 
FOLFOX regimen was widely adopted across Europe. Three major trials have also examined 
the benefit of combining irinotecan with 5-FU (FOLFIRI). PETACC (Pan-European Trial in 
Adjuvant Colorectal Cancer) compared FOLFIRI to 5-FU/leucovorin with no significant 
improvement in disease free survival reported with the addition of irinotecan [210]. These 
findings were reproduced in the CALGB (Cancer and Leukemia Group B) 89803 and 
ACCORD (Action Clinique Coordonnées en Cancérologie Digestive) 02 trials [211, 212]. 
Interestingly, in the USA a large trial performed by the Irinotecan Study Group randomised 
patients with palliative disease to 5-FU/leucovorin, irinotecan or FOLFIRI. The used of 
FOLFIRI resulted in a significant increase progression free and overall survival. Tumour 
response rates were also increased and on this basis FOLFIRI is considered first line therapy 
in the USA [213]. 
Neoadjuvant chemotherapy in the context of non-metastatic disease, except for the radio-
sensitisation of rectal cancer, is currently not common in clinical practice. The feasibility 
study has been completed for the FOXTROT trial which randomises patients with T3/4 
colonic tumours to preoperative 5-FU, oxaliplatin, leucovorin and panitumumab followed 
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by surgery and adjuvant chemotherapy, or surgery and adjuvant chemotherapy combined 
with panitumumab [214]. The trial is currently recruiting in multiple centres across the UK. 
1.9.2 Adjuvant chemotherapy for metastatic disease in the liver 
The purpose of chemotherapy following the resection of colorectal liver metastases (stage 
IV disease) is to increase survival by treating occult residual disease. The evidence for 
adjuvant chemotherapy in this setting is unclear. The FFCD (Fédération Francophone de 
Cancérologie Digestive) AURC 9002 trial randomised 173 patients to liver resection alone or 
resection followed by 5-FU/leucovorin but failed to reach significance on its primary 
endpoint of 5-year overall survival despite a 6% increase in the adjuvant therapy group 
[215]. The EORTC (European Organisation for Research and Treatment of Cancer) 0923 
trial, which randomised to the same treatment arms, again failed to demonstrate any 
significant changes in overall survival. Both studies were underpowered, but a pooled 
multivariate analysis did report marginal but significant improvements in both disease free 
and overall survival [216]. 
The benefit of adjuvant combination regimens for stage IV liver disease is also unclear. 
Trials have compared the use of different combination regimens but are missing the 
important control arm of surgery alone. In one such study 306 patients were randomised to 
either FOLFIRI or 5-FU/leucovorin. Although median disease free survival was higher in the 
FOLFIRI group, this difference was not statistically significant (24.7 versus 21.6 months, p = 
0.44) [217]. Despite the lack of evidence in the literature most clinicians still choose to 
manage this patient group with adjuvant combination chemotherapy. 
1.9.3 Neoadjuvant chemotherapy for metastatic disease in the liver 
Neoadjuvant chemotherapy can be utilised to reduce disease volume, allowing the 
preservation of liver parenchyma and therefore function following resection, and treat 
micro-metastases not detectable on cross-sectional imaging. 
Attempts were made in early phase 2 studies to address the initial safety concerns of 
treating patients with cytotoxic agents prior to major surgery. Nearly 100% compliance was 
achieved in patients receiving preoperative chemotherapy, suggesting they are well 
tolerated. The perioperative morbidity was high, with complications reported in 21-50% of 
patients, but no perioperative deaths were recorded [218, 219]. 
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Studies have also attempted to define the benefit of neoadjuvant chemotherapy in 
patients with liver-limited metastatic disease. A retrospective study of 1474 patients 
presenting with a solitary, metachronoues liver metastases treated by surgery alone 
(n=169) or surgery with perioperative chemotherapy (n=1302) found an increased rate of 
complications in those receiving preoperative chemotherapy (37.2% versus 24%, p=0.006) 
with no improvement in overall survival. In contrast, postoperative chemotherapy was 
associated with better overall five-year survivals (65% versus 55%, p<0.01) [220].  
The international multicentre randomised EORTC Intergroup 40983 trial randomised 364 
patients with up to four resectable colorectal liver metastases to 12 cycles of perioperative 
FOLFOX or surgery alone. Powered for three-year progression free survival, with primary 
analysis performed on an intention to treat basis, it reported an improvement of 7% 
(p=0.04) in progression free survival in the chemotherapy group. However, reversible 
postoperative complications did occur more frequently in patients who received 
chemotherapy [221]. A more recent update of this trial confirmed the benefit to 
progression free survival with perioperative chemotherapy but found no difference in 
overall survival. Despite this, it did recommend that perioperative FOLFOX remain the 
reference treatment for this group of patients [222]. 
1.9.4 Chemotherapy for unresectable disease 
Chemotherapy may be given to patients with initially unresectable disease, with the aim of 
bringing them to resection through a reduction in disease volume, or as a palliative 
treatment to prolong survival and control symptoms. An unresectable primary tumour is 
unlikely to change significantly with systemic treatment, but a proportion of patients with 
colorectal liver metastases will have such a significant treatment effect that their disease 
may become technically resectable. 
Conversion to resection is estimated to be possible in 6-60% of patients, with the large 
variation reflecting many factors, including the local unit approach to chemotherapy and 
surgical resection, in addition to patient and disease factors [130]. The evidence for this 
management option is promising; five-year survivals for patients converted to resection are 
35-50%, similar to those who underwent resection at presentation [223]. This was 
confirmed in a more recent randomised trial, patients were allocated to FOLFIRI/cetuximab 
or FOLFOX/cetuximab with two monthly imaging to reassess resectability as part of the 
CELIM study. Patients converted to resection showed favourable outcomes with a 46% five-
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year overall survival rate [224]. Disease recurrence in this population is high (94%) but 
repeat resection is often feasible and can have a significant impact on survival [225].  
NICE currently recommends the use of FOLFOX (with cetuximab if appropriate) as first line 
treatment for all patients with unresectable liver-limited metastatic colorectal cancer; 
FOLFIRI is reserved for second line treatment. The efficacy of the two regimens is believed 
to be equivocal in patients with initially unresectable liver disease, a survival difference of 
approximately 1 month (21.5 versus 20.6 months) was reported in a two arm randomised 
cross-over study of FOLFIRI then FOLFOX versus FOLFOX then FOLFIRI respectively. 
However, FOLFIRI has been associated with increased toxicities, attributed to irinotecan, 
including diarrhoea and neutropenia [226].  
1.9.5 Biological therapy in metastatic colorectal cancer 
A number of trials have now investigated the use of monoclonal antibodies to EGFR and 
VEGF in the treatment of CRC.  
1.9.5.1 Cetuximab 
Cetuximab targets the EGFR receptor and has been the subject of a number of phase III 
clinical trials in combination with standard chemotherapy regimens. The large EPIC trial 
aimed to determine whether adding cetuximab to irinotecan prolonged survival in 1298 
patients with metastatic colorectal cancer who had failed therapy with 5-FU and 
oxaliplatin. Cetuximab added to irinotecan significantly improved progression free survival 
(Hazard ratio 0.7; P<0.0001) and recurrence rate (16.4% v 4.2%; P < .0001) compared with 
irinotecan alone. Despite this, there was no difference to overall survival between groups 
[227].  
The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of 
Metastatic Colorectal Cancer) study demonstrated that the addition of cetuximab to 
FOLFOX significantly improved response rate (odds ratio 2.6, p=0.003) and progression free 
survival (hazard ratio 0.6, p=0.006) time in 309 patients with KRAS exon 2 wild-type 
tumours [228]. 
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In the same setting, the phase III CRYSTAL (Cetuximab Combined with Irinotecan in First-
Line Therapy for Metastatic Colorectal Cancer) trial randomised 1198 patients with EGFR 
receptor positive unresectable metastatic colorectal cancer to FOLFIRI with or without 
cetuximab as a first line treatment [229]. No difference was seen in overall survival 
between groups but a significant increase was seen in tumour response rate in those 
receiving cetuximab (47% versus 39%, p=0.005) [229]. A retrospective assessment of KRAS 
status was performed in 1063 patients and confirmed no benefit to cetuximab in the KRAS 
mutant group, in contrast to the wild type group (response rate 57% versus 39%) [230].  
The publication of pooled data from the OPUS and CRYSTAL trials adds power to the 
findings of each study in KRAS wild type patients, providing some of the most compelling 
evidence to date. The addition of extended survival data for 845 patients with KRAS wild-
type tumours demonstrated that the use of cetuximab with standard chemotherapy led to 
a significant improvement in overall survival (hazard ratio 0.8, p=0.0062), progression free 
survival (hazard ratio 0.7, p<0.001) and recurrence rate (odds ratio 2.2, p<0.0001) [231].  
1.9.5.2 Bevacizumab 
Large observational studies have highlighted the benefit of bevacizumab in the treatment 
of CRC. One such example is the BRiTE (Bevacizumab Regimens: Investigation of Treatment 
Effects and Safety) study. This large prospective observational study of 1445 previously 
untreated patients with metastatic colorectal cancer from the USA classified patients who 
experienced disease progression into; no treatment post disease progression (n=253), 
treatment without bevacizumab (n=531), and treatment with bevacizumab (n=642) with 
reported overall survival rates of 12.6, 19.9 and 31.8 months respectively. Multivariate 
analyses associated the use of bevacizumab with improved survival (hazard ratio 0.5, 
p<0.01) [232].  
A number of clinical trials have also investigated the benefit of bevacizumab in combination 
with standard chemotherapy regimens. One of the largest of these compared FOLFIRI alone 
to FOLFIRI plus bevacizumab in a phase III randomised trial. The addition of bevacizumab 
significantly increased overall survival by five months (hazard ration for death 0.7, 
p<0.001), progression free survival by four months (hazard ratio for progression 0.5, 
p<0.001) and the response rate increased from 35% to 45% in this study of 823 patients 
[233]. Similar outcomes were illustrated in the Tree-1 and Tree-2 studies which compared 
various 5-FU/oxaliplatin based regimens with or without the addition of bevacizumab. The 
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addition of bevacezimab to fluoropyrimidine based chemotherapy increased survival by 
approximately six months. These studies highlight the benefit of bevacizumab as a first line 
therapy in the treatment of metastatic colorectal cancer.  
Comparisons have also been made between the efficacy of cetuximab and bevacizumab as 
a first line therapy in patient with metastatic CRC. FIRE-3 compared cetuximab or 
bevacizumab in combination with FOLFIRI in this setting. They concluded that the 
proportion of patients who achieved an objective response did not differ significantly 
between groups. However, FOLFIRI plus cetuximab resulted in significantly longer overall 
survival (29 versus 25 months, p=0.02) and could be the preferred first-line regimen for 
patients with KRAS exon 2 wild-type metastatic colorectal cancer [234]. 
The safety of bevacizumab has also been explored with a meta-analysis of randomised 
trials highlighting a statistically significant higher risk for eight of the 15 evaluated 
secondary endpoints including: a four-fold higher risk for hypertension, epistaxis, and 
gastrointestinal haemorrhage/perforation; a three-fold higher risk for any bleeding events; 
and an elevated risk for proteinuria, leukopenia, diarrhoea, and asthenia [235]. The use of 
bevacizumab must therefore be considered on an individual patient basis taking into 
account their personal risk. 
1.9.6 Predicting and modifying response to chemotherapy 
There is an extremely variable response to chemotherapeutics, irrespective of the setting in 
which the treatment is delivered. Variation in the pattern of disease and tumour biology, 
coupled with the mode of presentation, rapidity of diagnosis and treatment strategy 
employed may explain some of the differences in response.  
The ability to accurately predict the response, or the likelihood of acute toxicity, to 
chemotherapy would be extremely beneficial, allowing the avoidance of unnecessary over-
treatment and the associated side effects and toxicities. If response to a particular drug or 
combination of treatments could be predicted, then the regimen could be tailored to that 
individual. The value of KRAS testing in predicting the response to EGFR inhibitors has 
already been discussed in section 1.8.5, however a number of studies have sort to identify 
other potential predictive molecular biomarkers of response. These biomarkers are 
potentially identifiable through the analysis of mRNA, DNA or protein expression in the 
tumour itself or from the patient’s blood, stool, urine or any other accessible material. 
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The MRC FOCUS (Medical Research Council Fluorouracil, Oxaliplatin and Irinotecan: Use 
and Sequencing trial) demonstrated that expression of topoisomerase I, as established by 
IHC, could predict the response to irinotecan containing regimens, with higher expression 
associated with a more favourable response [236]. The value of assessing UGT1A1 
polymorphisms in predicting irinotecan toxicity has already been discussed section 1.8.4, as 
have the other pathways associated with irinotecan metabolism. Other studies have sort to 
identify subsets of patients who are more or less likely to respond to specific regimens. For 
example, it was demonstrated that MSI-H tumours are less likely to respond to 5-FU based 
regimens [237].  
The other approach to improving the efficacy of chemotherapeutics involves modulation of 
pathways in the tumour associated with either resistance to therapy or the metabolism of 
chemotherapeutics, allowing a modification of response. Successful adoption of this 
approach requires, not only the identification of potential candidate targets, but the 
development of target modulators that can be safely translated to the treatment of 
patients. Drug resistance to anti-cancer agents is complex and involves several biological 
processes including: drug uptake, efflux and metabolism; detoxifying and intra-cellular 
translocation systems; drug target modification; DNA repair processes; and cell cycle 
control. This variety of possible resistance mechanisms mean it is difficult to translate this 
approach to clinical practice, as highlighted by the dearth of phase II trials in CRC, despite a 
number pre-clinical and phase I studies [238]. Indeed, the combination of leucovorin with 
5-FU, as discussed in section 1.8.2, is one of the only examples of an enhancer of 
chemotherapy response that has been incorporated into the routine management of CRC 
to date.  
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1.10 Nuclear factor-erythroid 2-related factor 2 
Reactive oxygen species (ROS) are the by-products of different human physiological 
functions and have important functions in essential intracellular signalling pathways. The 
imbalance or overproduction of ROS produces oxidative stress. To counteract the oxidative 
or electrophilic stress in cells, human bodies organise an antioxidant response through 
signalling mechanisms, such as the Kelch-like ECH-associated protein 1 (Keap1)–nuclear 
factor-E2-related factor 2 (Nrf2)–antioxidant response element (ARE) pathway.  
The transcription factor Nrf2 is a member of the CNC-bZIP family. Often referred to as the 
master regulator of cytoprotection, Nrf2 is at least partially responsible for the regulation 
of an array of genes associated with intracellular redox balance, phase II detoxifying genes 
and drug transportation. These defensive mechanisms increase the chance of a cell 
surviving chemical or oxidative stress and allow the detoxification of potentially harmful 
drug metabolites [239]. Nrf2 has also been associated with the regulation of energy 
metabolism, inflammation and cellular proliferation [240]. 
1.10.1 Regulation of the Nrf2 pathway 
Under basal conditions Nrf2 expression is controlled at the post-transcriptional level by its 
interaction with Keap1, which sequesters Nrf2, targeting it for ubiquitination and rapid 
proteasomal degradation. As a result of this mechanism, Nrf2 is a high turnover protein 
with a half-life of less than 20 minutes, making detection difficult under basal conditions. 
Studies have established that Nrf2 binds to the dimeric Keap1 via two motifs, the ‘DLG’ and 
‘ETGE’ motifs, which have a low and high binding affinity respectively [241]. This two-site 
binding positions the lysine residues in the α-helix between the ‘DLG’ and ‘ETGE’ motifs in 
the correct orientation for ubiquitination by the Cullin-3–ring-box protein 1 E3 ubiquitin 
ligase. Consequently, ubiquitinated Nrf2 is released from Keap1 and degraded by the 
proteasome and free Keap1 is regenerated, maintaining Nrf2 homeostasis in the basal state 
[242]. 
Under conditions of stress the interaction of Keap1 with Nrf2 is disrupted and the 
transcription factor rapidly accumulates in the cell, translocates to the nucleus and enables 
the transcription of downstream genes. Keap1 is a cysteine-rich molecule well adapted to 
act as a sensor for cellular stress; oxidative and electrophilic species can modify the 
sulfhydryl groups of Keap1, altering its confirmation. This conformational change results in 
  
85 
detachment of the ‘DLG’ site and a subsequent alteration in the orientation of Nrf2, 
preventing its targeting for ubiquitination [243]. Keap1 molecules rapidly become 
saturated with Nrf2 and newly synthesised Nrf2 is free to translate to the nucleus.  
Once in the nucleus Nrf2 induces a number of cytoprotective genes containing a common 
ARE sequence in their promoter regions, including hemeoxygenase-1 (HO-1) and 
NAD[P]H:quinone oxidoreductase-1 (NQO1) [244, 245]. In order to bind to the ARE, Nrf2 
must form a heterodimer with other bZIP factors, including the Maf proteins. This results in 
the recruitment of coactivator proteins and transcription of ARE genes [239]. 
A number of other signalling pathways have been implicated in the regulation of Nrf2, most 
involve protein kinases and phosphorylation of Nrf2. For example, activation of the PI3 
kinase pathway is believed to induce Nrf2 expression at the genetic and protein level [246-
248]. Mutation of the proto-oncogene KRAS, resulting in its constitutive activation, has also 
been demonstrated to increase Nrf2 expression [249-251]. Many of these pathways are 
believed to be independent of Keap1, but their effects on Nrf2 signalling are relatively 
modest compared with Keap1 mediated regulation. 
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Figure 1.5 – The Nrf2 pathway. (a) Under basal conditions, Nrf2 is bound to Keap1, which targets 
Nrf2 for ubiquitination and subsequent proteosomal degradation. (b) Under conditions of 
oxidative stress, the interaction between Nrf2 and Keap1 is disrupted and Nrf2 is no longer 
targeted for degradation and is free to translocate to the nucleus. (c) In the nucleus Nrf2 dimerises 
with partners including small Maf proteins and binds to the ARE, mediating the transcription of 
cytoprotective genes. (Ub = ubiquitin) 
 
1.10.2 The protective role of Nrf2 
Activation of Nrf2 can offer protection against the effects of a number of diseases, 
including cancer. Induction of Nrf2 has been studied in neurodegenerative conditions such 
as Parkinson's disease and Huntington's disease, multiple sclerosis, diabetes, heart disease, 
kidney diseases, lung disorders and liver diseases [252]. In a phase II, double-blind, 
randomised, placebo-controlled trial of 227 adults with diabetes and chronic kidney 
disease pharmacological Nrf2 induction improved glomerular filtration rates [253]. 
However, a higher rate of cardiovascular events in the treatment group prompted early 
termination of the phase III trial [254]. Given its role in drug metabolism, detoxification and 
excretion it is unsurprising that induction of Nrf2 has also been demonstrated to protect 
against drug induced liver injury [255]. This could be particularly relevant to the study of 
chemotherapeutics, many of which cause significant hepatotoxicity. 
Multiple studies comparing Nrf2 knockout to wild-type mice describe the benefits of Nrf2 
signalling in chemoprevention. A 2-fold increase in the incidence of gastric cancer was 
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noted in Nrf2 knockout mice after the administration of the carcinogen benzo[a]pyrene 
[256]. These findings have been replicated in similar studies focusing on bladder cancer 
caused by N-nitrosobutyl(4-hydroxybutyl)amine [257] and skin cancer induced by 7,12-
dimethylbenz[a]anthracene/TPA [258]. In CRC, Nrf2 knockout mice were found to be more 
susceptible to colitis induced by dextran sulfate sodium (DSS), a risk factor for CRC [259, 
260]. This was explored further by co-dosing mice with DSS and the carcinogen 
azoxymethane, confirming that Nrf2 knockout mice had an increased incidence, multiplicity 
and size of all colorectal tumours in comparison to wild-type mice. The proportion of these 
tumours found to be adenocarcinomas was significantly higher in knockout (80%) than 
wild-type (29%) mice [261]. 
The cancer-preventative role of Nrf2 is attributed to its ability to induce, not only phase I 
and phase II drug-metabolising enzymes, but also antioxidant systems to optimise the 
capacity of the host to detoxify carcinogens, limit the formation of ROS and prevent DNA 
damage by the secondary metabolites formed by ROS.  
1.10.3 The exploitation of Nrf2 by malignant tumours 
In contrast to the acute physiological upregulation of Nrf2 in response to cellular stress, in 
neoplasia there is evidence for increased basal activation of Nrf2. Increased Nrf2 
expression has been noted in tumour tissue taken from patients with head and neck cancer 
[262], lung cancer [263], gall bladder cancer [264], ovarian cancer [265], osteosarcoma 
[266], breast cancer [267], bladder cancer [268], gastric cancer [269], pancreatic cancer 
[270] and colorectal cancer [271]. Many of these studies demonstrate poor outcomes and 
resistance to chemotherapy with increased Nrf2 expression. In vitro and in vivo data reflect 
the findings of these observational patient based studies. In CRC specifically, small-
interfering RNA (siRNA) or short-hairpin RNA knockdown of Nrf2 reduced cancer cell 
viability and tumour growth and increased sensitivity to 5-FU in vitro and in vivo 
respectively [272, 273]. 
A number of mechanisms could account for the increased expression of Nrf2 observed in 
malignant tissue. Loss of function somatic mutations in Keap1 were found to be relatively 
common in solid malignant tumours. An analysis of 499 cancer tissues from lung, breast, 
colon, stomach, liver, larynx and prostate by single-strand conformation polymorphism 
analysis detected somatic mutations of Keap1 in gastric (11.1%), hepatocellular (8.9%), 
colorectal (7.8%), lung (4.6%), breast (2.0%) and prostate (1.3%) carcinomas. Allelic losses 
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of the Keap1 locus were identified in 42.9% of cancers with Keap1 mutations, but no NRF2 
mutations were detected in these cancers indicating that Keap1 and Nrf2 mutations are 
mutually exclusive. Detected mutations tended to cluster in areas coding for Nrf2 binding 
sites and are therefore likely to result in increased Nrf2 expression [274]. Mutations of Nrf2 
itself have also been reported in lung (8%), head and neck (13%), oesophageal (11%) and 
skin (6%) cancer. In a study of 1145 cancer tissues nearly all of these mutations were found 
within or near the ETGE and DLG motifs, again preventing the binding of Nrf2 to Keap1 
[275]. Epigenetic modifications of Keap1 have also been demonstrated to decrease its 
expression. A gene sequencing study of ten CRC cell lines and 40 patient samples confirmed 
aberrant promoter methylation of Keap1 in 80% of the cell lines and 53% of tumour 
samples, resulting in decreased expression of Keap1 and a subsequent increase in the 
expression of Nrf2 [276]. 
Nrf2 serves a major function in oxidative stress-related disease and has thus been 
considered a therapeutic target. By contrast, persistent activation of Nrf2 has been shown 
to increase proliferation, reduce apoptosis and protect against chemotherapeutics in 
different types of cancer cells. This dual function of Nrf2 raises the question of whether 
induction or inhibition of Nrf2 is required in cancer therapy.  
1.10.4 The role of Nrf2 in irinotecan metabolism 
In addition to its effect on cell survival, proliferation and protection against chemotherapy 
cytotoxicity in cancer, Nrf2 is believed to induce expression of a number of the genes and 
proteins involved in the metabolism of irinotecan.  
Activation of Nrf2 increased mRNA expression of CES1A1 in three cell lines from different 
primary tumours (HepG2, Caco-2 and HeLa), this induction was lost when Nrf2 was 
inhibited using siRNA [277]. Similar findings have been reported in vivo with 
pharmacological induction of Nrf2 significantly increasing the expression of CES1G mRNA in 
murine liver tissue excised 24 hours after dosing [278]. In addition to exerting control on 
the inducible expression of the CES, Nrf2 may also influence the basal expression. CES1 
expression was 50% lower in liver tissue from Nrf2 knockout mice in comparison to their 
wild type counterparts on proteomic assessment using mass spectrometry [279]. Given 
that Nrf2 can alter the expression of CES, required for hydrolysis of irinotecan to SN-38, it is 
reasonable to hypothesize that induction of Nrf2 could increase the response to irinotecan 
through increased conversion to the active metabolite. 
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Balanced against this is the effect of Nrf2 on the expression of CYP3A, UGT1A1 and the ABC 
transporters, all of which can theoretically reduce the beneficial effects of irinotecan 
through conversion to inactive metabolites or increased excretion of SN-38. Members of 
the CYP3A family were found to be basally regulated by Nrf2 in vivo, as evidence by the 
significant reduction (50%) seen in the proteomic assessment of liver tissue from Nrf2 
knockout mice compared with wild-types [278]. UGT1A1 was induced in HepG2 cells 
following pharmacological activation of the Nrf2 pathway, with this effect blocked when 
Keap1 was overexpressed or Nrf2 inhibited by siRNA [280]. In the CRC cell line Caco-2 
induction of UGT1A1 was at least in part attributable to activation of the Nrf2 pathway 
[281]. In vivo data confirm these findings, demonstrating that UGT1A1 mRNA expression 
was increased in the hepatic parenchyma and small intestine of mice dosed with activators 
of the Nrf2 pathway. It was noted that UGT1A1 was inducible by four other transcription 
factors, implying the control of UGT1A1 to involve multiple pathways [282]. Finally, 
quantitative investigation of the induction of human ABC transporters mRNA by a redox-
active compound tert-butylhydroquinone (tBHQ) in HepG2 cells revealed increased mRNA 
expression with Nrf2 induction. Following siRNA inhibition of Nrf2 tBHQ-induced mRNA 
levels of ABCC2 and ABCG2 were significantly suppressed, suggesting this is a Nrf2 
dependent induction [283].  
Given its multiple roles in cytoprotection and drug metabolism, particularly in the context 
of the pro-drug irinotecan, the effect of Nrf2 modulation on irinotecan efficacy in the 
management of CRC is unpredictable. Especially considering the relationship between host 
and tumour, where hepatic activation of irinotecan may play a significant role and Nrf2 
induction may protect against the complications and side effects of therapy, including 
hepatotoxicity and chemotherapy induced colitis. 
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1.10.5 Pharmacological induction of Nrf2 
The activation of Nrf2 by dietary compounds has been traditionally considered to prevent 
cancer development. Natural phytochemicals; including sulforaphane (found in broccoli), 
curcumin, resveratrol, lycopene, and carnosol; have been reported to induce Nrf2 and act 
as chemoprevention agents in different human and animal models [284, 285]. Ten of 14 
dietary compounds were reported to induce Nrf2 in HepG2 cells with a combination extract 
made of coffee, thyme, broccoli, rosemary, turmeric and red onion fed orally to mice 
inducing Nrf2 activity in lung and adipose tissue [284].  
As a result of this protective effect of Nrf2 activation in cancer prevention and chronic 
illness a number of synthetic Nrf2 inducers have been described. The synthetic triterpenoid 
methyl-2-cyano-3,12-dioxooleano-1,9-dien-28-oate (CDDO-me) is the most potent of these, 
inducing Nrf2 at nanomolar (nM) concentrations. CDDO-me is an analogue of oleanolic 
acid, believed to induce Nrf2 through competitive binding to Keap1 [286]. Naturally 
occurring triterpenoids like oleanolic acid are weak Nrf2 inducers and CDDO-me was one of 
a number novel derivatives synthesised to increase this effect [287]. Multiple studies have 
confirmed the effectiveness of CDDO-me as a potent and relatively specific inducer of Nrf2 
at nM concentrations in vivo [278, 288], resulting in its administration to patients with 
diabetes and chronic kidney disease in the context of a phase III trial. Unfortunately the 
trial had to be abandoned die to cardiac complication in high-risk patients, but it did 
confirm significant improvements in glomerular filtration rates in patients receiving CDDO-
me [254].  
At higher concentrations CDDO-me has been reported to lose its specificity to Nrf2 and can 
target other proteins and pathways, including Actin-related protein 3 and other 
components of the cytoskeleton, and inhibit cell proliferation. Micromolar (uM) 
concentrations of CDDO-Me can even selectively induce apoptosis in cancer cells by 
targeting a number of key regulatory proteins and pathways that are frequently 
constitutively activated or overexpressed in cancer cells [289]. A phase I clinical trial 
administered CDDO-me to patients with a variety of solid malignancies and lymphomas, 
finding it was well tolerated to doses of 900mg/ml and anecdotally noting complete 
response in one patient with lymphoma and partial response in a patient with an anaplastic 
thyroid cancer [290]. 
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1.10.6 Pharmacological inhibition of Nrf2 
As initial studies suggested a beneficial effect in Nrf2 induction there are less data focusing 
on the therapeutic benefit of Nrf2 inhibition. A few compounds are reported to be Nrf2 
inhibitors in the literature. Chrysin (5,7-dihydroxyflavone) is a natural flavonoid that is 
found in many plant extracts. In doxorubicin resistant hepatocellular carcinoma cell line 
(BEL-7402/ADM), it significantly reduced Nrf2 expression by downregulating the PI3K-Akt 
and ERK pathways. Chemosensitivity was also improved through downregulation of Nrf2-
downstream genes including HO-1 [291]. Luteolin (3′,4′,5,7-tetrahydroxyflavone) is a 
polyphenolic flavonoid found in high concentrations in celery, green pepper, and parsley. In 
a study using a cell-based ARE-reporter assay, luteolin was found to be a potent Nrf2 
inhibitor and significantly sensitized A549 lung cancer cells oxaliplatin, bleomycin, and 
doxorubicin [292]. 
Perhaps one of the most widely studied Nrf2 inhibitors, brusatol is a quassinoid extracted 
from the aerial parts of the Brucea javanica plant. Fruit and seed oil from Brucea javanica 
was originally used in Chinese medicine for the treatment of various ailments, including a 
number of malignancies, before brusatol was isolated from the aerial parts of the plant 
[293]. Studies suggest brusatol is a potent inhibitor of Nrf2, selectively reducing Nrf2 at the 
protein level through enhanced ubiquitination and degradation of Nrf2 at nM 
concentrations. This resulted in an enhanced response to cisplatin treatment in A549 cells 
flank grafted into nude mice, with this effect lost in a variant of the same cell line following 
chronic ectopic overexpression of Keap1, suggesting the enhanced cisplatin response was 
mediated by Nrf2 [294]. These data were replicated in a mouse model of mutant 
KrasG12D-induced lung cancer; suppression of the Nrf2 pathway with the chemical 
inhibitor brusatol again enhanced the antitumor efficacy of cisplatin [249]. The cytotoxic 
effect of seven quassinoids was also investigated in pancreatic cancer cell lines (PANC-1 
and SW1990), with brusatol displaying the lowest half maximal inhibitory concentration 
(IC50) value [295]. There are currently no published data investigating the effects of 
brusatol in CRC.  
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1.11 Murine models of colorectal cancer 
Only 5 % of anticancer candidate therapies that enter clinical testing are approved by the 
Food and Drug Administration for clinical practice, suggesting that current murine models 
do not faithfully reflect the human disease [296, 297]. Maximising the conversion of 
potential therapeutic strategies from bench to bedside in the treatment of CRC, by 
selection and optimisation of the most appropriate murine model, requires an 
understanding of the options available, including: carcinogen-induced, genetically 
engineered and tumour implantation murine models.  
1.11.1 Spontaneous and chemically induced CRC in rodents 
The incidence of spontaneous CRC in rodents is less than 1% [298]. Higher incidences (30-
40%) have been reported in in-bred WF-Osaka rats, but none of these developed 
metastases and many of the tumours showed signs of spontaneous regression [299, 300]. 
Although these rats may develop carcinoma at an early age, the unpredictability of this 
model makes it inadequate for routine experimental use. This has resulted in the use of 
CRC-inducing carcinogens in rodents, the effectiveness of which varies between species 
and dose used as well as the duration of exposure. 
1.11.1.1 Dimethylhydrazine and azoxymethane 
1,2-dimethylhydrazine (DMH) and the metabolite azoxymethane (AOM) are 
methylazoxymethanol (MAM) precursors and the two most commonly used CRC inducing 
carcinogens. MAM, the carcinogen in cycad flour, yields a methyl diazonium ion that can 
alkylate macromolecules such as guanine in the liver and colon leading to tumour 
development [301, 302]. The majority of these tumours contain mutations in the β-catenin 
gene (Ctnnb1) which stabilise β-catenin and increases WNT signalling, driving 
tumourigenesis [303]. AOM is used more frequently due to increased potency and greater 
stability, inducing colonic malignancy in rodents when administered repeatedly over 6-8 
weeks via subcutaneous (sc) or intra-peritoneal (ip) injection; assessment of disease burden 
is undertaken from approximately 30 weeks [304].  
 AOM administered with DSS can provide a useful model of colitis induced CRC; 100% of 
Crj:CD-1 mice given a single ip injection of AOM followed by a week of oral DSS developed 
CRC within 20 weeks [305]. This AOM combined with DSS model has proved useful in 
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studying dietary chemoprevention of CRC by targeting factors that drive inflammation 
[306].  
1.11.1.2 Heterocyclic amines 
The heterocyclic amines (HCAs) 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) 
and 2-amino-33-methylimidazo[4,5-f]quinoline (IQ) are genotoxic compounds in cooked 
meat and fish. HCAs are activated by cytochrome P450s in the liver with conversion of an 
amino group to a hydroxyamino group. These are further activated by forming esters which 
induce carcinogenic DNA adducts [307, 308]. PhIP is the most abundant HCA in cooked 
meat and although it only induces aberrant crypt foci in mice it can cause colonic 
carcinomas in rats with prolonged administration; 50% of F344 rats fed continuously with 
high doses of PhIP for 52 weeks developed CRC [309]. In a recent study only 35% of the 
same animals developed carcinomas after 20 weeks of PhIP ingestion [310]. 
Interestingly many of the genetic mutations associated with colon cancer in humans are 
not noted in PhiP induced tumours, notably K-Ras and P53, an important consideration 
when undertaking studies on gene targeting therapies or interactions [311]. 
1.11.1.3 N-Methyl-N-nitro-N-nitrosoguanidine and N-methyl-N-nitrosourea 
N-Methyl-N-nitro-N-nitrosoguanidine (MNNG) and N-methyl-N-nitrosourea (MNU) are DNA 
alkylating agents that can induce malignancy in any organ through direct action. By 
transferring a methyl group to nucleobases these direct carcinogens lead to the 
accumulation of genetic mutations that can result in the development of carcinomas. 
Originally reported to cause gastric carcinoma following oral administration [312] it was 
later found that intra-rectal instillation caused carcinoma in the distal colon and rectum of 
rodents [313, 314] with 43% of F344 rats developing rectal cancers after 20 weeks of 
weekly administration [313]. Increasing the dosing frequency to three time a week in the 
same rat strain increased tumour incidence to 78% [315].  
1.11.1.4 Advantages, Limitations and Applications 
Many of the cellular and biochemical defects found in human carcinomas are present in 
chemically induced rodent models making them advantageous in the study of gene–
environment interactions and chemoprevention [316]. For example, the administration of 
the cyclooxygenase (COX)-2 inhibitor NS-398 to AOM-treated rats significantly reduced the 
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formation of preneoplastic lesions [317]. More recently diet induced obesity was found to 
promote CRC development in an AOM induced murine model [318]. 
The use of chemically induced CRC for therapeutic testing is limited. Assessment of disease 
burden is often only possible at necropsy with advanced imaging techniques required for 
longitudinal disease monitoring. Long latency periods of up to 52 weeks mean prolonged 
follow up periods are required and the formation of metastases is rare making this model 
unsuitable for studies on advanced disease [319, 320]. Significant variation in tumour 
development has been noted between murine strains and standardised dosing regimens 
are required to allow comparisons between studies [305, 321]. Despite their limitations, 
these models remain useful in improving our understanding of the molecular events 
underlying colorectal carcinogenesis and in the testing of chemo-preventative agents. 
(Table 1.12) 
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Carcinogen 
Example dosing 
regimens Common Applications Advantages Limitations Examples in literature 
AOM and 
DMH 
10mg/kg AOM 
injected weekly 
for 6 weeks 
Chemoprevention Inexpensive Long lead times (e.g. 30 weeks)   
    Assessing the influence of 
carcinogens 
Heterogeneous tumours Rarely metastatic   
    Dietary influence on 
tumour development 
Similar mutations to those seen in human 
CRC (e.g. APC, β-catenin and K-Ras) 
Limited options for non-invasive 
imaging (CT / MRI) 
Chemoprevention with COX2 
inhibition 
      Can combine with genetically predisposed 
animals to reduce lead time 
Large variations in tumour 
development between mouse strains 
Effect of obesity on CRC 
incidence 
AOM + oral 
DSS 
Single dose AOM 
then 5 ml 2.5% 
(wt/vol) DSS 
solution orally per 
day for a week 
Studies of colitis induced 
CRC 
Low mortality     
      Reliable (high tumour incidence)     
      Shortened lead time (e.g. 20 weeks)   Dietary chemoprevention with 
cinnamon 
PhIP Commonly Fischer 
344/NHsd rats fed 
0.2 g/kg daily for 
20-52 weeks 
Chemoprevention of HCA 
induced tumours 
Inexpensive Lack many of the mutations found in 
human CRC (e.g. K-Ras) 
  
      Heterogeneous tumours Unreliable / low incidence   
        Very long lead times (52 weeks) Dietary chemoprevention with 
tomato and broccoli 
MNNG and 
MNU 
MNU 0.5ml of 
0.4% rectal 
instillation 3 x per 
week 
Chemoprevention Inexpensive Direct action; needs rectal instillation   
    Dietary influence on 
tumour development 
Heterogeneous tumours Variable incidence (only 43% F344 rats 
dosed weekly for 20 weeks) 
Chemopreventive effect of 
benzoic Acid 
Table 1.12 - Summary of carcinogen induced murine models of colorectal cancer. Adapted from Evans, 2016 [322]. 
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1.11.2 Genetically Engineered Mouse Models (GEMMs) 
The mutations that mediate colonic carcinogenesis were discovered through studies on the 
hereditary CRC syndromes FAP and HNPCC. Mice with mutations in these genes have 
revealed phenotypes that are similar to human colon cancer and polyposis. 
1.11.2.1 Adenomatosis Polyposis Coli mouse (models of FAP) 
As discussed in section 1.4.2, the APC gene was identified on chromosome 5q as one of the 
genes commonly deleted in FAP [323]. It is associated with activation of the Wnt pathway, 
one of the key events in polyp initiation [324]. The first report of a mutation of Apc located 
on chromosome 18, the mouse homologue of human APC, occurred randomly in C57BL/6 
mice treated with ethylnitrosourea. Multiple intestinal neoplasia (ApcMin) mice carry a 
truncation mutation at codon 850 of the Apc gene. They develop tumours throughout their 
gastrointestinal tract, more frequently in the small intestine. Invasive cancers are reported 
in older mice but without metastases [325]. Most Apc mutant mice die young (4–5 months) 
as a result of anaemia and cachexia, often before developing invasive cancers.  
Several Apc mutations have been constructed using gene knockout technology in 
embryonic stem cells, allowing investigation of the complex genetics associated with the 
development of CRC. Both Apc∆716 and Apc1638N mice have a truncation mutation of Apc and 
develop histologically identical polyps. However, Apc∆716 knockouts typically develop 
approximately 300 polyps in comparison to 3 in Apc1638N mice [326, 327]. Both 
predominantly develop small bowel polyps but the addition of a heterozygous knock down 
of Cdx2 in the Apc∆716 mouse results in numerous polyps in the distal colon [328].  
The malignant potential of Apc mutant mice can be modified through the introduction of 
further genetic mutations. Inactivation of Smad4 through loss of heterozygosity in Apc∆716 
(cis-Apc/Smad4) mice results in the development of locally invasive carcinomas [329]. 
While an increase in the number and invasive potential of colonic polyps is also noted with 
a deficiency in the Wnt-target genes EphB receptor family [330, 331].  In contrast, 
transgenic loss of Prox1 in the intestinal epithelial cells of ApcMin mice reduces the 
progression of colonic adenomas to adenocarcinomas-in-situ [332].  
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1.11.2.2 Mouse Models for Lynch Syndrome 
As discussed in section 1.4.1, LS is characterised by mutations in MMR genes; commonly 
the MutL or MutS homologs MLH1, MSH2 and MSH6. MMR mutant mice are useful in 
determining how the loss of MMR function results in tumourigenesis. Despite the genetic 
abnormalities in MMR knockout mice correlating with those in humans there are significant 
differences in phenotype. Unlike humans with mutations in MLH1, MSH2 and MSH6, 
heterozygous mice carrying the corresponding mutations do not develop early-onset 
tumours. However, homozygous Mlh1, Msh2 and Msh6 knockout mice are prone to 
forming malignant tumours, including CRC, but die prematurely due to aggressive 
lymphomas [333-335]. Mice have been generated with disruptions in all known mammalian 
MutS and MutL homologues. Combining homozygous mutations for the MMR genes with 
various Apc mutations has allowed the development of mice with multiple early-onset 
colonic tumours [336].  
1.11.2.3 Conditional genetic models of colorectal cancer 
Cre-Lox recombination has allowed the conditional inactivation of genes associated with 
the development of CRC in transgenic mice by flanking the gene with ‘Lox-P’ binding sites. 
Cre-recombinase (Cre) recombines these two Lox-P sites, causing the gene to be skipped 
and preventing its transcription. Conditional inactivation can be used to reduce embryonic 
lethality or extra-intestinal features which often result in the premature death of the 
animal.  
The first conditional knockout mice were generated by flanking exon 14 of the Apc gene. 
Rectal instillation of recombinant adenovirus expressing Cre resulted in inactivation of both 
Apc alleles in the distal colon. Mice developed an average of 7 adenomas at this site, with 
50% developing invasive adenocarcinoma within a year [337].  Cre-Lox technology has 
subsequently been used to conditionally inactivate a number of the genes associated with 
the development of CRC. 
Combining Cre with specific promoters has allowed its expression to be targeted to the 
organ of interest. The fatty acid-binding protein (Fabp) promoter has been used to target 
Cre expression in murine colonic and small bowel epithelium with temporal control 
provided through the administration of doxycycline (Fapb-Cre mice) [338]. When Fabp-cre 
mice are crossed with Apc conditional knockout mice they develop colonic adenomas, with 
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half developing adenocarcinomas [339]. More recently the combination of Villin, an actin 
binding protein expressed mainly in the brush border of epithelia, with Cre has been used 
to target the expression of many CRC oncogenes or tumour suppressor gene in the murine 
intestine [340-344].  
1.11.2.4 Advantages, Limitations and Applications 
GEMMs are most useful in studies of chemoprevention, for example exploring the links 
between diet and CRC [345]. Such studies are likely to be translational to the clinical setting 
as they represent the natural history of tumour development in the correct 
microenvironment. The role of GEMMs in translational research was proven when it was 
found COX-1 and 2 inhibition significantly reduced polyp burden in ApcMin mice, providing 
the rationale for treating FAP patients with COX inhibitors [346-348]. 
The use of GEMMs in pre-clinical drug discovery is more limited due to the following: 
necropsy is required to assess disease burden unless advanced imaging techniques are 
employed; the incidence of invasive cancers is unpredictable; they are expensive and time 
consuming to develop and the development of small bowel tumours and other extra-
colonic manifestations limits their life span. Although the formation of spontaneous 
tumours in immune-competent mice more closely mimics the heterogeneity of CRC in 
humans, this can be disadvantageous in therapeutic studies as increased variance within 
groups necessitates large sample sizes to confidently detect significant effects. Additionally, 
the low metastatic rate means they are not a good mimic of advanced CRC. Conditional 
gene models have made it possible to generate tumours in a narrow time window and with 
greater confidence and consequently their use in chemotherapeutic studies may well 
increase. (Table 1.13) 
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GEMM model 
Examples of variations 
and modifiers Common applications Advantages Limitations 
All   Studying the role of  genes involved in 
carcinogenesis 
  Limited options for non-invasive imaging (would need CT / 
MRI capability) 
    Studies of chemoprevention   Expensive and time consuming to develop 
    Assessing the influence of carcinogens   Rarely metastases 
    Lifestyle / Dietary influence on tumour 
formation 
    
ApcMin Mice / 
models of FAP 
    Multiple adenomas, useful for studies of the early events in 
CRC tumourogenesis 
Most tumours located in small bowel 
        Die early of anaemia / cachexia 
        Rarely invasive cancers 
  Apc1638N and Apc∆716   Reduced polyp numbers in Apc∆716 than seen with Apc1638N   
  Apc∆716/Cdx2   Increases polyp number in distal colon in comparison to 
small bowel 
  
  Apc/Smad4    Develop locally invasive cancers Develop ampulla of Vater adenocarcinomas 
  Apc/Prox1   Develop adenocarcinomas Carcinoma-in-situ only 
  Apc/EphB2-B3   Develop invasive intestinal adenomas   
HNPCC mice MutS homologues: MSH2-/-   High tumour incidence Develop life-limiting aggressive lymphomas 
                                                     
MSH6-/ 
  High tumour incidence Develop endometrial carcinoma 
      Live longer than MSH2-/- (up to 18 months) Less MSI than MSH2-/-  
  MutL homologue:  MLH1-/-   High MSI Develop life-limiting aggressive lymphomas and skin 
tumours 
Combination Mlh1/Apc1638N mice   Early-onset of intestinal tumours   
      No increase in incidence of lymphomas   
Conditional 
GEMMs 
    Allow studies of mutations that would otherwise result in 
embryonic lethality 
  
      Reduce premature deaths associated with extra-intestinal 
manifestations 
  
      Temporal control possible by drug administration (e.g. 
tamoxifen, doxcycline) 
  
  APCflox/flox     Requires rectal instillation of recombinant adenovirus 
expressing Cre  
  Targeted promoters (e.g. 
Villin-Cre and Fapb-Cre) 
  Use tissue specific promoters in intestinal mucosa to target 
gene knockout 
  
      Some invasive adenocarcinomas seen   
      Can be used to target specific  tumour suppressor or 
oncogenes (e.g. k-Ras, APC, MSH2) 
  
Table 1.13 - Summary of genetically engineered mouse models of colorectal cancer. Adapted from Evans, 2016 [322]. 
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1.11.3 Tumour Implantation Models 
CRC cells have been implanted in mice since the 1960s; the simplicity and relatively low 
cost of this model make it popular in the testing of novel therapeutics. Immortalised 
human CRC cell lines are commercially available for orthotopic, intra-portal, intra-splenic or 
intra-hepatic implantation into nude or severe combined immune deficiency (SCID) mice. 
As a result of prolonged in vitro propagation, cell lines may not recapitulate the inherent 
heterogeneity of spontaneous CRC and patient derived xenografts (PDX) have been used to 
overcome this problem. Establishment rates of 67%-77% are reported for subcutaneous 
grafting using this method and the resulting tumours in nude mice have been found to 
maintain the genetic and molecular profile of the patient tumours they were derived from 
[349, 350]. This approach is labour intensive and requires access to human CRC tissue. 
The development of immortalised murine CRC cell lines, usually through chemical 
induction, has allowed the utilisation of syngeneic models in preclinical research. This 
involves the implantation of cell lines originally derived from a particular strain of rodent 
back into an immune-competent rodent of the same strain, allowing testing of immune-
therapies. Common examples include Ct26 cells in BALB/c mice [351-356], MCA38 cells in 
C57BL/6J mice [357, 358], CC531 cells in Wag/Rij rats [359] or DHD/K12-TRb cells in BDIX 
rats [360]. The rodent species used in these studies are usually cheaper and more robust 
than their immune-deficient counter-parts, reducing costs. 
1.11.3.1 Subcutaneous grafts 
The most commonly utilised model involves the subcutaneous inoculation of a suspension 
of CRC cells into the flank of a mouse. The main advantage of this model is its simplicity, 
allowing screening of candidate therapies in large numbers with longitudinal measurement 
of tumour growth possible via caliper measurements. The major disadvantage is the micro-
environment in which the tumour develops, which is markedly different from that of the 
colon. As interactions between the host environment and the tumour graft can determine 
tumour cell expression profiles, growth rates, tumour angiogenesis and metastatic 
behaviour the true translational benefit of this model may be limited. Metastatic liver 
disease has not been reported in subcutaneously grafted rodents [361-364]  limiting their 
use in studies of advanced CRC treatment or cell migration and invasion. Lung metastases 
have been reported from subcutaneously implanted primary cells derived from advanced 
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human CRC tissue and from cell lines established through serial propagation of tumours 
arising in GEMMs [365, 366]. 
1.11.3.2 Orthotopic implantation 
Orthotopic implantation refers to the grafting of tissue or cells to their natural position, for 
a murine model of CRC this would involve either the injection of a suspension of tumour 
cells or implantation of a fragment of tumour into the colon or rectum. This can overcome 
the problems associated with tumour development in an artificial micro-environment and 
allows replication of tumour invasion, vascular spread and metastasis to distal organs. It is 
therefore one of the truest mimics of the progression to advanced CRC in humans. For 
caecal implantation a midline laparotomy is performed aseptically under general 
anaesthesia, the caecum is exteriorised and a suspension of tumour cells injected into the 
bowel wall or a small fragment of tumour grown in another animal sutured onto it after 
lifting or damaging the serosa [367, 368]. Transanal injection of tumour cells has also been 
utilised as a model of rectal cancer, avoiding the need for laparotomy. This method again 
requires general anaesthesia, followed by anal dilatation with blunt forceps and the 
injection of a suspension of cells into the rectal mucosa [369, 370]. 
Metastatic rates vary depending on the cell line, site of implantation and murine strain.  
One of the first studies utilising this method reported the development of metastasis in 65-
75% of C57BL/6J mice 8 weeks after the intra-mural caecal injection of MCA38 cells [371]. A 
more recent study of immune-deficient mice orthotopically grafted with tissue fragments 
grown subcutaneously from 12 different human CRC cell lines found primary tumour 
uptake rates and metastatic potential varied significantly between cell lines. Six cell lines 
(KM20L2, HCT116, HCT15, SW480, SW620 and Colo320DM) had a 100% uptake rate, 
whereas intermediate uptake rates were observed for Co115 (90%), HCC2998 (88%) and 
HT29 (69%) and only 40% of mice implanted with CaCo2, WiDr and Co205 developed 
tumours. Liver metastases were only seen in 20% of mice grafted with SW620 tumours but 
nodal disease was common across all but two of the cell lines (SW480 and Colo320DM) 
[372]. Similar uptake rates were seen with HCT116 cells injected into the caecal submucosa 
using a specially designed micro-pipette technique with 75% developing a colonic primary; 
of these 100% had nodal disease, 67% hepatic metastases and 50% lung metastases [373]. 
Primary tumour uptake rates of 65% have also been reported using rectal injection, 
however only 3.3% developed metastases [374]. An orthotopic model was recently used to 
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investigate the effect of Weichang’an (a Chinese traditional medicine) and 5-fluorouracil on 
CRC development, highlighting the role of this model in the validation of candidate 
therapies prior to considering clinical trials [375]. 
PDX have also been utilised in a caecal injection model; cell suspensions isolated from five 
different patients resulted in primary tumours in 92% of NOD-SCID mice. Metastatic rates 
were not high (27% developed liver metastases and 23% lung metastases) but are similar to 
those observed in patients. It is noted that the highest tumour establishment rates were 
seen with tumours derived from patients with node positive disease and poor 
differentiation. Importantly the generated tumour xenografts maintain the same 
mutational status as the original patients’ carcinoma [376]. 
Isolation, culture and re-implantation of cells from liver metastases or from primary 
tumours with the highest metastatic potential improved metastatic rates to 90% in a 
syngeneic model [377]. This process is time consuming and labour intensive and should be 
reserved for studies where metastatic disease in essential.  
1.11.3.3 Ectopic implantation to sites of metastasis 
 Approximately 50% of patients with CRC develop liver metastases over the duration of 
their disease, with poor overall survivals seen in this group [378]. Lung metastases are less 
common, developing in 5 to 15 % of CRC patients [379]. Increased understanding of the 
metastatic process and the testing of novel therapies requires models that develop 
metastases more reliably than seen with orthotopic implantation. Inoculation of tumour 
cells to the spleen, portal vein or liver parenchyma of rodents can be used to mimic liver 
metastases, whilst tail vein injection can model lung metastases [380]. Although these 
models do require a degree of technical skill, high rates of metastatic disease can be 
achieved with a degree of certainty. 
Early attempts at intra-splenic injection of CRC cells generated through primary cell culture 
of primary or metastatic tumour from eight patients produced varying rates of liver 
metastases in nude mice sacrificed at 90 days. The rate of liver metastases varied 
considerably from 16% with one of the cell lines generated from liver metastases to 100% 
in a number of the other cells developed from rectal primary tumours or liver metastases 
[362]. Established cell lines give similar metastatic rates with 78% of mice inoculated with 
HT-29 cells developing macroscopic liver metastases within 6 weeks [381]. Similar success 
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has been reported with the use of syngeneic cell lines with 100% of C57Bl/6 mice injected 
with MCA38 cells developing hepatic metastases [382]. Uptake rates can be further 
improved by injection of cells isolated from liver metastases grown in vivo [383]. 
Splenectomy is often required following this technique to reduce haemorrhage and 
prevent formation of splenic metastases. A syngeneic model was recently used to assess 
the combined therapeutic efficacy of 188Re-liposomes and sorafenib on liver metastases, 
highlighting the role of this model in drug development [384].  
Intra-portal injection is technically more challenging but is a good mimic of the venous 
migration of CRC to the liver. It may be more reliable than intra-splenic injection with 
metastases reported in 100% of animals [385, 386]. However, a more recent publication 
highlighted the variability between cell lines with HCT116 cells exhibiting the highest rate 
of hepatic metastases (90% of animals within 30 days) [387]. A recent study utilising this 
model demonstrated a reduction in hepatic metastases formation following administration 
of pyrvinium pamoate [388]. 
Direct injection of CRC cells or implantation of tumour tissue into the liver parenchyma can 
reliably produce metastases in both immune-deficient and syngeneic models. This 
technique is particularly advantageous when a single metastasis or tumour confined to a 
single lobe is required and was recently utilised to study the effect of FOLFOX on the 
murine liver in the presence of colorectal metastases [358].  
1.11.3.4 Advantages, Limitations and Applications 
CRC implantation models offer a reproducible means of screening potential therapies in 
statistically significant numbers of animals. Before utilising such a model, it is important to 
consider a number of factors including: the site of implantation, bearing in mind the impact 
of tumour development outside its natural environment and the importance of metastatic 
disease; the importance of the immune system to treatment success; the resources and 
time available for development of the model; and whether the treatment may be 
dependent on human specific factors, as is generally the case with antibody-based 
therapies. 
Immune-deficient implantation models allow relatively rapid testing of candidate 
therapeutics on malignancies developed from human cell lines and therefore with human 
specific genes and proteins. The major disadvantage is the lack of host immunity which 
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rules out the testing of immune-therapies or the study of immuno-tumoural interactions. 
Immune-deficient rodents are less robust and more expensive than their immune-
competent counterparts. Syngeneic tumour models offer several advantages; they are 
relatively low cost, more robust and are generally non-immunogenic. However, the 
tumours express the rodent homologues of human tumour genes and this may limit-testing 
of targeted therapies. PDX may offer a solution to the lack of heterogeneity seen in 
established cell lines. Capturing the genetic profile of a patient’s tumour in a mouse model 
will allow validation of potential biomarkers in vivo but may also permit assessment of the 
metastatic potential and drug-response of an individual tumour, allowing therapy to be 
tailored to that specific case [389]. 
Subcutaneous implantation allows rapid screening in relatively large numbers with minimal 
technical expertise. Validation of these results should subsequently be considered in the 
presence of more advanced or orthotopically implanted disease. Although orthotopic 
implantation offers the most realistic replication model of the development of CRC it is 
unreliable with respect to metastases formation. If metastases are essential to the study 
then intra-splenic, intra-portal or liver parenchymal injection of tumour cells should be 
considered. (Table 1.14) 
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Implantation 
site Common Applications Advantages Limitations Examples in literature 
All Screening of candidate therapies and 
chemotherapeutics 
Options for longitudinal disease follow 
up 
Reliant on cell lines which may not be as 
heterogeneous as spontaneous tumours 
  
Subcutaneous Screening cytotoxic agents in large 
numbers of animals 
Relatively inexpensive Tumour develops in an artificial micro-
environment, may not translate well 
The anti-tumour effect of simultaneously targeting 
VEGF and PROK1  
    Minimal technical skill required Non-metastatic   
    Reproducible / good tumour uptake 
rates 
    
Orthotopic Analysing the pathogenesis of 
metastases 
Mimics colon tumour invasion, 
vascular spread, and metastasis 
Metastasis rates depend on cell lines and rodent 
strains and can be unreliable 
Combination of Weichang'an and 5-fluorouracil therapy 
on tumour growth and metastases 
  Assessing the effect of therapies on 
metastases 
Technically challenging     
  Evaluating drugs that influence the 
tumour  microenvironment 
      
  Evaluation of tumour stroma       
  Confirmation of the results of 
subcutaneous grafting 
      
Intrasplenic 
inoculation  
Investigation of therapies for 
suppression of metastatic disease 
Reproducible Metastasis rates depend on cell lines and rodent 
strains 
Therapeutic efficacy of 188Re-liposomes and sorafenib 
  Assessing the effect of therapies on liver 
metastases 
Mimics vascular spread of colorectal 
cancer 
No primary tumour   
  Drug safety (e.g. hepatoxicity in the 
presence of liver metastases) 
Technically less challenging     
Intraportal 
inoculation  
Investigation of therapies for 
suppression of metastatic disease 
Mimics vascular spread of colorectal 
cancer metastasis 
No primary tumour Impact of pyrvinium pamoate on colon cancer cell 
viability 
  Assessing the effect of therapies on liver 
metastases 
Technically challenging     
  Drug safety       
Intrahepatic 
inoculation  
Investigation of therapies for 
suppression of metastatic disease 
Reproducible Does not mimic the generally accepted hypothesis 
of hematogenous spread 
FOLFOX induced sinusoidal obstruction syndrome in the 
presence of metastases 
  Assessing the effect of therapies on liver 
metastases 
Can limit disease to a single lobe / 
segment if required 
No primary tumour   
  Drug safety Technically less challenging     
         
Tail vein 
injection 
Assessing the effect of therapies on lung 
metastases 
Reproducible No primary tumour Mechanism of tumour vascularization in lung 
metastases 
  Studying the pathophysiology of lung 
metastasis 
Technically less challenging     
Table 1.14 - Summary of tumour implantation models of colorectal cancer. Adapted from Evans, 2016 [322]. 
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1.11.4 In vivo imaging techniques 
Although simple caliper measurements are adequate for subcutaneous tumours, advanced 
imaging techniques are required for assessment of disease burden in other models without 
necropsy. Imaging live animals reduces the number of animals required for an experiment 
and provides increased statistical power with each animal functioning as its own control. 
MRI, CT, PET, single photon emission computed tomography (SPECT), fluorescence imaging 
(FI), bioluminescence imaging (BLI) and photoacoustic tomography (PAT) have all been 
used for in vivo imaging with each technique suited to a specific application [390]. Direct 
visualisation of the colonic mucosa via endoscopy has also been utilised for the monitoring 
of tumour development and growth. Endoscopy may be most beneficial in carcinogen 
induced models that previously required necropsy for the evaluation of tumour growth 
[391-393]. CT and MRI are best applied to the detailed anatomical reconstruction of tissues 
while nuclear imaging techniques (PET and SPECT) allow imaging of radiotracer molecules 
providing quantitative, longitudinal and functional images of tumour biology [394]. BLI and 
FI are ideal for the longitudinal assessment of disease burden but lack anatomical details 
with signals superimposed on a photo of the animal. PAT uses nonionizing laser 
illumination to generate an internal temperature rise which is converted to pressure waves 
via thermoelastic expansion. These waves are detected via an ultrasonic transducer and 
reconstructed to form an image [395]. Anatomical, functional and molecular assessment is 
possible by combining endogenous and exogenous contrasts. For example, haemoglobin 
can provide both anatomical and functional assessment such as the speed of blood flow 
based on endogenous contrast [396]. Exogenous contrast agents such as labelling dyes, 
nanoparticles and fluorescent proteins have enabled molecular imaging including 
assessment of tumour growth [397-399].  
MRI, CT, PET SPECT and endoscopy do not require implantation of genetically modified 
cells but they are expensive and user dependent; considerable skill is required for accurate 
interpretation of results and quantification of tumour growth can be challenging. 
Additionally, if the study requires frequent imaging then techniques reliant on radiation, 
such as CT, should be avoided [400]. The time for image acquisition with MRI particularly 
can also be a problem, with animals requiring prolonged general anaesthesia. Endoscopy is 
also time consuming (approximately one hour per animal) and carries a risk of bowel 
perforation. In contrast, FI and BLI offer rapid image acquisition with easy longitudinal 
disease monitoring but require stable gene transfections of cell lines prior to implantation 
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with either one of the luciferase family of photo-proteins for BLI or a fluorescent probe for 
FI. A number of plasmids are now commercially available for this, utilising antibiotic 
selection to maintain gene expression through co-transfection [401, 402]. A very sensitive 
charge-coupled device (CCD) detector, super-cooled to -90°C, is then used for detection 
after visible light is used to excite the subject for FI or after the administration of the 
substrate luciferin to the subject for BLI. This allows quantification of light emission and 
therefore disease burden without the need for sacrifice. BLI is limited by loss of signal as 
light passes through the animal, this can be as much as 10-fold for every centimetre of 
tissue, while background auto-fluorescence can limit assessment in FI [403]. PAT can offer a 
solution to this problem by providing higher penetration depths of 5-6cm with various 
photosensitizers available including fluorescent probes [404]. 
Multimodal imaging allows images of disease burden acquired by BLI and FI to be 
superimposed over the anatomical details provided by CT or MRI. However, the limited 
resources available in most centres mean selection of the most relevant imaging technique 
remains essential. 
1.11.5 Selecting the most appropriate murine model 
Selection of the most appropriate murine model is essential in the study of CRC. 
Understanding the ideal application of each increases the chance of acquiring relevant and 
translational results. The carcinogen induced murine models and GEMMs are most useful 
in studies of CRC development and chemoprevention whilst tumour implantation models 
are preferred for screening candidate therapeutics, with subcutaneous implantation 
allowing high throughput assessment of drugs for subsequent verification in orthotopic 
models. If the proposed intervention is designed solely for the treatment of metastatic 
disease then ectopic implantation to the liver or lungs offers the most reproducible 
assessment tool. The key is selecting the most appropriate model for each experimental 
application in order to achieve results translational to CRC and its treatment in humans.  
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1.13 Summary 
CRC is the fourth most common carcinoma and the second leading cause of cancer related 
death in the UK. Survival is worst for those patients presenting with advanced or metastatic 
disease. A number of dietary and lifestyle factors have been linked to the development of 
colorectal cancer including diets rich in unsaturated fats, red meat, excess alcohol, smoking 
and a sedentary lifestyle. Inflammatory bowel disease also increases the risk of developing 
CRC. 
The understanding of the genetics of colorectal carcinogenesis has improved significantly. 
The vast majority of colorectal tumours reflect a series of hereditary and somatic mutations 
in key genes (APC, KRAS, BRAF, DCC and p53). These mutations are most frequently 
associated with a CIN phenotype and are often acquired in a different order. A subset of 
tumours are initiated through inactivation of MMR function, which may be through 
inherited or somatic mutation, or alternatively epigenetic inactivation through 
hypermethylation (CIMP) leading to MSI-H. 
Patients presenting with CRC are assessed and staged through clinical, endoscopic and 
radiological investigation. Radiological assessment normally consists of CT, PET and, for 
rectal tumours or further evaluation of liver metastases, MRI. Commonly used staging 
systems include the Dukes’, UICC/AJCC TNM and Jass classifications, with complete 
pathological staging only possible post-resection. Surgery remains the mainstay of curative 
treatments but patients may be recommended to neoadjuvant or adjuvant chemo- or 
radiotherapy based on their disease stage, those with advanced or metastatic disease are 
normally offered chemotherapy. 
Irinotecan is a chemotherapy agent used in the combination treatment of CRC (FOLFIRI), it 
is often used as a second line therapy in the UK after failure of FOLFOX therapy. It is a 
prodrug converted to the active metabolite SN-38. A number of proteins including the CES, 
CYP3A, UGT1A1, ABC transporters and β-glucuronidase are involved in the metabolism and 
excretion of irinotecan. 
The tumour response to chemotherapy can vary significantly between patients and 
predicting or modifying this response could avoid unnecessary treatment and reduce the 
side effects or complications of treatment. This may be possible through the identification 
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and modulation of proteins associated with chemo-protection and drug metabolism. This is 
particularly relevant to irinotecan where inter-patient variations in any of the proteins 
associated with its metabolism can have an effect on chemo-response.  
Nrf2 is a transcription factor, controlled by the regulatory protein Keap1 in the quiescent 
state, that can induce expression of many of the proteins associated with irinotecan 
metabolism. It also activates the ARE genes, associated with cell survival and protection 
against cellular stress, in addition to having a role in cellular proliferation. Nrf2 is 
overexpressed in a number of malignancies, allowing them additional protection against 
cellular stress and perhaps playing a role in chemoresistance. It is feasible that induction of 
Nrf2 is useful in the protection of non-malignant tissue, reducing the damage done by 
cellular stress and protecting against DNA damage which can lead to mutations and 
malignant change. However, in cancer tissue Nrf2 inhibition may reduce cellular survival, 
proliferation and chemoresistance. The effects of modulation of Nrf2 on cancer cell survival 
and chemotoxicity are unpredictable, particularly in relation to irinotecan therapy where it 
could potentially alter metabolism and excretion of the drug. 
In order to investigate the translational benefit of potential therapies in the management 
of CRC and increase the conversion to clinical practice, robust and reproducible in vivo 
models are required. Tumour implantation models are most appropriate for the high 
through-put investigation of chemotherapeutics and chemo-sensitizers. Orthotopic 
implantation allows a tumour to be grown in the correct tumour environment with the 
potential to metastasise to the liver, while bioluminescent imaging provides an option for 
the longitudinal assessment of disease burden, with each animal acting as its own control. 
1.14 Hypothesis and study plan 
From review of the literature it is clear that new treatments and modifiers of the response 
to chemotherapy are required to improve outcomes in advanced CRC, and that modulation 
of Nrf2 may offer a potential strategy, particularly in the context of irinotecan based 
therapy. The effects of Nrf2 modulation in this setting are unpredictable and robust in vivo 
modelling is required to increase the chance of translating the findings to clinical practice. 
In order to attempt to investigate the potential benefits of Nrf2 modulation in the 
treatment of CRC a number of questions need to be addressed: 
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1. Is Nrf2 a relevant target for therapy in CRC? 
2. Is it possible to modulate Nrf2 expression in CRC cell lines either genetically (using 
siRNA) or pharmacologically (using CDDO-me and brusatol)? 
3. Does genetic or pharmacological modulation of Nrf2 in CRC cell lines effect cell 
viability and proliferation? 
4. Does modulation of Nrf2 in CRC cell lines alter their response to irinotecan based 
therapy? 
5. Can in vitro findings be replicated in a murine model of CRC that more accurately 
represents the development of the disease in humans? 
6. Can pharmacological modulation be achieved in vivo? 
7. Is Nrf2 modulation safe in vivo? 
In order to attempt to answer these questions the study plan will involve: 
1. Development and cloning of stably luminescent CRC cell lines to allow serial in vivo 
imaging and assessment of disease burden. 
2. Development of a murine model of CRC that allows longitudinal imaging and 
quantification of disease.  
3. Relative quantification of Nrf2 in matched CRC and normal colonic specimens from 
patients with stage IV disease. 
4. Assessment of Nrf2 expression in CRC cell lines and modulation of its expression by 
siRNA inhibition of Nrf2 or Keap1 or by the pharmacological inhibitor brusatol and 
inducer CDDO-me. 
5. Investigation of the effect of Nrf2 modulation on CRC cell viability and proliferation 
in vitro. 
6. Assessment of the effect of Nrf2 modulation on irinotecan CRC cell line cytotoxicity 
in vitro. 
7. Translation of in vitro findings into the murine model. 
8. Investigation of the effect of brusatol treatment on the proteome in vivo.  
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Chapter 2 – The development of a murine model of colorectal 
cancer 
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2.1 Introduction 
The ideal murine model would provide an exact recapitulation of human CRC. It should 
develop spontaneously throughout the colon and rectum, have a high incidence in the 
animals with a short latency period, follow the same metastatic pattern, occur in immune-
competent animals, allow non-invasive monitoring of disease progression and have the 
same molecular characteristics as the human disease. Perhaps not surprisingly, current 
animal models fail to fulfil all these criteria, but with advanced imaging modalities, 
numerous cell lines and improved transgenic modelling methods available there is a 
growing choice. Selection of the correct model for the individual research question is 
essential to ensure the timely acquisition of data that answers the study hypothesis. 
Specifically for the pre-clinical study of potential novel therapies in the treatment of CRC, a 
murine model is required that reliably and rapidly develops disease, allows serial 
longitudinal investigation of malignant burden in a single animal and mimics the disease 
pattern in humans as closely as possible. This requires a tumour that grows in the correct 
microenvironment with the potential to metastasise, particularly to the liver. Imaging 
assessment of disease burden should allow data acquisition from several animals in a short 
time frame and at a relatively low cost. 
Developments in bioluminescent imaging have allowed the detection of a relatively small 
numbers of cells in rodents and facilitated the assessment of disease burden without 
necropsy, resulting in a reduction in the number of mice required in experimental studies. 
Bioluminescence imaging (BLI) is considered superior to fluorescence imaging (FI) in animal 
studies as the background signal in FI can limit the detection of low cell numbers [403]. BLI 
also allows detection of signal in a number of animals simultaneously, decreasing the cost 
and time required for data acquisition considerably when compared with CT or MRI 
assessment. The main limitation of BLI is light quenching and scattering, significant light 
absorption can occur as a result of the melanin found in the skin of pigmented mice. 
Animal fur can also scatter light and attenuate signal and therefore shaving is required in 
furred animals [405]. 
BLI relies on the induced expression of the foreign protein luciferase, which is not normally 
expressed in the cell or organism of interest. Upon exposure to the luciferase enzyme the 
substrate luciferin is oxidised to the excited-state molecule that emits light. This reaction 
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requires oxygen and adenosine triphosphate (ATP) and therefore is only possible in viable 
cells, making luminescence a good marker of the number of live cells [406]. The light 
emitted from the reaction can be detected using a luminometer, usually utilised in the 
assessment of cells in culture, or a cooled charge-couple device (CCD) camera for animal 
studies. Luciferase expression, under promotor control, is frequently introduced into the 
cell of interest by plasmid transfection, with stability of luciferase expression achieved by 
antibiotic selection and clonal expansion (figure 2.1).  
 
Figure 2.1 – The ATP dependent conversion of D-luciferin to oxyluciferin, catalysed by luciferase, 
and resulting in the emission of light. (AMP = adenosine monophosphate and PPi = 
pyrophosphoric acid) 
The work in this chapter describes the development of a murine model of CRC through the 
caecal implantation of luminescent CRC cell lines, allowing the longitudinal assessment of 
disease burden and the detection of metastatic disease through serial BLI. This model was 
selected to allow the high-throughput investigation of novel therapies and the optimisation 
of irinotecan chemotherapy in a murine model that more accurately reflects the pattern of 
disease in humans, with a primary tumour growing in the correct microenvironment and 
with the potential to metastasise. A human and murine cell line were both used in model 
development, with the aim of developing both a nude and immune-competent syngeneic 
model. 
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2.2 Materials and methods 
2.2.1 Luminescent vectors 
Two vectors were utilised in the creation of luminescent CRC cell lines, 
pGL4.51[luc2/CMV/Neo] (Promega, Southampton, UK) and pSELECT-zeo-LucSh (Invivogen, 
Toulouse, France). The pGL4.51 vector encodes the luciferase reporter gene luc2 (Photinus 
pyralis), which has been codon optimised for mammalian expression. Luciferase expression 
is under control of the cytomegalovirus (CMV) promotor with a SV40 late poly(A) signal 
sequence downstream to ensure termination of transcription. The synthetic Neomycin 
resistance gene (G418) allows selection of successfully transfected cells and the Ampicillin 
resistance gene is included for bacterial amplification of the vector (figure 2.2).  
 
Figure 2.2 – The pGL4.51[luc2/CMV/Neo] vector 
The pSELECT-zeo-LucSh vector contains two expression cassettes. The first cassette relies 
on the hEF1-HTLV promotor to drive expression of luciferase (LucSh) with the SV40 
promotor again terminating transcription. The second cassette contains a CMV promotor 
to drive expression of the Zeocin resistance gene with the bacterial promotor EM7 allowing 
selection in both mammalian cells and E. coli, while the BGlo pAn sequence arrests 
transgene transcription (figure 2.3). 
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Figure 2.3 – The pSELECT-zeo-LucSh vector 
 
2.2.2 Transformation and amplification of vector 
In order to increase the quantity of the vectors available for subsequent experiments 
plasmids were transformed and amplified in E.coli bacteria. Four vials (50µl per vial) of One 
Shot® TOP10 Chemically Competent E. coli bacteria (ThermoFisher Scientific, Paisley, UK) 
were thawed on ice. Under aseptic conditions, 1µl of vector DNA was added to each vial, 
including the positive control DNA for transformation pUC19 (ThermoFisher Scientific, 
Paisley, UK, 10 pg/ul), which provides ampicillin resistance to transformed cells. Distilled 
water was added to the final vial as a negative control. 
Following the addition of DNA or water, vials were incubated on ice for 30 minutes prior to 
heating to 42°C for 30 seconds. After a further 3 minutes on ice, 900µl of pre-warmed SOC 
medium (ThermoFisher Scientific, Paisley, UK) was added to each vial. The contents of each 
vial were subsequently moved to separate 15ml Falcon tubes (Fisher scientific, 
Loughborough, UK) and gently shaken in a rocking-incubator at 250 revolutions per minute 
(rpm) and 37°C for one hour. 
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Luria Bertani Broth (LB)-Agar-ampicillin coated 100mm petri dishes (Greiner Bio-One, 
Stonehouse, UK) were made by combining 20g LB powder (Sigma-Aldrich, Dorset, UK) with 
15g agar granules (Melford Laboratories Ltd., Ipswich, UK) in 1L of sterile distilled water 
and adding ampicillin (Sigma-Aldrich, Dorset, UK) to a final concentration of 100µg/ml, with 
this mixture poured into the petri dishes and left to solidify. To ensure the development of 
individual well-spaced colonies, four different volumes of the contents from each falcon 
tube were spread over individual coated petri dishes and incubated at 37°C overnight, after 
which a 10µl filter tip was used to pick colonies. The 10µl tip was placed directly into a LB 
broth-ampicillin mixture in a 15ml Falcon tube and incubated overnight at 37°C. Once 
cloudy, the mixture was added to 1L of LB broth (20g LB powder in 1L water) and incubated 
at 37°C for 24 hours prior to the extraction of plasmid DNA.  
2.2.3 DNA / plasmid extraction from bacteria 
Plasmid DNA was extracted and purified using the QIAGEN-tip 500 Plasmid Midi Kit 
(QIAGEN, Manchester, UK) as per the manufacturer’s instruction. In brief, the bacteria 
were harvested from the culture / LB broth mixture by centrifugation at 6000g for 15 
minutes at 4°C. The bacterial pellet was resuspended in the buffers provided by the 
manufacturer and the plasmid DNA released into suspension by lysis of the bacterial pellet. 
The suspension was passed though the filters in the QIAGEN-tip before the DNA was eluted 
into a fresh 15ml falcon tube. DNA was precipitated by the addition of isopropanol (IPA), 
separated by centrifugation at 15 000g for 10 minutes and resuspended in 2ml TE buffer 
[10mM Tris base, 1nM Ethylenediaminetetraacetic acid (EDTA), pH 7.5] for storage. 
The concentration and purity of the plasmid DNA was determined by reference to the 
260:280nm ratio by placing 1µl of the buffered DNA on the Nanodrop™ ND-1000 UV 
spectrophotometer (Labtech International, East Sussex, UK) a per the manufacturer’s 
instructions. Only samples with a ratio ≥ 1.8 were used in subsequent experiments.  
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2.2.4 Cell culture 
Human (HCT116) cells and murine (CT26) CRC cell lines were purchased from the European 
Collection of Cell Cultures (ECACC) and American Type Culture Collection (ATCC) 
respectively. The CT26 cell line was developed from a colonic carcinoma induced by the 
administration of the carcinogen N-nitroso-N-methylurethane to BALB/c mice [407]. 
HCT116 and CT26 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) and 
Roswell Park Memorial Institute (RPMI) 1640 medium (both Sigma-Aldrich, Dorset, UK) 
respectively at 37°C in a humidified incubator containing 5% CO2. Media were 
supplemented with 10% heat inactivated fetal bovine serum, 584mg/L L-glutamine, 
100 units/ml penicillin G and 100 μg/ml streptomycin (all Sigma-Aldrich, Dorset, UK). The 
transfected luminescent cell lines were co-cultured with the selection antibiotics G-418 
(Promega, Southampton, UK) or Zeocin (Invivogen, Toulouse, France) at a pre-determined 
cytotoxic concentration. 
Cells were routinely cultured in 75cm2 Nunclon cell culture flasks (Nalge-Nuc international, 
C/O VWR International, Lutterworth, UK) and passaged under aseptic conditions in a class-
2 cell-culture hood when approximately 80% confluent. For passage, or when required for 
experiments, cells were washed with 5ml of unsupplemented medium prior to the addition 
of 5ml 0.25% trypsin-EDTA (Sigma-Aldrich, Dorset, UK). Flasks were returned to the 
incubator for up to 5 minutes to allow detachment of cells. The contents of the flask were 
transferred to a 15ml Falcon tube and a further 5ml of medium added before 
centrifugation at 2000 rpm for 3 minutes. The cell pellet was resuspended in 5ml of 
supplemented medium and dissociated with a 21-gauge needle and 5ml syringe. A 1:10 
split of the cell suspension was routinely used for continuity of the cell line in culture. 
For experiments where a specific number of cells were required, cells were counted using 
0.4% Trypan Blue solution and the Countess™ automated cell counter (both Invitrogen, 
Paisley, UK). After trypsinisation and suspension in media, an equal volume of trypan blue 
and the cell suspension were mixed by pipetting and 10µl injected into the chamber of the 
Countess™ automated cell counter slide (Invitrogen, Paisley, UK). The slide was inserted 
into the cell counter and the image focused prior to the determination of the concentration 
of viable cells (those that did not take up trypan blue). The volume required for the specific 
cell count could consequently be calculated and diluted in medium for seeding. 
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2.2.5 Determining lethal concentrations of selection antibiotics in cells 
To allow antibiotic selection of transfected cells the concentration required to kill all cells 
within a week was determined. To establish the lethal concentrations of G418 and zeocin, 
allowing selection following transfection with either vector in both cell lines, cells were 
plated out at 1x105 cells/well in 500µl of medium on a 24-well culture plate (Nalge-Nuc 
international, C/O VWR International, Lutterworth, UK) for assessment of cell viability using 
trypan blue and the Countess™ automated cell counter, or at 5000 cells/well in 100µl of 
medium on a 96-well culture plate (Nalge-Nuc international, C/O VWR International, 
Lutterworth, UK) for assessment by the MTS cell viability assay, and left to adhere 
overnight.  
For dosing with G418 a stock solution was made by dissolving the antibiotic to 1mg/ml in 
the appropriate growth media. Cells were dosed across a range of 12 concentrations from 
0 to 1000µg/ml in triplicate by dissolving the stock solution in the appropriate volume of 
growth medium and applying this to the cells in culture. For zeocin dosing the master stock 
solution (100mg/ml) was diluted in medium to 500µg/ml and then further diluted in 
appropriate volumes of medium for application to cells in triplicate across a range of eight 
concentrations from 0 to 500µg/ml.  
Media, containing the selection antibiotics, were changed every two to three days before 
the assessment of cell viability after 7 days using trypan blue and the Countess™ 
automated cell counter, as described in 2.2.4, or the MTS assay as described in 2.2.6. The 
concentration of antibiotic that caused complete cell death was subsequently used for the 
selection of transfected cells. 
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2.2.6 MTS cell viability assay 
An MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt] colorimetric assay was used to assess cell viability. The assay utilises 
MTS tetrazolium, which is reduced to a soluble formazan-coloured product by NAD(P)H-
dependent oxidoreductase enzymes in viable cells. This rapid colour change causes a 
detectable alteration in the absorbance of light [408]. 20μL of MTS reagent (CellTiter 96® 
AQueous One Solution Cell Proliferation Assay, Promega, Southampton, UK) was 
introduced to all wells and the plates incubated for 2 hours at 37°C. Light absorbance, at a 
wavelength of 490nm, was assessed using the Varioskan™ Flash Multimode Reader 
(ThermoFisher Scientific, Paisley, UK) and cell viability expressed as a percentage of control 
cells. 
2.2.7 Transfection of cells with luminescent vectors 
For the stable incorporation of luciferase expression into cell lines a liposomal transfection 
was carried out using Lipofectamine® 2000 (Invitrogen, Paisley, UK) as per the 
manufacturer’s instructions with both vectors. Cells were plated out at 1x105 cells/well in 
500µl of complete medium on a 24-well plate and left overnight to adhere. Lipofectamine® 
2000 was subsequently diluted in Opti-MEM Reduced Serum Media (Invitrogen, Paisley, 
UK) in sterile Eppendorf’s (Eppendorf UK Limited, Stevenage, UK) with varying 
volume/volume (v/v) ratios; Lipofectamine® 2000: Opti-MEM = 2µl : 50µl, 3µl : 50µl, 4µl : 
50µl and 5µl : 50µl. 5µg of plasmid DNA was also diluted in 250µl of Opti-mem before 50µl 
of the diluted DNA was mixed with 50µl of the four diluted Lipofectamine® 2000 mixtures. 
Following a 15-minute incubation at room temperature, the resulting four DNA-lipid 
complexes were added in duplicate to the medium on the cultured cells in a drop-wise 
fashion. This resulted in a final quantity of DNA of 500ng per well. As a Lipofectamine® 
2000 only control 5µl of the transfection reagent was added to 100µl of Opti-MEM and 
50µl added to duplicate wells of the 24-well plate. Cells were incubated at 37°C for 48 
hours before the assessment of luminescence as described below. The most luminescent 
population of cells were kept in culture and serially passaged in the appropriate selection 
antibiotic, at the pre-determined cytotoxic concentration.  
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2.2.8 Assessment of luminescence by the Bright-Glo™ Assay 
The Bright-Glo™ Luciferase Assay System (Promega, Southampton, UK) allows quantitation 
of firefly luciferase expression in mammalian cells and was one of the methods used to 
assess luminescence in cell lines. To assess the optimum transfection conditions, cells from 
one well of each pair of duplicates were lysed by aspirating the medium and adding 200µl 
of the supplied lysis buffer as per the manufacturer’s instructions. Following this the plate 
was rocked at 70rpm for 5 minutes. The lysis buffer was aspirated from each well and two 
serial 1:2 dilutions of the buffer performed before 80µl of each dilution was added to a 
separate well of a 96-well white-backed plate (Greiner Bio-One, Stonehouse, UK). 20µl of 
the Bright-Glo™ reagent was added to each well, the plate spun at 700rpm for 15 seconds 
and luminescence assessed on the Varioskan™ Flash Multimode Reader with an open filter. 
Luminescence was normalised to the protein content in each well in duplicate to prevent 
bias due to unequal loading. The bicinchoninic acid (BCA) assay [409], utilising the Pierce™ 
BCA Protein Assay Kit (ThermoFisher Scientific, Paisley, UK), was used for protein 
quantification. Samples were compared with a standard curve created by a serial 1:2 
dilution of bovine serum albumin with absorbance at 570nm read on the Varioskan™ Flash 
Multimode Reader.  
2.2.9 Assessment of luminescence with in vivo grade luciferin 
For the assessment of luminescence in vitro, without the need for cell lysis, in vivo grade 
luciferin can be applied to cells in culture. Cells were seeded on 96-well plates at the 
required cell count and left to adhere. A stock solution of VivoGlo™ firefly Luciferin 
(Promega, Southampton, UK) was created by diluting the powder to 15mg/ml in 1x 
phosphate buffered saline (PBS) (Invitrogen, Paisley, UK). This stock solution was further 
diluted 100-fold to 150µg/ml in growth medium and 100µl added to cells in culture on a 
96-well white backed plate for assessment in the Varioskan™ Flash Multimode Reader or 
on a clear plastic plate for the IVIS® Spectrum in vivo imaging system (Perkin-Elmer, 
Massachusetts, USA). For plate imaging in the IVIS® the stage was set to position C with the 
default settings of auto-exposure and medium binning used for image acquisition with an 
open filter.   
To establish the optimum imaging time after the application of luciferin to cells, plates 
were imaged every 5 minutes until peak signal was obtained and subsequent imaging 
performed at this time-point.  
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2.2.10 Clonal selection and expansion of cell lines 
Once a sufficient population of luminescent cells were available, through serial culture in 
increasing volumes to a 75cm2 Nunclon cell culture flask, clonal selection and expansion 
was performed. By selecting a single luminescent clone for subsequent experiments 
luminescent signal can be increased, the chances of achieving stable luminescence is 
improved and the heterogeneity associated with a mixed population of transfected cells is 
removed. This was achieved through serial dilution in 96-well culture plates to a single cell 
per well. A cell suspension of 2x104 cell/ml was created from the luminescent population 
and 200µl of this added to the first well (A1) of a 96-well plate. 100µl of culture medium 
was added to every other well on the plate before a 1:2 first dilution series was completed 
down the first column. An additional 100µl of medium was added to each well in column 
one to give wells in this column a total volume of 200µl. A second 1:2 serial dilution series 
was subsequently performed, moving 100µl from the first column to second, and this 
process repeated across the plate, with 100µl discarded from the final column. This was 
performed across 3 culture plates to increase the number of wells diluted to a single cell 
(figure 2.4).  
 
Figure 2.4 – Schematic of the dilution series used for clonal selection and expansion of 
luminescent cell lines on 96-well culture plates. 
After 24 hours, wells were reviewed under x200 magnification and those with a single cell 
visible marked. After a further 72 hours marked wells were examined again and those with 
a single colony of wells selected for serial passage and expansion under antibiotic selection. 
Once a sufficient population of cells were available, luminescence was assessed using the 
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methods described previously and the most luminescent clone cultured for use in murine 
experiments.  
2.2.11 Murine studies 
All animal experiments were performed in accordance with criteria outlined in a Home 
Office UK approved project licence (PPL 70/8457) granted under the Animals (Scientific 
Procedures) Act 1986 and approved by the Animal Ethics Committee at the University of 
Liverpool. Six to eight-week-old male immune-competent (BALB/cAnNCrl) or homozygous 
nude (BALB/cAnN.Cg-Foxn1nu/Crl) BALB/c mice were purchased from Charles River 
Laboratories (Margate, UK) and housed in a licenced specified pathogen free 
establishment. Mice were given free access to food and water and housed at a 
temperature between 19°C and 23°C under a 12-hour light-dark cycle. 
2.2.12 Subcutaneous injection of tumour cells 
For the sc flank injection of CRC cell lines, non-confluent cells were detached from the flask 
by trypsinisation, transferred to a 15ml Falcon tube, centrifuged to remove all trypsin and 
the pellet resuspended in growth medium for counting. Once the cell concentration was 
established the required volume of cell suspension was transferred to a new 15ml Falcon 
tube and centrifuged at 2500 rpm for 3 minutes before resuspension in the required 
volume of a 1/1 (v/v) mixture of ice-cold PBS / Matrigel® (Corning, Amsterdam, The 
Netherlands) so that each mouse received 1x106 cells in 100µl. The cell suspension was 
kept on ice until required. Prior to the injection of cells mice were placed into an 
anaesthetic chamber and general anaesthesia (GA) induced with 3% isoflurane and 
1L/minute of oxygen flow before being transferred to a nose cone and GA maintained on 
1.5% isoflurane. The right flank was shaved at the injection site and cells injected into the 
sc space using a 500µl insulin syringe with a 30-gauge needle after tenting the skin. Mice 
were ear clipped for identification and tumour growth monitored using BLI as described in 
section 2.2.14. 
2.2.13 Orthotopic caecal injection of tumour cells 
For the orthotopic injection of CRC cell lines, cells were suspended in PBS / Matrigel using 
the method described for sc injection in 2.2.12. Mice were weighed and received a sc 
preoperative dose of buprenorphine (0.1mg/kg). GA was induced and maintained as 
described in 2.2.12. Animals were transferred to a pre-warmed operating table and the 
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abdomen shaved and prepped with betadine for disinfection. Aseptic technique and 
meticulous draping was used to maintain sterility of the operative field.  
A 1-1.5cm lower midline laparotomy was performed and moistened (sterile 0.9% saline) 
cotton tips used to deliver the mobile caecum from the abdomen. A 500µl insulin syringe 
with a 30-gauge needle was used to draw up cells after dissociation by syringing through a 
21-gauge needle. 5x105 cells in 50µl of the PBS / Matrigel mixture were drawn up and 
allowed to warm for 45-60 seconds at room temperature to ensure a relatively viscous 
inoculum and prevent cell leakage. The entire volume was injected into the sub-serosal 
plane of the caecum under direct vision, ensuring a ‘bleb’ of the cell suspension was 
formed under the serosa. Attempts were made to standardise the injection site on the 
caecum, aiming to inject into the anti-mesenteric side of the anterior wall of the caecum. 
The needle entry site was gently compressed with a moistened cotton tip to prevent the 
leakage of cells and ensure haemostasis before returning the caecum to the abdomen, 
ensuring there was no rotation of the gut which could result in volvulus and the ensuing 
obstruction or ischaemia. The peritoneum and muscle layer were closed with a continuous 
6‐0 Vicryl™ (Ethicon, subsidiary of Johnson & Johnson, Norderstedt, Germany) suture. Skin 
was sutured using a subcuticular continuous technique using the same suture material 
(figure 2.5). 
Mice were ear-clipped for identification and allowed to recover in a warming chamber at 
37°. They were observed closely for signs of distress and additional buprenorphine 
analgesia given up to 0.05mg/kg every 8 hours if required. Tumour development, growth 
and the formation of metastases were monitored by bioluminescent imaging. 
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Figure 2.5 – The technique for orthotopic injection of tumour cells into the caecal wall. a) Animals 
were placed in the supine position and the abdomen shaved, sterilised with betadine and draped. 
b) A 1 cm lower midline laparotomy was performed and the caecum delivered. c) Tumour cells 
were injected into the subserosal plane; d) ensuring a good ‘bleb’ of cell suspension was achieved. 
e) The laparotomy wound was closed in two layers. 
2.2.14 Bioluminescent in vivo imaging 
Mice were imaged in the IVIS® Spectrum in vivo imaging system after the ip injection of 
luciferin. Animals were weighed and GA induced and maintained as described previously. 
The area of interest was shaved if required. Each mouse received a dose of 150mg/kg 
VivoGlo™ firefly luciferin by injecting 10µl/g bodyweight of the 15mg/ml stock solution 
prior to transfer to the IVIS® imager, where GA was maintained on the machine’s nose 
cones. For mice flank-injected with tumour cells, imaging was conducted in the prone or 
left lateral position, while orthotopically-injected mice were imaged supine. Imaging was 
conducted with an open filter, auto-exposure and medium binning.  
To attempt to establish an optimum imaging time following the ip injection of luciferin a 
kinetic imaging curve was conducted. Mice were placed in the IVIS® immediately after 
injection of the substrate and imaged every 2 minutes until the luminescent signal 
plateaued, these invariably occurred after 20 minutes in flank grafting mice and all imaging 
was conducted at this time-point after luciferin injection in this model. By imaging mice 
within this plateau period in later imaging points, or subsequent experiments, 
reproducibility could be maintained across replicates.  
To estimate signal depth in mice and assess if luminescent signal could be approximated to 
the liver, consistent with the development of metastasis, 3-dimensional (3D) tomographic 
reconstruction imaging by Diffuse Light Imaging Tomography (DLIT) was utilised. Mice 
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suspected to have metastatic disease on 2-dimensional imaging could be allocated to 3D 
imaging for clarification and to assess if multiple foci of luminescent signal were present. 
Animals allocated to this technique could only be assessed in pairs, as opposed to the five 
mice that can be imaged simultaneously in 2D imaging, with the stage in position C. The 
CCD camera was used to capture an image of the animal and a 3D tomography constructed 
by the software. Luminescent signal was then captured in five images over a range of 
spectral filters from 560 to 640nm (every 20nm). Using a set of linear equations, the 
software calculated the depth of signal based on the different penetrance of light 
wavelengths through tissue. Images were reconstructed by placing a representation of the 
luminescence source within a 3D reconstruction of the animal based on the tomographic 
image. The signal was approximated to skin, bones and organs within the mice using the 
software’s pre-saved templates. 
2.2.15 Bioluminescent ex vivo imaging 
To confirm that liver lesions were consistent with metastatic disease originating from the 
caecal implantation of luminescent CRC cell lines, organs were imaged ex-vivo. Upon 
sacrifice of mice by cervical dislocation, while luminescent signal was still present in vivo, 
necropsy was performed, caeca and livers with macroscopic disease were excised, placed 
in PBS and imaged with platform height set in position C, an open filter, auto-exposure and 
medium binning. 
2.2.16 Histological assessment and immunohistochemistry 
After schedule 1 cull of mice by cervical dislocation, tissue (livers and caeca) containing 
macroscopic disease were fixed in 4% paraformaldehyde (Sigma-Aldrich, Dorset, UK) and 
paraffin-embedded. 5um slices were cut on a rocking microtome, haematoxylin and eosin 
(H&E) stained and examined by the Veterinary Pathologist Dr Lorenzo Ressel to confirm the 
presence of adenocarcinoma.  
For the assessment of T-cell infiltration into tumours sections were de-waxed in xylene 
rehydrated with ethanol solutions of decreasing concentrations. Antigens were retrieved 
by microwaving (96-98°C) for 30 minutes and slides blocked with DAKO REAL™ Peroxidase 
Blocking Solution (Dako UK Ltd., Cambridgeshire, UK) in 0.1% Tris-buffered saline with 
tween (TBST) for 10 minutes. Slides were incubated with the primary antibody for CD3 
(Dako, A0452, 1:400 dilution) at 4°C overnight, washed in 0.1% TBST and Dako Envision and 
  
126 
System-HRP α rabbit secondary antibody added (Dako, K4003, 1:2000) for 30 minutes at 
room temperature. Slides were developed with diaminobenzidine tetrahydrochloride (DAB) 
(Fisher Scientific, Loughborough, UK) for 10 minutes and counterstained with haematoxylin 
(Merck, Nottingham, UK) for 1 minute. 
2.2.17 Data analysis for luminescent imaging 
IVIS® imaging quantifies light in photons / second. Utilising the Living Image™ software, 
areas of luminescent signal were marked as a region of interest (ROI). In cell-based 
experiments, a 96-well plate-grid was placed over the image of the plate and lined up to 
ensure each well was within its own square. To ensure reproducibility across time-points in 
animal studies the same size area was used to cover the abdominal area of each mouse for 
each time-point. The number of photons produced per second within each marked ROI was 
calculated by the software (total flux). The background luminescent signal for each image 
was subtracted from the ROI value. A well containing cells and medium without luciferin 
was used to calculate background signal for assessment of luminescence in cells. In animal 
studies background luminescence was calculated by placing an ROI on an area of a mouse 
without luminescent signal. 
To allow each mouse to act as its own control luminescence within the ROI was expressed 
as a fold change from the initial reading by dividing the luminescence at each time-point by 
the value obtained on the first imaging time-point. 
Graphical display and statistical analysis of data was performed using Prism® 7 (GraphPad 
Software, California, USA). 
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2.3 Results 
2.3.1 Cytotoxicity of G418 in cell lines 
Incubation of CT26 cells with neomycin resulted in cell death in a dose-dependent manner, 
as assessed by cell counting in the presence of trypan blue. Complete cell death, with no 
viable cells present, was achieved by 7 days at concentrations of G418 ≥ 600µg/ml. CT26 
cells transfected with the vector pGL4.51 were therefore cultured with the addition of 
600µg/ml G418 to medium to maintain selection pressure and therefore luminescence 
(figure 2.6). 
 
Figure 2.6 - a) Light microscopy images of CT26 cells in culture at varying magnifications (x100-
x200) taken before the application of 600µg/ml G418 and 2 and 7 days after dosing in treated 
cells. The increasing confluence of untreated control cells is also displayed for comparison. No 
viable cells were visible in the treated cells by 7 days as evidenced by the change in morphology 
and presence of necrotic debris. These data were represented graphically, displayed as mean +/- 
standard deviation (SD), after a 7-day incubation with G418 using both b) the total viable cell 
count /ml and c) the percentage of the total cells counted that were viable for each concentration. 
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The untransfected HCT116 cell line was relatively resistant to G418. Dosing with this 
antibiotic was unable to induce complete cell death in HCT116 cells up to the maximum 
working concentration of 1000µg/ml. Although there was a fall in the total viable cell count 
/ ml at the higher concentrations of G418, suggesting a reduction in proliferation, there 
were still viable cells present even at the highest concentration. For this reason culture in 
G418 for selection of transfected cells was not possible in this cell line and transfection 
with the pGL4.51 vector not undertaken (figure 2.7).  
 
Figure 2.7 - a) Light microscopy images of HCT116 cells in culture at varying magnifications (x100-
x200) taken before the application of 1000µg/ml G418 and 2 and 7 days after dosing in treated 
cells. The increasing confluence of untreated control cells is also displayed for comparison. Despite 
significant cell death, some viable cells were visible in the treated cells by 7 days, appearing 
brighter and with a more normal morphology than the surrounding necrotic cells. These data were 
represented graphically, displayed as mean +/- SD, after a 7-day incubation with G418 using both 
b) the total viable cell count /ml and c) the percentage of the total cells counted that were viable 
for each concentration. (N=3 in duplicate) 
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2.3.2 Cytotoxicity of zeocin in cell lines 
Zeocin was cytotoxic to both the CT26 and HCT116 cell lines. Dose-response curves, using 
the MTS cell viability assay, were similar in both with zero percent viability reached at 
400µg/ml. This concentration was subsequently used for the selection and maintenance of 
cells successfully transfected with the pSELECT-zeo-LucSh vector (figure 2.8). 
 
 
Figure 2.8 – Cytotoxicity dose-response curves, displayed as mean + SD, after a 7-day incubation 
with Zeocin were performed in a) CT26 and b) HCT116 cells using the MTS assay. Results are 
expressed as a percentage of untreated control cells left to proliferate for 7 days. There were no 
viable cells detectable at 7 days with 400µg/ml of zeocin in both cell lines. (N=3 in triplicate, 
graphs display mean +/- SD) 
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2.3.3 Assessing optimum transfection conditions in cell lines 
Luminescence was assessed using the Bright-Glo™ Assay in the CT26 cell line 48 hours after 
transfection with pGL4.51 plasmid DNA and normalised to the protein content of the well. 
The replicate well of the transfection conditions resulting in the highest luminescent signal 
per µg of protein were labelled CT26luc and kept and passaged in increasing volumes to 
expand the population (figure 2.9). These conditions were subsequently used for the 
transfection of CT26 cells with the pSELECT-zeo-LucSh vector.  
 
Figure 2.9 – a) Transfection in 40µl/ml of Lipofectamine® 2000 resulted in the highest luminescent 
signal at 48 hours, as measured by the Varioskan™ using the Bright-Glo™ Assay, in CT26 cells when 
normalised to the protein content of the well. b) The luminescent signal decreased proportionally 
with the 1 in 2 serial dilution of the 1:1 cell suspension. (RLU = relative luminescent units) 
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VivoGlo™ firefly Luciferin was used to assess the optimum conditions for the incorporation 
of the luciferase gene into HCT116 using the pSELECT-zeo-LucSh vector. Populations of 
transfected cells were re-plated in triplicate on to a 96-well plate for the assessment of 
luminescence and a 6-well plate for the continued culture. Only the most luminescent 
population of cells was kept and expanded in culture; labelled HCT116luc (figure 2.10).  
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Figure 2.10 – Varioskan™ assessment of luminescence in HCT116 cells 48 hours after transfection 
with the pSELECT-zeo-LucSh vector. Transfection in 20µl/ml of Lipofectamine® 2000 resulted in the 
highest luminescent signal with this population of cells continued in culture. Luminescent signal 
reflected the number of cells plated, with a halving of signal for every 1 in 2 serial dilution. 
(Performed in triplicate with graph displaying mean +/- SD) 
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2.3.4 Clonal selection and expansion 
After serial dilution of the CT26luc population (transfected with the pGL4.51 vector), which 
produced 7 photons/second/cell, and clonal expansion, analysis of luminescence in the 
thirteen clonal populations was performed on both the IVIS® and Varioskan™ after the 
application of VivoGlo™ firefly Luciferin. Only one clone (CT26lucA6) demonstrated any 
luminescent signal, suggesting poor initial transfection efficiency, and was expanded in 
culture. The CT26lucA6 clones produced 27 photons/second/cell.  
This process was repeated from a population of CT26 cells transfected with the pSELECT-
zeo-LucSh vector and the CT26lucA2 clone produced. This clone emitted 280 
photons/second/cell (figure 2.11). 
 
Figure 2.11 – a) IVIS® imaging demonstrated luminescent signal in only one (CT26lucA6) of the 13 
clones represented by the image in b) (performed in duplicate). c) This was confirmed using 
Varioskan™ assessment at two cell concentrations (performed in triplicate). d) Luminescent signal 
was compared between clones and the CT26luc population transfected with the pGL4.51 vector 
using the Varioskan™ and VivoGlo™ luciferin. The CT26lucA2 clone (transfected with pSELECT-zeo-
LucSh) was 10-fold more luminescent than the CT26lucA6 (performed in triplicate). (Graphs 
display mean +/- SD, s = seconds) 
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Clonal selection was also carried out from the HCT116luc population. Seventeen clones 
were assessed and the most luminescent of these, HCT116lucB4 (producing 120 
photons/second/cell), kept and expanded in culture for future experimental work (figure 
2.12). 
 
 
 
 
Figure 2.12 –Varioskan™ assessment with VivoGlo™ luciferin demonstrated luminescence in 15 of 
the 17 clones, with the HCT116lucB4 clone the most luminescent of these. (Performed in triplicate, 
graph displays mean +/- SD). 
 
 
 
 
  
134 
2.3.5 Optimum imaging time with VivoGlo™ firefly Luciferin. 
In order to establish an optimum imaging time after the application of VivoGlo™ firefly 
Luciferin to cells, and ensure reproducibility across studies, a kinetic imaging curve was 
performed in both cell lines. Peak signal was achieved by 20 minutes in cell lines and 
remained at this level for at least a further 10 minutes, subsequent imaging with VivoGlo™ 
firefly Luciferin was therefore conducted at 20 minutes (figure 2.13).  
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Figure 2.13 – Kinetic imaging assessment of luminescence in CT26lucA6 cells using IVIS® imaging 
after the application of in VivoGlo™ firefly Luciferin. This curve was generated to guide the timing 
of imaging after the application of luciferin in subsequent experiments. (N=3 in triplicate with 
graph displaying mean +/- SD, min = minutes) 
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2.3.6 Luminescence signal reflects the live cell count 
To ensure luminescent signal was an accurate reflection of the number of viable cells 
present, luminescence was plotted against the number of cells seeded in a well. There was 
a strong positive correlation between cell count and luminescent signal in all cell lines and 
clones tested (figure 2.14).  
 
 
 
Figure 2.14 – A positive correlation was noted between luminescence and the live cell count / well 
in a) and b) CT26lucA6 cells (r2 = 0.98, p<0.0001, Pearson R) and c) and d) HCT116lucB4 cells (r2 = 
0.99, p<0.0001, Pearson R). (N=3, performed in triplicate, graphs display mean +/- SD) 
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2.3.7 Luminescent stability in cell lines 
To assess the stability of luminescence in clonal populations across passages, repeated 
IVIS® imaging of cell lines was undertaken using VivoGlo™ at approximately 1 month, 3 
months and 6 months after the development of clones. Differences in luminescent signal 
were minimal in clonal cell lines across these time-points, despite increasing passage 
number and freeze-thawing on at least one occasion (figure 2.15).  
 
 
 
 
 
Figure 2.15 – Graphs display the minimal differences in luminescent signal in the a) CT26lucA6c 
and b) HCT116lucB4 clonal cell lines at increasing time-points following clonal selection. 
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2.3.8 Subcutaneous injection of the CT26lucA6 clone 
To ensure cells would propagate in vivo, and assess the intensity and stability of 
luminescence, CT26lucA6 cells were injected in to the right flank of 6 BALB/c immune-
competent mice. Mice underwent IVIS® imaging from the 3rd day after the injection of cells 
and then twice weekly until sacrifice. A kinetic imaging curve was performed at each 
imaging time-point until day 14, these consistently demonstrated a plateau in signal 
intensity from 20-30 minutes after the ip injection of luciferin, with mice imaged within this 
time window in subsequent studies utilising the flank grafting of cells (figure 2.16).  
 
 
Figure 2.16 – Representative kinetic imaging curves from two individual BALB/c mice 14 days after 
the flank injection of CT26lucA6 cells, displaying total flux from their tumours against time after 
the injection of luciferin. 
 
The tumour uptake rate was 100%, with all 6 mice developing tumours. Luminescent signal 
increased throughout the imaging period as the tumour increased in size. However, the 
increase in luminescent signal varied substantially between mice leading to a relatively 
wide standard error when data were combined (figure 2.17). The severity limits of the 
licence, due to the size of tumours, were reached by the 18th day. Due to this rapid 
development of tumours a lower cell count of 5x105 cells in 50µl was injected in future 
studies using the CT26 cell line. 
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Figure 2.17 – a) Representative images of 3 BALB/c immune-competent mice serially imaged in the 
IVIS® after the sc injection of CT26A6 cells. b) Luminescence signal increased throughout the study 
period in a relatively exponential manner, as displayed for individual mice in a graph of time 
versus luminescence. c) When data were combined the standard error in the mean (SEM) was 
relatively wide, reflecting the variable growth rates and therefore luminescent signal in mice. 
(N=6, Graph displays mean +/- SEM) 
At the end of the study, tumours were excised after schedule 1 cull. The largest of these 
was dissected with a scalpel blade and individual tumour lumps placed in wells of a 6-well 
culture plate. RPMI 1640 medium, with the selection antibiotic G418, was added and after 
3 days the tumour lumps were removed, leaving the adherent tumour cells in culture. This 
allowed the development of an in vivo-conditioned cell line for caecal implantation, 
labelled CT26lucA6c. 
  
139 
2.3.9 Caecal implantation of the CT2lucA2 clone 
The CT26lucA2 clone was developed after the sc injection of the CT26lucA6 clone, from the 
original parent cell line and not from transfected cells, in attempt to produce a more 
luminescent cell line for use in the orthotopic model, with increased luminescent signal 
allowing the early detection of primary tumours and metastatic disease. As the CT26lucA2 
clone had been developed from the same parent cell line as the CT26lucA6 clone, which 
had developed rapidly growing flank tumours when injected sc, it was not-tested as a sc 
graft initially and was taken straight to orthotopic implantation. 
In the first group of four immune-competent BALB/c mice orthotopically implanted with 
the CT26lucA2 clone, three (75%) developed detectable luminescent signal by the first 
imaging point (5 days after caecal injection). The total flux increased for all three mice until 
day 7 in one mouse and day 13 in the other two, at which point signal continued to fall 
until the study was abandoned on the 23rd day after orthotopic injection.  
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Figure 2.18 – Initial pilot study involving orthotopic implantation of the CT26lucA2 cell line into 4 
BALB/c mice. a) Representative images acquired using the IVIS® demonstrate a decrease in 
luminescent signal from day 13. b) This occurred in all mice with detectable signal at the initial 
imaging point, as demonstrated graphically by plotting total flux against time for each individual 
mouse. 
This study was repeated with a further nine mice receiving orthotopic, and one mouse 
flank injection, of the CT26lucA2 cell line. The inclusion of a sc-injected mouse allowed 
direct visual assessment of the tumour to confirm whether tumours were truly regressing 
or the cells losing their luminescent signal in vivo. Initial tumour uptake was similar to the 
first group, six (67%) of the orthotopically implanted mice developed detectable signal on 
day 5, but again signal had peaked by day 10 in all mice and then continued to fall until the 
study was terminated. The tumour in the flank-grafted mouse grew until the 10th day after 
the injection of cells, after which visible tumour regression and a decrease in tumour 
volume were noted; this change in volume was reflected by a fall in the luminescent signal 
(figure 2.19). 
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Figure 2.19 – Findings were similar in the 2nd group of 9 BALB/c mice following caecal injection of 
the CT26lucA2 clone, with a fall in luminescent signal, as demonstrated in a) representative 
images and b) graphically for each individual mouse, noted from day 7 onwards. The inclusion of a 
flank grafted mouse in this group allowed visual confirmation of tumour regression. 
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On necropsy, very small (1mm) tumour nodules were noted in the caeca of mice with 
detectable signal. Histology confirmed these nodules to be consistent with a poorly 
differentiated adenocarcinoma. However, staining for the CD3 antigen confirmed dense 
infiltration of T-cells into the tumour, suggesting an immune response (figure 2.20). 
 
Figure 2.20 – a) Photographic image of a tiny tumour nodule (long arrow) in the caecum of a 
BALB/c mouse, taken 23 days after the orthotopic injection of the CT26lucA2 cell line. b) Light 
microscopy (x400) confirmed a poorly differentiated adenocarcinoma but with a c) dense T-cell 
(solid triangles) infiltrate when stained for the CD3 antigen. 
2.3.10 Caecal implantation of the CT2luc6A6c clone 
Due to the failure of the CT26lucA2 cell line to propagate in vivo the CT26lucA6c 
conditioned cell line was used to develop the syngeneic orthotopic murine model. To 
establish the optimum imaging times, growth rate of primary tumours and frequency of 
metastatic disease, eight immune-competent BALB/c mice underwent orthotopic injection 
of the CT26lucAc6 cell line in the caecal sub-serosa. There was no peri-operative morbidity 
or mortality up to the study end-point. Primary tumours developed in five (63%) mice, with 
luminescent signal continuing to increase throughout the study period, consistent with 
tumour growth.  
Due to the large variation in signal at the first imaging point, subsequent luminescent 
values were expressed as the fold change in luminescence by dividing by the signal from 
the first imaging day. This meant each mouse was able to act as its own control, allowing 
standardisation and comparisons between mice by reducing the variations in signal likely to 
result from the operative technique and position of injection into the caecum. The study 
was ended on the 18th day post-implantation due to one mouse reaching the severity limits 
of the project licence due to symptoms of obstruction (figure 2.21).  
a) b) c)
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One (20%) mouse developed ectopic signal consistent with the development of a liver 
metastasis and was subject to 3D imaging which suggested that signal may be originating 
from within the liver. This was confirmed on necropsy, ex-vivo imaging and histologically 
(figure 2.22). 
 
Figure 2.21 – a) Representative IVIS® images from the first attempt at caecal implantation using 
the CT26lucA6c clone. Imaging was consistent with development of a primary tumour in the left 
iliac fossa of the mouse, with ectopic signal developing on day 17 in the right upper quadrant, 
consistent with the development of a liver metastasis. b) Results were combined as fold change in 
luminescence for graphical display, confirming an increase in luminescence throughout the study 
period. (N=5, Graph displays mean +/- SEM) 
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Figure 2.22 – 3D spectral un-mixing imaging can be useful for estimating the depth of luminescent 
signal within the mouse, suggesting luminescent signal arising from within the liver. Ex-vivo 
assessment confirmed the presence of a liver metastasis, with signal present in both the caecum 
and liver on IVIS® imaging. 
 
Mice with luminescent signal all had macroscopic primary tumours at necropsy. One mouse 
was also found to have peritoneal disease and ascites. Primary tumours were confirmed to 
be poorly differentiated neoplastic growths of epithelial origin, displaying clear infiltrative 
behaviour. There was no striking evidence of lymphocytic infiltration of the tumour as 
noted in previous experiments with the CT26lucA2 cell line (figure 2.23). 
 
 
Figure 2.23 – Photograph and histology from a large caecal carcinoma (marked by *) excised 18 
days after implantation. Histology confirmed tumour growth in the wall of the caecum, originating 
below the epithelium and invading into the muscularis. 
*
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Establishing an optimum time for imaging after the injection of luciferin was more difficult 
in the orthotopic model than with the sc injection of cells. The timing of peak signal tended 
to vary considerably between mice (ranging from 4-25 minutes) and the plateau period was 
short, perhaps reflecting variation in blood supply to the tumour. Mice were therefore 
imaged every 2 minutes until luminescent signal fell and the highest signal achieved used in 
data analysis (figure 2.24).  
Figure 2.24 – Graphs displaying kinetic imaging curves (imaged every 2 minutes) for individual 
mice orthotopically implanted with the CT26lucA6c cell line. The timing of peak signal varied 
considerably between mice. 
A total 68 immune-competent BALB/c mice have undergone caecal implantation of the 
CT26lucA6c cell line, with many allocated to the treatment groups described in subsequent 
work.  There have been no complications from the procedure or peri-operative deaths in 
this model. Weight loss is common (occurring in all mice) in the first 3-4 days post-
operatively but tends to be minimal and most mice have reached or exceeded their pre-
operative weight by 7 days.  
Primary tumours have developed in 44 (65%) mice and of these nine (20%) have developed 
liver metastases; no more than 2 metastases have been identified in a single mouse. Liver 
metastases are believed to have occurred through a mixture of haematological and trans-
coelomic spread. Metastases via the haematological route occur within the hepatic 
parenchyma while those spread through the peritoneal cavity can be seen to originate on 
the liver capsule (figure 2.25). Gross peritoneal disease developed in seven (16%) of the 
mice and these were excluded from data analysis in experimental studies. One mouse in 
the experimental groups had to be culled prior to the study endpoint due to symptomatic 
colonic obstruction. 
0 1 0 2 0 3 0
0
7 .51 0 6
1 .51 0 7
T im e  (m in s )
T
o
ta
l 
F
lu
x
 (
P
h
o
to
n
s
 /
 s
)
0 1 0 2 0 3 0
0
1 .01 0 8
2 .01 0 8
T im e  (m in s )
T
o
ta
l 
F
lu
x
 (
P
h
o
to
n
s
 /
 s
)
  
146 
 
Figure 2.25 – Microscopic images of H&E stained sections of liver metastases originating from 
implantation of the CT26lucA6c cell line. a) Metastases originating by haematological spread occur 
within the hepatic parenchyma, whereas b) those resulting from trans-coelomic spread grow on 
the liver capsule. 
 
2.3.11 Implantation of the HCT116lucB4 clone 
An attempt was made to establish an orthotopic xenograft model of CRC by implanting the 
luminescent human CRC clonal cell line, HCT116lucB4 into homozygous nude BALB/c mice. 
Caecal injection of the cell line was performed in fifteen mice. A single mouse had a 
superficial dehiscence of his skin on the first post-operative day and was re-sutured. Only 
five (33%) mice developed detectable signal by the 7th post-operative day. Unfortunately 
signal fell in most mice from this imaging point and, due to the low tumour uptake rate and 
falling luminescent signal, the study was terminated on the 14th day post-implantation. At 
necropsy only very small (≤1mm) tumour nodules were visible in mice with detectable 
luminescent signal. No mice had macroscopic evidence of tumour formation within the 
peritoneal cavity or liver (figure 2.26). 
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Figure 2.26 – a) Representative IVIS® images and b) data presented graphically confirm a falling 
luminescent signal from day 7 in the 5 out of 15 nude BALB/c mice orthotopically-injected with 
the HCT116lucB4 clonal cell that originally had detectable luminescence. 
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2.4 Discussion 
This chapter describes the development of a syngeneic orthotopic metastatic murine 
model of CRC, from the development of luminescent populations of cell lines from a single 
clone, to the injection of these cell lines into the caecum of BALB/c mice and the 
longitudinal assessment of disease burden by IVIS® imaging.  
The pilot study of this model, described in section 2.3.10, allowed improvement of the 
injection technique, the establishment of imaging protocols and the determination of the 
ideal imaging frequency, the tumour uptake rate, the frequency of metastatic disease and 
the likely duration of murine studies. These data were used to guide further studies 
applying this model to the testing of potential therapies in vivo. As a direct result of this 
pilot, future studies utilising the model followed a set protocol which included: the use of a 
lower cell count (4x105 cells), allowing the study period to be prolonged to 21 days after 
implantation before tumour-related symptoms developed; the warming of matrigel 
suspended cells at room temperature for up to a minute to increase the viscosity of the 
inoculum and prevent leakage; the use of the 7th day post-implantation as the first imaging 
time-point, giving time for the tumour to become established, but reducing the larger 
variations in signal seen between mice at later imaging points; the use of kinetic imaging 
(every 2 minutes until peak signal) in each mouse at every time-point, improving 
comparisons between time-points; and the expression of data as a fold change from the 
initial luminescent imaging point, allowing each mouse to act as its own control and 
narrowing the standard deviation. Imaging frequency was also increased to three times a 
week for murine experiments comparing treatment groups due to the rapid growth of the 
tumour and resulting large changes in total flux that can occur in short time periods. 
A distinct advantage of this syngeneic model is the short time-frame required for the 
establishment and development of primary tumours. This allows rapid screening of 
potential therapies in vivo, within a three-week window. This is in contrast to the results 
demonstrated in publications utilising orthotopic xenografting of human CRC cell lines. In 
one example 2x106 cells were injected into the caecal wall and tumour growth assessed 8 
weeks after implantation [410]. The use of BLI IVIS® imaging also increased through-put as 
up to five mice could be imaged simultaneously, permitting the relatively rapid acquisition 
of larger data sets. Up to 15 mice were often imaged in a single session lasting no more 
than two hours. 
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The rate of liver metastases (20%) demonstrated in the syngeneic model is similar to the 
incidence of synchronous liver metastasis seen in patients with CRC; recent data report 
metastatic disease in 21% of patients at presentation [411]. This suggests that the murine 
model is a reasonable representation of the presentation of CRC in patients, but limits its 
use in studies where liver metastases are a requirement. In this scenario, direct injection 
into the liver parenchyma, portal vein or the spleen is likely to be more reproducible, with 
take rates of 100% described in the literature [412]. Rates of metastases could potentially 
have been increased through the re-culturing of cells isolated from the liver metastasis that 
developed in mice, selecting a population of cells with the highest metastatic potential. A 
metastatic rate of 20% is also considerably lower than demonstrated in recent studies 
utilising orthotopic injection of the CT26 cell line. One study demonstrated liver metastases 
in 67% of mice 14 days after the caecal injection of CT26 cells. However, this study utilised 
MRI imaging, which could have improved detection rates, on a small number of mice (n=6) 
[351]. MRI imaging was considered, but BLI imaging selected due to its high-throughput 
and relatively low cost for the assessment of potential therapies. 
Another limitation of the model is the late development of metastases, often only 
detectable on IVIS® imaging as a distinct area of luminescence separate from the primary 
tumour towards the end of the study period. Attempts were made to develop a more 
luminescent CT26 clone, utilising the pSELECT-zeo-LucSh vector, which could potentially 
have allowed the earlier detection of liver metastases or the inoculation of a lower cell 
count, perhaps delaying the onset of bowel obstruction and allowing more time for 
metastases to develop. Unfortunately, most likely as a result of a T-cell mediated immune 
response in the mice, this clonal population of cells were unable to propagate in vivo.  
Other techniques could have been utilised in an attempt to develop increased luminesce in 
cell lines. It is possible to design vectors that allow cells to be dual-tagged with genes 
coding for luciferase and Green Fluorescence Protein under the control of a single 
promotor, permitting selection of the successfully transfected luminescent cells by 
Fluorescence-activated cell sorting (FACS) and removing the need for serial dilution to 
randomly select clones [413, 414]. Attempts were made to sort cells by flow cytometry 
using luminescence during this thesis (data not shown); although the wavelengths of light 
produced by luminescence can in theory be detected by FACS, the signal intensities were 
found to be too low.  
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Alternate transfection techniques or reagents could also have been considered. 
Comparisons of commercially available non-viral transfer reagents demonstrated cell line 
dependent variations in transfection efficiency [415]. Various transfection techniques have 
also been compared in the literature; in human dental follicle cells the use of 
electroporation resulted in a greater transfection efficiency than chemical techniques, 
including liposomal transfection [416]. Viral transfection methods could also have been 
considered; lentiviruses are particularly well studied and shown to integrate well into the 
host genome, resulting in stable and long-term gene expression. As with all gene transfer 
methods there are drawbacks; production is often labour intensive and there is the 
potential for the activation of latent disease, particularly with retroviral vectors [417, 418]. 
Clustered regularly interspaced short palindromic repeats (CRISPR) gene editing is a 
relatively new technique, allowing a cell’s genome to be cut at a desired location and a new 
gene to be inserted [419]. CRISPR relies on an enzyme called Cas9 which uses a guide RNA 
molecule to identify its target DNA, then edits the DNA to disrupt genes or insert desired 
sequences. CRISPR could be used to splice the luciferase gene into the genome of a cell, 
removing the problems associated with poor transfection efficiencies and stability of 
expression.  
The relatively large variations in the growth rate of tumours, as assessed by luminescent 
imaging, seen in the model can also present problems with data analysis as larger groups of 
animals may be required to achieve significance between data sets. A number of factors 
could contribute to this, such as the blood supply of the tumour and variations in 
expression of genes and proteins, such as growth factors, between individual mice. Studies 
have described the suturing of a small lump of tumour tissue on to the caecal wall after 
deliberate serosal damage, to allow implantation [420]. This technique could potentially 
have reduced some of the variation in signal seen at the initial imaging points, which are 
likely to result from the injection technique and inoculation of variable cell numbers. This 
effect was at least partially controlled through the expression of data in terms of fold 
change. 
Unfortunately attempts to establish a xenograft model using the same technique were 
unsuccessful during the time allocated for completion of this thesis. The reasons for the 
poor tumour uptake rate and tumour regression demonstrated in the xenograft model 
were not established. The athymic development of T-cells and natural killer cells is possible 
in nude mice, and is more common in nudes on a BALB/c background. Athymic mice are 
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also able to produce B-cells and are therefore capable of mounting some humoral 
response. It is theoretically possible that the hEF1/HTLV promotor in the pSELECT-zeo-
LucSh vector, which contains part of the human T-cell leukaemia virus gene sequence, 
induced an immune response. This would also explain the lack of success in the syngeneic 
model in cells transfected with this plasmid. Unfortunately, the size of any lesions noted at 
necropsy in the nude mouse study described in 2.3.11 made histological assessment of 
tumour tissue difficult. The use of a different mouse strain, such as SCID mice, may have 
improved the chances of developing a xenograft model. However, due to the success of the 
syngeneic model, and the greatly increased cost associated with the purchase and use of 
nude mice, the syngeneic model was considered to be superior. 
The aim of the work presented in this chapter was to create a murine model of CRC that 
more accurately reflected the pattern of disease found in patients than with the sc flank 
injection of tumour cells into rodents. A murine model was created that relatively reliably 
developed primary colonic tumours in the correct microenvironment that were capable of 
metastasising to the liver. Disease also occurred in the presence of an intact immune 
system. The model had some distinct advantages for the testing of potential therapies: the 
use of BLI imaging allowed the longitudinal acquisition of data in larger numbers of mice 
than is achievable with other imaging modalities, with cull not required for the assessment 
of disease burden; the rapid development of disease meant that studies could be 
conducted over relatively short time periods; and the use of immune-competent mice 
meant the model was relatively inexpensive in comparison to immune-deficient models.                                 
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Chapter 3 – The expression and modulation of Nrf2 in 
colorectal cancer; application to the optimisation of 
irinotecan therapy. 
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3.1 Introduction 
Chemotherapy is frequently utilised in the treatment of advanced CRC. Patients with a 
colonic primary and liver metastases may receive chemotherapy in an attempt to bring 
them to resection or to prolong life in the palliative setting. Rectal cancer may be treated 
with neoadjuvant LCCRT to reduce the risk of margin positivity and local recurrence 
following resection. Adjuvant chemotherapy may be given to any patient found to have a 
high-risk tumour, usually due to lymph node positivity, following resection and 
histopathological assessment of the primary. Unfortunately, response to chemotherapy 
can vary significantly due to a number of factors. These include the biology of the tumour 
itself, in addition to the ability of the patient to metabolise the active and toxic metabolites 
of the drug. Specifically, in reference to irinotecan therapy, variations in the expression of 
CES, CYP3A, UGT1A1 or the ABC transporters in both the patient’s liver and tumour could 
all influence clinical response and the severity of side effects and toxicity, as discussed in 
section 1.8.4. 
Despite the frequent utilisation of chemotherapy in the treatment of patients with stage III 
or IV CRC, which in the adjuvant setting is thought to confer a 10% improvement in 
absolute survival, outcomes for these groups remain worse than for those presenting with 
low risk tumours [421]. The identification and modulation of therapeutic biomarkers could 
potentially improve these outcomes, either through the development of novel standalone 
therapies or as enhancers of response to standard chemotherapy regimens. A biomarker 
can be defined as a molecular marker that can be obtained through analysis of mRNA, DNA 
or proteins to stratify patients for treatment benefit, prognosticate patient outcome or 
predict and modify response to therapy [422].  
Nrf2 has the potential to act as a prognostic, predictive or therapeutic biomarker due to its 
roles in cell proliferation, cell survival, protection against ROS and drug metabolism, as 
discussed in section 1.10. High Nrf2 expression could theoretically confer a survival 
advantage to tumour cells and increase proliferation, potentially resulting in a more 
aggressive tumour, and a worse prognosis for patients. It could also render cells more 
resistant to chemotherapy through the activation of drug metabolising or cell survival 
pathways, predicting a worse response to therapy. A number of recent publications have 
correlated high Nrf2 expression in a variety of malignant tumours, including bladder, gastric 
and ovarian cancers, with worse absolute survivals and chemoresistance  [268, 423, 424]. 
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Inhibition of Nrf2 in cancer cells could therefore be potentially therapeutic, reducing the 
activation of pro-survival and chemoresistance pathways. 
Nrf2 modulation could be particularly relevant to treatment with the pro-drug irinotecan. 
The metabolism of irinotecan and the proteins and enzymes associated with this pathway 
were discussed in section 1.8.4. The involvement of Nrf2 in regulation of a number of these 
proteins was highlighted in sections 1.10.4. To summarise these sections, irinotecan is 
converted to the active metabolite SN-38 by the CES and UGT1A1 detoxifies SN-38 to SN-
38G for excretion. Irinotecan can also be directly metabolised to the inactive compounds 
APC and NPC by CYP3A. The ABC transporters aid in the active excretion of both irinotecan 
and SN-38 from cells. Expression of CES, UGT1A1 and a number of the ABC transporters 
have all been demonstrated to be inducible through activation of the Nrf2 pathway. As a 
result, the effect of Nrf2 modulation in CRC, particularly in reference to irinotecan therapy, 
is unpredictable and involves the complex interactions between drug metabolism and cell 
survival pathways. 
A benefit to the continued investigation of Nrf2 as a therapeutic biomarker in cancer is the 
presence of pharmacological inducers and inhibitors. Two of the more promising and most 
well publicised of these, the inducer CDDO-me and inhibitor brusatol, were discussed in 
sections 1.10.5 and 1.10.6 respectively. These compounds potentially allow Nrf2 
modulation to be translated into clinical practice without the need for complex gene based 
therapies. 
The work in this chapter describes the expression of Nrf2 in CRC patient samples and cell 
lines, demonstrates modulation of Nrf2 expression in vitro both genetically and 
pharmacologically, examining the effect this has on cell proliferation and survival in 
isolation and when combined with irinotecan based chemotherapy, before translating 
these findings in vivo utilising the murine model described in chapter 2. 
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3.2 Methods 
3.2.1 Tissue microarray construction 
NHS Research Ethics Committee and Research and Development approval was obtained for 
all work on patient samples (12/NW/0011). Only patients with metastatic CRC were 
included in the study. Archived samples of formalin-fixed paraffin embedded patient 
primary and metastatic colorectal cancer tissue were obtained from contributing research 
sites within the Merseyside and Cheshire cancer network. Normal adjacent colonic mucosa 
was also obtained where available. Blocks and corresponding H&E stained slides were 
reviewed and marked to identify representative areas of both tumour and normal tissue.  
Tissue Microarrays (TMAs) were constructed using a tissue microarrayer (Beecher 
Instruments Incorporated, Wisconsin, USA) with 0.6mm cores retrieved from donor blocks 
and transferred into the recipient master paraffin block in triplicate as described in the 
literature [425]. Normal liver tissue was also transferred to each TMA in triplicate to act as 
a control. Samples of primary tumour, normal colon and liver metastases were randomised 
across 3 TMAs. To allow inter-array comparisons, a sample set containing all three tissue 
types from a single patient was placed on each of the TMAs. TMAs were incubated at 37°C 
overnight, placed on ice and 5μm sections were cut on a rocking microtome and placed 
onto coated glass slides. 
3.2.2 IHC analysis of Nrf2 expression in patient samples 
To establish optimal conditions, 3 dilutions of the primary antibody for Nrf2 were used on a 
series of test slides with concentrations spanning those suggested by the manufacturer 
(1:20, 1:50, 1:200, 1:500). Nrf2 is ubiquitously expressed, but examination of Protein Atlas 
(www.proteinatlas.org) suggested a high intensity staining would be expected in normal 
liver tissue, and this was included on each of the test slides to guide staining protocols. 
Antibody diluent only and a mouse IgG1 isotype control (Abcam, ab91353, Cambridge, UK) 
were used as negative control for background staining. 
Sections were de-waxed in xylene and rehydrated with ethanol solutions of decreasing 
concentrations. After blocking with 3% hydrogen peroxide in 100% methanol, antigens 
were retrieved by microwaving for 20 minutes in 10mM citrate buffer and further blocked 
with 10% goat serum in 0.1% TBST. Slides were incubated with a 1:50 dilution of the 
primary antibody for Nrf2 (Santa Cruz, SC-722, California, USA) for 2 hours followed by a 
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1:200 horseradish peroxidase conjugated secondary antibody for 30 minutes (Dako UK Ltd, 
E0433, Cambridgeshire, UK). Following incubation with the Vectastain Elite® ABC reporter 
system (Vectorlabs, Burlingame, USA), slides were developed with DAB and counterstained 
with haematoxylin. 
Stained sections of the TMA were reviewed by light microscopy and scanned using the 
Aperio Scanscope (Leica Biosystems, Wetzlar, Germany) and semi-quantification of protein 
expression performed using Tissue Studio v.2.0 (Definiens AG, Munich, Germany). Software 
training was required prior to scoring. In brief this consisted of nuclear and cell membrane 
identification to enable cellular recognition, followed by the setting of intensity thresholds 
for weak, moderate and intense staining. Minor adjustments within the software were 
made until concordance with a 10% sample similarly scored by eye was achieved. 
Staining intensities from the automated system allowed the generation of H-scores for 
cores as described by Shousha [426]. This involved assigning scoring intensities of negative, 
weak (1), moderate (2) or high (3) to cells with the H-score calculated utilising the 
equation: H-score = (1 x percentage of cells scored 1) + (2 x percentage of cells scored 2) + 
(3 x percentage of cells scored 3). 
3.2.3 Cell culture 
General cell culture, cell counting and details specific to the culturing of the HCT116 and 
CT26 cell lines were described in section 2.2.4. The benign human colonic cell line, CCD-
33CO, was also purchased from the American Type Culture Collection and cultured in 
Eagle's Minimum Essential Medium (EMEM) (Sigma-Aldrich, Dorset, UK) supplanted with 
10% fetal bovine serum and antibiotics (100 units/ml penicillin G and 100 μg/ml 
streptomycin). 
3.2.4 siRNA modulation of the Nrf2 pathway 
siRNA silencing was utilised to modulate Nrf2 in CRC cell lines. Cell were plated out and left 
to adhere overnight at 5000 cells/well in 100μl of medium on 96-well plates for viability 
experiments, or 3x105 cells/well in 1ml of medium on 12-well plates (Nalge-Nuc 
international, C/O VWR International, Lutterworth, UK) for western immunoblotting. siRNA 
targeting human or murine Nrf2 or Keap1 (see table 3.1 for details of siRNA sequences and 
manufacturers) were purchased from Dharmacon or Qiagen and prepared as per the 
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manufacturer’s instruction. A non-targeting scrambled siRNA (referred to as siRNA control) 
was used as a control in all experiments. 
Species Target Company Name Target Sequence 
Human Nrf2 Dharmacon siGenome D-003755-05-
0020 NFE2L2 
NM_001145413  
5'-UGACAGAAGUUGACAAUUA-3' 
Human Keap1  Dharmacon siGenome D-012453-03-
0020 Nm_012289 
5'-GGGCGUGGCUGUCCUCAAU-3' 
Human Control Dharmacon siGenome D-001210-03-
20 Non-targeting siRNA 
Proprietary 
Murine Nrf2 Dharmacon siGenome MQ-040766-
00-0002 NM_010902 
5'-AAAGACTCAAATCCCACCTTA-3' 
Murine Keap1  Qiagen FlexiTube Mm_Keap1_7 
NM_001110305 
5'-TTCCTGCAACTCGGTGATCAA-3' 
Murine Control Qiagen xiTube siRNA AllStars 
Negative Control siRNA 
(SI03650318) 
Proprietary 
Table 3.1 – siRNA used for transfection of cell lines and modulation of the Nrf2 pathway. 
For the transfection of cells plated out on a 12-well plate, a mixture of Lipofectamine® 
RNAiMAX (Invitrogen, Paisley, UK), siRNA stock and Opti-MEM was prepared in a nuclease 
free Eppendorf and incubated at room temperature for 15 minutes as per the 
manufacturer’s instructions (Invitrogen). 135μl of this mixture was added drop-wise to 1ml 
of medium in each cell-containing well and plates incubated at 37°C for 48 hours, ensuring 
modulation of protein expression before confirmation by western immunoblotting. The 
same protocol was used for the siRNA transfection of cells in the 96-well format with 10μl 
of the RNA / transfection reagent mixture added to 90μl of medium in each cell containing-
well 48 hours before the application of chemotherapeutics in viability experiments. The 
volume of Lipofectamine® RNAiMAX applied per well was 0.5ul or 1uL and the quantity of 
RNA 1.5pmol or 20pmol RNA in the 96 or 12-well formats respectively after optimisation. 
3.2.5 Treatment of cells with chemicals and compounds 
Stock concentrations of all drugs, including irinotecan (80mM, J&H Chemical, Shanghai, 
China), 5-FU (Sigma-Aldrich, Dorset, UK), CDDO-me (90μM, Cayman chemicals, Michigan, 
USA) and brusatol (270μM, kind gift from Zhi-Xiu Lin), were prepared in dimethyl sulfoxide 
(DMSO) (Fisher Scientific, Loughborough, UK) for dose-response experiments. A 1 in 3 serial 
dilution of drug stocks was performed in DMSO and these added to medium to produce the 
final concentrations required for application to cells, ensuring a maximum of 0.5% (v/v) 
DMSO. For the co-dosing of chemotherapeutics with CDDO-me or brusatol on HCT116 cells, 
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stock solutions of 60μM or 200μM and 30μM or 200μM respectively were produced in 
DMSO and diluted x2000-fold in medium for application to cells, in combination with 
irinotecan or 5-FU. This resulted in final concentrations of 30nM or 100nM for CDDO-me 
and 15nM or 100nM for brusatol. For CT26 cells a stock solution of 600μM brusatol was 
created and diluted as above to produce a final concentration of 300nM for application to 
cells. 
For the MTS viability assay cells were plated out at 5000 cells/well and left overnight to 
adhere. They were then dosed in triplicate with either irinotecan, 5FU, CDDO-me, brusatol 
or combinations of these across a range of concentrations. To assess the effect of Nrf2 
modulation on chemosensitivity cells were either pre-transfected with siRNA as described 
in section 3.2.4, and chemotherapeutics applied after 48 hours, or were co-dosed with 
CDDO-me or brusatol. All results were calculated as a percentage of a vehicle control (0.5% 
DMSO in medium or control siRNA) treated cells after 48 hour incubations with 
chemotherapeutics.  
For western immunoblot analysis cells were plated out on 12-well plates at 3x105 cells/well 
and treated with siRNA, CDDO-me or brusatol prepared in DMSO as described and added 
to medium to produce the desired concentrations for application to cells. Cells were 
subsequently incubated at 37°C and lysed at 48 hours for assessment of siRNA, increasing 
time-points for time-course experiments or after three hours for dose-response analysis of 
drugs.  All experiments described in this section were performed in triplicate on at least 
three occasions.   
3.2.6 Preparation of cell lysates 
After the required period of incubation with drugs or siRNA, medium was aspirated from 
cells and wells washed twice with ice-cold PBS. 50μl of radioimmunoprecipitation RIPA 
buffer (150mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% sodium 
dodecyl sulphate (SDS), 50 mM Tris, pH 8.0, Sigma-Aldrich, Dorset, UK) containing x100 
diluted protease inhibitor cocktail (Sigma-Aldrich, Dorset, UK) was added to each well of a 
12-well plate and left for 5 minutes on ice. Cells were then scraped off wells and pipetted 
into an Eppendorf. Eppendorfs were spun at 15 000 rpm for 15 minutes at 4°C and the 
supernatant collected and stored at -80°C prior to determination of the protein content 
and western immunoblotting.  
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3.2.6 Western immunoblotting 
Prior to western immunoblotting the bicinchoninic acid (BCA) assay, utilising the Pierce™ 
BCA Protein Assay Kit (ThermoFisher Scientific), was used for protein quantification of 
samples as described in the literature [409]. 40μg of total protein was loaded in 4x Laemmli 
buffer (BioRad, California, USA) in each well of a Mini-PROTEAN® TGX™ Precast Gel 
(BioRad, California, USA) after denaturing proteins by heating for 5 minutes at 100°C.  4μl 
of the PrecisionPlus kaleidoscope molecular weight marker (BioRad, California, USA) was 
added to one well on every gel as a reference. 
Gels were subjected to electrophoresis in running buffer (25mM Tris, 190nM glycine, 20% 
methanol and 0.01% SDS) at 90 volts until resolved and then 150 volts until the blue dye 
front reached the bottom of the gel. Following electrophoresis gels were transferred to a 
Hybond nitrocellulose sheet (GE Lifesciences, Pittsburgh, USA) using a blotting sandwich in 
a transfer unit containing transfer buffer at 230 mA for 2 hours. Membranes were washed 
briefly in TBST and the quality of transfer assessed using a Ponceau S stain (Sigma-Aldrich, 
Dorset, UK). The stain was removed by washing with TBST and the membrane blocked in 
non-fat milk (Biorad, California, USA) in TBST on an orbital shaker before addition of the 
primary antibody. The optimal conditions for antibody incubations were determined by 
experimentation and the final conditions used displayed in table 3.2.  
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Primary 
antibody 
Primary 
Manufacturer Blocking 
Primary 
Dilution 
Secondary 
antibody 
Secondary 
Manufacturer 
Secondary 
Dilution 
TBST 
Washes 
Nrf2 
16396-1-AP 
Proteintech, 
Illinois, USA  
5% milk 2 
hours 
x1000 in 
5% milk 
overnight 
Anti-rabbit 
HRPA9169 
Sigma-Aldrich, 
Dorset, UK 
x5000 
dilution 5% 
milk 1hour 
3x20 mins. 
Keap1 
10503-2-AP 
Proteintech, 
Illinois, USA 
5% milk 2 
hours 
x2000 in 
5% milk 
overnight 
Anti-rabbit 
HRPA9169 
Sigma-Aldrich, 
Dorset, UK 
x5000 
dilution 5% 
milk 1hour 
3x20 mins. 
CES1 
AF7929 
R&D Systems, 
Minneapolis, 
USA 
10% milk 
1 hour 
x400 in 2% 
milk 
overnight 
Anti-sheep 
HRP A3145 
Sigma-Aldrich, 
Dorset, UK 
x10 000 2% 
milk 1hour 
3x5 mins. 
NQO1  
ab28947 
Abcam, 
Cambridge, 
UK 
10% milk 
30 mins. 
x2000 in 
2% milk 
overnight 
Anti-goat 
HRP P0449 
Dako, 
Cambridge, UK 
x2000 
dilution 2% 
milk 1hour 
3x5 mins. 
HO-1 
ab13243 
Abcam, 
Cambridge, 
UK 
10% milk 
30 mins. 
x10 000 in 
2% milk 
Anti-rabbit 
HRP A9169 
Sigma-Aldrich, 
Dorset, UK 
x10 000 2% 
milk 1hour 
3x5 mins. 
Actin 
ab6726 
Abcam, 
Cambridge, 
UK 
10% milk 
overnight 
x10 000 in 
2% milk 
Anti-mouse 
HRP A9044 
Abcam, 
Cambridge, UK 
x10 000 2% 
milk 1hour 
3x5 mins. 
Table 3.2 – Antibodies and conditions used in western blotting experiments 
Following incubation with the primary antibody and secondary antibodies, membranes 
were washed in TBST and chemiluminescence visualised in the dark by addition of the 
Enhanced Western Lightening reagents (Hyperfill ECL; Perkin Elmer, Massachusetts, USA). A 
film placed over the membrane was subsequently developed in Kodak developer and fixer 
solution and densitometry performed on bands of interest utilising Image-J (National 
Institutes of Health, Maryland, USA); each sample was normalised to actin as a loading 
control. 
3.2.7 MTS cell viability assay 
The MTS cell viability assay was utilised for the generation of dose-response curves as 
described in section 2.2.6.  
3.2.8 Colony forming (clonogenic assay) 
The reproductive integrity of cells following treatment with brusatol was assessed in both 
cancer cell lines using a colony forming assay. Cells were plated out on 24-well plates at 
2x104 cells/well and left to adhere and then exposed to treatment regimens including a 24-
hour exposure to a vehicle (0.5% DMSO) control or brusatol across a range of 
concentrations. Cells were then re-plated on 6-well plates at 200 live cells/well and left for 
7-10 days to allow the formation of colonies. Growth medium was aspirated, wells washed 
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with PBS, fixed with methanol for 15 minutes, stained for 30 minutes with 0.5% crystal 
violet in methanol and colonies counted using GelCount™ (Oxford Optronix, Oxford, UK). 
The surviving fraction (SF) for each treatment was then calculated as a percentage of the 
vehicle control using the method described by Franken et al. [427].  
To ensure the accurate counting of colony numbers, settings on the GelCount™ were 
adjusted until concordance was reached with manual counting by eye. The final settings for 
the CT26 and HCT116 lines are displayed in table 1.16. 
 
 
  CT26 HCT116 
Edge detection sensitivity 96 70 
Detection mode dark in light dark in light 
Centre detection send 15 80.4 
Colony diameter range 400-3000um 250-1700um 
Centre to centre separation 200um 250um 
Smoothing 3 3 
Circulatory factor 64 34 
Edge distance threshold 0.95 0.9 
Number of spokes 32 32 
Good edge factor 0.7 0.25 
Overlap threshold 0.5 0.5 
Shape filtering Gaussian 
smooth filter 4 
Gaussian 
smooth filter 3 
Shape processing best fit circle best fit circle 
Colony intensity 0.1-1.5 0.1-1.5 
Table 3.3 – Settings utilised on the GelCount™ for the determination of surviving fractions of 
colonies. 
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3.2.9 Murine studies 
The housing conditions of mice, in addition to the ethical and legal considerations of the 
animal work covered in this thesis are described in section 2.2.11. Both sc flank injection 
and the orthotopic syngeneic caecal implantation murine model described in chapter 2 
were used in the experiments described in this chapter using the CT26lucA6c cell line.  
3.2.10 Assessment of brusatol efficacy in a subcutaneous tumour model 
A pilot study was conducted in 6 male 6-8 week old BALB/c mice comparing brusatol 
treatment (2mg/kg via ip injection) to vehicle control (1% DMSO in PBS). This study was 
designed to assess the safety of chronic dosing with brusatol and ensure Nrf2 inhibition in 
tumour tissue before confirming findings in the more complex orthotopic model. Mice 
received a sc injection of 5x105 CT26lucA6c cells into the right flank as described in 2.2.12 
and, after a 7-day period to allow establishment of tumours, mice (n=3) were randomised 
to treatment groups. For ip injection of brusatol 20mg/ml was dissolved in DMSO and then 
diluted x100 in PBS, with each mouse receiving 10μl/g of bodyweight. The same volume to 
weight ratio was used for the ip dosing of mice with the vehicle control. 
Mice were dosed and imaged according to the schedule laid out in figure 3.1. Tumour 
growth was monitored by simultaneous luminescent IVIS® imaging and caliper 
measurement. Tumour volume was calculated from caliper measurements using the 
equation; tumour volume = maximum width2 x maximum length x ½, as described in the 
literature [428]. IVIS® imaging was conducted as described in 2.2.14. After 21 days (14 days 
of dosing) mice were culled by cervical dislocation and tumours excised and snap frozen in 
liquid nitrogen for use in subsequent experiments and confirmation of Nrf2 inhibition by 
western blotting.  
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Figure 3.1 – a) Study plan and b) dosing regimens used in the pilot study comparing brusatol 
treatment to a vehicle control following the flank grafting of CT26lucA6c cells. 
3.2.11 In vivo assessment in the syngeneic orthotopic model 
This study utilised the orthotopic syngeneic murine model developed in chapter 2 and the 
method is described in section 2.2.13. In brief, 6-8 week old immune-competent male 
BALB/c mice were injected with 4x105 CT26lucA6c into caecal sub-serosa following 
laparotomy and delivery of the caecum. Bioluminescent imaging of mice using the IVIS® 
was commenced on the seventh post-operative day and mice with detectable signal 
randomised to treatment regimens including: vehicle control, brusatol alone (2mg/kg ip), 
irinotecan alone (20mg/kg ip) or irinotecan plus brusatol (for dosing regimens see figure 
3.2). For dosing with irinotecan the drug was dissolved at 2mg/ml in PBS and each mouse 
received 10μl/g of bodyweight. Brusatol dosing is described in 3.2.10. 
Imaging was conducted thrice weekly until the study end-point. Three mice initially treated 
with brusatol were imaged for a further seven days after cessation of treatment to ensure 
the effect could be attributed to the drug.  
Luminescent signals were quantified in photons/second and tumour growth expressed as 
the fold change in luminescence signal from the first imaging day (pre-treatment), with 
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each mouse acting as its own control. At the study end-point mice were sacrificed and 
tumour tissue stored in 4% paraformaldehyde prior to paraffin embedding for histological 
assessment and immunohistochemical staining. 
 
 
 
 
 
Figure 3.2 – a) Study plan and b) dosing regimens for the study comparing brusatol, irinotecan and 
irinotecan with brusatol to a vehicle control following the orthotopic injection of CT26lucA6c cells. 
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3.2.12 Homogenisation of flank tumours 
Sections of tumours (50mg) from the mice flank-grafted with the CT26A6c cell line in the 
study described in section 3.2.10 were homogenised in 250μl of ice-cold 0.5M 
triethylammonium bicarbonate (TEAB) / 0.1% SDS buffer using a MM400 oscillating bead 
mill (Retsch, Haan, Germany). Samples were subjected to a freeze-thaw cycle (-80°C for 1 
hour) and sonicated 3 times for 10 seconds each at an amplitude of 5μm. The homogenate 
was centrifuged at 14 000rpm for 10 minutes at 4°C and the supernatant retained. The 
supernatant was centrifuged again at the same rpm for a further 5 minutes. The protein 
concentration of the supernatant was determined using the BCA assay as described in 
section 2.2.8 and stored until required for proteomic analysis. Western blotting of tumour 
homogenates was conducted as described in section 3.2.6. 
3.2.13 Histology, IHC staining and analysis of murine tumours 
From paraffin-embedded tumour blocks, consecutive 4-microns thick sections were 
obtained and stained with haematoxylin eosin (HE) for morphological confirmation of the 
neoplastic process.  Representative sections of the lesions were selected for IHC. All tissue 
sections were placed in an automated staining system (Link 48 Immunostainer; Dako, 
Germany), within which samples were deparaffinised, rehydrated and processed for 
epitope retrieval using computer-controlled antigen retrieval system (PT Link-Low pH; 
Dako, Germany) according to the manufacturer’s recommendations. Primary anti-Nrf2 
antibody (16396-1-AP, Proteintech, UK 1:100 dilution for 30 minutes) was applied and the 
anti-mouse/rabbit EnVision FLEX (Dako, Germany) detection system used. Upon 
completion of the immunostaining, sections were counterstained with Mayer’s 
haematoxylin. BALB/c mice livers treated with CDDO-me were used as a positive control, 
while livers from Nrf2 knockout mice were employed as a negative control. Consecutive 
tumour sections incubated with non-immune rabbit serum served as technical negative 
control. Morphological evaluation and confirmation of tumour formation was performed 
by a board certified veterinary pathologist (LR) upon brightfield microscope examination of 
HE sections. Evaluation of Nrf2 expression was semiquantitative, using the methods 
described for the calculation of H-scores in section 3.2.1. Scoring was performed blinded to 
the experimental conditions.  
  
166 
3.2.14 Statistical analysis 
GraphPad Prism® 6 statistical software was used for the generation of dose-response 
curves, the calculation of IC50 values and for comparisons of statistical significance. 
Statistical significance was assumed at p<0.05 (*p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001). IC50 values were calculated by fitting a four parameter log-concentration 
versus response curve to the data. Drug combinations were assessed for synergy by 
calculation of combination indexes (CI) using the Chou-Talalay method and the software 
package Compusyn® (CI < 1 indicates synergy) [429]. For mouse studies the slope of a line 
of best fit for each individual mouse was calculated as a surrogate marker of tumour 
growth rate. Growth rates for treatment groups were then compared with those in 
untreated controls with significance assessed by one-way ANOVA. SPSS statistics 21® was 
used to analyse patient data. In all data a Shapiro-Wilk normality test was used to guide 
appropriate statistical test selection. Tests used in each analysis are included with the 
presented data. 
 
 
 
 
 
 
 
 
 
 
  
167 
3.3 Results 
3.3.1 Nrf2 expression in CRC patient samples 
Fifty-nine patients with metastatic CRC were included in the TMA, 50 (85%) with cores of 
primary CRC, 43 (73%) with cores of liver metastases and 34 (58%) with normal colon 
available. Matched primary and metastatic samples were available for 34 (58%) patients. 
Available clinicopathological variables for patients, divided by tissue type, are displayed in 
table 3.4. 
A moderate positive correlation was seen in Nrf2 H-scores between matched primary and 
metastatic samples (r=0.4, p=0.03, Pearson R), implying that Nrf2 expression in the 
metastasis reflects that of the primary (figure 3.3). Mean Nrf2 expression was significantly 
higher in primary (H-score = 30) and metastatic (H-score = 43) tumour tissue than normal 
colon (H-score 6, Kruskal-Wallis with Dunn’s multiple comparisons test), highlighting an 
increased expression of Nrf2 in CRC (figure 3.4). Nrf2 expression did not vary significantly 
with T stage or nodal status (table 3.5). 
There was no difference in Nrf2 expression in the primary or metastatic samples of chemo-
naïve patients when compared with those who received neoadjuvant chemotherapy, 
suggesting overexpression of Nrf2 is not simply a marker of the increased cellular stress 
associated with chemotherapy, but that Nrf2 is constitutively activated (figure 3.5). 
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Table 3.4 – There were no statistically significant differences in clinicopathological variables 
between patients included in the analysis of tissue cores on the TMA when grouped by tissue 
type. 
 
 
Table 3.5 – Nrf2 expression did not vary significantly with gender, T stage or N stage in any of the 
available tissue types. 
Primary Tumour Liver Metastases Normal Colon P value
78 (40-98) 78 (40-98) 79 (40-98) p = 0.834 (ANOVA)
Male 35 (70) 29 (67) 23 (68)
Female 15 (30) 14 (33) 11 (32)
1 0 0 0
2 8 (16) 4 (9) 4 (13)
3 33 (66) 31 (72) 24 (71)
4 9 (18) 8 (19) 6 (18)
0 14 (28) 11 (26) 11 (23)
1 26 (52) 25 (58) 21 (62)
2 10 (20) 7 (16) 2 (6)
Yes 31 (62) 22 (51) 22 (65)
No 17 (34) 17 (40) 11 (32)
Unknown 2 (4) 4 (9) 1 (3)
50 43 34Total
N stage (%) p = 0.486 (Chi-Square)
p = 0.597 (Chi-Square)Chemotherapy (%)
Variable
Median age (range)
Gender (%)
T stage (%)
p = 0.958 (Chi-Square)
p = 0.911 (Chi-Square)
Mean H-score 
(95% CI) P value
Mean H-score 
(95% CI) P value
Mean H-score 
(95% CI) P value
Male 27 (20-36) 39 (34-72) 5 (2-9)
Female 36 (21-51) 53 (28-46) 8 (3-14)
1 NA NA NA
2 39 (14-65) 54 (25-82) 2 (0-11)
3 27 (19-36) 43 (33-52) 6 (2-9)
4 33 (19-46) 41 (22-59) 11 (4-18)
0 32 (16-49) 50 (34-66) 6 (0.2-12)
1 27 (18-36) 39 (29-49) 6 (2-10)
2 36 (19-54) 28 (24-75) 7 (0-20)
30 (24-36) 43 (37-50) 6 (0-13)Totals
p = 0.442 (ANOVA)
Variable
Gender
T stage
N stage
 Primary-tumour Liver metastases Normal colon
p = 0.556 (ANOVA) p = 0.334 (ANOVA)
p = 0.265 (ANOVA) p = 0.07 (ANOVA)
p = 0.986 (ANOVA)
p = 0.269 (ANOVA)p = 0.673 (ANOVA)
p = 0.403 (ANOVA)
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Figure 3.3 – a) Representative tissue cores displaying cellular recognition (green for cytoplasm and 
blue for nucleus) and Nrf2 staining intensity as assigned by the software; white represents 
negative, yellow weakly positive, orange moderately positive and red strongly positive cells. b) 
Nrf2 expression, measured by the calculation of H-scores, confirmed a positive correlation 
between matched primary tumour and liver metastases in patient samples (r=0.4, p=0.03, Pearson 
R).  Analysed by Tissue Studio v.2.0 
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Figure 3.4 – Mean Nrf2 expression was significantly higher in primary (H-score = 30) and 
metastatic (H-score = 43) tumour tissue than normal colon (H-score = 6, Kruskal-Wallis with 
Dunn’s multiple comparisons test). (Graphs displays mean with 95% confidence interval with each 
data point representing an individual patient) 
 
 
Figure 3.5 - Comparison of H-scores in chemo-naïve and treated patients found no significant 
differences in Nrf2 expression in a) primary or b) metastatic tissue (Mann-Whitney test). (Graphs 
display mean with 95% confidence interval) 
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3.3.2 Western blot confirmation of Nrf2 modulation in cell lines 
Confirmation of Nrf2 modulation was demonstrated by western immunoblotting in 
response to genetic silencing of Nrf2 or Keap1 utilising siRNA (figure 3.6), or to 
pharmacological induction of Nrf2 with CDDO-me or inhibition with brusatol in the HCT116 
and CT26 cell lines.  
siRNA inhibition of Nrf2 achieved an 11-fold reduction in expression of the protein in the 
CT26 cell line and a 4-fold reduction in the HCT116 cell line, as assessed by western 
immunoblotting and densitometry. Nrf2 protein expression was increased by 4-fold in the 
CT26 cells and 3-fold in the HCT116 cells following inhibition of Keap1 by siRNA. 
A higher concentration of brusatol was required to significantly inhibit Nrf2 in CT26 
(300nM) than HCT116 (100nM) cells (figure 3.7). In both cell lines brusatol mediated 
inhibition of Nrf2 was transient, with maximum inhibition seen at three hours (figure 3.8). 
A rebound in Nrf2 expression was also observed in both cell lines between 12 and 24 hours. 
CDDO-me was a potent Nrf2 inducer with significantly higher expression noted with 
concentrations ≥30nM in both cell lines (figure 3.7). The induction of Nrf2 by CDDO-me 
peaked between 1-3 hours after dosing but persisted for up to 24 hours (figure 3.8). 
In the CT26 cells a concentration of 300nM of brusatol resulted in a 10-fold reduction in 
Nrf2 expression, while in HCT116 100nM of brusatol decreased Nrf2 expression by 13-fold 
after 3 hours. Conversely, a 12-fold increase in Nrf2 expression was noted in the CT26 cell 
and a 3-fold increase in the HCT116 cell on western immunoblotting following a 3-hour 
incubation with CDDO-me. 
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Figure 3.6 – Confirmation of significant inhibition of Nrf2 48 hours after transfection with siRNA 
targeting Nrf2; representative western blot images and relative expression are displayed for the a) 
CT26 and b) HCT116 cell lines. Inhibition of Keap1 with siRNA resulted in significant induction of 
Nrf2. (one-way ANOVA with Holm-Sidak’s multiple comparison test, N=4, bar charts display mean 
+/- SD) 
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Figure 3.7 – Representative western blot images and bar charts displaying significant Nrf2 
inhibition at 100nM and 300nM of brusatol as assessed by densitometry in the a) CT26 and b) 
HCT116 cell lines respectively. Significant induction was demonstrated at 30nM of CDDO-me in 
both. (one-way ANOVA with Holm-Sidak’s multiple comparison test, N=4, bar charts display mean 
+/- SD, C= 0.5% DMSO vehicle control) 
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Figure 3.8 – Representative western blot images and graphs displaying the transient inhibition of 
Nrf2 by brusatol as assessed by densitometry in a) CT26 and b) HCT116 cell lines respectively. 
CDDO-me induction resulted in upregulation of Nrf2 for greater than 24 hours. (N=3, graphs 
display mean +/- SD, C= 0.5% DMSO vehicle control) 
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3.3.3 Western blotting for Nrf2 downstream proteins in cell lines 
Western immunoblotting of CRC cell lines was undertaken to examine the effects of 
genetic (using siRNA) or pharmacological (using CDDO-me or brusatol) Nrf2 modulation on 
downstream effector proteins of the Nrf2 pathway. Cells were lysed 48 hours after siRNA 
transfection or 24 hours after treatment with CDDO-me or brusatol for western 
immunoblotting. Increased expression of CES1, NQO1 and HO-1 was noted in response to 
induction of Nrf2. The effects of Nrf2 inhibition on downstream effectors were less 
obvious, with the exception being NQO1 expression in the CT26 cell line 48 hours after 
transfection with a siRNA targeting Nrf2. As demonstrated in figure 3.8, the inhibition of 
Nrf2 by brusatol is transient and therefore chronic application to cells over a period of time 
may be required to decrease the expression of downstream effector proteins in response 
to this. 
 
Figure 3.9 – Representative western immunoblotting images of CRC cell lines confirmed induction 
of CES1 expression following overexpression of Nrf2 using siRNA to inhibit Keap1 in a) CT26 and b) 
HCT116 cells. The effect of siRNA inhibition of Nrf2 on CES1 expression was minimal. Nrf2 
induction by CDDO-me in c) CT26 and d) HCT116 cells also increased the expression of CES1. The 
effects of Nrf2 inhibition with brusatol on CES1 expression in e) CT26 and b) HCT116 were 
minimal. 
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Figure 3.10 – Representative western immunoblotting images of CRC cell lines confirmed 
induction of NQO1 expression following overexpression of Nrf2 using siRNA to inhibit Keap1 in a) 
CT26 and b) HCT116 cells. siRNA inhibition of Nrf2 did inhibit NQO1 expression in the a) CT26 but 
not in the b) HCT116 cell lines. Nrf2 induction by CDDO-me in c) CT26 and d) HCT116 cells also 
increased the expression of NQO1. The effects of Nrf2 inhibition with brusatol on NQO1 
expression in e) CT26 and b) HCT116 were minimal. 
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Figure 3.11 – Representative western immunoblotting images of CRC cell lines confirmed 
induction of HO-1 expression following overexpression of Nrf2 using siRNA to inhibit Keap1 in a) 
CT26 and b) HCT116 cells. siRNA inhibition of Nrf2 did not inhibit HO-1 expression in either CRC 
cell line. Nrf2 induction by CDDO-me in c) CT26 and d) HCT116 cells also increased the expression 
of HO-1. The effects of Nrf2 inhibition with brusatol on HO-1 expression in e) CT26 and b) HCT116 
were minimal. 
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3.3.4 The effect of Nrf2 modulation on cell viability  
siRNA inhibition of Nrf2 resulted in a 14% and 23% reduction in cell viability in HCT116 and 
CT26 cells respectively. The opposite trend was seen for overexpression of Nrf2 through 
Keap1 inhibition in HCT116 cells, with an increase in viability of 21%. There was a non-
significant 7% increase in the viability of CT26 cells with Keap1 inhibition (figure 3.12).  
 
Figure 3.12 – Bar charts displaying the significant decrease in cell viability noted with siRNA 
inhibition of Nrf2 in a) CT26 and b) HCT116 cells as assessed using the MTS assay 96 hours after 
transfection and compared with the siRNA control. siRNA inhibition of Keap1 only produced an 
increase in proliferation / viability in the HCT116 cell line. (one-way ANOVA with Holm-Sidak’s 
multiple comparison test, N=6 in triplicate, graphs display mean +/-SD) 
Dosing of cells with brusatol also caused reductions in cell viability in both cancer cell lines 
in a dose-dependent manner. The brusatol IC50 value for the CT26 cell line was higher than 
in the HCT116 cell line, reflecting the fact that a higher concentration of brusatol was 
required to achieve Nrf2 inhibition in this cell line. In HCT116 cells CDDO-me caused slight 
increases in cell viability in a dose-dependent manner. This effect was not noted in the 
CT26 cells, which have higher basal expression of Nrf2 as assessed by western blotting. 
The safety of brusatol treatment was assessed in the benign cell line CCD-33Co, with a 
reduced fall in viability noted at the highest concentration of brusatol (300nM) compared 
with that seen in the cancer cell lines. The IC50 value for the benign cell line was nearly 2-
fold higher than seen in the CT26 cell line, perhaps suggesting a decreased dependence on 
Nrf2 in benign tissue (figure 3.13). 
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Figure 3.13 – a) Graph displaying dose-response curves for the CT26, HCT116 and benign colonic 
cell line CCD-33Co, as assessed using the MTS assay 48 hours after the application of CDDO-me or 
brusatol. (N=3 in triplicate, graphs display mean +/-SD, results expressed as a percentage of cells 
treated with the vehicle 0.5% DMSO control). b) Table demonstrating the significantly different 
IC50 values between cell lines, as assessed by the sum-of-squares F test.  
 
Having noted a fall in cell viability with brusatol treatment the ability of both CRC cell lines 
to form colonies was evaluated to determine the effect of brusatol treatment on cellular 
reproductive potential. Brusatol treatment significantly reduced the surviving fraction in 
both cancer cell lines in a dose-response manner, similar to seen with the MTS assay. The 
IC50 values were 21nM (95% CI, 19-23nM) and 373nM (95% CI, 277-502nM) in HCT116 and 
CT26 cells respectively, suggesting a reduction in reproductive integrity following brusatol 
treatment (figure 3.14). 
 
 
Cell line IC50 Brusatol (nM) 95% confidence interval (uM) Significance  (F test)
CCD-33Co 453.8 377.9 to 544.8 ****
CT26 256.1 240.6 to 272.5 ****
HCT116 87.4 63.1 to 121.2 ****
a)
b)
1 1 0 1 0 0 1 0 0 0
0
5 0
1 0 0
1 5 0
C o n ce n tra tio n  [n M ]
V
ia
b
il
it
y
 (
%
 c
o
n
tr
o
l)
B ru s a to l (C C D -3 3 C o )
C D D O -m e  (C C D -3 3 C o )
C D D O -m e  (H C T 1 1 6 )
B ru s a to l (H C T 1 1 6 )
B ru s a to l (C T 2 6 )
C D D O -m e  (C T 2 6 )
  
180 
 
Figure 3.14 – Assessment of reproductive integrity following exposure to brusatol confirmed 
inhibition of colony formation, represented graphically by calculation of surviving fractions 
expressed as a percentage of untreated cells, and as representative images of wells, in a) CT26 and 
b) HCT116 cells. (N=5 in triplicate, graphs display mean +/-SD, * C= 0.5% DMSO vehicle control) 
 
 
3.3.5 The effect of Nrf2 modulation on irinotecan chemosensitivity  
Having established an effect with Nrf2 modulation in cell lines, the effect of siRNA or 
pharmacological Nrf2 modulation was assessed in combination with irinotecan.  
Inhibition of Nrf2 with siRNA (figure 3.15) or brusatol (figure 3.16) significantly decreased 
the IC50 value of irinotecan in both CRC cell lines, signifying an increased sensitivity to 
irinotecan therapy following Nrf2 depletion. A non-cytotoxic dose of brusatol (15nM) 
significantly enhanced irinotecan response but with the effect on IC50 more marked with 
the higher brusatol concentrations (100nM in HCT116 and 300nM in CT26 cells), known to 
significantly inhibit Nrf2 expression on western immunoblotting.  
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The cyto-protective effect of Nrf2 overexpression was again more marked in the HCT116 
cell line than CT26 (figures 3.15 and 3.16). Combinations of irinotecan with high-dose 
(100nM) CDDO-me in the CT26 cell line only just increased the IC50 value for irinotecan 
significantly, this was in contrast to the HCT116 cell line where even a low dose of CDDO-
me reached significance. This perhaps signifies a biological limit to the protective effect of 
activation of the Nrf2 pathway in the CT26 cell line.  
 
 
 
Figure 3.15 – Graphs display the effect of siRNA modulation of Nrf2 on cell lines dosed with 
irinotecan as measured by the MTS assay. siRNA inhibition of Nrf2 significantly increased the 
cytotoxicity of irinotecan in a) CT26 and c) HCT116 cells as reflected by the decreased IC50 values 
when compared with treatment with irinotecan alone, displayed in tables b) for CT26 cells and d) 
for HCT116 cells (extra sum-of-squares F test). The cytoprotective effect of overexpression of Nrf2 
by Keap1 inhibition was non-significant in the CT26 but reached significance in the HCT116 cell 
line. (IR = irinotecan, siRNA cont = siRNA control, N=3 in triplicate, graphs display mean +/-SD, NS 
= non-significant, NA = not applicable) 
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Figure 3.16 – Graphs display the effect of pharmacological modulation of Nrf2 with brusatol and 
CDDO-me in combination with irinotecan dosing of cell lines using the MTS assay. The same trends 
were noted as observed with siRNA in both the a) CT26 and b) HCT116 cell lines. Tables c) and d) 
demonstrate the change in the irinotecan IC50 values with the pharmacological modulation of 
Nrf2 in the CT26 and HCT116 cell lines respectively (extra sum-of-squares F test). (IR = irinotecan, 
N=3 in triplicate, graphs display mean +/-SD, NS = non-significant, NA = not applicable) 
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CIs for irinotecan combined with brusatol confirmed drug synergy in both cancer cell lines 
(figures 3.17) across a range of irinotecan concentrations, implying brusatol enhances the 
cytotoxicity of irinotecan in CRC cell lines. 
 
 
 
Figure 3.17 – Heat map tables displaying calculated combination indices for treatment with 
varying concentrations of irinotecan and brusatol. These confirm drug synergy in a) CT26 and b) 
HCT116 cells across a range of concentrations. Red, yellow and orange signify decreasing degrees 
of synergy, with cells highlighted in green demonstrating an antagonistic effect. (Synergy assumed 
at CI<1) 
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3.3.6 The effect of Nrf2 modulation on 5-FU chemosensitivity  
To assess whether the effects of Nrf2 modulation on chemosensitivity were limited to the 
use of irinotecan the same experiments undertaken in section 3.3.5 were repeated with 5-
FU. Trends were the same as noted with irinotecan dosing; Nrf2 inhibition by siRNA (figure 
3.18) or brusatol treatment (figure 3.19) significantly decreased the IC50 of 5-FU. Only the 
higher brusatol dose (300nM) significantly decreased the IC50 of 5-FU in the CT26 cell line.   
 
 
 
 
Figure 3.18 – Graphs display the effect of siRNA modulation of Nrf2 on cell lines dosed with 5-FU 
as measured by the MTS assay. siRNA inhibition of Nrf2 significantly increased the cytotoxicity of 
5-FU in a) CT26 and c) HCT116 cells, as reflected by the decrease IC50 values, when compared with 
treatment with 5-FU alone as displayed in tables b) for CT26 cells and d) for HCT116 cells (extra 
sum-of-squares F test). The cytoprotective effect of overexpression of Nrf2 by Keap1 inhibition 
meant IC50 values could not be calculated. (siRNA cont = siRNA control, N=3 in triplicate, graphs 
display mean +/-SD) 
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Figure 3.19 – Graphs display the effect of pharmacological modulation of Nrf2 with brusatol and 
CDDO-me in combination with 5-FU dosing of cell lines using the MTS assay. The same trends were 
noted as observed with irinotecan in both the a) CT26 and b) HCT116 cell lines, although to a 
lesser extent. Tables c) and d) demonstrate the change in the 5-FU IC50 values with the 
pharmacological modulation of Nrf2 in the CT26 and HCT116 cell lines respectively (extra sum-of-
squares F test). (N=3 in triplicate, graphs display mean +/-SD, NS = non-significant, NA = not 
applicable) 
 
Although the trend was the same as noted with irinotecan, drug synergy was achieved at 
fewer concentrations than noted with irinotecan, particularly in the HCT116 cell line. 
Additionally, the degree of synergy, as described by a lower CI value, never reached those 
noted with irinotecan (figure 3.20). This could suggest that the effects of combining Nrf2 
inhibition with irinotecan may be due to alterations in drug metabolism and cellular 
survival; Nrf2 modulation is not known to have any effect on 5-FU metabolism and 
therefore the observed effect may be solely due to the loss of cellular protection.    
a) b) 
c) d) 
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Figure 3.20 – Heat map tables displaying calculated combination indexes for treatment with 
varying concentrations of 5-FU and brusatol. Drug synergy was seen at fewer concentrations and 
to a lesser extent in a) CT26 and b) HCT116 cells than noted with irinotecan. Red and orange 
signify a degree of drug synergy, with cells highlighted in yellow and green demonstrating an 
antagonistic effect. (Synergy assumed at CI<1) 
3.3.7 Assessment of brusatol therapy in a subcutaneous murine tumour model  
Based on the in vitro findings, with both CRC cell lines displaying the same trend towards 
reduced proliferation and viability following brusatol treatment, in vivo investigation was 
first completed in six immune-competent BALB/c mice sc injected with the CT26lucA6c cell 
line. Prior to in vivo investigation, brusatol dose-response curves and growth rates were 
compared between the CT26 parent population and CT26ucA6c cell line to ensure 
phenotypic equivalence prior to in vivo investigation (see Appendix 1 for data).  
Mice were randomised to treatment with brusatol or a vehicle control on the 7th day post-
tumour injection (N=3/group), according to the dosing regimen described in figure 3.1. 
Tumour growth was monitored using both caliper measurements and luminescence to 
ensure luminescence was an accurate reflection of tumour size. Tumour growth was 
significantly inhibited in brusatol-treated mice over the 14-day study period. No adverse 
effects were noted in either group of mice (figure 3.21). To ensure luminescence accurately 
reflected tumour volume, data points were individually plotted for each mouse at each 
time-point with a significant positive correlation achieved (figure 3.22).  
Western immunoblotting confirmed successful Nrf2 inhibition by brusatol at the study end-
point (figure 3.23), indicating that brusatol was able to reach the tumour tissue. Nrf2 
protein expression was reduced by 74%, as assessed by western immunoblotting and 
densitometry, in biological replicates treated with brusatol compared with the saline-
treated controls. 
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Figure 3.21 – a) Representative IVIS® images of a BALB/c mouse from the brusatol--treated and 
control group after sc flank injection of the CT26lucA6c cell line. b) Graph displays the significant 
inhibition of tumour growth in mice treated with brusatol in comparison with vehicle-treated 
controls (multiple t-tests, N=3/group, mean +/-SEM). c) Photographs of the flank tumours excised 
from mice (scale in 1mm increments) 21 days after implantation. 
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Figure 3.22 – A significant positive correlation was observed between caliper measurements and 
luminescence for brusatol-treated and untreated mice sc injected with the CT26lucA6c cell line (r2 
= 0.94, p < 0.0001, Pearson R). 
 
Figure 3.23 – a) Western blotting and b) densitometry confirmed significant inhibition of Nrf2 in 
the flank tumours excised from mice treated with brusatol (p=0.03, unpaired t-test). (Bar chart 
displays mean +/- SD, C = control, BRU = brusatol) 
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3.3.8 Assessment in the syngeneic orthotopic model  
The effects of treatment with brusatol, irinotecan or a combination of irinotecan and 
brusatol on tumour growth in the syngeneic orthotopic model (N=8 per group) were 
compared with tumour growth in vehicle controls. Dosing and imaging regimens are 
described in figure 3.2.  
A significant reduction in tumour growth rate (as represented by the fold change in 
luminescence) was noted over the study period (p<0.01, one-way ANOVA) in mice treated 
with brusatol. No detrimental effects were noted in mice receiving brusatol. In contrast, a 
number of mice in the control group began to exhibit tumour-related symptoms, including 
ascites, weight loss and obstruction, limiting the study end-point to ensure severity limits 
were not exceeded.  
There was a trend towards improved irinotecan efficacy in mice treated with a combination 
of brusatol and irinotecan as evidenced by a reduced rate of growth. In comparison to the 
control group, greater significance was achieved for combination therapy (p<0.001, one-
way ANOVA) than with each treatment in isolation (p<0.01, one-way ANOVA). However, a 
significant inhibition of tumour growth rate was not achieved between treatment groups 
(figure 3.24). Lines of best fit and slope comparisons (representative of tumour growth) are 
displayed in appendix 2). When the fold change in luminescence between treatment 
groups was compared on the 14th and final day of treatment there was a significant 
difference between mice who received irinotecan alone compared with those on a 
combination of irinotecan and brusatol (p<0.05, t-test). 
A continuation study was carried out in three mice from the brusatol-treated group to 
ensure the effect was attributable to therapy. Cessation of brusatol resulted in an increase 
in luminescence with mice reaching the humane end-point of the study one week later, at 
which point the fold change in luminescence was similar to that seen in controls one week 
earlier (figure 3.25). 
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Figure 3.24 – a) Representative serial IVIS® images from BALB/c mice orthotopically implanted 
with CT26lucA6c cells and randomised to treatment groups. b) Data displayed graphically as fold 
change in luminescence from the first day of treatment. All treatments inhibited tumour growth 
significantly when compared with the control group (one-way ANOVA comparing tumour growth 
rate calculated from lines of best fit). c) Fold change in luminescence on the 14th day post-
treatment was significantly different in mice on the combination therapy rather than irinotecan 
alone (Mean fold change = 144.1, SEM 46.34 versus 26.4, SEM 8.4 unpaired t-test with welch 
correction). (N=8, IR = irinotecan, BRU = brusatol, graphs display mean +/- SEM) 
 
a)
b)
c)
0 5 1 0 1 5
0 .1
1
1 0
1 0 0
1 0 0 0
T im e  p o s t-tre a tm e n t (d a y s )
F
o
ld
 c
h
a
n
g
e
 i
n
 l
u
m
in
e
s
c
e
n
c
e
C o n tro l
Ir in o te c a n
IR  +  B R U
B ru s a to l
* *
* *
* * *
B
ru
s
a
to
l
Ir
in
o
te
c
a
n
IR
 +
 B
R
U
0
2 0 0
4 0 0
6 0 0
F
o
ld
 c
h
a
n
g
e
 i
n
 l
u
m
in
e
s
c
e
n
c
e
*
  
191 
 
 
 
Figure 3.25 – a) Representative serial IVIS® images from BALB/c mice from the onset of treatment 
with brusatol (day 0). Treatment was stopped after 14 days and imaging continued for a week. b) 
Data displayed graphically as fold change in luminescence from the first day of treatment with the 
signal increasing exponentially after the cessation of therapy. (N=3, graph displays mean +/- SEM) 
 
Weight loss was common in all groups for the first week post-operatively, but never 
approached the 20% limit stipulated in the project licence. Most mice in treatment groups 
gained weight from this point with no significant weight loss. Some weight loss was noted 
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in control mice leading up to the study end-point: this was attributed to malignant burden. 
Several mice in the control group began to exhibit tumour-related symptoms including 
ascites, weight loss and obstruction, limiting the study end-point to ensure severity limits 
were not exceeded. Animal weights for treatment groups are displayed graphically in figure 
3.26. No additional detrimental effects were noted in mice receiving brusatol therapy in 
isolation. Acute diarrhoea was common in mice receiving irinotecan or combination 
therapy: a single mouse receiving combination therapy experienced prolonged diarrhoea 
(lasting greater than 48 hours) resulting in early cull (data excluded from analysis). No mice 
underwent early cull due to tumour-related symptoms in the treatment groups.  
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Figure 3.26 – Graph displaying the bodyweight of BALB/c mice orthotopically implanted with the 
CT26lucA6c cell line over time. Treatment was initiated on day 7 post-surgery. (Graph displays 
mean +/- SEM, IR = irinotecan, BRU = brusatol). 
 
IHC staining for Nrf2 of three randomly selected caecal tumours excised from 
orthotopically implanted BALB/c mice at the end of the study period demonstrated 
reduced staining in the mice treated with brusatol (mean Nrf2 H-score = 53.3, SD 40.1) 
when compared with the saline-treated controls (mean Nrf2 H-score = 190, SD 63) (figure 
3.27).  
 
  
193 
 
Figure 3.27 – Light microscopy representative images from tissue stained for Nrf2 by IHC. Strong 
staining is demonstrated in the a) positive control of liver from BALB/c mice treated with CDDO-
me. b) Livers from Nrf2 knockout mice were used as a negative control and displayed weak 
staining. There was strong staining demonstrated in caecal tumours excised from mice in the c) 
control group and staining was reduced in the tumours from mice treated with d) brusatol. e) 
Graphical display of data reveals significantly (p=0.04 unpaired t-test with Welch's correction) 
reduced Nrf2 H-scores in brusatol-treated mice (N=3, graph displays mean +/- SD) 
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3.4 Discussion 
The TMA analysis of normal colon, primary CRC and liver metastases from patients with 
advanced disease confirmed increased expression of Nrf2 in CRC tissue. Nrf2 expression in 
matched liver metastases reflected that in the primary tumour, suggesting that information 
on expression of the protein can be obtained from the primary lesion without the need for 
biopsy of the liver lesion. This is beneficial given the risks of track seeding and poor 
outcomes associated with biopsy of liver metastases, as highlighted in section 1.5.5. 
The analyses reported in this chapter consistently suggest reduced proliferation and 
survival of CRC cells when Nrf2 is inhibited. The effect of Nrf2 modulation on irinotecan 
efficacy was also explored, with data suggesting drug synergy for combinations of brusatol 
with irinotecan in vitro. Several mechanisms could account for this. For example, Nrf2 
activation stimulates transcription of antioxidant proteins including glutathione S-
transferases, NQO1, thioredoxin and thioredoxin reductase, reducing the production of 
ROS and protecting the cell from chemotherapy-induced cell death [430]. Additionally, 
inhibition of Nrf2 may decrease UGT1A1 expression, preventing glucuronidation and 
therefore excretion of SN-38 [280]. These multiple Nrf2-mediated mechanisms involved in 
irinotecan metabolism could explain the reduced drug synergy noted with 5-FU when 
combined with brusatol, where the only benefit to inhibition of Nrf2 is the impairment of 
cell survival pathways.  
These findings were, for the first time, translated into a robust pre-clinical murine model of 
CRC, confirming the effectiveness and safety of prolonged brusatol treatment in early 
animal testing, and demonstrating the reduced expression of Nrf2 in tumour tissue in vivo 
with brusatol treatment. Although tumour growth was slowed by the combination of 
irinotecan with brusatol, in comparison to each treatment in isolation, significance was not 
reached between treatment arms in tumour growth rates, and the high degree drug 
synergy noted in vitro perhaps not achieved. This may be due to the large variation in 
tumour growth rates between mice in each treatment group, in addition to the 
effectiveness of both brusatol and irinotecan treatment in isolation. It also highlights the 
importance of assessing the effect of Nrf2 inhibition in vivo, where the role of the CES 
enzymes in converting irinotecan to SN-38 in the liver becomes relevant. With the liver 
potentially responsible for 50% of the conversion of irinotecan to SN-38, it is possible that 
brusatol inhibited inducible CES expression in the liver by targeting Nrf2 and subsequently 
  
195 
reduced irinotecan activation. Further work examining this effect could be achieved by 
utilising liquid chromatography–mass spectrometry (LC-MS) to measure irinotecan and its 
metabolites in the serum or liver homogenates of animals dosed with irinotecan following 
pharmacological modulation of Nrf2. A reliable LC-MS assay has been developed in-house 
to Food and Drug Administration standards and used within the context of a clinical trial 
investigating the use of irinotecan releasing beads [173]. 
Data presented in this chapter agree with those in the published literature, with higher 
Nrf2 expression contributing to chemoresistance in CRC cell lines in a number of published 
studies [272, 273, 431]. Additionally, clinico-pathological data have correlated high Nrf2 
expression in human CRC samples to poor clinical outcomes [271] and advanced disease 
[432], implying Nrf2 may have a role as a prognostic biomarker. However, this is the first 
study to demonstrate the effects of brusatol on CRC tumour cells in vitro and in vivo, 
utilising a robust murine model of the disease process, with the tumour growing in the 
correct microenvironment with an intact immune system. 
Brusatol allows the potential for Nrf2 inhibition to be translated into the clinical setting. 
The mechanism by which brusatol achieves Nrf2 inhibition is undetermined. Studies on a 
lymphocytic leukaemia tumour cell line were some of the first to report the anti-neoplastic 
effect of an ester of brusatol in vivo, demonstrating that protein and nucleic acid 
metabolism were inhibited in a manner which correlated positively with their antileukemic 
activity [433]. It was postulated that quassanoids bound to the 80s ribosome, inhibiting 
protein elongation [434]. Recently published data acquired on a Keap1 mutant lung cancer 
(A549) cell line, through whole proteomic analysis by mass spectrometry (MS), postulated 
that brusatol inhibits the translation of a number of short half-life proteins. However, these 
proteins showed only minimal changes on western immunoblotting, with no reporting of 
statistical significance in the data. Additionally, the doses of brusatol used in this study 
were far higher than those demonstrated to cause Nrf2 inhibition both in the data 
presented in this thesis and in the majority of the published literature [435].  
The pattern of Nrf2 inhibition by brusatol in cell lines described in this chapter is similar to 
data presented by Olayanju et al. in Hepa-1c1c7 cells and primary human hepatocytes, with 
rapid transient depletion of Nrf2 seen on western immunoblotting [436]. It is possible that 
brusatol achieves such significant inhibition of Nrf2 as a result of the proteins extremely 
short half-life. However, it is difficult to examine the effect of brusatol on protein 
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translation in cancer cells, with doses causing significant Nrf2 inhibition invariably 
associated with cytotoxicity, which in itself may alter expression of a number of proteins. 
As a result of this uncertainty around the specificity of brusatol as an inhibitor of Nrf2 the 
next chapter of this thesis will attempt to examine the effects of brusatol treatment on 
protein expression in vivo, using the livers excised from brusatol-treated mice. 
The main limitation of the data in this chapter could be the reliance on luminescence as a 
marker of tumour growth in the orthotopic model. Starting luminescent signal can vary 
substantially between mice in the same treatment group as a result of the caecal injection 
technique, resulting in varying cell inoculums and injection sites on the caecum. Attempts 
were made to ensure cells were injected into the same point of the caecum, but this was 
not always possible, and the mobility of the murine caecum mean the depth of tumours 
between mice can vary substantially. With a 10-fold loss of signal for every 1cm of tissue, 
this can cause significant differences in total flux between animals. These large variations 
are likely to have reduced the chance of finding significant differences between treatment 
arms although this effect was partially negated by the expression of data as a fold change 
in luminescence; this allowed each animal to act as its own control. 
Given the lack of knowledge of the mechanism of action of brusatol, there were concerns 
regarding the effects it could have on luminescence. One reason for conducting the flank 
tumour study described in section 3.3.7. was to ensure that luminescence remained an 
accurate reflection of tumour volume in vivo and that brusatol therapy was not reducing 
luminescent signals. Given the findings of the flank study in BALB/c mice, with the 
luminescent data mirroring that obtained from callper measurement, in combination with 
data from the orthotopic model, it was felt luminescence accurately reflected disease 
burden and data were a reliable reflection of tumour growth. It was in fact noted in the 
orthotopic model that brusatol treatment actually resulted in a more rapid increase in 
luminescence in the first 3-5 days after initiation of treatment when compared with 
administration of a vehicle control, as demonstrated in figure 3.22 b). This could possibly 
be explained by Nrf2-mediated inhibition of the ABC transporters, responsible for the efflux 
of luciferin from cells, by brusatol [437]. This effect would subsequently be lost as cell 
viability fell and luminescence began to reflect this. 
This chapter provides an extensive overview of the role of Nrf2 in CRC, highlighting a 
potential role as a therapeutic biomarker. The presented data also suggest brusatol acts as 
  
197 
a potent anti-tumorigenic agent in its own right. Further work is needed to clarify the effect 
Nrf2 modulation has on irinotecan metabolism and not just on the therapeutic effect. 
Investigation into the mechanism by which brusatol achieves Nrf2 inhibition is also 
essential before considering its use in clinical trials. 
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Chapter 4 – Exploring the effects of brusatol in vivo 
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4.1 Introduction 
The controversy surrounding the mechanism of action of brusatol treatment and its 
specificity as an Nrf2 inhibitor were highlighted in the discussion of chapter three. There 
are relatively few studies involving the use of brusatol to date, with most of these focusing 
on the therapeutic effect of the compound in malignancy. Even fewer have sought to 
investigate its mechanism of action or specificity towards Nrf2 inhibition, with none having 
examined this in vivo. 
In 1981 Willingham et al. attempted to clarify the effects of brusatol on protein synthesis in 
rabbit reticulocytes by comparing its effects to a number of protein inhibitors with known 
mechanisms of action. They suggested that brusatol was inhibiting peptide bond formation 
during translation by preventing the peptidyl transferase reaction, resulting in the rapid 
inhibition of protein synthesis. However, endogenous protein inhibition was only achieved 
at high (micromolar) concentrations of brusatol in reticulocyte lysates rather than the 
nanomolar concentrations noted to cause inhibition of Nrf2 [438]. In 1983 similar findings 
were reported with brusatol and another quassinoid bruceantin. The authors suggested 
both compounds bound reversibly to the 80S ribosome in reticulocytes at concentrations 
of 100μM, temporarily preventing protein synthesis [439]. At a similar time to these studies 
bruceantin was being investigated in phase II clinical trials. Phase I trials in patients with a 
variety of solid tumours reported minor but frequent side effects including hypotension, 
nausea and vomiting at high concentrations of bruceantin but only minor haematological 
toxicity in the form of thrombocytopenia [440, 441]. Phase II trials were subsequently 
conducted in metastatic breast cancer [442] and malignant melanoma [443]; both trials 
were terminated due to lack of objective tumour regression. Patient numbers in both trials 
were however very small, with only 15 and 22 patients recruited in the studies of breast 
cancer and melanoma respectively. No published studies to date report the use of brusatol 
in treating patients. 
More recent publications have attempted to clarify the effect of brusatol on the expression 
of a number of short half-life proteins. Ren et al. demonstrated that, out of a panel of 
proteins, only c-Myc was depleted in response to brusatol on western immunoblotting of 
the A549 cell line, albeit to a lesser extent than Nrf2. They concluded that brusatol 
selectively inhibited the Nrf2 pathway through enhanced ubiquitination and degradation of 
Nrf2 [294]. Olayanju et al. examined the effect of brusatol on a number of short half-life 
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proteins in Hepa-1c1c7 cells, including cyclin A, HIF-1α, p53 and survivin. They concluded 
that the inhibitory effect of brusatol was specific, and not a consequence of a broader 
effect on protein synthesis, at the nanomolar concentrations required to deplete Nrf2 
[436]. 
The application of mass spectrometric profiling to study the effects of brusatol in the A549 
cell line was briefly mentioned in section 3.4. The method utilised in this study combined 
multiplexed mass spectrometry (MS) with a cellular thermal shift assay (CESTA). CESTA 
relies on detection of the conformational changes and alterations in thermal stability that 
occur in proteins due to the binding of small molecules. Using this method on lysates from 
the lung cancer A549 cell line, following a four-hour incubation with 500nM brusatol, 
Vartanian et al. reported lower abundance of the majority of identified proteins. There 
were 37 proteins found to be upregulated, of which half were associated with ribosomal 
assembly and protein translation. As a result of these findings the authors suggested that 
the modulation of protein translation could be the mechanism whereby brusatol decreases 
Nrf2. However, the study also reported a loss in viability of nearly 100% in A549 cells 
treated with 500nM of brusatol for 48 hours. It is feasible that the decrease in short half-
life proteins seen with brusatol are the result of functional disruption to the cells due to the 
profound cytotoxicity associated with the inhibition of Nrf2 induced by brusatol [435]. 
Separating the loss of viability observed in cancer cell lines with brusatol treatment from 
the effects of the compound on protein expression is challenging, as concentrations 
associated with Nrf2 depletion invariably result in a loss of cellular viability. No studies to 
date have examined the effect of brusatol treatment on the proteome in vivo.  
Isobaric tagging for relative and absolute quantification (iTRAQ) is a proteomic technique 
designed to determine the protein profile of a number of different samples within a single 
experiment, often comparing this to a control sample included in each experimental run. 
Cysteine residues in the samples are reduced and alkylated prior to tryptic digestion, 
whereby proteins are cleaved at the carboxyl side of the amino acids lysine and arginine 
(except where either is followed by proline). This produces peptides that are subsequently 
labelled by incubating samples with a specific isotope-labelled molecule which covalently 
binds to the N-terminus and side-chains within each sample. This iTRAQ isotope tag 
contains a reporter moiety, which allows quantification during analysis, and a balance 
moiety. All tags have the same 1450Da mass but the reporter moieties in each tag have 
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differing masses. When each tag binds to a peptide which is present in all samples then all 
labelled peptides should have an identical mass. 
Prior to MS, peptides are separated into fractions of certain ionic charges by cation 
exchange. Fractions are then subject to nano LC-MS/MS, where they are ionised and 
separated by mass, producing parent ion molecules. Each parent ion, represented by a 
single peak, is isolated and directed to a collision chamber, where tagged peptides are 
fragmented by a collision gas. During this process, reporter and balance moieties are 
cleaved from each other and the peptide they are bound to. The peptide itself is also 
broken into fragment ions, which are cross-referenced with a database of known proteins, 
allowing identification. The reported molecules, with their differing masses, are used to 
quantify the relative abundance of the peptides they were originally bound to by 
calculating ratios of the reporter molecules (figure 4.1). The abundance of each protein is 
normalised to a common ‘pool’ of the samples which can be used across multiple runs to 
ensure consistency of analysis [444]. 
iTRAQ analysis offers the potential to examine the relative expression of proteins in tissue 
excised from mice treated with brusatol. The work presented in this chapter aims to 
examine the protein profile and Nrf2-related gene expression in tissues excised from mice 
following chronic treatment with brusatol.  
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Figure 4.1 – Schematic of the labelling and analysis of iTRAQ samples. iTRAQ allows the 
simultaneous quantification of up to eight samples. a) Proteins in each sample undergo tryptic 
digestion prior to labelling of peptides with a reporter tag. b) Each reporter tag is associated with 
a balance to ensure all tags have the same mass. The balance and reporter tags separate during 
MS with analysis permitting the relative quantification of peptides in each sample after proteins 
are identified through comparison to a database. 
a)
b)
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4.2 Methods 
4.2.1 Animal Studies 
Details of animal husbandry, in addition to the ethical and legal considerations of the 
animal work covered in this thesis, are described in section 2.2.11. Male 6-8 week old 
immune-competent BALB/c mice chronically dosed with brusatol over a two-week period 
as part of the tumour-based experiments presented in chapter three were utilised in the 
work described in this section. 
To assess the effects of brusatol on normal tissue including liver and colon (where 
available) from mice exposed to brusatol over a two-week period, within the study 
described in section 3.2.11, was excised following cull by cervical dislocation. Cull was 
undertaken three hours following the final dose of brusatol. Tissue was immediately 
excised and snap frozen in liquid nitrogen before storage at -80°C until required. 
4.2.2 Tissue homogenisation 
Sections of colon (50mg) or liver (100mg) were homogenised in ice-cold iTRAQ buffer 
[0.5M triethylammonium bicarbonate (TEAB) / 0.1% SDS] using a MM400 oscillating bead 
mill (Retsch, Haan, Germany). Colons were homogenised in 250μl and livers in 500μl of 
iTRAQ buffer. Samples were subjected to a freeze-thaw cycle (-80°C for 1 hour) and 
sonicated three times for 10 seconds each at an amplitude of 5μm. The homogenate was 
centrifuged at 14 000rpm for 10 minutes at 4°C and the supernatant retained. The 
supernatant was centrifuged again at the same rpm for 5 minutes. The protein 
concentration of the supernatant was determined at multiple dilutions (x100, x200 and 
x400) using the well-established method of Bradford [445].  
4.2.3 Coomassie staining 
To ensure accurate quantification of samples, and as an assessment of protein quality, a 
Coomassie stain of liver tissue was undertaken prior to iTRAQ analysis. 10μg of total 
protein was loaded in 4x Laemmli buffer in each well of a Mini-PROTEAN® TGX™ Precast 
Gel after denaturing proteins by heating for 5 minutes at 100°C.  4μl of the PrecisionPlus 
kaleidoscope molecular weight marker was added to one well on every gel as a reference. 
Gels were subjected to electrophoresis in running buffer (25mM Tris, 190nM glycine, 20% 
  
204 
methanol and 0.01% SDS) at 90 volts until resolved and then 150 volts until the blue dye 
front reached the bottom of the gel after which a Coomassie stain was performed.  
Gels were placed in 7% glacial acid with 40% methanol for one hour to fix proteins and 
then stained with one-part Brilliant Blue G 250 (Sigma-Aldrich, Dorset, UK) in four parts 
methanol for one hour. Gels were then rinsed in 10% acetic acid in methanol for 60 
seconds and destained in 25% methanol for approximately 24 hours until bands appeared.  
4.2.4 Western immunoblotting 
Western immunoblotting of tissue homogenates was conducted for Nrf2 relative 
expression as described in section 3.3.2. Tissue samples from brusatol-treated or vehicle 
control mice were run on a single 10 or 15 well gel to allow comparison of Nrf2 expression 
across samples. 
4.2.5 iTRAQ labelling 
For iTRAQ analysis, 100μg of total protein from each liver sample was suspended in 20μl of 
iTRAQ buffer. A pooled reference sample with the same total protein content was created 
from all samples for inclusion in duplicate on all iTRAQ runs. iTRAQ reagents are available in 
an 8-plex format, restricting samples to six per run and two pooled samples. A random 
selection of liver samples, including three from brusatol-treated and three from control 
mice, were included in the run. Labelling with iTRAQ reagents was carried out according to 
the Applied Biosystems protocol for an 8-plex procedure (Life Technologies, Paisley, UK). In 
brief, samples were reduced with Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) and 
sulphydryl groups capped with methylmethanethiosulfate (MMTS), before overnight 
digestion with trypsin (Promega, Southampton, UK). Peptides were then labelled with 
isobaric tags, pooled and diluted to 5ml with 10mM potassium dihydrogen phosphate/25% 
acetonitrile (ACN: w/v) and acidified to a pH of <3 with phosphoric acid. 
4.2.6 Cation exchange 
Samples were fractionated on a Polysulfoethyl A strong cation-exchange column (200 × 
4.6mm, 5μm, 300Å; Poly LC, Columbia, MD) at 2ml/minute using a gradient from 10mM 
potassium dihydrogen phosphate/25% ACN (w/v) to 0.5M potassium chloride/10mM 
potassium dihydrogen phosphate/25% ACN (w/w/v) in 75 minutes. Fractions of 2ml were 
collected and dried by centrifugation under vacuum (SpeedVac, Eppendorf UK Ltd, 
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Stevenage, UK) before reconstitution in 1ml of 0.1% trifluoroacetic acid (TFA) and desalting 
using a mRP Hi Recovery protein 4.6 x 50mm column (Agilent, Berkshire UK) on a Vision 
Workstation (Applied Biosystems/Life Technologies, Paisley, UK) prior to mass 
spectrometric analysis. 
4.2.7 Mass spectrometry 
Desalted fractions were reconstituted in 40μl of 0.1% formic acid and 5μl aliquots were 
delivered into a Triple TOF 6600 (AB Sciex, Warrington, UK) via an Eksigent NanoUltra 
cHiPLC System (AB Sciex) mounted with a microfluidic trap and analytical column (15 cm × 
75 μm) packed with ChromXP C18−CL 3μm. A NanoSpray III source was fitted with a 10μm 
inner diameter PicoTip emitter (New Objective, Woburn, USA). The trap column was 
washed with 2% ACN/0.1% (v/v) formic acid for 10 minutes at 2μL/minute before switching 
in-line with the analytical column. A gradient of 2−50% ACN/0.1% formic acid (v/v) over 90 
minutes was applied to the column at a flow rate of 300nl/min.  
Spectra were acquired automatically in positive ion mode using information-dependent 
acquisition powered by Analyst TF 1.5.1. software (AB Sciex, Massachusetts, USA). Up to 25 
MS/MS spectra were acquired per cycle (approximately 10Hz) using a threshold of 100 
counts per second and with dynamic exclusion for 12 seconds. The rolling collision energy 
was increased automatically by selecting the iTRAQ check box in Analyst, and manually by 
increasing the collision energy intercepts by 5. 
4.2.8 iTRAQ protein identification and data analysis 
Acquired data were searched using ProteinPilot 4.2 and the Paragon algorithm (AB Sciex, 
Massachusetts, USA) against the latest version of the SwissProt database, with MMTS as a 
fixed modification of cysteine residues and biological modifications allowed. The data were 
also searched against a reversed decoy database and only proteins lying within a 1% global 
false discovery rate (FDR) were taken forward for analysis. Quantitation of proteins was 
relative to the common pool sample present in the iTRAQ-MS experiment. iTRAQ data for 
proteins identified with at least 95% confidence of correct sequence assignment, or by a 
single peptide with at least 99% confidence were log2 transformed, batch corrected and 
included in subsequent analyses. Proteins present in all samples were taken forward for 
further analysis. 
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Mean fold changes in protein expression were calculated and analysis conducted on the 
logged fold-change values. Brusatol dependent protein expression was defined by 
comparing the proteome in the vehicle (1% DMSO in x1 PBS) treated control mice livers to 
those dosed with the drug over a period of 2 weeks.  
4.2.9 Pathway analysis 
The accession numbers of proteins identified as significantly differentially expressed were 
subjected to analysis with Ingenuity Pathway Analysis (Redwood City, USA) to identify 
pathways altered by treatment with brusatol. Ingenuity Pathways Analysis computes a 
score for each network according to the fit of that network with the identified proteins of 
interest (referred to as the focus proteins). The score is derived from a p-value and 
indicates the probability of the focus proteins in a network being found together due to 
random chance. A score of 2 indicates that there is a 1 in 100 chance that the focus 
proteins are together in a network due to random chance, therefore scores greater than 2 
have at least a 99% confidence of not being generated by random chance alone. Analysis 
must also take into account both the number of focus proteins identified and total known 
proteins in each network. Significant canonical pathways were identified with a threshold p 
value of <0.05 (after correction). If there are n proteins in a pathway, and f have been 
identified through iTRAQ, the p-value is the probability of finding f or more proteins in a set 
of n proteins randomly selected from the global molecular network.  
4.2.10 RNA isolation 
RNA isolation was performed using the RNeasy Mini-kit (QIAGEN, Manchester, UK) 
according to the manufacturer’s instructions. Approximately 30mg of liver tissue was 
weighed out and 600μl of buffer RLT added. Tissue was homogenised using the MM400 
oscillating mill (Retsch, Haan, Germany) and centrifuged at 18 000g for 3 minutes. The 
supernatant was retained and 600μl of 70% ethanol added. The solution was passed 
through an RNeasy spin column by centrifugation at 10 000g for 15 seconds and the RNA, 
which had bound to the spin column, washed in three subsequent centrifugation steps 
using the buffers provided. RNA was eluted in RNase-free dH2O and the concentration 
determined using a Nanodrop™ ND-1000 UV spectrophotometer (Labtech International, 
East Sussex, UK). 
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4.2.11 cDNA synthesis (Reverse Transcription) 
cDNA synthesis was carried out using the GoScript™ Reverse Transcription System 
(Promega, Southampton, UK) according to the manufacturer’s instructions with some 
minor modifications. 0.5μg of RNA were combined with 1μl of oligo and 1μl of random 
primers and made up to a total volume of 10μl with RNase-free dH2O. The solution was 
incubated at 70°C for 5 minutes and then cooled on ice. A master mix containing 8μl of 5x R 
buffer, 4μl of 25nM MgCl2, 2μl dNTPs, 2μl reverse transcriptase and 14μl of RNase-free 
dH2O was added to each RNA sample. Strands were annealed (25°C; 5 minutes) and 
extended (42°C; 1 hour), before the reverse transcriptase was inactivated (70°C; 15 
minutes). cDNA concentration was subsequently determined using the Nanodrop™ ND-
1000 UV spectrophotometer as described in section 2.2.3. 
4.2.12 Microfluidic TaqMan low density array cards 
Custom TaqMan® low density gene expression array cards (TLDA, ThermoFisher Scientific, 
Paisley, UK) were designed to include well established Nrf2-regulated genes, as identified 
from in-house data and the literature. In addition to the 18S gene, used as a housekeeper 
to correct loading errors, 47 Nrf2 genes were included on each plate. The represented 
genes and plate layout are detailed in figure 4.1 and table 4.2. Eight samples could be run 
on each card, which included a pool of cDNA from all samples to allow data comparison 
across plates and a negative control (nuclease-free dH2O). Samples were randomised 
across plates by group so that an equal number of samples from control or brusatol-
treated mice were run on each. All samples were run in duplicate and the average values 
used for comparisons between brusatol-treated and control groups of mice. 
The previously synthesised cDNA was diluted in nuclease-free dH2O to a concentration of 
20ng/μl. This cDNA solution was subsequently mixed with 50μl of TaqMan® Gene 
Expression Master Mix (ThermoFisher Scientific, Paisley, UK) to give 1000ng of total cDNA. 
Samples were vortexed and transferred by pipette to the appropriate well of the TaqMan 
array card. Pooled cDNA samples were prepared in the same way. Once loaded, cards were 
centrifuged twice at 331g for 1 min, sealed and wells removed. Cards were run on the 
7900HT Fast Real-Time Polymerase Chain Reaction (PCR) System (Applied Biosystems, 
California, USA) with a 10-minute denaturation at 95°C followed by 40 amplification cycles 
(15 seconds at 95°C and 1 minute at 60°C) and a final cooling period of 5 minutes at 70°C. 
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4.2.13 Microfluidic card data analysis 
Data were analysed using the comparative CT method (ΔΔCT) to allow relative 
quantification [446]. CT values were determined using the RQ manager 1.2 component of 
the 7900HT Fast System software. The threshold was manually set to a value of 0.3 for all 
plates. Gene expression was quantified relative to the sample pool run on the same plate 
and normalised to 18S gene expression. Statistical analysis was performed to compare 
relative expression of genes in brusatol-treated and control mice where CT values were 
available for ≥3 animals in each group. A Shapiro-Wilk test was used to assess the normality 
of the data with normal data analysed using an unpaired t-test and non-normal data 
analysed using a Mann-Whitney U test. Statistical significance was assumed at p<0.05. 
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Table 4.1 – Gene symbols and names represented on the Microfluidic TaqMan low density array 
card. 
Gene 
symbol Gene ID Gene Name
Abcc1 Mm00456156_m1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1
Abcc2 Mm00496899_m1 ATP-binding cassette, sub-family C (CFTR/MRP), member 2
Abcc3 Mm00551550_m1 ATP-binding cassette, sub-family C (CFTR/MRP), member 3
Abcc4 Mm01226381_m1 ATP-binding cassette, sub-family C (CFTR/MRP), member 4
Abcc5 Mm01343626_m1 ATP-binding cassette, sub-family C (CFTR/MRP), member 5
Aox1 Mm00437482_m1 aldehyde oxidase 1
Cat Mm00437992_m1 catalase
Cbr1 Mm04207333_g1 carbonyl reductase 1
Cbr3 Mm00557339_m1 carbonyl reductase 3
Ces1g Mm00491334_m1 carboxylesterase 1G
18S 18S-Hs99999901_s1 Eukaryotic 18S rRNA
Ces2c Mm01250994_m1 carboxylesterase 2C
Cyp2a4 Mm00487248_g1 cytochrome P450, family 2, subfamily a, polypeptide 4
Entpd5 Mm00514245_m1 ectonucleoside triphosphate diphosphohydrolase 5
Ephx1 Mm00468752_m1 epoxide hydrolase 1, microsomal
Ephx2 Mm01313813_m1 epoxide hydrolase 2, cytoplasmic
Fth1 Mm00850707_g1 ferritin heavy chain 1
Ftl1 Mm03030144_g1 ferritin l ight chain 1
G6pdx Mm00656735_g1 glucose-6-phosphate dehydrogenase X-linked
Gclc Mm00802655_m1 glutamate-cysteine ligase, catalytic subunit
Gclm Mm00514996_m1 glutamate-cysteine ligase, modifier subunit
Gsr Mm00439154_m1 glutathione reductase
Gss Mm00515065_m1 glutathione synthetase
Gsta2 Mm03019257_g1 glutathione S-transferase, alpha 2 (Yc2)
Gsta3 Mm00494798_m1 glutathione S-transferase, alpha 3
Gsta4 Mm00494803_m1 glutathione S-transferase, alpha 4
Gstm1 Mm00833915_g1 glutathione S-transferase, mu 1
Gstm2 Mm00725711_s1 glutathione S-transferase, mu 2
Gstm3 Mm00833923_m1 glutathione S-transferase, mu 3
Gstm4 Mm00728197_s1 glutathione S-transferase, mu 4
Gstp1 Mm04213618_gH glutathione S-transferase, pi 1
Hmox1 Mm00516005_m1 heme oxygenase 1
Keap1 Mm00497268_m1 kelch-like ECH-associated protein 1
Me1 Mm00782380_s1 malic enzyme 1, NADP(+)-dependent, cytosolic
Mgst1 Mm00498294_m1 microsomal glutathione S-transferase 1
Nampt Mm00451938_m1 nicotinamide phosphoribosyltransferase
Nfe2l2 Mm00477784_m1 nuclear factor, erythroid derived 2, l ike 2
Nqo1 Mm01253561_m1 NAD(P)H dehydrogenase, quinone 1
Prdx1 Mm01621996_s1 peroxiredoxin 1
Prdx6 Mm00725435_s1 peroxiredoxin 6
Slc22a12 Mm01236822_m1 solute carrier family 22 (organic anion/cation transporter), member 12
Srxn1 Mm00769566_m1 sulfiredoxin 1 homolog (S. cerevisiae)
Txn1 Mm00726847_s1 thioredoxin 1
Txnrd1 Mm00443675_m1 thioredoxin reductase 1
Ugdh Mm00447643_m11 UDP-glucose dehydrogenase
Ugt1a1 Mm02603337_m1 UDP glucuronosyltransferase 1 family, polypeptide A1
Ugt2b5 Mm01623253_s1 UDP glucuronosyltransferase 2 family, polypeptide B5
PGD Mm00503037_m1 phosphogluconate dehydrogenase
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Table 4.2 – Microfluidic TaqMan low density array card layout. Eight samples were run on each plate. Each loading well corresponds to two adjacent rows of the plate. 
The gene names for each gene code are detailed in table 4.1
Sample 
number
1 Abcc1 Abcc2 Abcc3 Abcc4 Abcc5 Aox1 Cat Cbr1 Cbr3 Ces1g 18S Ces2c Cyp2a5 Entpd5 Ephx1 Ephx2 Fth1 Ftl1 G6pdx Gclc Gclm Gsr Gss Gsta2
Gsta3 Gsta4 Gstm1 Gstm2 Gstm3 Gstm4 Gstp1 Hmox1 Keap1 Me1 Mgst1 Nampt Nfe2l2 Nqo1 Prdx1 Prdx6 Slc22a12 Srxn1 Txn1 Txnrd1 Ugdh Ugt1a1 Ugt2b5 Pgd
2 Abcc1 Abcc2 Abcc3 Abcc4 Abcc5 Aox1 Cat Cbr1 Cbr3 Ces1g 18S Ces2c Cyp2a5 Entpd5 Ephx1 Ephx2 Fth1 Ftl1 G6pdx Gclc Gclm Gsr Gss Gsta2
Gsta3 Gsta4 Gstm1 Gstm2 Gstm3 Gstm4 Gstp1 Hmox1 Keap1 Me1 Mgst1 Nampt Nfe2l2 Nqo1 Prdx1 Prdx6 Slc22a12 Srxn1 Txn1 Txnrd1 Ugdh Ugt1a1 Ugt2b5 Pgd
3 Abcc1 Abcc2 Abcc3 Abcc4 Abcc5 Aox1 Cat Cbr1 Cbr3 Ces1g 18S Ces2c Cyp2a5 Entpd5 Ephx1 Ephx2 Fth1 Ftl1 G6pdx Gclc Gclm Gsr Gss Gsta2
Gsta3 Gsta4 Gstm1 Gstm2 Gstm3 Gstm4 Gstp1 Hmox1 Keap1 Me1 Mgst1 Nampt Nfe2l2 Nqo1 Prdx1 Prdx6 Slc22a12 Srxn1 Txn1 Txnrd1 Ugdh Ugt1a1 Ugt2b5 Pgd
4 Abcc1 Abcc2 Abcc3 Abcc4 Abcc5 Aox1 Cat Cbr1 Cbr3 Ces1g 18S Ces2c Cyp2a5 Entpd5 Ephx1 Ephx2 Fth1 Ftl1 G6pdx Gclc Gclm Gsr Gss Gsta2
Gsta3 Gsta4 Gstm1 Gstm2 Gstm3 Gstm4 Gstp1 Hmox1 Keap1 Me1 Mgst1 Nampt Nfe2l2 Nqo1 Prdx1 Prdx6 Slc22a12 Srxn1 Txn1 Txnrd1 Ugdh Ugt1a1 Ugt2b5 Pgd
5 Abcc1 Abcc2 Abcc3 Abcc4 Abcc5 Aox1 Cat Cbr1 Cbr3 Ces1g 18S Ces2c Cyp2a5 Entpd5 Ephx1 Ephx2 Fth1 Ftl1 G6pdx Gclc Gclm Gsr Gss Gsta2
Gsta3 Gsta4 Gstm1 Gstm2 Gstm3 Gstm4 Gstp1 Hmox1 Keap1 Me1 Mgst1 Nampt Nfe2l2 Nqo1 Prdx1 Prdx6 Slc22a12 Srxn1 Txn1 Txnrd1 Ugdh Ugt1a1 Ugt2b5 Pgd
6 Abcc1 Abcc2 Abcc3 Abcc4 Abcc5 Aox1 Cat Cbr1 Cbr3 Ces1g 18S Ces2c Cyp2a5 Entpd5 Ephx1 Ephx2 Fth1 Ftl1 G6pdx Gclc Gclm Gsr Gss Gsta2
Gsta3 Gsta4 Gstm1 Gstm2 Gstm3 Gstm4 Gstp1 Hmox1 Keap1 Me1 Mgst1 Nampt Nfe2l2 Nqo1 Prdx1 Prdx6 Slc22a12 Srxn1 Txn1 Txnrd1 Ugdh Ugt1a1 Ugt2b5 Pgd
7 Abcc1 Abcc2 Abcc3 Abcc4 Abcc5 Aox1 Cat Cbr1 Cbr3 Ces1g 18S Ces2c Cyp2a5 Entpd5 Ephx1 Ephx2 Fth1 Ftl1 G6pdx Gclc Gclm Gsr Gss Gsta2
Gsta3 Gsta4 Gstm1 Gstm2 Gstm3 Gstm4 Gstp1 Hmox1 Keap1 Me1 Mgst1 Nampt Nfe2l2 Nqo1 Prdx1 Prdx6 Slc22a12 Srxn1 Txn1 Txnrd1 Ugdh Ugt1a1 Ugt2b5 Pgd
8 Abcc1 Abcc2 Abcc3 Abcc4 Abcc5 Aox1 Cat Cbr1 Cbr3 Ces1g 18S Ces2c Cyp2a5 Entpd5 Ephx1 Ephx2 Fth1 Ftl1 G6pdx Gclc Gclm Gsr Gss Gsta2
Gsta3 Gsta4 Gstm1 Gstm2 Gstm3 Gstm4 Gstp1 Hmox1 Keap1 Me1 Mgst1 Nampt Nfe2l2 Nqo1 Prdx1 Prdx6 Slc22a12 Srxn1 Txn1 Txnrd1 Ugdh Ugt1a1 Ugt2b5 Pgd
Gene symbols
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4.3 Results 
4.3.1 Effect of brusatol on Nrf2 expression in vivo 
Brusatol caused a significant reduction in the level of Nrf2, as assessed by western 
immunoblotting, in flank tumours (data displayed in figure 3.23), normal colon (figure 4.2) 
and normal liver tissue (figure 4.3) excised from BALB/c mice repeatedly dosed with the 
compound over two weeks. Nrf2 protein expression, as assessed by western 
immunoblotting and densitometry, was reduced by 74%, 95% and 97% in the flank 
tumours, normal colon and normal liver tissue excised from brusatol-treated mice in 
comparison to the saline-treated controls respectively. 
 
 
Figure 4.2 – a) Western immunoblot image displaying inhibition of Nrf2 in colon tissue excised 
from BALB/c mice after dosing with brusatol for two weeks. b) Graphical display of densitometry 
confirmed significant inhibition of Nrf2 (p = 0.01 unpaired t-test with Welch's correction). (N=3, 
graph displays mean +/- SD, c = saline control, BRU = brusatol) 
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Figure 4.3 – a) Western immunoblot image displaying inhibition of Nrf2 in liver tissue excised from 
BALB/c mice after dosing with brusatol. b) Graphical display of densitometry confirmed significant 
inhibition of Nrf2 (p = 0.02 unpaired t-test with Welch's correction). (N=7, graph displays mean +/- 
SD, C = saline control, BRU = brusatol) 
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4.3.2 Coomaissie staining of samples 
Prior to running iTRAQ analysis, protein electrophoresis and Coomaisse blue staining was 
completed to verify accurate quantification of the total protein content of samples and 
ensure adequate sample quality. iTRAQ analysis was only undertaken on normal liver 
excised from mice either treated with brusatol or a saline control. The quantity and quality 
of colonic and tumour tissue was considered inadequate for proteomic assessment. 
 
 
 
 
Figure 4.4 – Image of a Coomaissie stain of normal liver tissue samples used in the iTRAQ analysis 
excised from BALB/c mice treated with either brusatol or a saline control. (C = saline control, BRU 
= brusatol, MW = molecular weight) 
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4.3.3 iTRAQ analysis of mouse liver tissue 
Liver samples from three mice treated with brusatol and three mice receiving vehicle alone 
were subject to iTRAQ analysis in a single run and compared with the average of a common 
pooled sample, which was run in duplicate. A fold-change value for each detected protein 
in each sample was obtained, relative to the pooled samples, and utilised to compare the 
fold-change in protein expression between brusatol-treated and control liver tissue.  
A total of 3515 proteins were identified in the iTRAQ run. An unpaired t-test was used to 
identify proteins with significantly different expression between mouse groups. 
Significance was assumed at two-tailed p value of <0.05. By applying a relatively non-
stringent statistical analysis, the expression of 262 liver proteins were deemed statistically 
different between brusatol-treated and control mice. Brusatol exposure significantly 
increased the expression of 137 proteins (Table 4.3) and decreased the expression of 125 
(Table 4.4) in murine liver. Differences in protein expression between control mouse liver 
tissue and that taken from mice treated with brusatol were generally subtle, which could 
be considered advantageous in the context of a potential therapeutic compound.   
Whilst this level of statistical analysis is insufficient for unequivocal designation of brusatol 
associated proteins, it provides a sufficient number of potentially regulated proteins to 
allow meaningful pathway analysis. As noted by Subramanian et al.[447], the application of 
stringent multiple testing correction algorithms (such as Bonferroni or Benjamini Hochberg 
analyses) to large scale global analysis data can preclude the identification of modest 
expression changes that can collectively modulate a specific pathway.  
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     Relative expression to pool 
  
SwissProt. 
Acc No. Name 
Avg. 
percentage 
coverage (%) 
Avg. 
number of 
Peptides 
Mean 
Pool 
Mouse 
C1 
Mouse 
C2 
Mouse 
C3 
Mean 
Control 
Control 
SD 
Mouse 
Bru1 
Mouse 
Bru2 
Mouse 
Bru3 
Mean 
Brusatol 
Brusatol 
SD 
Fold-change 
Bru/C p value 
O08547 Vesicle-trafficking protein SEC22b 45.50 30 1.34 0.62 0.76 0.15 0.51 0.32 4.13 2.70 3.87 3.57 0.76 6.99 0.00301 
Q9CPQ3 Mitochondrial import receptor subunit TOM22 
homolog 
2.42 1 0.19 0.25 0.04 0.04 0.11 0.12 0.69 0.89 0.67 0.75 0.12 6.80 0.00281 
Q3TW96 UDP-N-acetylhexosamine pyrophosphorylase-
like protein 1 
8.50 1 2.09 0.06 0.08 0.34 0.16 0.15 0.87 0.79 1.05 0.90 0.13 5.63 0.00319 
Q9CZS1 Aldehyde dehydrogenase X, mitochondrial 4.39 1 0.86 0.15 0.42 0.09 0.22 0.18 0.93 0.47 1.06 0.82 0.31 3.68 0.04410 
Q61733 28S ribosomal protein S31, mitochondrial 3.70 2 0.32 0.16 0.24 0.23 0.21 0.04 0.64 0.74 0.86 0.75 0.11 3.61 0.00136 
Q8R035 Peptidyl-tRNA hydrolase ICT1, mitochondrial 2.43 3 0.09 0.21 0.67 1.49 0.79 0.65 3.34 1.94 2.19 2.49 0.75 3.16 0.04073 
P48036 Annexin A5 62.70 30 1.34 0.70 1.16 0.81 0.89 0.24 2.54 2.49 3.02 2.68 0.29 3.01 0.00121 
Q3TC93 HCLS1-binding protein 3 37.31 17 0.74 0.59 0.72 0.50 0.60 0.11 2.33 1.69 1.14 1.72 0.60 2.86 0.03360 
Q5F2F2 Abhydrolase domain-containing protein 15 3.77 1 0.43 0.34 0.04 0.42 0.26 0.20 0.64 0.77 0.81 0.74 0.09 2.80 0.01905 
P63330 Serine/threonine-protein phosphatase 2A 
catalytic subunit alpha isoform 
16.19 2 1.03 0.56 0.95 0.68 0.73 0.20 2.09 2.44 1.47 2.00 0.49 2.75 0.01411 
Q8BRK8 5'-AMP-activated protein kinase catalytic 
subunit alpha-2 
51.91 15 0.86 0.68 0.70 0.21 0.53 0.28 1.63 1.16 1.49 1.42 0.24 2.69 0.01388 
P34022 Ran-specific GTPase-activating protein 9.11 2 1.31 0.41 0.32 0.57 0.43 0.13 1.08 1.21 1.10 1.13 0.07 2.62 0.00124 
P49312 Heterogeneous nuclear ribonucleoprotein A1 2.36 2 0.70 0.62 0.39 0.29 0.43 0.17 1.02 1.14 1.10 1.08 0.06 2.51 0.00331 
Q9ET01 Glycogen phosphorylase, liver form 10.26 4 0.94 0.48 0.49 0.46 0.48 0.02 1.07 1.25 1.27 1.19 0.11 2.50 0.00039 
Q9QXA5 U6 snRNA-associated Sm-like protein LSm4 5.76 2 1.64 0.65 0.70 1.10 0.81 0.25 2.05 1.71 2.25 2.00 0.27 2.46 0.00505 
Q9DB27 Malignant T-cell-amplified sequence 1 61.26 42 1.25 1.02 1.10 0.21 0.77 0.49 2.13 1.89 1.58 1.87 0.27 2.41 0.02811 
O70493 Sorting nexin-12 56.47 56 0.90 0.86 0.70 0.17 0.57 0.36 1.57 1.31 1.21 1.36 0.19 2.38 0.02800 
Q8CBE3 WD repeat-containing protein 37 24.68 10 1.00 0.46 0.49 0.51 0.48 0.02 0.90 1.21 1.29 1.14 0.21 2.35 0.00550 
P10648 Glutathione S-transferase A2 7.72 4 2.78 0.83 2.83 2.25 1.97 1.03 3.87 5.20 4.83 4.63 0.69 2.35 0.02024 
Q9CPU4 Microsomal glutathione S-transferase 3 66.09 40 0.76 0.66 0.69 0.54 0.63 0.08 1.64 1.66 1.13 1.48 0.30 2.34 0.00947 
Q8R1I1 Cytochrome b-c1 complex subunit 9 21.96 11 1.11 0.58 0.54 0.28 0.47 0.16 0.75 1.13 1.39 1.09 0.32 2.33 0.04075 
Q99PU5 Long-chain-fatty-acid--CoA ligase ACSBG1 52.41 42 1.67 0.85 0.94 0.60 0.80 0.17 1.89 1.77 1.89 1.85 0.07 2.32 0.00061 
Q91W43 Glycine dehydrogenase (decarboxylating), 
mitochondrial 
30.88 5 0.20 0.37 0.28 0.38 0.35 0.06 0.71 0.72 0.95 0.80 0.14 2.30 0.00623 
Q9CZ91 Serum response factor-binding protein 1 29.30 27 0.68 0.44 0.53 0.47 0.48 0.05 1.25 0.96 0.91 1.04 0.18 2.16 0.00658 
Q91Y97 Fructose-bisphosphate aldolase B 21.91 3 1.32 0.69 1.13 1.22 1.01 0.28 2.11 2.56 1.82 2.16 0.37 2.13 0.01319 
P58389 Serine/threonine-protein phosphatase 2A 
activator 
61.29 112 1.96 0.76 1.22 1.13 1.04 0.25 2.19 2.05 2.38 2.21 0.16 2.13 0.00237 
Q60649 Caseinolytic peptidase B protein homolog 3.74 1 0.60 0.92 0.49 0.21 0.54 0.36 1.21 1.03 1.20 1.15 0.10 2.12 0.04707 
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Q9DBJ1 Phosphoglycerate mutase 1 3.42 1 0.95 0.98 0.48 0.35 0.60 0.33 1.41 1.16 1.20 1.26 0.13 2.08 0.03463 
P45376 Aldose reductase 44.56 15 1.57 0.95 1.25 0.60 0.93 0.32 2.09 1.61 2.11 1.94 0.28 2.08 0.01514 
Q8R081 Heterogeneous nuclear ribonucleoprotein L 75.49 18 1.72 1.00 1.54 1.00 1.18 0.31 2.81 2.03 2.49 2.44 0.39 2.07 0.01187 
Q8VC30 Triokinase/FMN cyclase 68.90 56 1.61 1.10 1.21 1.13 1.15 0.06 2.49 1.82 2.75 2.35 0.48 2.05 0.01252 
Q80UU9 Membrane-associated progesterone receptor 
component 2 
19.27 7 0.69 0.69 0.65 0.52 0.62 0.09 1.18 1.33 1.26 1.26 0.08 2.03 0.00068 
Q8CI94 Glycogen phosphorylase, brain form 22.32 7 0.76 0.84 1.05 0.52 0.80 0.27 1.46 1.72 1.67 1.62 0.14 2.02 0.00943 
Q61081 Hsp90 co-chaperone Cdc37 48.80 23 1.96 1.42 1.32 1.24 1.32 0.09 3.25 2.33 2.40 2.66 0.51 2.01 0.01123 
P10605 Cathepsin B 39.17 4 0.67 0.62 0.60 0.23 0.48 0.22 1.00 0.82 1.05 0.95 0.12 1.98 0.03119 
P56656 Cytochrome P450 2C39 34.69 15 1.31 0.95 0.65 0.85 0.82 0.16 1.50 1.57 1.74 1.60 0.12 1.96 0.00234 
Q9EPB5 Serine hydrolase-like protein 29.41 2 1.58 1.18 2.33 1.10 1.54 0.69 3.44 2.96 2.63 3.01 0.40 1.96 0.03333 
Q9DC70 NADH dehydrogenase [ubiquinone] iron-sulfur 
protein 7, mitochondrial 
23.51 11 1.06 0.41 0.86 0.90 0.72 0.27 1.47 1.57 1.18 1.41 0.20 1.94 0.02481 
Q6ZPJ0 Testis-expressed sequence 2 protein 46.41 23 1.32 0.55 0.89 0.61 0.68 0.18 1.45 1.16 1.37 1.32 0.15 1.94 0.00877 
Q99KY4 Cyclin-G-associated kinase 1.99 1 1.60 1.15 1.14 1.85 1.38 0.41 2.70 2.05 3.22 2.66 0.59 1.93 0.03637 
P51855 Glutathione synthetase 36.57 9 1.80 1.10 1.37 1.08 1.18 0.16 2.44 2.23 2.09 2.25 0.18 1.91 0.00153 
Q9QZ23 NFU1 iron-sulfur cluster scaffold homolog, 
mitochondrial 
17.66 6 0.73 0.60 0.64 0.23 0.49 0.23 1.03 0.79 0.99 0.94 0.13 1.91 0.04313 
P28650 Adenylosuccinate synthetase isozyme 1 7.38 6 1.13 0.52 0.69 0.64 0.61 0.09 1.12 1.42 0.97 1.17 0.23 1.90 0.01704 
P34884 Macrophage migration inhibitory factor 49.71 22 0.95 0.64 0.79 0.37 0.60 0.21 1.34 1.15 0.92 1.14 0.21 1.90 0.03512 
Q7TMF3 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 12 
36.46 5 1.45 1.34 1.38 1.12 1.28 0.14 2.13 2.61 2.51 2.42 0.25 1.89 0.00249 
P46061 Ran GTPase-activating protein 1 1.61 1 0.82 0.52 0.37 0.29 0.39 0.12 0.86 0.58 0.74 0.73 0.14 1.86 0.03325 
Q921S7 39S ribosomal protein L37, mitochondrial 56.40 69 1.45 1.15 0.98 1.18 1.10 0.11 2.00 2.36 1.79 2.05 0.29 1.85 0.00600 
P52840 Sulfotransferase 1A1 64.80 90 1.72 1.13 1.85 0.86 1.28 0.51 2.65 2.27 2.19 2.37 0.25 1.85 0.02968 
Q64433 10 kDa heat shock protein, mitochondrial 42.99 51 1.18 1.04 0.77 0.36 0.72 0.34 1.28 1.50 1.22 1.34 0.15 1.85 0.04605 
P17751 Triosephosphate isomerase 4.13 1 0.79 0.63 0.73 0.45 0.60 0.14 1.00 1.34 0.98 1.11 0.20 1.84 0.02402 
P62774 Myotrophin 24.74 12 0.56 0.53 0.69 0.58 0.60 0.08 0.88 1.43 1.01 1.11 0.29 1.84 0.04370 
Q9D1P0 39S ribosomal protein L13, mitochondrial 8.56 3 0.74 1.05 0.87 0.67 0.86 0.19 1.89 1.54 1.32 1.58 0.29 1.84 0.02224 
Q9DCD0 6-phosphogluconate dehydrogenase, 
decarboxylating 
13.36 2 2.05 1.87 1.80 1.80 1.83 0.04 2.88 4.21 2.88 3.33 0.76 1.82 0.02740 
Q61133 Glutathione S-transferase theta-2 34.17 7 0.82 0.32 0.75 0.67 0.58 0.23 1.17 1.02 0.95 1.04 0.11 1.80 0.03539 
P29391 Ferritin light chain 1 32.87 19 1.49 1.03 1.22 0.80 1.02 0.21 2.19 1.64 1.64 1.83 0.31 1.79 0.02092 
Q9CPU2 NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 2, mitochondrial 
27.02 27 0.72 0.64 0.79 0.87 0.77 0.12 1.46 1.36 1.24 1.35 0.11 1.75 0.00335 
Q9CWS0 N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 1 
22.37 7 1.60 0.85 0.80 0.81 0.82 0.02 1.13 1.79 1.38 1.43 0.33 1.75 0.03358 
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Q60855 Receptor-interacting serine/threonine-protein 
kinase 1 
39.76 15 0.54 0.52 0.55 0.63 0.57 0.05 1.06 0.77 1.11 0.98 0.18 1.72 0.01980 
Q920B9 FACT complex subunit SPT16 1.92 2 0.65 0.51 0.72 0.73 0.65 0.13 1.22 1.02 1.12 1.12 0.10 1.71 0.00799 
P48758 Carbonyl reductase [NADPH] 1 14.58 8 0.89 0.69 0.66 1.17 0.84 0.29 1.36 1.58 1.37 1.44 0.13 1.71 0.03025 
P35123 Ubiquitin carboxyl-terminal hydrolase 4 33.88 39 1.01 0.83 0.79 0.77 0.80 0.03 1.46 1.13 1.43 1.34 0.18 1.68 0.00741 
P80314 T-complex protein 1 subunit beta 74.02 43 1.36 1.25 1.33 1.17 1.25 0.08 2.17 1.80 2.29 2.09 0.25 1.67 0.00549 
P63147 Ubiquitin-conjugating enzyme E2 B 67.47 30 1.41 1.09 1.29 0.93 1.10 0.18 2.15 1.51 1.80 1.82 0.32 1.65 0.02744 
Q8R1T1 Charged multivesicular body protein 7 8.79 2 0.90 0.77 0.93 0.76 0.82 0.10 1.69 1.15 1.20 1.35 0.30 1.65 0.04322 
Q9WV55 Vesicle-associated membrane protein-
associated protein A 
32.30 20 1.12 0.76 0.94 0.82 0.84 0.09 1.46 1.53 1.15 1.38 0.20 1.65 0.01346 
Q80UG5 Septin-9 5.30 2 0.49 0.92 0.51 0.98 0.80 0.26 1.15 1.33 1.47 1.32 0.16 1.64 0.04294 
O55071 Cytochrome P450 2B19 25.85 7 1.08 0.97 1.03 0.57 0.86 0.25 1.31 1.63 1.27 1.40 0.20 1.64 0.04144 
P24549 Retinal dehydrogenase 1 25.45 7 1.21 0.76 1.00 0.76 0.84 0.14 1.50 1.28 1.31 1.36 0.12 1.62 0.00779 
P42125 Enoyl-CoA delta isomerase 1, mitochondrial 25.56 10 1.27 1.24 1.34 0.63 1.07 0.38 1.72 1.64 1.79 1.72 0.07 1.61 0.04531 
Q9CR59 Growth arrest and DNA damage-inducible 
proteins-interacting protein 1 
56.41 94 1.04 0.63 0.86 0.53 0.67 0.17 1.04 0.97 1.22 1.08 0.13 1.60 0.02926 
Q9WVL3 Solute carrier family 12 member 7 6.97 2 1.08 1.28 0.98 0.82 1.03 0.23 1.75 1.79 1.39 1.64 0.22 1.60 0.02888 
Q8C196 Carbamoyl-phosphate synthase [ammonia], 
mitochondrial 
29.10 7 1.09 0.89 0.80 1.14 0.94 0.17 1.57 1.61 1.33 1.51 0.15 1.60 0.01367 
Q8C142 Low density lipoprotein receptor adapter 
protein 1 
24.57 17 0.65 0.59 0.44 0.59 0.54 0.08 0.86 0.81 0.92 0.86 0.06 1.59 0.00556 
Q9CY18 Sorting nexin-7 5.20 1 0.88 0.78 0.52 0.58 0.63 0.14 1.06 1.06 0.86 0.99 0.11 1.59 0.02317 
Q6DFW4 Nucleolar protein 58 2.66 3 1.08 0.67 0.95 0.76 0.79 0.14 1.18 1.32 1.22 1.24 0.07 1.57 0.00798 
Q8BX90 Fibronectin type-III domain-containing protein 
3A 
13.11 4 0.96 0.84 0.53 0.58 0.65 0.17 1.17 0.93 0.95 1.02 0.13 1.57 0.03981 
Q9ESY9 Gamma-interferon-inducible lysosomal thiol 
reductase 
3.54 1 1.21 1.12 1.07 1.25 1.14 0.09 1.85 1.94 1.56 1.78 0.20 1.56 0.00757 
P97478 5-demethoxyubiquinone hydroxylase, 
mitochondrial 
79.38 91 2.91 2.11 3.02 2.78 2.64 0.47 4.66 3.34 4.29 4.09 0.68 1.55 0.03771 
P97371 Proteasome activator complex subunit 1 24.11 98 0.92 0.82 0.57 0.48 0.62 0.17 0.99 0.88 1.00 0.96 0.07 1.54 0.03636 
P97872 Dimethylaniline monooxygenase [N-oxide-
forming] 5 
46.52 62 1.06 1.26 1.14 0.70 1.03 0.30 1.75 1.50 1.47 1.58 0.16 1.53 0.04759 
O70475 UDP-glucose 6-dehydrogenase 41.97 15 0.91 0.92 0.90 0.65 0.82 0.15 1.21 1.08 1.45 1.25 0.19 1.52 0.03752 
O54774 AP-3 complex subunit delta-1 36.28 21 1.36 1.24 1.43 1.53 1.40 0.15 2.33 1.96 2.05 2.11 0.20 1.51 0.00721 
Q3TYX3 SET and MYND domain-containing protein 5 72.56 29 1.04 1.28 1.28 1.01 1.19 0.16 2.01 1.60 1.75 1.79 0.21 1.50 0.01680 
P61164 Alpha-centractin 10.66 4 1.16 0.86 0.58 0.82 0.75 0.16 1.27 1.00 1.13 1.13 0.14 1.50 0.03376 
Q99KI0 Aconitate hydratase, mitochondrial 15.29 3 0.90 0.70 0.79 0.55 0.68 0.12 1.02 1.04 1.01 1.02 0.01 1.50 0.00892 
Q91X78 Erlin-1 6.16 4 1.53 1.82 1.42 1.72 1.65 0.21 2.27 2.21 2.96 2.48 0.42 1.50 0.03789 
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P38647 Stress-70 protein, mitochondrial 4.43 1 1.77 1.77 1.47 1.56 1.60 0.15 2.56 2.56 1.96 2.36 0.35 1.47 0.02555 
Q61823 Programmed cell death protein 4 14.63 4 1.05 0.55 0.70 0.55 0.60 0.09 0.93 0.75 0.97 0.88 0.12 1.47 0.02919 
P50427 Steryl-sulfatase 11.18 1 0.50 0.45 0.57 0.39 0.47 0.09 0.65 0.73 0.69 0.69 0.04 1.47 0.01835 
Q9CQE3 28S ribosomal protein S17, mitochondrial 7.00 1 0.64 0.52 0.64 0.50 0.55 0.08 0.67 0.93 0.81 0.80 0.13 1.45 0.04458 
Q9DCA2 28S ribosomal protein S11, mitochondrial 12.62 2 0.99 0.54 0.59 0.61 0.58 0.04 0.84 0.86 0.80 0.83 0.03 1.44 0.00071 
Q924T2 28S ribosomal protein S2, mitochondrial 31.68 23 0.87 1.01 0.90 0.68 0.86 0.17 1.08 1.34 1.21 1.21 0.13 1.41 0.04743 
Q8BZS9 Putative pre-mRNA-splicing factor ATP-
dependent RNA helicase DHX32 
16.62 5 1.50 0.95 1.17 0.99 1.04 0.12 1.50 1.37 1.43 1.43 0.07 1.38 0.00703 
Q9CY02 Alpha-hemoglobin-stabilizing protein 21.10 4 0.77 0.67 0.65 0.65 0.65 0.01 1.06 0.79 0.85 0.90 0.14 1.37 0.04172 
P46664 Adenylosuccinate synthetase isozyme 2 7.59 2 1.33 1.21 1.10 0.98 1.10 0.12 1.61 1.25 1.64 1.50 0.22 1.37 0.04833 
Q9QYR9 Acyl-coenzyme A thioesterase 2, mitochondrial 1.37 1 0.89 0.88 0.88 0.98 0.91 0.06 1.14 1.39 1.21 1.25 0.13 1.37 0.01578 
Q921F4 Heterogeneous nuclear ribonucleoprotein L-like 42.96 3 1.08 0.68 0.75 0.73 0.72 0.04 0.98 0.99 0.96 0.98 0.01 1.36 0.00036 
Q8K2M0 39S ribosomal protein L38, mitochondrial 43.22 5 1.37 1.26 1.42 1.43 1.37 0.10 1.85 1.66 1.98 1.83 0.16 1.34 0.01301 
Q9QYY8 Spastin 26.76 15 1.37 1.08 0.90 1.18 1.05 0.14 1.32 1.46 1.43 1.40 0.07 1.34 0.01980 
Q9CW42 Mitochondrial amidoxime-reducing component 
1 
14.85 14 2.23 1.39 1.58 1.21 1.40 0.19 2.00 1.77 1.75 1.84 0.13 1.32 0.02887 
Q9WVA4 Transgelin-2 54.48 10 0.93 0.86 0.74 0.70 0.77 0.09 1.03 0.98 1.01 1.01 0.02 1.31 0.00955 
A6H8H2 DENN domain-containing protein 4C 28.13 6 0.84 1.07 1.16 0.86 1.03 0.16 1.32 1.45 1.24 1.33 0.11 1.30 0.04777 
Q9QXS1 Plectin 5.24 1 1.01 1.12 1.04 1.03 1.06 0.05 1.54 1.22 1.36 1.37 0.16 1.30 0.03128 
Q9R0M4 Podocalyxin 3.09 3 0.73 1.01 0.79 0.92 0.91 0.11 1.11 1.24 1.15 1.16 0.07 1.28 0.02497 
Q61151 Serine/threonine-protein phosphatase 2A 56 
kDa regulatory subunit epsilon isoform 
1.99 2 0.64 0.77 0.67 0.81 0.75 0.07 0.94 1.06 0.88 0.96 0.09 1.27 0.03581 
Q5SWD9 Pre-rRNA-processing protein TSR1 homolog 62.41 40 1.63 1.58 1.69 1.41 1.56 0.14 1.96 1.77 2.19 1.97 0.21 1.26 0.04830 
Q99LC3 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 10, mitochondrial 
1.34 4 0.92 0.84 0.82 0.95 0.87 0.07 0.97 1.21 1.11 1.10 0.12 1.26 0.04578 
P09411 Phosphoglycerate kinase 1 17.87 3 1.18 0.88 0.86 0.93 0.89 0.03 1.05 1.26 1.06 1.12 0.12 1.26 0.03258 
Q62351 Transferrin receptor protein 1 16.98 8 1.47 1.28 1.32 1.28 1.29 0.02 1.61 1.50 1.74 1.62 0.12 1.25 0.00982 
O88811 Signal transducing adapter molecule 2 38.14 11 0.81 0.78 0.78 0.80 0.79 0.01 0.97 0.99 0.98 0.98 0.01 1.25 0.00003 
Q8K4H1 Kynurenine formamidase 7.59 4 0.70 0.82 0.64 0.84 0.77 0.11 0.94 1.00 0.92 0.95 0.04 1.24 0.04899 
Q4VA53 Sister chromatid cohesion protein PDS5 
homolog B 
17.57 10 1.03 0.93 0.93 0.86 0.90 0.04 1.15 1.12 1.10 1.12 0.03 1.24 0.00170 
Q99M87 DnaJ homolog subfamily A member 3, 
mitochondrial 
57.94 29 1.54 1.14 1.25 1.26 1.21 0.07 1.58 1.53 1.38 1.50 0.11 1.23 0.01721 
Q8K114 Integrator complex subunit 9 50.00 5 1.01 1.06 1.05 1.00 1.03 0.03 1.25 1.34 1.24 1.28 0.06 1.23 0.00322 
P31001 Desmin 2.43 1 0.99 0.87 0.99 1.11 0.99 0.12 1.19 1.16 1.28 1.21 0.06 1.22 0.04602 
O08600 Endonuclease G, mitochondrial 11.76 4 0.94 0.95 1.07 0.96 0.99 0.07 1.19 1.22 1.21 1.21 0.02 1.22 0.00497 
Q9JKX6 ADP-sugar pyrophosphatase 3.85 2 1.04 0.76 0.96 0.86 0.86 0.10 1.07 1.04 1.04 1.05 0.02 1.22 0.03664 
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Q8R2K1 Fucose mutarotase 6.22 2 1.00 0.82 0.92 0.79 0.84 0.07 1.10 0.94 1.03 1.02 0.08 1.21 0.04380 
Q923D5 WW domain-binding protein 11 12.41 3 0.99 0.91 0.98 0.91 0.94 0.04 1.10 1.14 1.15 1.13 0.03 1.21 0.00239 
P28653 Biglycan 66.07 157 1.02 0.99 1.04 0.93 0.99 0.05 1.26 1.13 1.15 1.18 0.07 1.20 0.02030 
Q8R104 NAD-dependent protein deacetylase sirtuin-3 22.29 9 0.95 1.01 0.97 0.85 0.94 0.08 1.18 1.14 1.06 1.12 0.06 1.19 0.04067 
P97470 Serine/threonine-protein phosphatase 4 
catalytic subunit 
2.21 4 0.89 0.86 0.89 0.82 0.86 0.04 0.92 1.05 1.09 1.02 0.09 1.19 0.04004 
Q9R0N0 Galactokinase 3.74 2 0.81 0.97 1.01 0.85 0.94 0.08 1.14 1.12 1.07 1.11 0.04 1.17 0.03730 
Q8K1J6 CCA tRNA nucleotidyltransferase 1, 
mitochondrial 
4.78 4 1.32 1.33 1.27 1.21 1.27 0.06 1.45 1.45 1.57 1.49 0.07 1.17 0.01586 
Q8BWY7 Zinc transporter ZIP11 10.69 4 0.97 1.01 1.02 1.00 1.01 0.01 1.08 1.24 1.20 1.17 0.08 1.16 0.02928 
Q9D1H9 Microfibril-associated glycoprotein 4 13.28 3 1.11 0.88 0.80 0.83 0.84 0.04 0.95 1.05 0.91 0.97 0.07 1.16 0.04303 
Q8K1Z0 Ubiquinone biosynthesis protein COQ9, 
mitochondrial 
1.72 1 2.07 1.34 1.25 1.41 1.33 0.08 1.47 1.64 1.51 1.54 0.09 1.16 0.03820 
Q6VNB8 WD repeat and FYVE domain-containing 
protein 3 
3.86 1 0.91 1.08 1.15 1.12 1.11 0.04 1.25 1.29 1.32 1.29 0.04 1.16 0.00418 
Q8K2T8 RNA polymerase II-associated factor 1 homolog 24.09 10 1.22 1.12 1.08 0.96 1.05 0.08 1.19 1.20 1.24 1.21 0.02 1.15 0.02996 
P17879 Heat shock 70 kDa protein 1B 33.33 7 0.87 0.75 0.76 0.74 0.75 0.01 0.85 0.87 0.82 0.85 0.02 1.13 0.00270 
Q8BIW1 Protein prune homolog 22.17 3 1.08 1.05 1.00 1.03 1.03 0.02 1.13 1.14 1.13 1.13 0.01 1.10 0.00171 
Q8VCB3 Glycogen [starch] synthase, liver 4.25 4 0.86 0.87 0.86 0.91 0.88 0.03 0.97 0.93 0.97 0.96 0.03 1.09 0.02243 
P07901 Heat shock protein HSP 90-alpha 82.42 173 1.00 0.99 0.98 0.98 0.98 0.01 1.05 1.09 1.05 1.06 0.02 1.08 0.00495 
Q8BJZ4 28S ribosomal protein S35, mitochondrial 33.33 3 1.13 1.02 0.97 0.95 0.98 0.04 1.06 1.06 1.03 1.05 0.02 1.07 0.04279 
Q9R0P3 S-formylglutathione hydrolase 11.32 3 1.06 0.93 0.94 0.92 0.93 0.01 0.97 1.02 0.96 0.99 0.03 1.06 0.03376 
Q9DC16 Endoplasmic reticulum-Golgi intermediate 
compartment protein 1 
28.37 12 1.07 1.01 1.01 0.97 1.00 0.02 1.06 1.05 1.07 1.06 0.01 1.06 0.01117 
Q8VEH5 EPM2A-interacting protein 1 80.53 785 1.01 1.01 0.99 0.99 1.00 0.01 1.07 1.04 1.03 1.04 0.02 1.05 0.02305 
 
Table 4.3 – The 137 proteins significantly upregulated in the livers of BALB/c mice following chronic dosing with brusatol in comparison to the vehicle-treated controls. 
All values are expressed relative to the common pooled sample included in duplicate on the iTRAQ run. An unpaired t-test was utilised to compare between treatment 
groups. Proteins are listed according to their expression in brusatol-treated mice relative to control animals in descending order of the fold-change value. (Acc. = 
accession, Avg. = average, C = control, Bru = brusatol). 
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Relative expression to pool 
  
SwissProt. 
Acc. No. Name 
Avg. 
percentage 
coverage (%) 
Avg. 
number of 
Peptides 
Mean 
Pool 
Mouse 
C1 
Mouse 
C2 
Mouse 
C3 
Mean 
Control 
Control 
SD 
Mouse 
Bru1 
Mouse 
Bru2 
Mouse 
Bru3 
Mean 
Brusatol 
Brusatol 
SD 
Fold-change 
Bru/C p value 
P08226 Apolipoprotein E 43.09 29 1.18 2.03 1.80 0.82 1.55 0.64 0.69 0.34 0.08 0.37 0.31 0.24 0.04496 
P58044 Isopentenyl-diphosphate Delta-isomerase 1 31.28 7 1.24 1.53 1.51 2.70 1.92 0.68 0.67 0.61 0.21 0.50 0.25 0.26 0.02788 
Q8JZK9 Hydroxymethylglutaryl-CoA synthase, 
cytoplasmic 
29.23 13 1.47 2.56 1.79 3.77 2.70 1.00 0.78 0.49 0.90 0.73 0.21 0.27 0.02833 
Q9JKX3 Transferrin receptor protein 2 9.15 6 2.15 2.42 2.36 1.53 2.10 0.50 0.42 0.74 0.70 0.62 0.17 0.30 0.00835 
P40936 Indolethylamine N-methyltransferase 42.80 26 1.16 2.51 2.75 1.33 2.20 0.76 0.44 0.60 0.95 0.67 0.26 0.30 0.03009 
P22599 Alpha-1-antitrypsin 1-2 52.06 77 1.34 1.74 1.92 2.75 2.14 0.54 0.27 0.67 1.07 0.67 0.40 0.31 0.01933 
P29788 Vitronectin 12.34 4 0.89 1.58 0.82 1.66 1.36 0.46 0.23 0.62 0.42 0.42 0.20 0.31 0.03226 
Q9DBE0 Cysteine sulfinic acid decarboxylase 33.27 25 1.08 1.54 2.51 1.43 1.83 0.59 0.89 0.52 0.40 0.60 0.25 0.33 0.03032 
P11725 Ornithine carbamoyltransferase, 
mitochondrial 
70.62 70 1.16 1.66 1.50 0.91 1.36 0.39 0.45 0.41 0.49 0.45 0.04 0.33 0.01659 
E9Q414 Apolipoprotein B-100 5.62 19 0.86 0.98 1.05 0.95 0.99 0.05 0.55 0.28 0.19 0.34 0.19 0.34 0.00419 
P11881 Inositol 1,4,5-trisphosphate receptor type 1 2.55 9 0.92 0.95 0.66 0.71 0.78 0.16 0.33 0.33 0.16 0.28 0.10 0.35 0.00989 
Q8QZT1 Acetyl-CoA acetyltransferase, mitochondrial 70.52 73 1.29 1.56 2.61 2.03 2.06 0.53 1.10 0.38 0.74 0.74 0.36 0.36 0.02265 
Q8R086 Sulfite oxidase, mitochondrial 49.82 32 1.13 1.34 1.50 0.90 1.25 0.31 0.36 0.50 0.50 0.45 0.08 0.36 0.01321 
P21614 Vitamin D-binding protein 43.49 19 0.91 1.47 1.72 1.84 1.68 0.19 0.97 0.35 0.56 0.63 0.32 0.38 0.00780 
Q8R1J9 Torsin-2A 8.72 2 1.26 1.96 1.72 2.91 2.20 0.63 1.03 0.90 0.56 0.83 0.24 0.38 0.02446 
G5E870 E3 ubiquitin-protein ligase TRIP12 2.47 4 1.61 2.17 1.75 1.98 1.97 0.21 1.22 0.77 0.26 0.75 0.48 0.38 0.01599 
Q8CIM7 Cytochrome P450 2D26 45.20 47 1.34 1.36 1.43 1.34 1.38 0.05 0.71 0.60 0.38 0.56 0.17 0.41 0.00132 
O54749 Cytochrome P450 2J5 41.92 48 1.28 1.31 1.51 1.34 1.39 0.11 0.73 0.56 0.44 0.58 0.15 0.41 0.00160 
Q63836 Selenium-binding protein 2 87.71 207 1.24 1.45 1.39 0.98 1.27 0.25 0.69 0.46 0.45 0.53 0.13 0.42 0.01099 
Q8VCU1 Carboxylesterase 3B 43.08 42 1.42 2.19 2.11 1.60 1.97 0.32 1.04 0.38 1.05 0.82 0.38 0.42 0.01632 
Q06890 Clusterin 14.06 6 1.79 2.38 1.32 2.05 1.92 0.54 0.84 0.49 1.11 0.81 0.31 0.42 0.03762 
Q8BWQ1 UDP-glucuronosyltransferase 2A3 35.02 29 1.14 1.39 1.50 0.77 1.22 0.39 0.46 0.41 0.69 0.52 0.15 0.42 0.04387 
P48776 Tryptophan 2,3-dioxygenase 13.05 6 1.05 1.64 1.03 1.07 1.25 0.35 0.69 0.48 0.42 0.53 0.14 0.43 0.02943 
Q921X9 Protein disulfide-isomerase A5 24.76 16 1.16 1.02 0.92 1.46 1.13 0.29 0.48 0.38 0.61 0.49 0.12 0.43 0.02315 
Q8CF02 Protein FAM25C 43.82 2 1.38 1.13 1.77 1.13 1.34 0.37 0.68 0.45 0.64 0.59 0.12 0.44 0.02922 
Q78XF5 Oligosaccharyltransferase complex subunit 
OSTC 
8.05 2 1.89 1.29 1.91 2.33 1.84 0.52 1.06 0.42 0.97 0.82 0.34 0.44 0.04668 
O55242 Sigma non-opioid intracellular receptor 1 8.52 3 1.08 1.49 1.08 0.80 1.12 0.34 0.45 0.64 0.42 0.50 0.12 0.45 0.04205 
P11352 Glutathione peroxidase 1 83.08 73 1.16 1.26 1.46 0.91 1.21 0.28 0.61 0.63 0.42 0.55 0.11 0.46 0.01915 
P50247 Adenosylhomocysteinase 70.83 109 2.38 2.68 2.25 1.94 2.29 0.37 0.76 0.86 1.64 1.09 0.48 0.48 0.02699 
Q8BZW8 NHL repeat-containing protein 2 5.52 3 1.27 1.71 1.60 2.07 1.79 0.25 0.56 0.60 1.41 0.86 0.48 0.48 0.03918 
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Q3UNX5 Acyl-coenzyme A synthetase ACSM3, 
mitochondrial 
22.59 11 0.81 0.85 1.37 1.37 1.19 0.30 0.64 0.45 0.69 0.59 0.13 0.50 0.03307 
P60229 Eukaryotic translation initiation factor 3 
subunit E 
19.55 9 1.39 1.60 1.84 2.70 2.05 0.58 1.14 1.06 0.87 1.02 0.14 0.50 0.04106 
Q9QXD6 Fructose-1,6-bisphosphatase 1 72.49 118 1.60 1.67 2.38 2.99 2.35 0.66 1.31 0.96 1.28 1.18 0.19 0.50 0.04250 
P42225 Signal transducer and activator of transcription 
1 
9.88 8 0.92 1.34 1.03 1.00 1.12 0.19 0.81 0.44 0.45 0.57 0.21 0.51 0.02716 
Q8VCH6 Delta(24)-sterol reductase 6.01 4 1.18 1.53 1.79 2.09 1.80 0.28 1.45 0.76 0.54 0.92 0.47 0.51 0.04903 
P01029 Complement C4-B 26.24 36 1.01 1.19 1.06 1.31 1.18 0.12 0.61 0.77 0.44 0.61 0.17 0.51 0.00871 
Q64464 Cytochrome P450 3A13 14.12 9 0.99 0.50 0.58 0.82 0.63 0.17 0.24 0.41 0.32 0.32 0.08 0.51 0.04639 
P55050 Fatty acid-binding protein, intestinal 45.45 10 1.11 1.47 1.82 1.37 1.55 0.24 0.78 0.76 0.88 0.81 0.06 0.52 0.00617 
Q9D051 Pyruvate dehydrogenase E1 component 
subunit beta, mitochondrial 
36.21 19 2.40 2.25 2.05 2.33 2.21 0.14 0.87 1.31 1.27 1.15 0.24 0.52 0.00284 
Q00896 Alpha-1-antitrypsin 1-3 55.83 79 1.01 1.66 1.22 1.66 1.51 0.25 0.79 0.63 1.00 0.81 0.19 0.53 0.01706 
P97290 Plasma protease C1 inhibitor 13.89 5 0.77 1.02 0.89 1.18 1.03 0.15 0.70 0.55 0.39 0.55 0.15 0.53 0.01730 
Q9DBT9 Dimethylglycine dehydrogenase, 
mitochondrial 
63.18 98 1.64 1.58 1.66 1.43 1.56 0.12 0.80 0.63 1.07 0.83 0.22 0.53 0.00733 
Q8BWP5 Alpha-tocopherol transfer protein 54.32 21 0.95 0.95 1.21 1.26 1.14 0.17 0.77 0.72 0.41 0.63 0.20 0.55 0.02684 
Q9JIF0 Protein arginine N-methyltransferase 1 5.39 2 1.18 0.82 0.86 0.92 0.87 0.05 0.47 0.29 0.70 0.49 0.21 0.56 0.03763 
Q9Z1G3 V-type proton ATPase subunit C 1 11.26 3 1.39 0.97 1.01 1.27 1.08 0.16 0.60 0.47 0.76 0.61 0.14 0.56 0.01931 
Q7TNE1 Succinate--hydroxymethylglutarate CoA-
transferase 
18.35 7 1.12 1.07 1.03 0.85 0.98 0.12 0.29 0.69 0.68 0.55 0.22 0.56 0.04292 
Q01339 Beta-2-glycoprotein 1 20.58 6 1.77 2.40 1.71 2.38 2.16 0.39 1.26 0.98 1.42 1.22 0.22 0.56 0.02261 
Q9QZ73 DCN1-like protein 1 6.56 2 0.84 0.60 0.63 0.45 0.56 0.10 0.35 0.39 0.22 0.32 0.09 0.57 0.03396 
Q6PAM1 Alpha-taxilin 5.78 2 0.71 0.79 0.64 0.59 0.67 0.10 0.53 0.27 0.36 0.39 0.13 0.58 0.04322 
Q91VA0 Acyl-coenzyme A synthetase ACSM1, 
mitochondrial 
52.01 39 1.92 1.53 2.07 1.41 1.67 0.35 0.98 0.72 1.19 0.96 0.24 0.58 0.04570 
Q8JZQ2 AFG3-like protein 2 3.62 4 1.98 2.03 1.77 1.54 1.78 0.25 0.82 1.05 1.26 1.04 0.22 0.58 0.01783 
Q9DBG1 Sterol 26-hydroxylase, mitochondrial 47.84 39 1.29 1.41 1.77 1.12 1.43 0.33 1.00 0.71 0.80 0.84 0.15 0.59 0.04584 
Q99MN9 Propionyl-CoA carboxylase beta chain, 
mitochondrial 
56.38 36 1.47 1.24 1.18 0.86 1.09 0.20 0.75 0.65 0.54 0.65 0.11 0.59 0.02768 
Q01853 Transitional endoplasmic reticulum ATPase 68.49 110 1.42 1.41 1.77 1.98 1.72 0.29 1.15 0.87 1.05 1.02 0.14 0.60 0.01995 
P27612 Phospholipase A-2-activating protein 11.34 7 0.98 1.11 1.46 1.11 1.22 0.20 0.97 0.63 0.59 0.73 0.21 0.60 0.04321 
P70302 Stromal interaction molecule 1 7.88 4 1.07 1.16 1.26 1.14 1.19 0.06 0.76 0.53 0.83 0.71 0.16 0.60 0.00826 
P52633 Signal transducer and transcription activator 6 2.87 3 1.29 1.51 1.36 1.71 1.52 0.18 0.90 1.10 0.74 0.91 0.18 0.60 0.01345 
Q8K182 Complement component C8 alpha chain 12.10 7 0.64 1.00 1.53 1.49 1.34 0.29 0.93 0.78 0.72 0.81 0.11 0.60 0.04283 
Q9R112 Sulfide:quinone oxidoreductase, mitochondrial 49.56 23 1.18 1.12 1.46 1.11 1.23 0.20 0.95 0.72 0.58 0.75 0.19 0.61 0.04095 
Q8VC97 Beta-ureidopropionase 29.52 10 1.31 1.41 1.34 1.39 1.38 0.03 0.71 0.86 0.97 0.85 0.13 0.61 0.00245 
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Q9D0R2 Threonine--tRNA ligase, cytoplasmic 41.55 33 1.17 1.09 1.03 1.08 1.06 0.03 0.83 0.74 0.41 0.66 0.22 0.62 0.03474 
Q8CCJ3 E3 UFM1-protein ligase 1 18.92 12 0.67 0.81 0.90 1.00 0.90 0.10 0.67 0.65 0.38 0.56 0.16 0.62 0.03530 
P55302 Alpha-2-macroglobulin receptor-associated 
protein 
11.39 7 1.00 1.03 0.85 1.17 1.01 0.16 0.63 0.53 0.74 0.63 0.11 0.62 0.02715 
P70362 Ubiquitin fusion degradation protein 1 
homolog 
15.64 5 1.00 1.05 1.36 1.26 1.22 0.16 0.90 0.66 0.74 0.76 0.12 0.63 0.01626 
Q9QXT0 Protein canopy homolog 2 37.36 7 1.10 0.98 0.89 1.12 1.00 0.12 0.57 0.63 0.68 0.62 0.05 0.63 0.00736 
P58021 Transmembrane 9 superfamily member 2 11.33 6 1.11 1.25 1.10 1.56 1.30 0.23 0.79 0.67 1.02 0.83 0.18 0.64 0.04930 
P14576 Signal recognition particle 54 kDa protein 25.79 12 1.47 1.27 1.51 1.87 1.55 0.30 1.11 0.82 1.05 0.99 0.15 0.64 0.04533 
Q91X34 Bile acid-CoA:amino acid N-acyltransferase 47.14 38 1.19 1.37 1.47 1.13 1.32 0.18 0.89 0.82 0.92 0.87 0.05 0.66 0.01373 
Q9CQA5 Mediator of RNA polymerase II transcription 
subunit 4 
4.81 1 0.77 1.75 1.53 1.45 1.58 0.16 0.81 1.34 1.01 1.05 0.27 0.67 0.04480 
Q61183 Poly(A) polymerase alpha 3.25 2 1.02 1.04 1.00 1.09 1.04 0.04 0.74 0.63 0.73 0.70 0.06 0.67 0.00149 
Q8C1B7 Septin-11 7.66 3 1.39 1.42 1.20 1.57 1.40 0.19 1.08 0.72 1.04 0.94 0.20 0.68 0.04382 
Q91ZA3 Propionyl-CoA carboxylase alpha chain, 
mitochondrial 
35.50 36 1.16 1.14 1.15 0.98 1.09 0.09 0.75 0.72 0.74 0.74 0.01 0.68 0.00304 
Q9Z2I8 Succinyl-CoA ligase [GDP-forming] subunit 
beta, mitochondrial 
59.82 54 1.56 1.66 2.07 1.57 1.77 0.27 1.38 1.00 1.28 1.22 0.20 0.69 0.04641 
O55029 Coatomer subunit beta' 27.96 24 1.22 1.15 1.26 1.49 1.30 0.17 0.88 0.86 0.98 0.91 0.07 0.70 0.02127 
Q9D5T0 ATPase family AAA domain-containing protein 
1 
17.17 5 0.97 1.19 0.93 0.90 1.01 0.16 0.72 0.77 0.64 0.71 0.07 0.71 0.04449 
P54823 Probable ATP-dependent RNA helicase DDX6 28.16 10 1.07 1.17 1.05 1.25 1.15 0.10 0.85 0.78 0.83 0.82 0.04 0.71 0.00559 
Q9R1P0 Proteasome subunit alpha type-4 27.97 6 1.22 1.39 1.31 1.25 1.32 0.07 1.15 0.93 0.72 0.93 0.21 0.71 0.04203 
Q9ER72 Cysteine--tRNA ligase, cytoplasmic 19.25 12 0.96 1.06 1.36 1.26 1.22 0.15 0.74 0.88 0.99 0.87 0.12 0.71 0.03576 
P58281 Dynamin-like 120 kDa protein, mitochondrial 20.52 23 1.25 1.29 1.14 1.20 1.21 0.08 0.75 1.00 0.84 0.86 0.13 0.71 0.01541 
P48024 Eukaryotic translation initiation factor 1 63.72 12 1.09 0.86 0.95 0.95 0.92 0.05 0.62 0.72 0.64 0.66 0.06 0.72 0.00396 
Q9Z2W0 Aspartyl aminopeptidase 28.54 14 0.95 1.10 1.15 1.34 1.20 0.13 0.89 0.95 0.74 0.86 0.11 0.72 0.02532 
Q6P5E4 UDP-glucose:glycoprotein glucosyltransferase 
1 
18.96 19 1.08 1.08 1.06 1.22 1.12 0.09 0.72 0.77 0.92 0.80 0.10 0.72 0.01717 
Q8BGQ7 Alanine--tRNA ligase, cytoplasmic 45.45 44 1.49 1.42 1.69 1.67 1.59 0.15 1.13 0.98 1.33 1.15 0.18 0.72 0.02871 
O55060 Thiopurine S-methyltransferase 67.08 21 1.77 1.43 1.82 1.79 1.68 0.21 1.18 1.17 1.28 1.21 0.06 0.72 0.02215 
Q8BVE3 V-type proton ATPase subunit H 9.11 3 1.12 1.41 1.27 1.42 1.37 0.08 0.95 0.92 1.10 0.99 0.10 0.72 0.00651 
Q9Z2U1 Proteasome subunit alpha type-5 52.28 24 1.51 1.60 1.67 1.69 1.65 0.05 1.20 1.29 1.12 1.20 0.09 0.73 0.00152 
Q9D662 Protein transport protein Sec23B 20.08 16 2.23 2.17 2.38 2.83 2.46 0.34 1.82 1.75 1.80 1.79 0.03 0.73 0.02767 
Q8R0F9 SEC14-like protein 4 42.18 28 1.17 1.75 1.72 1.50 1.66 0.14 1.31 1.29 1.03 1.21 0.16 0.73 0.02062 
P70195 Proteasome subunit beta type-7 22.02 7 2.25 1.64 2.00 2.05 1.90 0.22 1.49 1.36 1.36 1.40 0.08 0.74 0.02080 
O08807 Peroxiredoxin-4 38.32 13 1.11 1.45 1.31 1.46 1.40 0.08 0.87 1.07 1.17 1.04 0.15 0.74 0.02141 
Q9EQ32 Phosphoinositide 3-kinase adapter protein 1 2.96 2 0.56 0.69 0.66 0.77 0.71 0.05 0.49 0.63 0.48 0.53 0.08 0.75 0.03637 
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P09055 Integrin beta-1 9.90 8 0.87 0.79 0.81 0.95 0.85 0.09 0.64 0.59 0.68 0.64 0.04 0.75 0.01995 
Q9EPU4 Cleavage and polyadenylation specificity factor 
subunit 1 
1.11 2 1.17 1.10 1.15 1.11 1.12 0.03 0.81 0.93 0.84 0.86 0.06 0.77 0.00279 
Q9D8V0 Minor histocompatibility antigen H13 8.47 4 1.08 1.20 1.01 1.21 1.14 0.11 0.88 0.90 0.86 0.88 0.02 0.77 0.01721 
Q80YQ8 Protein RMD5 homolog A 6.39 2 1.31 1.38 1.34 1.37 1.36 0.02 1.25 0.97 0.95 1.06 0.17 0.77 0.03353 
Q6P2B1 Transportin-3 3.79 3 0.97 0.95 1.04 0.95 0.98 0.05 0.77 0.72 0.79 0.76 0.04 0.78 0.00413 
Q99M96 Suppressor of tumorigenicity 7 protein 4.16 3 1.19 1.19 1.22 1.29 1.24 0.05 1.06 0.96 0.89 0.97 0.08 0.78 0.00976 
P32921 Tryptophan--tRNA ligase, cytoplasmic 7.07 3 0.79 0.82 0.78 0.81 0.80 0.02 0.67 0.65 0.58 0.63 0.05 0.79 0.00468 
Q8VHG0 Dimethylaniline monooxygenase [N-oxide-
forming] 4 
6.43 4 1.13 1.17 0.95 1.04 1.05 0.11 0.86 0.86 0.78 0.83 0.04 0.79 0.03348 
Q9Z0J0 Epididymal secretory protein E1 6.04 1 1.33 1.46 1.27 1.43 1.39 0.10 1.16 1.04 1.10 1.10 0.06 0.79 0.01336 
Q9D2R6 Cytochrome c oxidase assembly factor 3 
homolog, mitochondrial 
9.26 1 0.88 1.33 1.31 1.20 1.28 0.07 1.01 1.08 0.98 1.02 0.05 0.80 0.00601 
Q4U4S6 Xin actin-binding repeat-containing protein 2 1.08 8 0.83 0.95 0.98 0.98 0.97 0.02 0.73 0.82 0.77 0.78 0.05 0.80 0.00273 
Q9JM93 ADP-ribosylation factor-like protein 6-
interacting protein 4 
8.73 1 0.63 0.79 0.86 0.90 0.85 0.05 0.65 0.72 0.70 0.69 0.04 0.81 0.01208 
O54833 Casein kinase II subunit alpha' 7.14 3 1.01 1.14 1.18 1.14 1.15 0.02 0.89 0.87 1.09 0.95 0.12 0.82 0.04502 
Q8R121 Protein Z-dependent protease inhibitor 9.82 3 0.99 1.26 1.18 1.29 1.24 0.06 1.04 1.06 1.00 1.03 0.03 0.83 0.00477 
B2RY56 RNA-binding protein 25 6.80 4 0.96 0.96 0.90 1.04 0.97 0.07 0.89 0.74 0.79 0.81 0.08 0.83 0.04985 
P35922 Fragile X mental retardation protein 1 
homolog 
3.26 2 1.03 1.13 1.12 1.02 1.09 0.06 0.86 1.00 0.89 0.91 0.08 0.84 0.03618 
Q8CC86 Nicotinate phosphoribosyltransferase 47.21 22 1.32 1.10 1.09 0.93 1.04 0.09 0.87 0.86 0.90 0.87 0.02 0.84 0.04213 
Q9ES74 Serine/threonine-protein kinase Nek7 8.28 3 0.92 0.98 1.11 1.11 1.06 0.07 0.97 0.82 0.90 0.90 0.07 0.84 0.04866 
O35744 Chitinase-like protein 3 3.77 1 0.48 0.59 0.53 0.61 0.58 0.04 0.49 0.49 0.49 0.49 0.00 0.84 0.02259 
P63085 Mitogen-activated protein kinase 1 22.07 5 0.97 1.10 1.11 1.03 1.08 0.04 0.93 0.85 0.99 0.92 0.07 0.86 0.03294 
P16301 Phosphatidylcholine-sterol acyltransferase 3.20 1 0.96 0.96 0.94 0.95 0.95 0.01 0.84 0.79 0.84 0.82 0.03 0.87 0.00264 
Q8VCR2 17-beta-hydroxysteroid dehydrogenase 13 60.86 24 1.03 1.06 1.05 1.11 1.07 0.03 0.92 0.92 0.99 0.94 0.04 0.88 0.01334 
P48760 Folylpolyglutamate synthase, mitochondrial 4.94 2 1.13 1.34 1.24 1.25 1.28 0.06 1.16 1.17 1.10 1.14 0.04 0.90 0.03054 
Q8C7X2 ER membrane protein complex subunit 1 15.35 12 0.94 1.00 0.95 1.01 0.99 0.03 0.86 0.93 0.86 0.88 0.04 0.90 0.02822 
P24547 Inosine-5'-monophosphate dehydrogenase 2 18.29 8 1.01 1.08 1.10 1.11 1.09 0.02 0.96 1.01 0.97 0.98 0.02 0.90 0.00251 
Q60749 KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 
6.55 2 1.08 1.05 1.07 1.00 1.04 0.03 0.95 0.97 0.90 0.94 0.04 0.91 0.03412 
Q9CY62 E3 ubiquitin-protein ligase RNF181 4.85 1 0.91 0.86 0.80 0.82 0.83 0.03 0.74 0.77 0.75 0.75 0.01 0.91 0.01184 
O54984 ATPase Asna1 14.08 4 0.98 1.06 1.06 1.04 1.05 0.01 0.99 0.94 0.95 0.96 0.03 0.92 0.00623 
Q61702 Inter-alpha-trypsin inhibitor heavy chain H1 9.70 5 0.91 1.08 1.03 1.06 1.05 0.02 0.91 0.98 1.00 0.96 0.05 0.92 0.04216 
Q9QYC7 Vitamin K-dependent gamma-carboxylase 10.57 6 0.96 1.03 1.11 1.04 1.06 0.04 1.00 0.96 0.97 0.98 0.02 0.93 0.04400 
P12367 cAMP-dependent protein kinase type II-alpha 
regulatory subunit 
31.92 10 1.04 1.08 1.06 1.12 1.08 0.03 1.01 1.02 1.00 1.01 0.01 0.93 0.01598 
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Q9JIG7 Coiled-coil domain-containing protein 22 13.88 5 0.89 0.93 0.91 0.93 0.92 0.01 0.87 0.85 0.88 0.87 0.02 0.94 0.00656 
P46735 Unconventional myosin-Ib 22.94 25 1.04 1.05 1.02 1.07 1.04 0.02 0.99 1.00 1.00 1.00 0.01 0.95 0.02980 
Q6PD26 GPI transamidase component PIG-S 10.09 4 0.97 0.93 0.95 0.91 0.93 0.02 0.90 0.88 0.88 0.89 0.01 0.95 0.03116 
 
Table 4.4 – The 125 proteins with significantly lower expression in the livers of BALB/c mice following chronic dosing with brusatol in comparison to the vehicle-treated 
controls. All values are expressed relative to a common pooled sample included in duplicate on the iTRAQ run. An unpaired t-test was utilised to compare between 
treatment groups. Proteins are listed according to their expression in brusatol-treated mice relative to control animals in ascending order of the fold-change value. (Acc. 
= accession, Avg. = average, C = control, Bru = brusatol). 
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4.3.4 Pathway analysis of iTRAQ data 
Ingenuity core pathway analysis of proteins with significantly different expression in the 
livers of mice following administration of brusatol identified the Nrf2-mediated Oxidative 
Stress Response pathway in the top 40 most likely pathways to be associated with brusatol 
therapy (Table 4.5, p=0.002, Ingenuity Analysis). It is important to note that many of the 
pathways more significantly associated with brusatol therapy are linked to drug 
metabolism and detoxification (e.g. Xenobiotic Metabolism Signaling) or oxidative stress 
response (e.g. Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 
pathway), and therefore may be involved in the metabolism of the compound itself, or 
modified by the Nrf2 pathway. Additionally, many of the pathways, including those linked 
to lipid metabolism, have been associated with the Nrf2 pathway in the published 
literature as discussed in the conclusion to this chapter. The 40 most significantly altered 
pathways are displayed in table 4.5. 
Ingenuity Canonical Pathways p value Ratio Molecules 
FXR/RXR Activation 0.00000004   2/21 C4A/C4B, BAAT, APOE, APOB, APOH, 
LCAT, CYP27A1, VTN, FBP1, SERPINA1, 
GC, CLU 
Xenobiotic Metabolism Signaling 0.00000044   1/18 CYP3A7, ALDH1B1, MAPK1, PPP2CA, 
GSTA5, FMO5, ESD, GSTT2/GSTT2B, FTL, 
ALDH1A1, PPP2R4, HSP90AA1, PPP2R5E, 
FMO4, MGST3, CYP2C8 
LPS/IL-1 Mediated Inhibition of RXR 
Function 
0.00000309   1/17 GSTT2/GSTT2B, ALDH1B1, APOE, 
CYP3A7, FABP2, ACSBG1, ALDH1A1, 
GSTA5, FMO5, FMO4, HMGCS1, MGST3, 
CYP2C8 
Glycolysis I 0.00001072   1/5  PGK1, ALDOB, TPI1, PGAM1, FBP1 
LXR/RXR Activation 0.00001660   7/94 C4A/C4B, APOE, APOB, APOH, LCAT, 
VTN, SERPINA1, GC, CLU 
Superpathway of Methionine 
Degradation 
0.00003236  
14/87 
PCCA, PCCB, SUOX, PRMT1, AHCY 
Nicotine Degradation II 0.00011220   2/21 CYP3A7, UGT2A3, INMT, FMO5, FMO4, 
CYP2C8 
PI3K/AKT Signaling 0.00013490   2/31 ITGB1, CDC37, MAPK1, PPP2CA, PPP2R4, 
HSP90AA1, PPP2R5E, GYS2 
Sucrose Degradation V (Mammalian) 0.00013804   1/3  ALDOB, TPI1, TKFC 
Gluconeogenesis I 0.00021380   4/25 PGK1, ALDOB, PGAM1, FBP1 
Purine Nucleotides De Novo 
Biosynthesis II 
0.00026915   3/11 ADSS, ADSSL1, IMPDH2 
Superpathway of Cholesterol 
Biosynthesis 
0.00033884   1/7  DHCR24, IDI1, ACAT1, HMGCS1 
Mevalonate Pathway I 0.00045709   3/13 IDI1, ACAT1, HMGCS1 
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Production of Nitric Oxide and 
Reactive Oxygen Species in 
Macrophages 
0.00058884   2/43 APOE, APOB, MAPK1, PPP2CA, PPP2R4, 
SERPINA1, PPP2R5E, STAT1, CLU 
α-Adrenergic Signaling 0.00066069   2/29 MAPK1, PRKAR2A, PYGB, PYGL, ITPR1, 
GYS2 
Clathrin-mediated Endocytosis 
Signaling 
0.00067608   1/22 ITGB1, APOE, CSNK2A2, APOB, GAK, 
TFRC, SERPINA1, LDLRAP1, CLU 
Cell Cycle Regulation by BTG Family 
Proteins 
0.00081283   9/79 PPP2CA, PPP2R4, PPP2R5E, PRMT1 
Methylmalonyl Pathway 0.00085114   1/2  PCCA, PCCB 
Superpathway of 
Geranylgeranyldiphosphate 
Biosynthesis I (via Mevalonate) 
0.00104713   3/17 IDI1, ACAT1, HMGCS1 
PXR/RXR Activation 0.00112202   1/13 CYP3A7, ALDH1A1, CES3, PRKAR2A, 
CYP2C8 
tRNA Charging 0.00123027   7/68 CARS, WARS, TARS, AARS 
CDK5 Signaling 0.00128825   2/33 ITGB1, MAPK1, PPP2CA, PPP2R4, 
PRKAR2A, PPP2R5E 
2-oxobutanoate Degradation I 0.00141254   2/5  PCCA, PCCB 
Glutathione Redox Reactions I 0.00147911   3/19 GSTT2/GSTT2B, GPX1, MGST3 
Aryl Hydrocarbon Receptor Signaling 0.00158489   1/20 GSTT2/GSTT2B, ALDH1B1, ALDH1A1, 
MAPK1, GSTA5, HSP90AA1, MGST3 
Tryptophan Degradation III 
(Eukaryotic) 
0.00199526   1/7  AFMID, TDO2, ACAT1 
IL-12 Signaling and Production in 
Macrophages 
0.00204174   1/21 STAT6, APOE, APOB, MAPK1, SERPINA1, 
STAT1, CLU 
Urea Cycle 0.00208930   1/3  OTC, CPS1 
NRF2-mediated Oxidative Stress 
Response 
0.00245471   1/24 GSTT2/GSTT2B, FTL, MAPK1, GSTA5, 
VCP, DNAJA3, CBR1, MGST3 
Tryptophan Degradation to 2-amino-
3-carboxymuconate Semialdehyde 
0.00389045   1/4  AFMID, TDO2 
Protein Ubiquitination Pathway 0.00398107   3/85 PSMB7, PSME1, UBE2B, USP4, HSPE1, 
HSPA9, PSMA5, PSMA4, HSP90AA1 
Acute Phase Response Signaling 0.00457088   1/24 C4A/C4B, SERPING1, FTL, RIPK1, APOH, 
MAPK1, SERPINA1 
Glutathione-mediated Detoxification 0.00501187   7/68 GSTT2/GSTT2B, GSTA5, MGST3 
Ketogenesis 0.00616595   1/5  ACAT1, HMGCS1 
Melatonin Degradation I 0.00676083   2/31 CYP3A7, UGT2A3, Sult1a1, CYP2C8 
Glycogen Degradation II 0.00741310   2/11 PYGB, PYGL 
AMPK Signaling 0.00831764   1/27 MAPK1, PPP2CA, PPP2R4, PRKAA2, 
PRKAR2A, PPP2R5E, GYS2 
Mitotic Roles of Polo-Like Kinase 0.00831764   2/33 PPP2CA, PPP2R4, HSP90AA1, PPP2R5E 
Dopamine Degradation 0.00851138   3/35 ALDH1B1, ALDH1A1, Sult1a1 
Synaptic Long Term Depression 0.00870964   3/73 LCAT, MAPK1, PPP2CA, PPP2R4, ITPR1, 
PPP2R5E 
Table 4.5 – Pathway analysis for proteins both upregulated and downregulated in the in the livers 
of BALB/c mice following chronic dosing with brusatol. The ratio identifies the number of focus 
molecules identified (numerator) in the pathway (denominator). 
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4.3.5 TLDA analysis of Nrf2 related gene expression 
In order to determine the effects of brusatol on the gene expression of Nrf2 and 
downstream effectors, cDNA reverse transcribed from RNA extracted from the livers (N=6) 
of brusatol-treated and saline control BALB/c mice was amplified by real-time PCR using 
the TLDA cards. A common pooled sample was run on each plate, with gene expression of 
all other samples expressed relative to the pool and normalised to expression of the 18s 
house-keeper gene. 
Mean relative gene expression was calculated and compared between animals form the 
two treatment arms. Two genes (Slc22a12 and Txn1) were excluded from the analysis due 
to incomplete data sets, with gene expression only available for less than three out of the 
six samples.  
There was a generalised decrease in gene expression across the panel of Nrf2-regulated 
genes, as shown in figure 4.5. 35 of the 44 Nrf2-dependent genes analysed in the excised 
murine liver tissue demonstrated a numerical decrease in expression, although none of 
these achieved statistical significance, possibly due to the low number of replicates and the 
variability in gene expression noted in both the treatment and control groups. mRNA 
expression of Nrf2 was slightly increased in mice treated with brusatol, indicating that the 
inhibition of Nrf2 by brusatol occurs at the post-transcriptional level. The levels of Keap1 
mRNA were unchanged by brusatol treatment. In relation to the metabolism of irinotecan, 
Ces1g and Ces2g gene expression was decreased in the livers of mice dosed with brusatol, 
which could affect conversion to SN-38 if this is reflected at the protein level. Ugt1a1 
expression was very similar in treatment arms, suggesting the glucuronidation of SN-38 
may not be affected by brusatol, and that co-administration with irinotecan may not alter 
the safety profile of the chemotherapeutic. 
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Figure 4.5 - Relative levels of mRNA expression in livers of control and brusatol-treated BALB/c mice as detected by Microfluidic TaqMan low density array analysis. 
Decreased mRNA expression was noted in 35 of the 45 Nrf2 related genes measured. (Bar chart displays mean +/- SEM)
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4.4 Discussion 
The inhibition of Nrf2 in murine liver and colon by brusatol, as demonstrated in this 
chapter, has not previously been documented by western immunoblotting in the published 
literature, with studies to date focusing on the effects of brusatol in tumour tissue and cell 
lines. Verifying the profound inhibition of Nrf2 by brusatol in murine liver allowed 
proteomic analysis, with confidence that the dose of brusatol utilised was effective. The 
inhibition of a number of Nf2-related downstream effector genes, although not reaching 
significance, also allowed reassurance that the pathway was being inhibited by brusatol. 
Interestingly, Nrf2 was not inhibited at the mRNA level by brusatol, reinforcing the belief 
that brusatol inhibits Nrf2 at the post-transcriptional level [294, 436].  
The Ingenuity core pathway analysis of iTRAQ data identified a number of pathways 
associated with lipid and drug metabolism and cellular stress response. The Farnesoid X 
receptor (FXR) / retinoid X receptor (RXR) pathway, identified as most likely to be 
associated with brusatol therapy, is linked to the control of lipid, fatty acid and bile acid 
metabolism. Chen et al. recently demonstrated that induction of Nrf2 by oleanolic acid in 
mice acted as a direct antagonist to FXR, reducing bile acid production, highlighting a 
possible association between the Nrf2 and FXR pathways [448]. Further evidence of a link 
between Nrf2 and lipid metabolism has been demonstrated in the proteomic data from 
two animal studies. These noted that many of the differentially regulated proteins in either 
Nrf2 knockout mice, compared with their wild type counterparts, or following Nrf2 
induction in wild type mice were associated with lipid metabolism [278, 279]. It is therefore 
feasible that the FXR / RXR pathway acts as the link between the Nrf2 pathway and the 
control of lipid metabolism. The link between lipid metabolism and brusatol therapy 
continues throughout the pathway analysis, both the Superpathway of Cholesterol 
Biosynthesis [449] and the AMPK Signaling pathways [450] are associated with lipid 
metabolism. Interestingly, the RXR nuclear receptor featured in the FXR / RXR pathway also 
acts as a key link in four of the forty pathways included in this analysis, and is reportedly 
required for the activation of many phase II metabolising enzymes [451].  
 Drug metabolising and detoxification protein families feature repeatedly in the pathway 
analysis of the iTRAQ data. The phase-I drug metabolising cytochrome P450s CYP27A1, 
CYP3A7 and CYP2C8 are included in seven of the top forty pathways associated with 
brusatol therapy, while the glutathione S-transferases (GSTs), a major group of detoxifying 
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enzymes, GSTT2 and GSTA5 are involved in six of the top forty pathways. The Glutathione 
Redox Reactions I and Glutathione-mediated Detoxification pathways both feature in the 
pathway analysis. Previously published proteomic data from murine liver tissue 
demonstrated that the proteins found to be down-regulated in Nrf2 knockout mice were 
predominantly phase-II drug metabolising enzymes, or those involved in the glutathione 
system [279]. More recently Lin et al. demonstrated that Nrf2 was required for the 
upregulation of GSTs in rat primary hepatocytes [452], again highlighting a link between 
Nrf2 and many of the pathways associated with brusatol administration.  
The mitogen-activated protein kinase (MAPK) family are involved in directing cellular 
responses to an array of stimuli, including mitogens, oxidative stress, osmotic stress, heat 
shock and proinflammatory cytokines, through the regulation of cell adhesion, cell cycle 
progression, cell migration, cell survival, differentiation, metabolism, proliferation and 
transcription [453]. MAPK1, also known as Extracellular signal Regulated Kinase 2 (ERK2), 
appears in eleven of the forty brusatol associated pathways. Studies have linked the 
control of Nrf2 to the ERK and PI3K (also significantly altered in the pathway analysis) 
signaling cascades [454]; in human glioblastoma cells inhibition of ERK and PI3K suppressed 
the nuclear accumulation of Nrf2 and decreased cellular expression of the protein [455]. 
These findings were replicated by Choi et al., who demonstrated that ERK2 inhibitors 
prevented phosphorylation of Nrf2, reducing its protective effect in HepG2 cells and in the 
murine liver in vivo [456]. 
There are some limitations to the data presented in this chapter. Firstly, the brusatol 
dosing study in mice was not designed to allow the assessment of this compound on the 
liver proteome, but rather as a study of the effects of brusatol on CRC burden. As a result, a 
dosing time-course study was not completed to assess when the maximum inhibition of 
Nrf2 and its downstream effector proteins was achieved after administration. However, the 
multiple dosing regimens the mice received over a period of two weeks should have 
allowed alteration of downstream proteins, despite the transient nature of Nrf2 inhibition 
by brusatol noted in vitro. Secondly, the mice included in the study had undergone the 
caecal implantation of tumour cells and had varying degrees of disease burden at the time 
of cull. This variation in disease burden, and therefore the health status of each mouse, 
could also be reflected at the genetic and proteomic level in murine liver tissue. This could 
perhaps explain the relatively large variations noted between individual mice in both the 
control and brusatol-treated groups, preventing the mRNA data from reaching statistical 
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significance. Thirdly, the proteomic data and pathway analysis may have picked up changes 
not related to the effects of brusatol but due to metabolism of the drug itself. It is 
therefore possible that a number of the significantly altered proteins and pathways are 
involved in the metabolism and excretion of brusatol, rather than the direct result of Nrf2 
inhibition. 
Although many of the pathways presented in the analysis of proteomic data may be linked 
to Nrf2 directly or indirectly, through cellular stress response signalling and drug 
metabolism molecules and pathways, the limitations discussed above and the small 
numbers of mice included in the study mean it is not possible to state definitively that 
brusatol is a specific Nrf2 inhibitor in vivo. However, the relatively subtle changes in protein 
expression noted in the murine liver following the repeated administration of brusatol, 
perhaps as a result of its transient effect on Nrf2, hint at its potential safety and help to 
explain why it is perceived to be so well tolerated in the animal studies presented in this 
thesis and the published literature[294]. 
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Chapter 5 – Concluding discussion 
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5.1 Summary of aims and major findings 
The neoadjuvant and adjuvant treatment of CRC with chemotherapy currently relies on 
standardised regimens based on data from clinical trials, without taking into account the 
tumour biology or metabolic profile of each individual patient; the only exception to this 
being the use of KRAS in predicting response to EGFR inhibitors. Response to standard 
therapy can vary substantially, with a number of patients experiencing potentially life-
threatening complications and side effects yet deriving no clinical benefit due to tumour 
resistance. The identification of biomarkers, in the tumour or normal tissue, capable of 
predicting or modifying the response to therapy could revolutionise the use of 
chemotherapy in the management of CRC. 
Irinotecan is a pro-drug converted to the activate metabolite SN-38, which acts as a 
topoisomerase I inhibitor, preventing cell division and replication. Its metabolism is 
complex, relying on the CESs, predominantly in the liver and tumour, for conversion to SN-
38, UGT1A1 for glucuronidation to SN-38G and the ABC transporters for excretion into bile. 
Nrf2 is a transcription factor bound to the regulatory protein Keap1 in the quiescent state. 
Under conditions of cellular stress, Keap1 is no longer able to target Nrf2 for degradation 
and it accumulates in the nucleus, where it binds to the ARE in a range of genes, thus 
activating their expression. The expression of the CES [277, 278], UGT1A1 [280] and the 
ABC transporters [283] have all been demonstrated to be regulated either basally or in an 
inducible manner by Nrf2. Nrf2 is also responsible for the activation of cell survival 
pathways and proteins such as NQO1 and HO-1, which confer protection against ROS 
induced DNA damage and apoptosis. These effects of Nrf2 activation have been noted to 
be exploited by malignant tissue to confer a survival advantage and resistance to 
chemotherapy, as discussed in chapter 1. 
Given the multiple roles of Nrf2, this transcription factor has the potential to act as a 
predictive or therapeutic biomarker, particularly in relation to irinotecan-based therapy, 
and the effects of Nrf2 modulation in this context are difficult to predict. 
The overall aim of this thesis was to develop a murine model of CRC capable of testing the 
hypothesis that Nrf2 modulation could alter the efficacy of irinotecan chemotherapy. In 
vivo testing is essential when investigating the effects of potential modulators of irinotecan 
efficacy. A complete system is required due to the complex interaction between normal 
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tissue, such as the liver, and the tumour in the activation and excretion of the pro-drug. 
Although Nrf2 inhibition may be beneficial in tumour tissue, where it may reduce the 
activity of cell defence mechanisms, it may inhibit SN-38 production in the liver and 
subsequently drug efficacy.  
Chapter 2 describes the development of a syngeneic orthotopic murine model of CRC, 
required for testing the effects of Nrf2 modulation on irinotecan efficacy in vivo. 
Luminescent populations of cells were developed by transfection with plasmids containing 
luciferase DNA. Clonal selection and expansion was carried out from a single luminescent 
cell and this clone implanted, initially in the flank of an immune-competent mouse, before 
caecal injection and assessment of disease burden by BLI. 
This model had several distinct advantages, including: the rapid development of primary 
tumours, allowing high throughput assessment of potential therapies; the growth of 
tumours in the correct microenvironment, ensuring drug delivery was possible to the 
required site; the potential to develop liver metastases, accurately replicating the disease 
process in humans; and the use of BLI for the longitudinal assessment of disease burden, 
allowing continual monitoring of tumour progression in the same animal and reducing the 
number of animals required in experiments. Additionally, the use of immune-competent 
animals significantly reduced costs and would allow the testing of immune-therapies if 
required. Unfortunately, attempts to develop an immune-deficient model were 
unsuccessful, as was the implantation of more luminescent clones, reliant on a different 
vector for expression of luciferase, in the syngeneic model.  
In chapter 3 the murine model was applied to the in vivo assessment of data generated in a 
human and murine CRC cell line. Significantly higher expression of Nrf2 was demonstrated 
by IHC in sections from primary tumours and liver metastases in comparison to normal 
colon taken from patients, suggesting a benefit to overexpression of Nrf2 in cancer. In vitro 
findings consistently demonstrated reduced CRC cellular proliferation and viability in 
response to Nrf2 inhibition using siRNA or the pharmacological inhibitor brusatol. The 
cytotoxicity of irinotecan was also enhanced, as evidenced by a decrease in IC50 values, 
following genetic or pharmacological inhibition of Nrf2. When irinotecan was combined 
with brusatol, drug synergy was achieved across a number of concentration combinations. 
Translation of these findings into the murine model again demonstrated a significant 
reduction in tumour growth, as assessed by BLI, following treatment with the Nrf2 inhibitor 
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brusatol. The degree of synergy noted when combining irinotecan and brusatol in vitro was 
perhaps not replicated in vivo, although a trend towards increased efficacy was noted with 
combination therapy. It is possible that statistical significance for the combination of 
brusatol with irinotecan may not have been reached due to the effectiveness of each 
treatment in isolation. However, the data generated in this chapter consistently 
demonstrate that brusatol acts as a potent anti-tumorigenic agent, capable of significantly 
inhibiting Nrf2 in malignant cells or tumour tissue both in vitro and in vivo. 
In an attempt to explore the specificity of brusatol as an Nrf2 inhibitor, investigate its 
safety profile and improve understanding of its mechanism of action, the work described in 
chapter 4 utilised liver tissue excised from mice chronically exposed to the compound over 
two weeks to investigate protein and mRNA expression in comparison with mice receiving 
a vehicle control; this is the first study to investigate this. The ability of brusatol to inhibit 
Nrf2 in normal liver and colon was first demonstrated by western immunoblotting before 
iTRAQ proteomic analysis was conducted on the liver tissue. Although multiple pathways 
were significantly altered in the livers of mice administered brusatol, many of these could 
be linked to the Nrf2 pathway or were involved in drug metabolism. The data in this 
chapter does have to be regarded with a degree of caution given the relatively small 
number of animals included in the proteomic assessment and the varying degrees of 
tumour burden the mice had a cull. Although all macroscopic disease was excluded from 
the analysis, mice with advanced disease or bowel obstruction may have an altered protein 
profile due to their disease state.  
Nrf2 mRNA expression did not decrease in liver tissue taken from mice following treatment 
with brusatol, a non-significant increase was noted, agreeing with findings in the published 
literature demonstrating that brusatol works at a post-transcriptional level [294, 436]. The 
slight increase in Nrf2 mRNA is likely to be in compensation to the decrease in the Nrf2 
noted at the protein level.   
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5.2 Advances in the animal modelling of CRC 
Many of the recent publications surrounding each topic covered in this thesis are included 
in the discussion sections of each chapter. However, some notable advances have been 
made in the murine modelling of CRC for the investigation of potential chemotherapeutic 
agents.  
Significant advances have been made in small animal endoscopy with a recent publication 
describing the development of metastatic CRC in mice using a minimally invasive 
endoscopic technique to inject tumour cells into the colonic submucosa. Interestingly, this 
technique failed to induce tumours in CD-1 nude mice but had a high uptake rate in SCID 
mice (5 out of 6 mice), with many developing liver metastases [457]. This technique is less 
invasive than surgical orthotopic implantation and could have reduced the stress response 
in mice following laparotomy and surgical implantation. However, specialist equipment and 
expertise is required, further increasing costs and training time. Selective portal vein 
injection of CRC tumour cells has also been used to generate syngeneic murine models of 
CRC liver metastases. This technique relies on portal vein injection with selective clamping 
of liver lobes to induce liver metastases in the required liver segment. This method could 
have removed the need for primary tumour pre-growth, reduced the incidence of extra-
hepatic metastases and prolonged the survival time in untreated mice due to complications 
from the primary tumour, while still allowing investigation of the effects of therapies on 
liver localised disease. However, the lack of a primary colonic tumour reduces the accuracy 
of the model in replicating the disease process in humans [412]. 
BLI imaging was recently validated in comparison to MRI for the imaging of CRC liver 
metastases in mice. A strong positive correlation between disease burden, as assessed by 
MRI, and luminescent signal was noted, supporting the use of BLI in pre-clinical studies. 
They did however note that BLI may overestimate tumour growth rates at earlier imaging 
points and smaller variations in tumour growth may not be detected, making it more 
difficult to reach significance between treatments arms, as noted in the data presented in 
this thesis. Significant variations in tumour doubling time were also noted between 
untreated animals, far greater than noted with traditional ectopic models, which is again in 
concordance with the data presented in this thesis [458]. 
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5.3 The role of Nrf2 in CRC 
Data continues to be published examining the role of Nrf2 in CRC. Po-Lin et al. recently 
demonstrated that in 160 patients with CRC, cytoplasmic overexpression of Nrf2 was 
associated with poor overall survival. Nrf2 knockdown, using a short-hairpin RNA, was 
subsequently found to decrease CRC cell invasion and growth, with the opposite being true 
for Nrf2 induction. The mechanism for the decreased invasive potential following Nrf2 
inhibition was believed to be via activation of PSMD4, a proteasomal gene overexpressed 
on induction of Nrf2, which in turn activated β-catenin and promoted cellular invasion. 
These findings were verified in vivo in a model of CRC lung metastases, with no tumours 
developing in mice injected with the Nrf2 knockout cell line [459]. This highlighted the 
potential for Nrf2 to act as a prognostic biomarker, with increased expression of the 
protein associated with an aggressive tumour type. 
Zhao et al. attempted to establish a link between Nrf2 expression and resistance to 5-FU. 
They found increased Nrf2 and HO-1 expression in CRC cells with induced resistance to 5-
FU in comparison to the parent cell line. Bisulphate DNA sequencing of the Nrf2 promoter 
region revealed significant demethylation in 5-FU resistant cells compared with the parent 
population [460]. This study highlighted the role of Nrf2 in chemoresistance and its ability 
to act as a predictive biomarker, with increased expression resulting from promotor 
demethylation leading to drug resistance.  
In contrast, Yokoo et al. sought to define the role of Nrf2 in the chemoprevention of CRC. 
This study explored the risk of developing neoplastic small bowel lesions in Nrf2 knockout 
mice, in comparison to their wild type counterparts, following exposure to the carcinogen 
potassium bromate. A significant increase in the number of pre-neoplastic and neoplastic 
lesions was noted in the Nrf2 knockout mice [461]. 
The role of Nrf2 in the development and treatment of CRC is yet to be fully appreciated. 
The data presented in this thesis is the first time Nrf2 inhibition has been explored in 
relation to the cytotoxicity of irinotecan and utilising the Nrf2 inhibitor brusatol in the 
treatment of CRC, both in vitro and in a complex murine model of CRC. 
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5.4 Advances in irinotecan therapy 
No major changes have been made to the treatment of patients with irinotecan since the 
commencement of the work reported in this thesis, however the possibility of direct 
delivery of SN-38 has been explored in pre-clinical experiments. Preliminary data 
comparing the cytotoxicity of SN-38 loaded into three different nanoparticle formulations 
on CRC cell lines was undertaken during the research time for this thesis (data not shown) 
in conjunction with the Chemistry Department at the University of Liverpool. These data 
have been included in a successful grant application to Cancer Research UK to explore the 
possibility of nano-particle delivery of SN-38 further. Funding was obtained for three PhD 
students and two post-doctoral researchers across the Departments of Pharmacology and 
Chemistry at the University. Using co-nanoprecipitation of branched hydrophobic 
Copolymers and A–B amphiphilic block copolymers rapid formation of sterically stabilised 
nanoparticles in aqueous medium was possible. These were capable of encapsulating SN-
38 in the hydrophobic core of the nanoparticle, while the outer hydrophilic copolymers 
improved solubility [462]. Cytotoxicity of SN-38 encapsulated in nanoparticles was not 
significantly different to SN-38 dissolved in DMSO in the CT26 and HCT116 cell lines and 
provided a more sustained release of the drug in vivo as assessed by LC-MS. 
These findings are similar to those seen in a number of recent publications investigating 
the use of nanoparticles for the direct delivery of SN-38. Mosallaei et al. demonstrated 
significant cytotoxicity in the CT26 and HCT116 CRC cell lines using SN-38 encapsulated in 
solid lipid nanoparticles and PEGylated solid lipid nanoparticles in vitro. The ability of the 
SN-38 loaded nano-particles to inhibit tumour growth in vivo was also explored in a 
syngeneic flank injection model using the CT26 cell line. Tumour growth was significantly 
inhibited by the SN-38 nanoparticles formulations when compared with irinotecan 
dissolved in 5% dextrose [463]. This study demonstrated not only the efficacy of nano-
particle delivery of SN-38 but also its safety in the pre-clinical setting. 
Similar findings were reported by Essa et al. with SN-38 encapsulated in poly(D,L-lactide-co-
glycolide) nanoparticles enhancing solubility, stability and cellular uptake of the drug. 
Nanoparticles were also able to protect the active lactone ring of SN-38 against inactivation 
under physiological conditions, with significant cytotoxicity demonstrated against the 
COLO-205 CRC cell line [464]. 
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Nanoparticle drug delivery offers the potential to improve drug pharmacokinetics, by 
allowing a sustained release, rapid increases in the serum and tissue concentrations of 
drugs can be avoided, which may reduce toxicity and improve efficacy. Specifically in the 
context of SN-38 delivery, nanoparticles avoid the problems associated with variable 
conversion of irinotecan to SN-38 by the CES and allow the drug to be delivered in a 
pharmacologically acceptable solution. Their use warrants further investigation. 
5.5 Advances in the understanding of brusatol 
It is clear from the recent increase in the number of publications examining the 
pharmacokinetics, method of action and cytotoxicity of brusatol that interest in the 
compound is increasing. Many of the recently published studies have already been 
discussed but recent attempts have been made to understand the pharmacokinetics of 
brusatol. Zhang et al. developed an ultra-performance liquid chromatography tandem 
mass-spectrometry technique capable of quantifying brusatol in rat plasma with high 
accuracy at concentrations down to 1ng/ml. They demonstrated rapid clearance of brusatol 
in rat plasma in the first two hours, with half the drug cleared within an hour after i.v. 
dosing at three different concentrations up to 2mg/kg rat bodyweight [465]. The rapid 
excretion of brusatol may contribute to its apparent safety in murine studies, with rapid 
clearance preventing accumulation and toxicity, despite the profound effects on tumour 
growth. 
The debate over the specificity of brusatol as an Nrf2 inhibitor, and not a global inhibitor of 
short half-life proteins, in relation to the paper by Vartanian et al., has been discussed 
[435]. A recent publication by Chio et al. may offer a possible explanation for the inhibition 
of a number of short half-life proteins noted by Vartanian. Chio demonstrated that in 
pancreatic cancer tumour organoids, Nrf2 regulated the activity of the translational 
machinery, with Nrf2 deficiency impairing protein synthesis. The mechanism for this was 
postulated to be through impaired redox homeostasis, with Nrf2 exercising redox-
dependent control over multiple aspects of the translational machinery. Global cysteine 
proteomics, using a selectively cleavable cysteine-reactive reagent followed by iTRAQ 
analysis of pancreatic tumour organoids, revealed that Nrf2 depletion induced cysteine 
oxidation of components of the translational machinery. The functional role of Nrf2 in 
mRNA translation was then examined in pancreatic cancer cells, demonstrating that 
deletion of Nrf2 led to a measurable decrease in polysomes, with a corresponding increase 
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in monosomes, suggesting a decrease in translation efficiency in cancer cells when Nrf2 is 
absent. The authors also noted that Nrf2 knockdown by shRNA adversely affected tumour 
organoid development, with little effect noted in organoids developed from normal 
pancreatic tissue. In vivo tumour growth rate of the Suit2 cell line flank grafted in to nude 
mice was also inhibited following Nrf2 deletion. These data again highlight the role of Nrf2 
in tumour survival and proliferation [466].  
The findings by Chio et al. could explain the conclusions postulated by Vartanian et al.; it is 
feasible that the inhibition of Nrf2 by brusatol results in the decreased expression of a 
number of short half-life proteins following brusatol application, rather than it being a 
direct action of brusatol itself. 
5.6 Future work 
This thesis has provided data on the effect of Nrf2 inhibition in reducing tumour CRC cell 
line proliferation and in vivo growth, and in enhancing chemosenstivity to irinotecan. It has 
not established the mechanisms by which Nrf2 exerts these effects or how Nrf2 modulation 
alters the metabolism of irinotecan; further work should concentrate on these aspects. 
A logical approach to the assessment of the effect of Nrf2 modulation on irinotecan 
metabolism would involve the modulation of Nrf2 in cell lines using siRNA targeting Nrf2 or 
Keap1, followed by the measurement of irinotecan and its metabolites in media and cell 
lysates using LC-MS. This would allow quantification of the conversion of irinotecan to SN-
38 and its subsequent deactivation by glucuronidation, in addition to assessing drug uptake 
and excretion through comparisons of the concentrations of metabolites in media and 
lysates. Positive findings could subsequently be validated in vivo. The quantification of 
irinotecan and its metabolites in serum and tissue taken at necropsy from mice dosed with 
irinotecan following pharmacological modulation of Nrf2 expression could allow 
assessment of the effect of this on irinotecan metabolism. Significant work is likely to be 
required to ensure that alteration of Nrf2 expression, and that of the downstream proteins 
involved in irinotecan metabolism, has been achieved before dosing cells or mice with 
irinotecan. 
The work in this thesis also established brusatol as a potent Nrf2 inhibitor and anti-
tumorigenic agent in CRC both in vitro and in vivo, with no published literature currently 
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available on the effect of brusatol on Nrf2 expression in normal tissue excised from mice. 
However, it was not established whether brusatol’s chemotherapeutic effects are purely 
mediated through its effects on the Nrf2 pathway. 
CRISPR gene editing technology, as described in the discussion of chapter 2, could allow the 
creation of stable Nrf2 deleted CRC cell lines which could be utilised in exploring whether 
the effects of brusatol are Nrf2 specific. If the effects of brusatol on CRC cell lines are Nrf2 
mediated, then the compound should exert little additional cytotoxicity or alteration in 
chemosensitivity in a Nrf2 depleted cell line. The use of CRISPR could also allow in vivo 
assessment of tumour growth following Nrf2 inhibition in its own right and in response to 
brusatol therapy. This work could be limited if the Nrf2 knockout cell lines fail to propagate 
in vitro and in vivo, although this would demonstrate the profound effect Nrf2 inhibition on 
CRC cell viability.  
The ultimate aim would be to translate the use of brusatol to the treatment of patients 
with CRC, either as a standalone chemotherapeutic or as addition to current standardised 
chemotherapy regimens to enhance their efficacy by overcoming chemoresistance. It could 
be delivered to patients with advanced disease in attempt to bring them to resection, or 
given as an adjuvant therapy post-resection to improve outcomes. Establishing the 
variation in tumour response to treatment with brusatol in patients could allow selection 
to therapy by relative Nrf2 expression or KEAP1 function, it would be logical that tumours 
with higher Nrf2 expression, possibly through KEAP1 mutations, are likely to be more 
dependent on the protein and therefore may demonstrate a greater response to 
treatment.  
Although brusatol was well tolerated in the murine studies presented in this thesis, there 
are as yet unanswered questions on its mechanism of action, which raise concerns about 
its use in humans. One approach to limiting possible systemic off-target effects of brusatol 
is direct drug-delivery techniques, such as nano-particle formulations or chemo-
embolisation, allowing more targeted delivery and enhancing its safety.  
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5.7 Final conclusions 
In the introduction to this thesis a number of hypotheses were generated for assessment, 
these included: 
1. Is Nrf2 a relevant target for therapy in CRC? 
Proven – Nrf2 expression was demonstrated to be 5-fold higher in primary CRC tumours 
and 7-fold higher in liver metastases than in normal colon, suggesting a survival advantage 
to tumour cells with increased Nrf2 expression in CRC tissue. 
2. Is it possible to modulate Nrf2 expression in CRC cell lines either genetically (using 
siRNA) or pharmacologically (using CDDO-me and brusatol)? 
Proven – Significant upregulation of Nrf2 was achieved in two CRC (human and murine) cell 
lines by targeting Keap1 with siRNA or following the application of CDDO-me. Both siRNA 
targeting Nrf2 and brusatol caused significant inhibition of Nrf2. The effects of brusatol 
were transient, with maximum inhibition achieved at 3 hours and with baseline expression 
returning between 8-12 hours following application to cells. 
3. Does genetic or pharmacological modulation of Nrf2 in CRC cell lines effect cell 
viability and proliferation? 
Proven – Both siRNA and brusatol inhibition of Nrf2 resulted in a significant decrease in the 
viability of the two CRC cell lines. 
4. Does modulation of Nrf2 in CRC cell lines alter their response to irinotecan-based 
therapy? 
Proven – In vitro inhibition of Nrf2 significantly decreased the IC50 of irinotecan, with drug 
synergy noted across a number of concentration combinations when irinotecan was 
combined with brusatol. 
5. Can in vitro findings be replicated in a murine model of CRC that more accurately 
represents the development of the disease in humans? 
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Partially proven – A murine model was created that accurately reflects the metastatic rates 
reported at presentation in patients with tumours occurring in the presence of an intact 
immune system and developing in the correct microenvironment. This model was utilised 
to evaluate in vitro findings in the presence of a complete system. This was essential in 
relation to irinotecan therapy, with a large proportion of conversion of the pro-drug to SN-
38 occurring in the liver. 
As demonstrated in vitro, brusatol acted as a potent anti-tumourigenic agent in vivo, 
significantly inhibiting tumour growth. When combined with irinotecan there was a trend 
towards increased efficacy, but this did not significantly decrease the tumour growth rate 
when compared with irinotecan alone. However, at the final time-point the fold change in 
luminescence noted in the mice on the combination regimen was significantly different 
from the mice treated with irinotecan monotherapy. 
6. Can pharmacological modulation be achieved in vivo? 
Proven – Significant inhibition of Nrf2, as assessed by western immunoblotting or IHC, was 
achieved in tumour tissue, normal colon and normal liver excised from mice treated with 
brusatol over the study period. 
7. Is Nrf2 modulation safe in vivo? 
Partially proven – Although no obvious side-effects or significant toxicity was noted in mice 
treated with brusatol for up to two weeks the longer term effects of brusatol therapy are 
unknown. 
8. Is brusatol a specific Nrf2 inhibitor? 
Unknown – although brusatol is a potent inhibitor of Nrf2 both in vitro and in vivo at 
nanomolar concentration, and many of the pathways altered in the proteomic data could 
be under basal or inducible Nrf2 control, the data limitations and the number of altered 
pathways mean a definitive answer cannot be given. 
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Appendix 1 – comparison of phenotypes in the CT26 parent and CT26lucA6c clonal 
populations 
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Figure A1 – a) Graph displays the growth rate of the CT26 parent population in comparison to the 
CT26lucA6c clonal cell line used in vivo, assessed by cell counting using the Countess™ automated 
cell counter. No significant differences were observed. b) Brusatol dose-response curves 
demonstrated similar IC50 values in the parent and clonal population (CT26 versus CT26lucA6c 
brusatol IC50 = 266 versus 290, non-significant by sum of squares F-test) 
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Appendix 2 – lines of best fit and comparison of tumour growth rates between 
treatment groups in the orthotopic model 
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Figure A2 – a) Graph displays the lines of best fit for fold change in luminescence for each 
individual mouse, with the slope representing tumour growth rate; colours divide mice by 
treatment group. b) Scatter plots display the slope values for each individual mouse with the 
mean +/- SD for each treatment group. All treatments inhibited tumour growth significantly (one-
way ANOVA). (IR = irinotecan, BRU = brusatol) 
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